
<html lang="en"     class="pb-page"  data-request-id="a44c21ba-02ac-4654-9094-b06a57b0017f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c01669;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1" /></meta><meta name="dc.Creator" content="Celeste N.  Alverez" /></meta><meta name="dc.Creator" content="Jung-Eun  Park" /></meta><meta name="dc.Creator" content="Kiran S.  Toti" /></meta><meta name="dc.Creator" content="Yangliu  Xia" /></meta><meta name="dc.Creator" content="Kristopher W.  Krausz" /></meta><meta name="dc.Creator" content="Ganesha  Rai" /></meta><meta name="dc.Creator" content="Jeong K.  Bang" /></meta><meta name="dc.Creator" content="Frank J.  Gonzalez" /></meta><meta name="dc.Creator" content="Kenneth A.  Jacobson" /></meta><meta name="dc.Creator" content="Kyung S.  Lee" /></meta><meta name="dc.Description" content="As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catal..." /></meta><meta name="Description" content="As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catal..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 11, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01669" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01669" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01669" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01669" /></link>
        
    
    

<title>Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01669" /></meta><meta property="og:title" content="Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0032.jpeg" /></meta><meta property="og:description" content="As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catalytic domain inhibitors were tested in preclinical and clinical studies, their efficacies are limited by dose-limiting cytotoxicity, mainly from off-target cross reactivity. The C-terminal noncatalytic polo-box domain (PBD) of Plk1 has emerged as an attractive target for generating new protein–protein interaction inhibitors. Here, we identified a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-a]quinazolin-5(1H)-one scaffold that efficiently inhibits Plk1 PBD but not its related Plk2 and Plk3 PBDs. Structure–activity relationship studies led to multiple inhibitors having ≥10-fold higher inhibitory activity than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT (Kd ∼ 450 nM). In addition, S-methyl prodrugs effectively inhibited mitotic progression and cell proliferation and their metabolic stability was determined. These data describe a novel class of small-molecule inhibitors that offer a promising avenue for future drug discovery against Plk1-addicted cancers." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01669"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01669">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01669&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01669&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01669&amp;href=/doi/10.1021/acs.jmedchem.0c01669" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 14087-14117</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01526" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jmv063i022_1432735" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Celeste N. Alverez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celeste N. Alverez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry Section, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</div><div class="loa-info-affiliations-info">Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celeste+N.++Alverez">Celeste N. Alverez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jung-Eun Park</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jung-Eun Park</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry Section, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jung-Eun++Park">Jung-Eun Park</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kiran S. Toti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kiran S. Toti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kiran+S.++Toti">Kiran S. Toti</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4528-4858" title="Orcid link">http://orcid.org/0000-0002-4528-4858</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yangliu Xia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yangliu Xia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry Section, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yangliu++Xia">Yangliu Xia</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kristopher W. Krausz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kristopher W. Krausz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry Section, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kristopher+W.++Krausz">Kristopher W. Krausz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ganesha Rai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ganesha Rai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ganesha++Rai">Ganesha Rai</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9763-9641" title="Orcid link">http://orcid.org/0000-0001-9763-9641</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeong K. Bang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeong K. Bang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Magnetic Resonance, Korea Basic Science Institute, Cheongju 28119, Republic of Korea</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeong+K.++Bang">Jeong K. Bang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5916-0912" title="Orcid link">http://orcid.org/0000-0001-5916-0912</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frank J. Gonzalez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frank J. Gonzalez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry Section, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frank+J.++Gonzalez">Frank J. Gonzalez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenneth A. Jacobson</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenneth A. Jacobson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#c5aea0ababa0b1adaf85abaca1a1aeebabacadeba2aab3"><span class="__cf_email__" data-cfemail="79121c17171c0d11133917101d1d1257171011571e160f">[email protected]</span></a>. Phone: 301-496-9024.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+A.++Jacobson">Kenneth A. Jacobson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8104-1493" title="Orcid link">http://orcid.org/0000-0001-8104-1493</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Kyung S. Lee</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kyung S. Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Chemistry Section, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#2843515d464f444d4d684549414406464140064f475e"><span class="__cf_email__" data-cfemail="ee85979b8089828b8bae838f8782c0808786c0898198">[email protected]</span></a>. Phone: 240-760-7276.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kyung+S.++Lee">Kyung S. Lee</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8326-7162" title="Orcid link">http://orcid.org/0000-0001-8326-7162</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01669&amp;href=/doi/10.1021%2Facs.jmedchem.0c01669" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 14087–14117</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 11, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>23 September 2020</li><li><span class="item_label"><b>Published</b> online</span>11 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01669" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01669</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14087%26pageCount%3D31%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DCeleste%2BN.%2BAlverez%252C%2BJung-Eun%2BPark%252C%2BKiran%2BS.%2BToti%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c01669%26title%3DIdentification%2Bof%2Ba%2BNew%2BHeterocyclic%2BScaffold%2Bfor%2BInhibitors%2Bof%2Bthe%2BPolo-Box%2BDomain%2Bof%2BPolo-like%2BKinase%2B1%26numPages%3D31%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14117%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01669"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">764</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01669" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Celeste&quot;,&quot;last_name&quot;:&quot;N. Alverez&quot;},{&quot;first_name&quot;:&quot;Jung-Eun&quot;,&quot;last_name&quot;:&quot;Park&quot;},{&quot;first_name&quot;:&quot;Kiran&quot;,&quot;last_name&quot;:&quot;S. Toti&quot;},{&quot;first_name&quot;:&quot;Yangliu&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Kristopher&quot;,&quot;last_name&quot;:&quot;W. Krausz&quot;},{&quot;first_name&quot;:&quot;Ganesha&quot;,&quot;last_name&quot;:&quot;Rai&quot;},{&quot;first_name&quot;:&quot;Jeong&quot;,&quot;last_name&quot;:&quot;K. Bang&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;J. Gonzalez&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;A. Jacobson&quot;},{&quot;first_name&quot;:&quot;Kyung&quot;,&quot;last_name&quot;:&quot;S. Lee&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14087-14117&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01669&quot;},&quot;abstract&quot;:&quot;As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catalytic domain inhibitors were tested in preclinical and clinical studies, their efficacies are limited by dose-limiting cytotoxicity, mainly from off-target cross reactivity. The C-terminal noncatalytic polo-box domain (PBD) of Plk1 has emerged as an attractive target for generating new protein–protein interaction inhibitors. Here, we identified a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-a]quinazolin-5(1H)-one scaffold that efficiently inhibits Plk1 PBD but not its related Plk2 and Plk3 PBDs. Structure–activity relationship studies led to multiple inhibitors having ≥10-fold higher inhibitory activity than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT (Kd ∼ 450 nM). In addition, S-methyl prodrugs effectively inhibited mitotic progression and cell proliferation and their metabolic stability was d&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01669&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01669" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01669&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01669" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01669&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01669" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01669&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01669&amp;href=/doi/10.1021/acs.jmedchem.0c01669" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01669" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01669" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01669%26sid%3Dliteratum%253Aachs%26pmid%3D33175530%26genre%3Darticle%26aulast%3DAlverez%26date%3D2020%26atitle%3DIdentification%2Bof%2Ba%2BNew%2BHeterocyclic%2BScaffold%2Bfor%2BInhibitors%2Bof%2Bthe%2BPolo-Box%2BDomain%2Bof%2BPolo-like%2BKinase%2B1%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D14087%26epage%3D14117%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">As a mitotic-specific target widely deregulated in various human cancers, polo-like kinase 1 (Plk1) has been extensively explored for anticancer activity and drug discovery. Although multiple catalytic domain inhibitors were tested in preclinical and clinical studies, their efficacies are limited by dose-limiting cytotoxicity, mainly from off-target cross reactivity. The C-terminal noncatalytic polo-box domain (PBD) of Plk1 has emerged as an attractive target for generating new protein–protein interaction inhibitors. Here, we identified a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one scaffold that efficiently inhibits Plk1 PBD but not its related Plk2 and Plk3 PBDs. Structure–activity relationship studies led to multiple inhibitors having ≥10-fold higher inhibitory activity than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT (<i>K</i><sub>d</sub> ∼ 450 nM). In addition, <i>S</i>-methyl prodrugs effectively inhibited mitotic progression and cell proliferation and their metabolic stability was determined. These data describe a novel class of small-molecule inhibitors that offer a promising avenue for future drug discovery against Plk1-addicted cancers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Members of the polo subfamily of Ser/Thr protein kinases [collectively, polo-like kinases (Plks)] play a key role in regulating various aspects of the cell cycle and cell proliferation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Among them, Plk1 is critically required for proper mitotic progression, whereas other members play distinct roles during interphase progression and exhibit little functional overlap with other Plk family members.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In accordance with its importance in promoting mitosis, Plk1 is largely upregulated in a broad range of human cancers and its level of overexpression appears to correlate with aggressiveness and poor prognosis for a wide spectrum of human cancers.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Notably, various cancer cells, but not their isogenic normal cells, are addicted to high Plk1 levels and consequently require Plk1 overexpression for their viability.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> As the reversal of addicted protein functions in cancer cells has proven to be an attractive strategy to selectively kill cancer cells,<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Plk1 is considered a discriminating target for anticancer therapy.</div><div class="NLM_p">Plk1 contains an N-terminal kinase domain (KD) for ATP-dependent catalysis and is characterized by the presence of the C-terminal noncatalytic, but functionally essential, polo-box domain (PBD).<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> The PBD plays a key role in mediating Plk1 functions by targeting its N-terminal catalytic activity to distinct subcellular structures, such as centrosomes, kinetochores, and midbody, through specific protein–protein interactions (PPIs).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> For more than a decade, extensive efforts were made to develop Plk1 inhibitors targeting the KD, resulting in several advanced Plk1 ATP-competitive inhibitors (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), such as volasertib/BI6727 <b>1</b>,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> BI2536 <b>2</b>,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> GSK461364 <b>3</b>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> NMS-P937 <b>4</b>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and TAK-960 <b>5</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> that have been examined against various cancers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, they all showed limited efficacy with more-than-acceptable dose-limiting toxicity in various preclinical or clinical trials. As dose-limiting toxicity arises mainly from nonspecific activity of these inhibitors,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> improving the Plk1 specificity is likely the major concern that needs to be addressed to achieve better clinical outcomes. In fact, one of the common problems associated with the currently available Plk1 ATP-competitive inhibitors appears to be their low degree of selectivity against other kinases,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> including two closely related Plk2 and Plk3 with potential tumor suppressor roles.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structures of Inhibitors of the KD (<b>1–5</b>) and the PBD (<b>6</b>) of Plk1</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Unlike the KD inhibitors aimed at annihilating all Plk1 catalytic activity-dependent processes, inhibiting the Plk1 PBD is expected to be less drastic because it could selectively mitigate a subset of essential Plk1 functions requiring PBD-dependent interactions.<a onclick="showRef(event, 'ref7 ref24'); return false;" href="javascript:void(0);" class="ref ref7 ref24">(7,24)</a> In addition, given a high affinity (low nM <i>K</i><sub>d</sub> values) interaction between Plk1 PBD and its binding target sequence,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> the effect of PBD inhibition is expected to be less severe than that of KD inhibition. As Plk1 is also required for the viability of normal cells, a moderate level of inhibition could serve as a fail-safe mechanism that helps prevent undesirable normal cell killing.</div><div class="NLM_p">At the structural level, Plk1 PBD represents a well-characterized PPI domain that interacts with its short phosphopeptide targets with a high affinity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> The unique nature of PBD, which requires strict structural elements for binding, holds the promise of generating specific inhibitors capable of overcoming nonspecific toxicities associated with the KD inhibitors.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Intriguingly, the blockade of Plk1 PBD-dependent PPIs by short peptides or peptide mimetics is sufficient for effectively abrogating the proper mitotic progression, thus imposing potent mitotic arrest and apoptotic cell death in cancer cells but less in normal cells.<a onclick="showRef(event, 'ref7 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref7 ref25 ref26">(7,25,26)</a> These findings suggest that PBD is an attractive target amenable for in vitro PPI- and in vivo cell-based assays required to carry out optimization and preclinical studies for potential leads.</div><div class="NLM_p">Over the years, various Plk1 PBD inhibitors were generated by either derivatizing the well-characterized minimal phosphopeptide, PLHSpT <b>6a</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> or isolating small molecules interfering with Plk1 PBD-dependent PPI.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> However, although peptide-derived inhibitors provide valuable insights into the binding interface of Plk1 PBD-dependent interactions, whether they can serve as a lead for developing anti-PBD agents is disputable, largely because of their poor permeability and limited bioavailability.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In addition, although multiple small molecule inhibitors targeting the Plk1 PBD were reported, most exhibit a low level (IC<sub>50</sub> of 50–1000 μM) of anti-Plk1 activity in cell-based assays,<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35">(28−35)</a> while others are not sufficiently characterized at the cellular level.<a onclick="showRef(event, 'ref36 ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39 ref40 ref41">(36−41)</a></div><div class="NLM_p last">Here, we report the identification and exploration of triazoloquinazolinone-based small-molecule compounds that exhibit specific anti-Plk1 PBD activity in both in vitro biochemical and cell-based assays. These compounds are anticipated not to be chemically reactive as are many of the current probes of Plk1 PBD that contain electrophilic groups.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Their low molecular weight (MW) (generally ∼300–400 Da) along with moderate hydrophobicity and activity of uncharged analogues predict facile availability in intracellular compartments. Notably, the two heterocyclic moieties of the inhibitors (i.e., quinazoline and triazole) are frequently found in various FDA-approved drugs, suggesting the potential druggability of this inhibitor class. We propose the triazoloquinazolinone-based compounds described here as attractive compounds that may lead to the development of a new class of anti-PBD therapeutics against various Plk1-addicted cancers.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Screening Small Molecules to Target Plk1 PBD</h3><div class="NLM_p">A small chemical library of ∼400 drug-like molecules in the Molecular Recognition Section, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), was screened for the ability to bind to the PBD of Plk1. The principle screening assay consisted of an ELISA-based Plk1 PBD inhibition assay that utilizes the specific interaction between the full-length human Plk1 and a specific phospho-Thr (pT)-containing peptide (Biotin-Ahx-C-ETFDPPLHSpTAI-NH<sub>2</sub>) derived from a kinetochore-localizing Plk1-binding protein, PBIP1.<a onclick="showRef(event, 'ref27 ref44'); return false;" href="javascript:void(0);" class="ref ref27 ref44">(27,44)</a> When necessary, secondary fluorescence polarization (FP) assays were carried out using a 5-carboxyfluorescein-labeled peptide (FITC-Ahx-DPPLHSpTAI-NH<sub>2</sub>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> to confirm the anti-Plk1 PBD activity from the primary ELISA-based assay and eliminate false positives.</div><div class="NLM_p">Among four hits identified was triazoloquinazolinone <b>7</b> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), which inhibited PBD binding in the ELISA assay with an IC<sub>50</sub> of 4.38 μM. When compared to the previously characterized phosphopeptide, PLHSpT <b>6a</b> (IC<sub>50</sub> of 14.74 μM), showing a <i>K</i><sub>d</sub> of ∼450 nM,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the affinity of the lead compound <b>7</b> is anticipated to be at least threefold higher than that of peptide <b>6a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Compound <b>7</b> was previously reported as a weak hit in a structure-based in silico screen to identify ligands of the adenosine receptors.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> From this hit, a family of congeners was synthesized by substitutions introduced on all of the moieties of the lead compound <b>7</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Various substituents were introduced as R<sup>1</sup> groups, and aza analogues of the phenyl ring were also introduced. Many alkyl, heteroalkyl, and arylalkyl modifications of the R<sup>2</sup> group (phenylethyl in compound <b>7</b>) were included. Some of the analogues were obtained from commercial sources and their identity confirmed by <sup>1</sup>H NMR and mass spectrometry.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Delineation of zones of SAR focus in the triazoloquinazolinone series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Activity of Triazoloquinazolinones Modified in Zones 5 and 6 at the Plk1 PBD<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0010.gif" alt="" id="GRAPHIC-d7e559-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0011.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">(IC<sub>50</sub> values are <i>n</i> = 3 unless noted in parentheses) and microsomal half-life, PAMPA assays, and aqueous solubility.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">ND, not determined.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Chemical Synthesis</h3><div class="NLM_p">The synthesis of analogues of <b>7</b> generally began with either the corresponding isatoic anhydride (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) or anthranilic acid (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). An isatoic anhydride (e.g., <b>10</b>) was heated in the presence of the desired amine to give the corresponding intermediate 2-aminobenzamide (structure not shown). This intermediate was heated in the presence of carbon disulfide and potassium hydroxide to give the cyclized 2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one derivative (e.g., <b>11</b>), which was isolated by precipitation with treatment of water, followed by filtration. The corresponding 3-thione-1,2,4-triazole (e.g., <b>12</b>) was then typically formed in a one-pot procedure by first stirring with hydrazine in refluxing ethanol to form the hydrazine intermediate. This intermediate, after cooling, was treated with pyridine and carbon disulfide. The desired triazoloquinazolinone <b>12</b> was formed after heating the reaction again to 80 °C. The 2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one intermediate could also be formed by reacting the desired 2-aminobenzoic acid with an isothiocyanate. However, because of the limited availability of isothiocyanates, the preferred route for preparation of the triazoloquinazolinones is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. With the core triazoloquinazolinone formed, additional analogues could be generated with a terminal amine (e.g., <b>13</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Amides of this amino congener (e.g., <b>14</b>) were selected as a primary focus, and (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (COMU) was found to be the best coupling agent and therefore used to synthesize all additional analogues.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of 7-Fluoro Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Zone 4 Amides</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Structure–Activity Relationship</h3><div class="NLM_p">The structure–activity relationship (SAR) of the 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one scaffold as PBD inhibitors was explored (compounds <b>15–138</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<named-content content-type="anchor" rid="tbl2" type="simple"></named-content><named-content content-type="anchor" rid="tbl3" type="simple"></named-content><named-content content-type="anchor" rid="tbl4" type="simple"></named-content><named-content content-type="anchor" rid="tbl5" type="simple"></named-content><named-content content-type="anchor" rid="tbl6" type="simple"></named-content><named-content content-type="anchor" rid="tbl7" type="simple"></named-content><named-content content-type="anchor" rid="tbl8" type="simple"></named-content><a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>). All compounds were evaluated for their efficacy against the full-length human Plk1 in an ELISA assay (representative data shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and for their in vitro physiochemical properties (half-life, permeability, and solubility). Because of the lack of structural information for the binding of <b>7</b> to the PBD domain of Plk1, early SAR studies began by exploring the 2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thione moiety to determine empirically the requirements for binding. Despite the prevalence of sulfur atoms in small-molecule drug discovery, we began by replacing and modifying the thiourea portion of the molecule. First, we replaced the sulfur with a range of additional atoms including oxygen in <b>15</b>. We found that any replacement of the sulfur resulted in complete loss of activity, indicating that a free 1-thioxo group is essential for activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). To determine whether the thiocarbonyl was required, sulfur was methylated and product <b>19</b> tested, but this methyl thioether was also inactive. In addition, many alkyl groups were tried, and all were found to be inactive (see Table S1, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). This showed that unmodified thiourea was required for activity.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative inhibition curves in the ELISA assay. A previously characterized phosphopeptide, PLHSpT <b>6a</b> (<i>K</i><sub>d</sub> of ∼450 nM<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>), is included for comparison. The curve numbers correspond to compound numbers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Activity of Early Triazoloquinazolinones Modified in Zones 3 and 4 at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0012.gif" alt="" id="GRAPHIC-d7e722-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0013.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Racemic. ND, not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activity of Zone 5-Modified Triazoloquinazolinone Derivatives at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0014.gif" alt="" id="GRAPHIC-d7e743-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0015.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Inhibitory Activity of Triazoloquinazolinones Modified in Zones 1 and 2 at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0016.gif" alt="" id="GRAPHIC-d7e764-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup>=</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> (μM, ELISA)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (min, RLM)</th><th class="colsep0 rowsep0" align="center">PAMPA (1 × 10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center">solub. (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">4.38 ± 0.41 (6)</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="char" char="±">12.92 ± 1.85</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">77.0</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">7-Br</td><td class="colsep0 rowsep0" align="char" char="±">14.74 ± 0.81</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">162</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">7-I</td><td class="colsep0 rowsep0" align="char" char="±">30.71 ± 1.31</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">1025</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">7-Me</td><td class="colsep0 rowsep0" align="char" char="±">11.29 ± 0.92</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">7-NHAc</td><td class="colsep0 rowsep0" align="char" char="±">2.19 ± 0.10</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">253</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">7-N(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">2.77 ± 0.33</td><td class="colsep0 rowsep0" align="left">13.3</td><td class="colsep0 rowsep0" align="left">356</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">7-(1-morpholino)</td><td class="colsep0 rowsep0" align="char" char="±">1.54 ± 0.21</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">8-F</td><td class="colsep0 rowsep0" align="char" char="±">8.29 ± 0.59</td><td class="colsep0 rowsep0" align="left">22.7</td><td class="colsep0 rowsep0" align="left">91.0</td><td class="colsep0 rowsep0" align="left"><1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">9-F</td><td class="colsep0 rowsep0" align="char" char="±">2.58 ± 0.12</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">141</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">H (6-aza)</td><td class="colsep0 rowsep0" align="char" char="±">6.16 ± 0.44</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">16.8</td><td class="colsep0 rowsep0" align="left">26.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">H (8-aza)</td><td class="colsep0 rowsep0" align="char" char="±">27.78 ± 4.07</td><td class="colsep0 rowsep0" align="left">15.8</td><td class="colsep0 rowsep0" align="left">202</td><td class="colsep0 rowsep0" align="left">17.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">H (9-aza)</td><td class="colsep0 rowsep0" align="char" char="±">7.55 ± 0.44</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">51.8</td><td class="colsep0 rowsep0" align="left">4.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Inhibitory Activity of Triazoloquinazolinones Modified in Combined Zones 1, 2, 3, and 4 at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0017.gif" alt="" id="GRAPHIC-d7e1039-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0018.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibitory Activity at the Plk1 PBD of Triazoloquinazolinones Modified in Zones 3 and 4 with a Preferred 7-Fluoro Substitution, Except for <b>69</b> with 9-Fluoro (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0019.gif" alt="" id="GRAPHIC-d7e1062-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0020.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Racemic.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Relative stereochemistry, trans.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">TFA salt.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Free base. ND, not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Inhibitory Activity of Amide-Containing Triazoloquinazolinones Modified in Zones 3 and 4 with Preferred 7-Fluorine at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0021.gif" alt="" id="GRAPHIC-d7e1097-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0022.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Relative stereochemistry, trans.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Racemic. ND, not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Inhibitory Activity of 4 Phenylacetic Acid Amide Triazoloquinazolinone Derivatives Modified in Zones 3 and 4 with Preferred 7-Fluorine at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses) and Microsomal Half-Life, PAMPA Assays, and Aqueous Solubility<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0023.gif" alt="" id="GRAPHIC-d7e1123-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0024.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">ND, not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Inhibitory Activity of Prodrug Triazoloquinazolinones and Their Corresponding Parent Drugs at the Plk1 PBD (IC<sub>50</sub> Values Are <i>n</i> = 3 Unless Noted in Parentheses)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0025.gif" alt="" id="GRAPHIC-d7e1143-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup>=</th><th class="colsep0 rowsep0" align="center">R<sup>5</sup>=</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.03 ± 0.08 (9)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="left">H<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.16 ± 0.06 (12)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>139</b></td><td class="colsep0 rowsep0" align="left">9-F</td><td class="colsep0 rowsep0" align="left">H<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2.06 ± 0.07 (4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>140</b></td><td class="colsep0 rowsep0" align="left">9-Cl</td><td class="colsep0 rowsep0" align="left">H<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2.49 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>141</b></td><td class="colsep0 rowsep0" align="left">9-OMe</td><td class="colsep0 rowsep0" align="left">H<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2.43 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>142</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ac</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>143</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>144</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>145</b></td><td class="colsep0 rowsep0" align="left">9-F</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>146</b></td><td class="colsep0 rowsep0" align="left">9-Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>147</b></td><td class="colsep0 rowsep0" align="left">9-OMe</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">>50</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Shown as the enol tautomers, while this series is shown in the thiocarbonyl form elsewhere. ND, not determined.</p></div></div></div><div class="NLM_p">We also explored <i>S</i>-methyl and <i>S</i>-acetyl derivatives (compounds <b>139–144</b>, <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) as potential prodrugs of the corresponding active 1-thioxo derivatives. By decreasing the polarity of the molecules, we expected to achieve better intracellular levels of the active species, with the expectation that the masking moiety on the S could be labile prior to reaching the site of action.</div><div class="NLM_p">We then explored the SAR of the side chain, R<sup>2</sup>, by systematically modifying the length and composition of the linker as well as the end group of the side chain. First, we simplified the side chain by removing the terminal phenyl ring and maintaining the simpler alkyl chain of various lengths (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>20–34</b>). All alkyl chain lengths tested, from the shorter ethyl group through the pentyl group, which maintain a linear length similar to that of <b>7</b>, showed improved potency relative to the aryl-containing <b>7</b>. This suggests a potential size restriction in the area of the pocket where the side chain binds. To further explore this, branching was introduced into the alkyl side chain with the 3-methylbutane of <b>25</b> and the isopropyl group of <b>26</b>. However, these bulkier alkyl groups, relative to their linear counterparts <b>23</b> and <b>20</b>, respectively, maintained potency in the range of 1–2 μM, suggesting that the improvement in potency was not strictly due to removal of the bulkier phenyl group.</div><div class="NLM_p">Next, we tried to evaluate if incorporation of heteroatoms on the alkyl group (R<sup>2</sup>) was tolerated (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>27–29</b>). The CF<sub>3</sub> group of <b>27</b> also had the added benefit of blocking potential cytochrome P450 (CYP)-mediated metabolism of the side chain. Though there was no observable change in the metabolic stability of <b>27</b> relative to <b>21</b>, <b>27</b> did maintain a potency relative to that of <b>21</b>. Incorporation of oxygen to give ether side chains also improved the activity of <b>28</b> and <b>29</b> relative to <b>7</b> and maintained the activity relative to the hydrocarbon chains. We also incorporated amide groups into the side chain to see if there were additional H-bonding interactions that could be established with the PBD (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>30–32</b>). All three amide-containing analogues showed a slight improvement over <b>7</b> (IC<sub>50</sub> = 2.92–3.90 μM vs IC<sub>50</sub> = 4.38 μM, respectively) but reduced activity relative to the alkyl chain-containing analogues (IC<sub>50</sub> = 2.92–3.90 μM vs IC<sub>50</sub> = 1.03–1.97 μM, respectively). This reduction in potency relative to the alkyl chain-containing analogues could be due to the branching of the fragment attached at the nitrogen, although branching appeared to be tolerated for analogues <b>25</b> and <b>26</b>. In addition, the combination of the branching along with the carbonyl of the amide resulted in an apparently less favorable orientation of the side chain and reduced potency. The final side chains tested for these early SARs studied included shorter-chain aryl groups (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>33</b> and <b>34</b>). For analogue <b>33</b>, the 2,3-dimethylphenyl group was attached directly to the core and resulted in an improved activity relative to <b>7</b> (IC<sub>50</sub> = 1.85 μM vs 4.38 μM, respectively). However, when the 4-fluorobenzyl group was present, it failed to show significant improvement over <b>7</b> (IC<sub>50</sub> = 3.54 μM vs 4.38 μM, respectively). This indicates that, unless directly connected to the core, phenyl groups are not well tolerated when a linker is present.</div><div class="NLM_p">Once an initial SAR was analyzed for the 2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thione and the side chain, we chose to revisit the triazole and determined whether alkylation of <i>N</i>-2 could be tolerated. Four analogues (<b>35–38</b>) included a tertiary amine with various small alkyl groups (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). All four N-substituted triazole analogues showed good activity, particularly the three analogues where R<sup>2</sup> was the longer propyl group (IC<sub>50</sub> = 1.63–1.83 μM). The ketone-containing analogue <b>39</b> lacking a basic nitrogen was inactive (IC<sub>50</sub> > 50 μM).</div><div class="NLM_p">We then explored the fused phenyl ring of the core to determine whether substitution would be tolerated in this region. First, we began with halogenation at the 7-position (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, <b>40–42</b>). As the size of the halogen increased, the affinity decreased (F, IC<sub>50</sub> = 12.9 μM; Br, IC<sub>50</sub> = 14.7 μM; I, IC<sub>50</sub> = 30.7 μM). The larger, hydrophobic 7-methyl group (<b>43</b>) showed a potency similar to that of the 7-F analogue. However, these analogues were still less potent overall than the unsubstituted <b>7</b>. We then wanted to determine if larger substituents would be tolerated if a heteroatom was introduced to make additional interactions. The 7-acetamide <b>44</b>, 7-dimethylamine <b>45</b>, and 7-(1-morpholino) <b>46</b> were prepared (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). All three of these analogues with H-bonding capabilities were approximately twofold more potent than <b>7</b> (IC<sub>50</sub> = 1.54–2.77 μM vs IC<sub>50</sub> = 4.38 μM, respectively). Next, we explored the substitution pattern around the ring. To do so, the mono-fluoro analogues were prepared including 7-F (<b>40</b>), 8-F (<b>41</b>), and 9-F (<b>42</b>). They were shown to increase in potency as the fluorine moved around the ring from the 7- to 8- to 9-position (IC<sub>50</sub> = 12.9, 8.29, and 2.58 μM, respectively). Finally, we explored the replacement of the phenyl ring with pyridine. The 6-aza (<b>49</b>), 8-aza (<b>50</b>), and 9-aza (<b>51</b>) analogues were prepared; however, these heteroaryl derivatives were found to be less potent than <b>7</b> (>2–6-fold).</div><div class="NLM_p">The next stage of our SAR exploration involved combining features from each of the regions explored so far (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). First, we incorporated substitutions on the phenyl ring and modified the side chain. On the 7-fluoro core, we shortened (<b>52</b>) and extended (<b>53</b>), the alkyl phenyl side chain. Both the longer propyl and shorter methyl homologues showed similar activity that was slightly less potent than that of the parent <b>7</b> with the ethyl linker (propyl, IC<sub>50</sub> = 6.63 μM; methyl, IC<sub>50</sub> = 6.42 μM; ethyl, IC<sub>50</sub> = 4.38 μM). We then revisited the alkyl chains with the 7-chloro core (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <b>54–57</b>). Compound <b>54</b> with the propyl side chain showed a small decrease in potency from the unsubstituted <b>21</b> (IC<sub>50</sub> = 1.77 μM and IC<sub>50</sub> = 1.03 μM, respectively). For compound <b>55</b> with the 3,3,3-trifluoropropane side chain, the 7-chloro core resulted in a nearly twofold loss of potency compared to its unsubstituted counterpart, <b>27</b> (IC<sub>50</sub> = 2.14 μM and IC<sub>50</sub> = 1.25 μM, respectively). The ether-containing analogue <b>56</b> was equipotent to its most similar <b>29</b>. The two amide-containing side chain analogues <b>57</b> and <b>58</b> with the 7-chloro and 7-methyl cores, respectively, were about twofold more potent than the unsubstituted <b>31</b> (IC<sub>50</sub> = 1.49 μM, IC<sub>50</sub> = 2.01 μM, and IC<sub>50</sub> = 3.90 μM, respectively).</div><div class="NLM_p">After the promising results shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> for the 7-acetamide <b>44</b>, three additional amides were prepared this time in the 8-position to determine the tolerability of a larger group in the 8-position. The 8-isopropyl amide with the propyl chain (<b>59</b>, IC<sub>50</sub> = 3.01 μM) was shown to be less potent than the unsubstituted <b>21</b> (IC<sub>50</sub> = 1.03 μM) but more potent than either the 8-fluoro (<b>47</b>, IC<sub>50</sub> = 8.29 μM) or the 8-aza (<b>50</b>, IC<sub>50</sub> = 27.8 μM). Compounds <b>60</b> and <b>61</b> have an 8-cyclopentyl amide substitution with alkyl side chains. However, when comparing <b>60</b> and <b>25</b>, both of which have a 3-methylbutane side chain, the substitution in the 8-position was not beneficial as <b>60</b> was found to be sixfold less potent than <b>25</b>. We had already discovered that modifying the thiourea portion of the 2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thione was not tolerated; however, we wanted to determine whether the triazole ring itself was required. To test this, we prepared the thiourea, <b>62</b>, which maintained the thiocarbonyl as well as the NH of the 2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thione. Similar to most other modifications of the 2,4-dihydro-3<i>H</i>-1,2,4-triazole-3-thione, the thiourea of <b>62</b> was not tolerated and also resulted in a highly metabolically labile analogue (IC<sub>50</sub> > 50 μM, <i>t</i><sub>1/2</sub> RLM = 2.2 min).</div><div class="NLM_p">Based on the observed results thus far, it became clear that we could make the most significant positive modifications to the chemotype in the side chain. Therefore, we made a large number of analogues on the 7-fluoro core and varied the side chain to expand our SAR. We began with linear alkyl groups, which we had previously found to lead to low micromolar affinity. The shorter ethyl group (<b>63</b>) led to a small reduction in affinity compared to the unsubstituted <b>20</b> (IC<sub>50</sub> = 1.98 μM and IC<sub>50</sub> = 1.49 μM, respectively), while the propyl analogue (<b>64</b>) was found to be equipotent to the unsubstituted equivalent (<b>21</b>). Previously the 3,3,3-trifluoropropyl group led to one of the most potent analogues. Therefore, we combined this group with the 7-F and found that the 7-F analogue <b>65</b> was at least as potent as the corresponding unsubstituted <b>27</b>. We then chose to introduce additional H-bonding groups that might increase interactions within the binding site. To this end, hydroxy (<b>66</b>), amino (<b>67–76</b>), and phosphorus (<b>77</b>, <b>78</b>) derivatives were synthesized and tested. The 1-propanol group, which is similar in length to the butyl analogue (<b>23</b>), maintained good potency at 1.44 μM. For the primary amines, both ethyl and propyl chains were tested, and the three-carbon linker was found to be twice as potent as the two-carbon linker. Also, as the 9-fluoro substitution was previously shown to be the most potent of the mono-fluoro substituents, the 9-F analogue with a propylamine chain (<b>69</b>) was prepared but found to be less potent than the 7-F derivative <b>68</b>. This is unexpected as it is opposite to the trend seen for the phenethyl series. When relatively simple dimethyl amine analogues <b>70</b> and <b>71</b> were prepared, <b>70</b> was shown to be slightly more potent than the equivalent primary amine <b>67</b>, while the branched 1-dimethylaminoprop-2-yl analogue (<b>71</b>) was slightly less potent. In the case of amide (<b>72–74</b>) and sulfonamide (<b>75</b> and <b>76</b>) derivatives, regardless of the linker length or the type of derivative, all analogues essentially performed similarly (IC<sub>50</sub> = ∼2.0 μM) with the benzamide <b>74</b> showing the most potent affinity of the five. The phosphorus-containing analogues, phosphonic acid <b>77</b> and phosphonate diester <b>78</b>, both showed significantly weaker affinity, with the phosphonic acid being essentially inactive. In addition to these heteroatom-containing analogues, several cyclopropane derivatives were prepared (<b>79</b> and <b>80</b>). Both <b>79</b> and <b>80</b>, which differ in the location of the cyclopropane in the chain, showed good potency of approximately 1.0 μM, indicating that although heteroatoms are well tolerated in the side chain, they are not required.</div><div class="NLM_p">Next, we explored the phenethyl side chain (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), first, by substituting the phenyl moiety with chloro groups (<b>81</b> and <b>82</b>). While the 4-chloro analogue maintained an affinity similar to that of <b>7</b> (<b>82</b>, IC<sub>50</sub> = 5.71 μM) and was over twofold more potent than <b>40</b>, the 2-chloro analogue was less potent than either <b>7</b> or <b>40</b> (<b>81</b>, IC<sub>50</sub> = 14.4 μM). This indicates that ortho substitution is not well tolerated, which supports the earlier conclusion that for the phenethyl derivatives the binding pocket around the phenyl group is restrictive, and substituents that make it bulkier led to negative interactions. Concluding that the space around the phenyl ring was sterically limited, we next chose to replace it with a pyridine to determine if H-bonding opportunities are available without increasing the steric bulk. All three pyridine analogues were synthesized, and all were found to be ≥12-fold more potent than the phenyl-containing <b>40</b>. The trend for the potency (4-pyridine ≈ 2-pyridine > 3-pyridine, best to worst) differs from that observed for the chloro substitution, which clearly indicated that the 4-position is the most favorable for affinity. However, in the case of the pyridines, all three <i>N</i> positions were well tolerated. This could be due to the chloro group extending into the pocket, creating steric clashes, which were absent for the pyridines. Nonaromatic heterocycles were also tested to determine whether they would be more beneficial than the aromatic heterocycles. Azetidine <b>86</b>, pyrrolidine <b>87</b>, and piperidine <b>88</b> were all prepared to determine if there was a size preference for the ring, and a clear preference was observed for the six-membered piperidine (IC<sub>50</sub> = 5.67 μM, IC<sub>50</sub> = 5.67 μM, and IC<sub>50</sub> = 1.51 μM, respectively). With this information, we then explored whether additional heteroatoms in the 4-position would be tolerated. The 4,4-difluoropiperidine <b>89</b> and the <i>N</i>-morpholino <b>90</b> were equipotent to <b>88</b>, that is, all near IC<sub>50</sub> = 1.5 μM. However, when a second nitrogen was incorporated into the ring in analogues <b>91</b> and <b>92</b>, a discrepancy was observed in the SAR. Based on the chloro-substituted phenyl rings, both <b>91</b> and <b>92</b> were expected to be potent; however, only <b>92</b> showed an affinity similar to the other six-membered ring heterocycles. Because the methyl group is much smaller than the Boc group, the difference in affinity is not due to the size of the group. The more likely source of the difference is the basicity of the nitrogen in the 4-position, given that the Boc group significantly decreases the p<i>K</i><sub>a</sub> of the nitrogen relative to <b>91</b>. Finally, we also prepared the carbocyclic version of <b>89</b> to determine if the heteroatom in the ring was required at all. Compound <b>93</b> maintained the difluoro substitution, which could potentially generate H-bonding interactions. However, there were no other heteroatoms with which to form H-bonds or salt bridges, and as a result, the potency showed a small (approximately twofold) decrease, indicating that though the nitrogen is not required, it is beneficial.</div><div class="NLM_p">Expanding upon the SAR established above, we continued to explore the side chain region by focusing on the propyl amide motif, given that this serves as a good handle for further modification to probe the binding pocket (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) and that compound <b>74</b> with the benzamide was one of the more potent analogues thus far. First, we prepared analogues <b>94</b> and <b>95</b> with polyethylene glycol (PEG) linkers to extend the primary amine further into the pocket. While both compounds maintained single-digit micromolar affinity, the Boc-protected <b>95</b> was more potent than the free amine <b>94</b> (IC<sub>50</sub> = 3.22 μM and IC<sub>50</sub> = 5.36 μM, respectively), which suggests a preference for a less basic group and that the size of the terminal group is unimportant. To determine whether this was related to a preference for uncharged species or unprotonated species, the <span class="smallcaps smallerCapital">l</span>-Glu derivatives were prepared (<b>96</b> and <b>97</b>). While the fully deprotected <b>96</b> was shown to be >twofold less potent than <b>94</b>, the <i>t</i>-butyl ester-protected <b>97</b> was <twofold less potent. This does support the conclusion that, in the region where these highly extended compounds reside, an uncharged species is preferred. We then chose to look at increasingly shorter chains to determine their tolerability in the binding pocket. The PEG<sub>3</sub> chain analogues (<b>98</b> and <b>99</b>) showed the same preference for the less basic, Boc-protected amine that was observed for the PEG<sub>4</sub> chain. However, when the chain was shorted further to the hexylamine, the primary amine and the corresponding Boc-protected amine were equipotent, indicating that the preference for uncharged species begins at greater distances from the main binding site for the chemotype. The Boc-<span class="smallcaps smallerCapital">d</span>-Glu-O<i>t</i>Bu (<b>102</b>) and Boc-<span class="smallcaps smallerCapital">l</span>-Glu-O<i>t</i>Bu (<b>103</b>) derivatives showed a preference for the natural amino acid derivative (>twofold more potent than <b>102</b>). Compound <b>103</b> was then deprotected, giving either the Boc deprotected <span class="smallcaps smallerCapital">l</span>-Glu-O<sup><i>t</i></sup>Bu <b>104</b> or the fully deprotected <b>105</b>. These analogues show that a negatively charged species is not well tolerated (<b>105</b> IC<sub>50</sub> = 12.7 μM). The succinic acid derivative, <b>106</b>, still exhibited an intolerance for negatively charged species as well, indicating that the two charges likely present in <b>105</b> are not beneficial either. Moreover, the sulfonamide <b>107</b>, which is thought to maintain many of the same potential interactions without being negatively charged, was shown to be the most potent of these extended linear analogues with an IC<sub>50</sub> = 2.18 μM.</div><div class="NLM_p">After determining that the shorter chain molecules were preferred, we focused on smaller, cyclic analogues. Beginning with carbocyclic groups, the cyclopentyl amide <b>108</b> showed a relatively good potency (IC<sub>50</sub> = 1.47 μM), but the sterically much bulkier <i>trans</i>-4-(<i>t</i>-butyl)cyclohexane amide <b>109</b> was inactive. Consistent with the finding that a highly bulky group was not tolerated, the 4-Boc-aminocyclohexane amide <b>110</b> was found to be moderately potent (IC<sub>50</sub> = 2.38 μM). However, once again, when the Boc group was removed (<b>111</b>), the potency decreased slightly, suggesting the preference for uncharged species. A series of piperidine analogues (<b>112–114</b>) were prepared to further assess this. In agreement with the data above, all three piperidines, despite the location of the nitrogen in the ring, were significantly less active and nearly inactive (IC<sub>50</sub> = 27.7–44.0 μM). Notably, 4-tetrahydropyran <b>115</b> was found to show good potency (IC<sub>50</sub> = 1.79 μM), indicating that the protonation of the amine, which likely occurs at physiological pH, is the feature not tolerated rather than the presence of a heteroatom in the ring. Three additional analogues with a methylene linker between the amide carbonyl and the heterocycle were also prepared (<b>116–118</b>). All three analogues contained a basic nitrogen in the ring and all three showed moderate affinity, reinforcing the preference for neutral compounds in this side chain region. Finally, a series of aromatic analogues of differing lengths were prepared (<b>119–121</b>). All three analogues, despite the presence of heteroatoms or the overall length of the side chain, showed good affinity (IC<sub>50</sub> = 1.23–1.78 μM).</div><div class="NLM_p last">Given that compound <b>120</b> showed the best affinity of these amide analogues, we decided to explore substitution around the phenylacetamide portion (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Beginning with simple halogen-containing analogues, compounds <b>122–125</b> were prepared. Though not all positions were tested for each halogen, a general trend did emerge. When comparing <b>122</b> and <b>123</b>, the position of the halogen was found not to have a significant impact on the potency (meta IC<sub>50</sub> = 1.42 μM and para IC<sub>50</sub> = 1.35 μM). Also, the halogen size had no effect on the affinity of the analogue as seen by all four analogues showing essentially the same potency, indicating that the size of the group does not have a large impact on binding. Next, we looked at substituents that would modulate the electronic character of the ring (<b>126–134</b>). For electron-donating groups, methyl (<b>126</b>), hydroxy (<b>127</b>), and methoxy (<b>128–130</b>) analogues were prepared. Overall, electron-donating groups were well tolerated, maintaining a similar affinity relative to <b>120</b>. Similar to the trend observed for the halogens, the location of these groups did not have a large impact on the potency of the compound either. The electron-withdrawing groups, trifluoromethyl (<b>131–132</b>) and cyano (<b>133–134</b>), showed similar results. They were also well tolerated in all positions, but the 3-CF<sub>3</sub> derivative (<b>132</b>) was the least potent but only slightly (<twofold) less potent than all other substituted phenylacetamide analogues. The Boc-protected 4-amino analogue was also twofold less potent than the parent <b>120</b>. Finally, in the case of a series of pyridine analogues prepared (<b>136–138</b>), all three analogues were less potent than the phenyl analogue <b>120</b> and 2-pyridine was the weakest at IC<sub>50</sub> = 5.34 μM.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Plk1 PBD Specificity</h3><div class="NLM_p">To determine whether the above modified compounds show Plk1 PBD-binding specificity, we carried out FP-based inhibition assays using fluorescein isothiocyanate (FITC)-labeled peptides that specifically bind to each of the PBDs from Plk1, Plk2, and Plk3.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Under these experimental settings, PLHSpT <b>6</b>, but not its respective nonphosphorylated peptide, specifically inhibited Plk1 PBD with an IC<sub>50</sub> of 22 μM (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Under the same conditions, representative, potent compound <b>79</b> inhibited Plk1 PBD with an IC<sub>50</sub> of 0.47 μM and failed to exhibit any detectable level of inhibition against the PBDs from Plk2 and Plk3. An approximately 40-fold increased potency for compound <b>79</b> over PLHSpT <b>6</b> is largely in good agreement with the data obtained with ELISA-based assays described above. Similar to this observation, expanded FP assays showed that several additional compounds tested showed approximately the same degree of Plk1 PBD specificity (Figure S3, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). The all-or-none selectivity for Plk1 PBD is significant, given that the well-characterized Plk1 KD inhibitor BI2536 exhibits Plk1 selectivity of only around fourfold.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> These data collectively suggest that, while the exact binding mode of these compounds is yet to be determined, they may at least partially block the canonical S-pT/pS-P/X-binding region of Plk1 PBD described previously.<a onclick="showRef(event, 'ref11 ref27'); return false;" href="javascript:void(0);" class="ref ref11 ref27">(11,27)</a></div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparative FP-based assays showing that compound <b>79</b> potently inhibits the PBD of Plk1 but not Plk2 and Plk3 with an IC<sub>50</sub> of 0.47 μM. Under the same experimental conditions, PLHSpT <b>6a</b> shows an IC<sub>50</sub> of 22 μM, whereas its control nonphosphorylated form, PLHST <b>6b</b>, exhibits no detectable activity. Bars, mean ± standard deviation (s.d.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Prodrug and Cellular Efficacy</h3><div class="NLM_p">Having confirmed that many of the compounds generated through SAR exhibited submicromolar IC<sub>50</sub> values with a superb specificity for Plk1 PBD, we then examined their activities in whole-cell studies. However, likely due to limited intracellular bioavailability arising from low membrane permeability, we failed to observe mitotic arrest, the phenotype that can be expected by interfering with the function of Plk1 PBD.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> We reasoned that alkylating the thiocarbonyl could improve the cellular uptake of the compounds. In addition, it would directly block oxidative metabolism of the thiourea as well as prevent potential oxidation of the phenyl ring via steric factors, consequently reducing clearance and allowing for greater exposure of the drug at a site of action. Therefore, we selected a small alkyl group or small alkyl ester as a starting point as they should be relatively readily cleaved within the body and could allow us to gauge the level of stability necessary for the prodrug to be beneficial. Accordingly, compounds <b>142–147</b> were prepared as thioester or S-methyl prodrugs and examined in the ELISA assay (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) and in metabolic studies (see below). The corresponding parent drugs were unsubstituted <b>21</b> for <b>142</b> and <b>143</b>, 7-F analogue <b>64</b> for <b>144</b>, 9-F analogue <b>139</b> for <b>145</b>, 9-Cl analogue <b>140</b> for <b>146</b>, and 9-OMe analogue <b>141</b> for <b>147</b>. Not surprisingly, these prodrugs, except the <i>S</i>-acyl group-containing <b>142</b>, were inactive with IC<sub>50</sub> > 50 μM (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Compound <b>142</b> appeared to rapidly become active by releasing the active parental compound <b>21</b> because of the reactivity of the <i>S</i>-acyl group toward electron-rich moieties (see below and Figure S4, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">In HeLa cells, compounds <b>143</b>, <b>144</b>, and <b>145</b> were compared for their ability to induce mitotic arrest and an antiproliferation effect, which are characteristics of Plk1 PBD inhibition.<a onclick="showRef(event, 'ref25 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref27">(25,27)</a> Results showed that treatment of cells with 100 μM of either compound <b>143</b> or <b>145</b> effectively induced rounded cells with apoptotic or aberrant chromosome morphologies (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B), indicative of a sustained mitotic arrest. Consequently, both compounds inhibited cell proliferation, decreasing the total cell population nearly by 50% 3 days after treatment. Considering that blocking the function of Plk1 PBD-dependent PPI is destined to be less drastic than that of Plk1 KD<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> and that several purported inhibitors reported to date show a low level (IC<sub>50</sub> of 50–1000 μM) of cellular activities,<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35">(28−35)</a> the activity of <b>143</b> or <b>145</b> is a modest but clear improvement. Treatment with compound <b>144</b> also induced mitotic arrest but at a somewhat reduced level, whereas control DMSO failed to induce any detectable phenotype under the same conditions. As expected, if the arrest was caused by interfering with the PBD-dependent Plk1 function, compound <b>143</b> significantly inhibited Plk1 localization to centrosomes (approximately 20% inhibition) and kinetochores (approximately 50% inhibition), frequently yielding cytosolic aggregates of delocalized Plk1 as observed previously<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). A weaker blocking of Plk1 localization to the centrosome is likely due to the presence of PBD-independent Plk1-binding targets at this structure. Consistent with impaired Plk1 localization, spindle bipolarity was significantly compromised in <b>143</b>-treated cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). Under the same conditions, the parent drugs, that is, <b>21</b>, <b>64</b>, and <b>139</b>, lacked a detectable level of cellular response. These findings suggest that, although the prodrugs themselves failed to inhibit Plk1 PBD (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) because of the absence of a free 1-thioxy group, the <i>S</i>-methyl thioethers had a more pronounced response, presumably by promoting cell membrane permeability while regenerating the parent drug intracellularly.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antiproliferative effect of <b>143</b> in HeLa cells. (A) Asynchronously growing HeLa cells were treated with 100 μM of compound <b>143</b> for 12 h, subjected to phase-contrast micrography (cells with a rounded morphology are marked with barbed arrows) and stained with DAPI. Cells exhibiting mitotic and apoptotic DNA morphologies (arrows in DAPI) (bottom left) and abnormally misaligned or lagging chromosomes (bottom right) were quantified from three independent experiments (<i>n</i> > 515 cells/sample/experiment). Bars, mean ± s.d., ***, <i>P</i> < 0.001 (unpaired two-tailed <i>t</i>-test). (B) Cell numbers at the indicated time points were quantified from three independent experiments (<i>n</i> = an average of 2547 cells/experiment for DMSO and 1673 cells/experiment for <b>143</b>). Bars, mean ± s.d. (C,D) Cells in (A) were immunostained with the indicated antibodies to reveal delocalized Plk1 signals from centrosomes (marker: Cep63) and kinetochores (marker: CREST) (C) and abnormal spindle morphologies (marker: α-tubulin) (D). Asterisks, centrosome-localized Plk1; brackets, kinetochore-associated Plk1. Arrowheads in (C), delocalized Plk1 aggregates in the cytosol. Quantification was carried out from three independent experiments [≥20 (DMSO) or 32 (<b>143</b>) centrosomes/sample/experiment and ≥42 (DMSO) or 64 (<b>143</b>) kinetochores (∼4 kinetochores per cell)/sample/experiment for (C); ≥106 (DMSO) or 102 (<b>143</b>) cells/sample/experiment for (D)]. Bars, means ± s.d., ***, <i>P</i> < 0.001 (unpaired two-tailed <i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Analysis of Pharmacokinetics</h3><div class="NLM_p last">To obtain metabolic stability information, the half-life of the selected compounds was determined in rat liver microsomes (RLMs) containing the NADPH-generating system, which permits CYP-mediated metabolic reactions.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Parallel artificial membrane permeability assay (PAMPA) permeability was measured using a high-throughput protocol, as reported.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Aqueous solubility was determined by a published procedure.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Most compounds tested showed a half-life of >30 min, indicating that they could be relatively stable in the CYP system. To further elucidate their metabolic pathway and to prioritize compounds for in vivo testing, several were selected as representative compounds from each group with different substitution patterns to characterize the metabolites that may be generated during incubation with CYP using mouse liver microsomes (MLMs). By inspection of the triazoloquinazolinone structures, they display a potential for CYP-mediated hydroxylation on the main quinazolinone aromatic ring as a preferred target. To our surprise, not only were the expected hydroxylated metabolites undetectable, but no other metabolites were produced in the CYP incubation system for most of the tested compounds. To further understand the metabolic pathways, similar MLM incubations of the selected compound set were conducted with uridine 5′-diphospho-glucuronic acid (UDPGA) as a cofactor to allow glucuronidation reactions. As shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Figure S1</a>, a new peak with 176 Da increase of the corresponding parent, which is a characteristic gain for a glucuronide, appeared for each of the tested compounds. It should be noted that for some of these compounds, two peaks with the MWs corresponding to one and two glucuronide additions were apparent, but for the remainder, only one peak appeared with the fragmentation pattern and MW representing a glucuronide. To characterize the glucuronidated site, the MS/MS analysis was performed to generate a fragment pattern for each of the glucuronides. Upon entering the source, however, the parent ions of the glucuronides fragmented into the daughter ions, which are generated from the parent ion, rather than giving a characteristic fragment to indicate the glucuronidation site (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Figure S2</a>). Examining the structure of these compounds, the thiocarbonyl S and the triazole ring secondary amine are two sites that could potentially be attacked by uridine 5′-diphospho-glucuronosyltransferase (UGT). Thus, it is highly likely that one of the two glucuronides was generated from the <i>S</i>-glucuronidation and the other from <i>N</i>-glucuronidation. Remarkably, a considerable amount of parent ion remained for the earlier-eluted glucuronides, while the parent ions of the later-eluted glucuronides almost completely fragmented. This is indicative of an <i>N</i>-glucuronide for the former and an <i>S</i>-glucuronide for the latter, given that the C–N bond linking the parent and the glucuronic acid in the former is much more stable than the corresponding C–S bond in the latter. In addition, only the <i>S</i>-glucuronide could be generated for the amide- or pyridine-containing compounds as the parent ions of their glucuronides were also completely fragmented. Thus, it is reasonable to hypothesize that the hydrogen-bonding capabilities of the amide- or pyridine-containing compounds may account for their altered glucuronidation profile where they interacted with UGT in a pattern from which <i>N</i>-glucuronidation was not favored. These results demonstrated that noncirculating metabolites other than the circulating products are expected to appear in vivo when these triazoloquinazolinones are administrated to mice.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Stability of Selected Compounds and Their Prodrugs in Mice</h3><div class="NLM_p">Despite the in vitro data suggesting that most analogues were stable in RLMs up to 30 min (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>), further assays were required to fully understand the stability in both in vitro and in vivo systems. Therefore, for selected compounds, additional microsome-based stability assays were performed to determine the major metabolites and class of enzymes responsible for the modifications. Several molecules including early hit-compounds (<b>23</b>, <b>46</b>) and compounds with submicromolar affinity (i.e., <b>65</b>, <b>79</b>, <b>83</b>, and <b>134</b>) were subjected to in vitro MLM assay. LC–MS/MS analysis revealed that glucuronidation is the major metabolite. Note that, in vitro glucuronidation resulted in two products, <i>S</i>- and <i>N</i>-glucuronides in varying amounts, which resulted in two glucuronidation peaks in LC-traces for some compounds (Figures S1 and S2, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). To mitigate this issue, the <i>S</i>-acetyl thioester prodrug <b>142</b> was made and found to be active but also toxic and rapidly cleaved by liver microsomes. The instability and toxicity of this compound was expected, given the reactivity of the <i>S</i>-acyl group toward electron-rich moieties. To confirm this hypothesis, a model reaction on <b>142</b> with ammonium acetate at pH 7.4 was performed, which resulted in efficient acyl transfer releasing the parent drug <b>21</b> (Figure S4, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). Therefore, to enhance the stability of prodrugs, our attention was turned to <i>S</i>-methyl thioether analogues (<b>143–145</b>), which exhibited anti-Plk1 PBD activity in HeLa cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Our analyses with two of these analogues (<b>143</b> and <b>144</b>) revealed that although they were stable in human, mouse, and rat cytosol with <i>t</i><sub>1/2</sub> values up to 120 min, unlike their parental <b>21</b> and <b>64</b>, they exhibited much shorter <i>t</i><sub>1/2</sub> values when reacted with the microsomes from the corresponding three species (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Table S2</a>). These findings suggest that the membrane-bound enzymes in the microsomes are mainly responsible for the metabolism of these prodrugs rather than the soluble cytosolic enzymes.</div><div class="NLM_p">The CYP-mediated reactions are the most likely metabolic pathways these prodrugs would undergo given the nature of the NADPH-containing microsome-based incubation system. To further identify the metabolites generated in the microsome reaction, <b>143</b> was incubated with MLMs for 1 h, and the resulting mixture processed and subjected to LC–MS/MS analysis (Figure S5A, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). As expected, CYP catalysis generated a hydroxylated product, which was further shown by MS/MS fragmentography to be hydroxylated on the main aromatic ring of the quinazolinone (Figure S5B, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). In addition, an S-demethylated metabolite, also mediated by CYP, was found, for which the structure was determined by comparing the fragmentation pattern with that of the parent drug, <b>21</b>. As demonstrated by the in vitro results of MLM-treated nonprodrugs (Figures S1 and S2, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>), a glucuronidation could also be expected for the demethylated product. To detect a subsequent glucuronidation, <b>143</b> was incubated in a mixed system containing both NADPH and UDPGA, the cofactor for UDP-glucuronosyltransferase. After MS analysis, glucuronidation of the demethylated metabolite was evidenced by the appearance of a new peak having a 176 Da increase compared to the demethylated product (Figure S5A, top, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p last">Next, to achieve a comprehensive understanding of the metabolic stability of the prodrugs, we performed the in vivo experiment by injecting <b>143</b> in mice [20 mg/kg, intraperitoneal (IP) injection] under a protocol approved by the National Cancer Institute Animal Care and Use Committee. During the whole period of the experiment, no signs of toxicity was observed under these conditions. Serum was collected at 15, 30, 60, 120, and 240 min after injection. In close agreement with in vitro results in <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Figure S5</a>, both the hydroxylated and demethylated products were detected in the serum ≥15 min postinjection (Figure S6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). While both metabolites decreased time-dependently, the demethylated product markedly increased in the serum ≥240 min postinjection (Figure S6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). A trace amount of the subsequent glucuronide of the demethylated metabolite was also seen in the serum as it could be promptly excreted from the liver to the bile, once generated, and can then undergo enterohepatic circulation through which the demethylated product is reabsorbed to the circulation. This could also serve as an explanation for the increased demethylated metabolite at the last time point. Compound <b>145</b> yielded similar metabolites with a somewhat improved <i>t</i><sub>1/2</sub> value of 51.26 min (Table S3 and Figure S6, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). These results illustrated that the prodrugs could release the corresponding parent drugs enzymatically, and the released parent drugs levels could be longer lasting because of an enterohepatic circulation. As the glucuronides are considered pharmacologically inactive, whether the hydroxylated metabolite could also interact with Plk1 to exert an inhibitory effect requires further investigation.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Antimitotic drugs, such as taxanes and vinca alkaloids, that are directed at inhibiting the dynamic function of microtubules (MTs), have proven to be effective in the treatment of cancer.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> However, given the significant side effects of these conventional anti-MT agents, targeting mitosis-specific and cancer cell-addicted Plk1 has been considered an attractive strategy for generating a cancer cell-selective therapeutic agent.<a onclick="showRef(event, 'ref3 ref20'); return false;" href="javascript:void(0);" class="ref ref3 ref20">(3,20)</a> Indeed, a large body of studies show that several Plk1 ATP-competitive inhibitors developed over the years exhibit significant activities against hematological malignancies<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55">(51−55)</a> and several advanced solid tumors,<a onclick="showRef(event, 'ref56 ref57 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref58 ref59 ref60">(56−60)</a> although their less-than-acceptable specificities and dose-limiting toxicities have hampered further clinical applications.</div><div class="NLM_p">PBD has emerged as an alternative target for developing a new class of Plk1 inhibitors that can potentially overcome the hurdles facing ATP-competitive inhibitors. As PBD inhibitors interfere only with the PBD-dependent Plk1 functions, they are anticipated to incur mitotic stress sufficient to induce cell death in cancer cells but not in normal cells.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Completely disrupting Plk1 function would be detrimental even for normal cell proliferation. While a high level of target specificity is one of the inherent advantages that PPI inhibitors can achieve, the primary challenge has been developing small (<500 Da) molecules that still exhibit high affinity to the shallow and often nondescript interface of a target PPI.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> Because of this difficulty, most of the purported PBD inhibitors reported to date exhibit a poor (IC<sub>50</sub> of 50–1000 μM) anti-Plk1 activity in cell-based assays.<a onclick="showRef(event, 'ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35">(28−35)</a> In addition, many of these compounds appear to exhibit cross-reacting alkylating activities<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> that could impose dose-limiting nonspecific cytotoxicity.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> SAR Summary</h3><div class="NLM_p">The overall conclusions of our SAR studies are summarized in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Our SAR studies identified six analogues which showed submicromolar affinity (<b>65</b>, <b>79</b>, <b>83</b>, <b>85</b>, <b>129</b>, and <b>134</b>), which is at least an order of magnitude more potent than the previously characterized Plk1 PBD-specific phosphopeptide, PLHSpT <b>6a</b> (<i>K</i><sub>d</sub> ∼450 nM). All the six compounds appeared to share two distinct features: (1) 7-F substitution in zone 1 and (2) an unsubstituted triazole (zone 5). These are distinct because in our initial analogues exploring zone 1, there was no obvious preference for the 7-substitution. Then, when we combined early zone 1 and zone 3/4 modification unsubstituted triazoles, the fluorine was not obviously the preferred group. The inactivity of thiourea-containing analogue <b>62</b> and preference for an intact triazole indicated that a π-stacking interaction rather than H-bonding of the free NH is the important interaction. In addition, five of the six analogues contained zone 4 groups that could form H-bonding interactions, either CF<sub>3</sub> (<b>65</b>), pyridine (<b>83</b>, <b>85</b>), or amides and an additional H-bond acceptor (HBA) (<b>129</b>, <b>134</b>). All five of these analogues contain HBA in positions that would all be in the same general region of the binding pocket. Compounds <b>129</b> and <b>134</b> have methoxy and cyano groups that might interact in adjacent regions of the pocket. The only submicromolar analogue that did not have additional H-bonding capabilities, that is, the methyl cyclopropane zone 3/4 analogue (<b>79</b>), might still establish stabilizing hydrophobic interactions.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Summary of SAR studies on a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one scaffold for inhibition of Plk1 PBD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Absorption distribution metabolism excretion (ADME) data were compared for the six most potent analogues (<b>65</b>, <b>79</b>, <b>83</b>, <b>85</b>, <b>129</b>, and <b>134</b>). Five of the six analogues had half-lives of >30 min in RLMs, and the sixth (<b>129</b>) had a fairly good (20.1 min) half-life (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Tables <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Notably, the PAMPA permeability at pH 7.4 was favorable for six compounds (<b>65</b>, <b>83</b>, <b>129</b>, and <b>134</b>) with moderate to good permeability (100 to >200 × 10<sup>–6</sup> cm/s). However, only three analogues (<b>65</b>, <b>79</b>, and <b>129</b>) showed moderate to good solubility (10 to >60 μg/mL). Only compound <b>129</b> displayed both good permeability and solubility (<i>P</i> = 311 × 10<sup>–6</sup> cm/s, <i>S</i> >65 μg/mL) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Despite its relatively shorter half-life than other analogues, <b>129</b> may represent the best balance of PLK1 PBD affinity and ADME properties.</div><div class="NLM_p">Some regions of the scaffold tolerated broad structural modification, while a few did not. In zone 1, interdependence on the groups in zones 3 and 4 defined the preferred substitution. This suggests that the core (zones 1, 2, and the quinazolinone) binding region might have been unfilled to allow for flexibility in the binding pose of molecules with various zone 1 substitutions. However, for the best analogues, the 7-position with a small H-bonding group is preferred; larger groups are tolerated but only with additional HBA groups. Zone 2 did not tolerate modification; the phenyl ring was optimal. Zones 3 and 4 proved to be the most generally amenable to modification. When zone 4 was cyclic, the linker length was best unmodified; however, when zone 4 was acyclic (an alkyl chain, a heteroatom, or another functional group), the entire chain could contain two or three carbons. This linker could also be sterically restricted with a <i>trans</i> cyclopropane, but this conclusion may not apply to all analogues differing in zone 4. In zone 4, removal and replacement of the phenyl group with unsubstituted heteroaryl groups was well tolerated, as was replacement with amides, especially for phenylacetyl derivatives. However, beyond the amide, hydrophilic or negatively charged moieties were disfavored. This extreme difference in affinity between phosphorus derivatives <b>77</b> and <b>78</b> and the other heteroatom-containing analogues could be due to the much larger size of these groups or the highly negatively charged phosphonic acid <b>77</b> at physiological pH.</div><div class="NLM_p">All three nitrogen atoms of the triazole played an important role in binding, and alkylation of the triazole NH but not the S was accommodated. The tertiary amine substituents in <b>35–38</b> likely reside in a region that was formerly not accessed by the scaffold and therefore can establish new interactions, allowing for the improvement in affinity. The reason for the inactivity of N-substituted triazole analogue <b>39</b> is undetermined tertiary amines can form salt bridges, which ketones cannot form, and this could account for the potency differences. The difference could be due to either electrostatic or steric interactions (the acetophenone group in <b>39</b> is both larger and less flexible than the tertiary amines <b>35–38</b>). Given that both tertiary amines and carbonyl oxygens can form H-bonding interactions, H-bonding may not account for the significant affinity difference.</div><div class="NLM_p">The results provided here suggest that a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one scaffold offers promising structural and chemical features that can be exploited for anti-Plk1 PBD drug discovery. While the triazole moiety is one of the main components of antifungal drugs widely used for the prophylaxis and treatment of invasive fungal disease,<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> the quinazoline moiety is frequently found in several FDA-approved EGFR or HER2 inhibitors, such as gefitinib, erlotinib, lapatinib, afatinib, and vandetanib.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> As these approved drugs have been extensively tested in humans for safety, available information from their prior clinical trials could facilitate further development of the above-described triazoloquinazolinone-based Plk1 PBD inhibitors. Drugs containing the conjoined triazoloquinazolinone backbone have not yet been reported in the drug depository (Drugbank; <a href="https://www.drugbank.ca/" class="extLink">https://www.drugbank.ca/</a>), indicating the uniqueness of the current triazoloquinazolinone leads. Remarkably, unlike previously reported several Plk1 PBD inhibitors with unacceptable alkylating activities,<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> the identified triazoloquinazolinone chemotype does not bear any hallmark structural features that could be a reactive liability. In addition, triazoloquinazolinone-based compounds generally remain inert in multiple inhibitor screenings<a onclick="showRef(event, 'ref66 ref67 ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68 ref69">(66−69)</a> and specific modifications, such as a methyl group at <i>N</i>-3 of the quinazolinone lead, are required to induce biological efficacy.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> These chemical properties suggest a lower likelihood of off-target effects when dosed. In fact, potential off-target interactions for the initial hit, <b>7</b>, and three other high-affinity compounds (<b>21</b>, <b>68</b>, and <b>127</b>) were not detected at 10 μM, when they were screened at 45 receptors and channels by the National Institute of Mental Health Psychoactive Drug Screening Program (<a href="https://pdsp.unc.edu/pdspweb/" class="extLink">https://pdsp.unc.edu/pdspweb/</a>) using standard radioligand binding and functional assay methods.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> The only hits among these compounds at 10 μM causing >50% binding inhibition were for the primary amine <b>68</b> at M<sub>3</sub> (100%), M<sub>4</sub> (73%), and M<sub>5</sub> (84%) muscarinic acetylcholine receptors. Thus, there was no pharmacological promiscuity observed for these four representative analogues.</div><div class="NLM_p last">The low MWs (300–450 Da) of several promising triazoloquinazolinone-based inhibitors described here offer considerable room for optimizations. Our extensive SAR analyses revealed distinct patterns (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) that could serve as a roadmap for further development. Notably, the ELISA-based IC<sub>50</sub> values for several compounds (<b>65</b>, <b>79</b>, <b>83</b>, <b>85</b>, <b>129</b>, and <b>134</b>) reached <1 μM. As the previously characterized Plk1 PBD-binding PLHSpT <b>6a</b> (<i>K</i><sub>d</sub> of ∼450 nM)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> shows an IC<sub>50</sub> of 14.74 μM under the same conditions, these compounds are expected to have at least an order-of-magnitude-higher affinity than <b>6a</b>. Moreover, the superb Plk1 PBD specificity of triazoloquinazolinone-derived inhibitors (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) along with the cellular efficacy of multiple prodrugs (<b>143</b>, <b>144</b>, and <b>145</b>) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) provides clear proof-of-principle evidence that intervene in the Plk1 PBD-mediated PPI is feasible with small drug-like compounds amenable for potential clinical applications.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions and Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In this study, we used a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one scaffold to synthesize <i>S</i>-methyl prodrugs that effectively inhibit PBD-dependent Plk1 function in cultured cells. Further development of these inhibitors may yield a new class of Plk1 PBD inhibitors that could offer superb specificity with versatile applicability either as a single agent or as a part of combination chemotherapy. Combination therapeutic regimens with various chemotherapeutic agents, including cisplatin, cytarabine, methotrexate, and doxorubicin, have already shown an improved antitumor activity with Plk1’s ATP-competitive inhibitors in numerous studies.<a onclick="showRef(event, 'ref52 ref54 ref73 ref74 ref75 ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref52 ref54 ref73 ref74 ref75 ref76 ref77">(52,54,73−77)</a> In addition, as the most advanced ATP-competitive inhibitor <b>1</b><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> was doomed in phase III clinical trials because of its less-than-acceptable tolerability, combination treatment strategy with this inhibitor may allow to achieve the synergistic anti-Plk1 efficacy without causing the dose-limiting toxicity that narrowed their therapeutic windows. As a promising avenue for anti-Plk1 drug discovery, PBD inhibitors may prove to be effective in overcoming the hurdles facing current anti-Plk1 therapy and improving clinical outcomes.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemical Synthesis</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Methods for Chemistry</h4><div class="NLM_p last">All reactions were carried out under the nitrogen atmosphere using anhydrous solvents. All moisture-sensitive reactions were also performed with oven-dried glassware. Chemical reagents and anhydrous solvents were obtained from commercial sources and used as-is. Room temperature or rt refers to 25 ± 2 °C. Preparative purification was performed on a Waters semipreparative HPLC equipment. The column used was a Phenomenex Luna C18 (5 μm, 30 × 75 mm) at a flow rate of 45 mL/min. The mobile phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic acid). A gradient of 10–50% acetonitrile over 8 min was used during the purification. Fraction collection was triggered by UV detection (220 nm). Initial analytical analysis during compound synthesis was performed on an Agilent 1200 LC–MS system (Agilent Technologies) using a 3-min gradient of 4–100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used with an 8-min run time at a flow rate of 1 mL/min. The purity of compounds newly synthesized was demonstrated on an Agilent 1200 LC–MS system (Agilent Technologies) using a 7-min linear gradient of 4–100% acetonitrile (containing 0.025% trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) followed by a 4.5 min run time at a flow rate of 1 mL/min and a Phenomenex Luna C18 column (3 μm, 3 × 75 mm) at 50 °C. The purity of the purchased compounds was determined using an Agilent ZORBAX Eclipse XDB C18 column (5 mm, 4.6 × 250 mm) with a linear gradient of 5–95% acetonitrile in water (containing 10 mM triethylammonium acetate) for 20 min at a flow rate of 1.0 mL/min. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on either a Varian 400 (100) MHz spectrometer or a Bruker 400 MHz spectrometer. Chemical shifts are given in ppm (δ), calibrated to the residual solvent signals and frequency calibrated internally by solvent for <sup>19</sup>F NMR (BrukerTopspin/MestReNova 10.0.2 or 14.1.0). High-resolution mass spectrometry was recorded on either an Agilent 6210 time-of-flight LCMS system or a Waters Micromass spectrometer equipped with a standard electrospray ionization (ESI) and modular LockSprayTM interface. The purity of all the tested compounds (including both newly synthesized and purchased, active compounds) were demonstrated to be >95% at 254 nm, except commercially procured compound <b>58</b>, which was 93.5% pure. The synthesis of compounds <b>7–64</b> is described in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_002.csv" class="ext-link">Supporting information</a>.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0026.gif" alt="" id="dgr1" /></img></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedure A</h4><div class="NLM_p last">To a solution of appropriate 2-aminobenzoic acid (1 equiv) and isothiocyanate (1.2 equiv) in EtOH (0.37 M) was added triethylamine (1.2 equiv). The reaction was stirred at 80 °C for 1–2 h. The reaction was cooled to room temperature (RT) and diluted with water. The solid (intermediate A) was filtered and dried under vacuum and used without further purification.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0027.gif" alt="" id="dgr2" /></img></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Procedure B</h4><div class="NLM_p last">A solution of isatoic anhydride (1 equiv) in acetonitrile (0.67 M) was added to the amine (1.5 equiv). In the case of amine salts, triethylamine (1.5 equiv) was added to a solution of the amine in acetonitrile (0.67 M), the salt was removed by filtration, and the free based amine solution was added to the reaction. The reaction was heated at 50 °C for 30 min. The reaction was cooled to RT and carbon disulfide (7 equiv) was added cold. The reaction was then heated to 120 °C for 45 min. The reaction was diluted with Et<sub>2</sub>O, filtered, rinsed with Et<sub>2</sub>O, and dried. The solid (intermediate A) was dried under vacuum and used without further purification.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0028.gif" alt="" id="dgr3" /></img></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure C</h4><div class="NLM_p last">A solution of isatoic anhydride (1 equiv) in acetonitrile (0.67 M) was added to the amine (1.5 equiv). In the case of amine salts, triethylamine (1.5 equiv) was added to a solution of the amine in acetonitrile (0.67 M), the salt was removed by filtration, and the free based amine solution was added to the reaction. The reaction was heated at 60 °C for 3 h. The reaction was concentrated and the residue dissolved in EtOH (0.67 M), and aq KOH (1.2 equiv) was added, followed by carbon disulfide (2 equiv). The reaction was then heated to 120 °C for 2 h. The reaction was cooled to RT, diluted with water, and washed with Et<sub>2</sub>O. The solid (intermediate A) was dried under vacuum and used without further purification.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0029.gif" alt="" id="dgr4" /></img></div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure D</h4><div class="NLM_p last">To a solution of intermediate A (1 equiv) in EtOH (0.25–0.35 M) was added hydrazine (7 equiv). The reaction was then heated to 80 °C for 4 h. The reaction was then cooled to RT and pyridine (10 equiv) and carbon disulfide (10 equiv) were added. The reaction was heated to 80 °C for 1–2 h. The reaction was poured into cold water, and the product was filtered and washed with water or purified by HPLC.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0030.gif" alt="" id="dgr5" /></img></div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Procedure E</h4><div class="NLM_p last">To a solution of intermediate A (1 equiv) in EtOH (0.35 M) was added water (2.8 equiv), followed by hydrazine (7 equiv). The reaction was then heated to 80 °C for 4 h. The reaction was then poured into cold water and concentrated. The crude material was purified on a Teledyne ISCO CombiFlash System by (dry-loading) (EtOAc/DCM: 0–3%) to give intermediate B.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0031.gif" alt="" id="dgr6" /></img></div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure F</h4><div class="NLM_p">To a solution of carboxylic acid (1.5 equiv) in DMF (0.2 M) was added COMU (1.5 equiv) and the reaction stirred at RT for 30–45 min. Then, the amine (1 equiv) was added, followed by DIPEA (2.2 equiv). The reaction was then stirred for 18 h or 2.5 d at RT. The crude material was purified by HPLC.</div><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 4-Phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>7</b>)</h5><div class="NLM_p">Note: Compound <b>7</b> previously appeared as an in silico hit in a screen for A<sub>2A</sub> adenosine receptor antagonists {compound <b>30</b> in PMC2865168}.</div><div class="NLM_p">2-Amino-<i>N</i>-phenethylbenzamide: A mixture of methylanthranilate (0.856 mL, 6.615 mmol) and phenethylamine (1.3 mL, 10 mmol) was stirred in a round-bottom flask at 190 °C for 5 h. The product was purified by silica-gel column chromatography (0.44 g, 28%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.40–7.14 (m, 6H), 6.68 (dd, <i>J</i> = 1.1, 8.1 Hz, 1H), 6.62 (ddd, <i>J</i> = 1.2, 7.2, 8.1 Hz, 1H), 6.06 (s, 1H), 5.49 (s, 2H), 3.70 (td, <i>J</i> = 5.8, 6.8 Hz, 2H), 2.94 (t, <i>J</i> = 6.9 Hz, 2H); HRMS: (M + H) for C<sub>15</sub>H<sub>16</sub>N<sub>2</sub>O calcd 241.1341; found, 241.1339.</div><div class="NLM_p">3-Phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one: Route 1: To a solution of 2-amino-<i>N</i>-phenethylbenzamide (100 mg, 0.416 mmol) in anhydrous DMF (2 mL) at RT was added carbon disulfide (72 μL, 1.248 mmol) and DBU (136 μL, 0.916 mmol) sequentially. After stirring the reaction mixture for 18 h at RT, cold 1 N aq HCl was added with vigorous stirring. The precipitate was collected by filtration, washed with cold water and hexanes, and dried to afford a practically pure product (60 mg, 50%). Route 2: To a solution of 2-amino-<i>N</i>-phenethylbenzamide (100 mg, 0.416 mmol) in anhydrous ethanol (2 mL) at RT were added carbon disulfide (75 μL, 1.25 mmol) and solid KOH (32 mg, 0.916 mmol) sequentially. The reaction mixture was stirred at 80 °C for 18 h at RT, cooled, and was added to a cold 1 N aq HCl with vigorous stirring. The precipitate was collected by filtration, washed with cold water and hexanes, and dried to afford a practically pure product (70 mg, 60%). Note: The product was purified further by silica-gel column chromatography using 0–2% methanol in dichloromethane as an eluent. The purified product gave better yield in the next step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.99 (s, 1H), 8.25–8.10 (m, 1H), 7.69 (ddd, <i>J</i> = 1.5, 7.3, 8.4 Hz, 1H), 7.45–7.40 (m, 2H), 7.38–7.32 (m, 2H), 7.27 (d, <i>J</i> = 5.6 Hz, 1H), 7.13 (dt, <i>J</i> = 0.7, 8.2 Hz, 1H), 4.82–4.65 (m, 2H), 3.19–3.07 (m, 2H); HRMS: (M + H) for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>OS calcd, 283.0905; found, 283.0909.</div><div class="NLM_p">2-Hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one: To a suspension of 3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one (200 mg, 0.708 mmol) in anhydrous ethanol (5 mL) was added anhydrous hydrazine (0.33 mL, 10.62 mmol) and heated at 85 °C for 18 h. The volatiles were evaporated under high vacuum, followed by coevaporation with toluene (2×), giving 2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one as a yellow solid and was used as such without further purification (200 mg, quantitative). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.16 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H), 7.68–7.56 (m, 1H), 7.45–7.14 (m, 5H), 4.21 (dd, <i>J</i> = 6.7, 8.4 Hz, 2H), 3.09–2.99 (m, 1H); HRMS: (M + H) for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O calcd, 281.1402; found, 281.1405.</div><div class="NLM_p last">4-Phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one: 2-Hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one (200 mg, 0.713 mmol) was dissolved in anhydrous ethanol (10 mL). To the solution was added carbon disulfide (0.13 mL, 2.14 mmol), followed by solid KOH (120 mg, 2.14 mmol), and it was heated to 80 °C for 18 h. The reaction mixture was cooled and poured into cold 1 N aq HCl solution. The precipitates were collected and purified by silica-gel column chromatography using 0–2% methanol in dichloromethane as an eluent to afford a pure product as a white solid (200 mg, 87%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.10 (s, 1H), 10.23 (dd, <i>J</i> = 1.1, 8.6 Hz, 1H), 8.22 (dd, <i>J</i> = 1.6, 7.9 Hz, 1H), 7.91 (ddd, <i>J</i> = 1.7, 7.3, 8.7 Hz, 1H), 7.62 (td, <i>J</i> = 1.1, 7.6 Hz, 1H), 7.38–7.15 (m, 4H), 4.32–4.15 (m, 2H), 3.08–2.92 (m, 2H); HRMS: (M + H) for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>OS, calcd 323.0967; found, 323.0966.</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 4-Phenethyl-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-1,5-dione (<b>15</b>)</h5><div class="NLM_p last">2-Hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one (35 mg, 0.117 mmol) was suspended in anhydrous toluene (2 mL), and to it was added carbonyl diimidazole (22 mg, 0.135 mmol) and heated to reflux (115 °C) for 1.5 h. The volatiles evaporated under vacuum and the residue was treated with 1 N aq HCl and 5% isopropanol-dichloromethane. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, evaporated, and the residue was purified by silica-gel column chromatography to afford <b>7b</b> as a white solid (13 mg, 34%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.07 (s, 1H), 8.65 (dd, <i>J</i> = 4.6, 9.1 Hz, 1H), 7.84 (dd, <i>J</i> = 3.0, 8.6 Hz, 1H), 7.75 (td, <i>J</i> = 3.1, 8.7 Hz, 1H), 7.35–7.19 (m, 4H), 4.26–4.05 (m, 2H), 3.08–2.92 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.33 (td, <i>J</i> = 4.5, 8.1 Hz); HRMS: (M + H) for C<sub>17</sub>H<sub>13</sub>N<sub>4</sub>O<sub>2</sub>F calcd, 325.1101; found, 325.1107.</div></div><div id="sec5_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 1-Amino-7-fluoro-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>16</b>)</h5><div class="NLM_p last">6-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. 6-Fluoro-2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one was synthesized according to General Procedure E. Then, to a solution of 6-fluoro-2-hydrazinyl-3-phenethylquinazolin-4(3<i>H</i>)-one (0.1 g, 0.335 mmol) and cyanogen bromide (0.036 g, 0.335 mmol) in ethanol (16.8 mL) was added sodium hydroxide (0.067 g, 1.675 mmol) and the reaction was stirred at RT for 3 h. The reaction was neutralized with sat. NaHCO<sub>3</sub> and the solid filtered. The solid was redissolved and purified by HPLC to give 1-amino-7-fluoro-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one, 2 TFA: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.29 (dd, <i>J</i> = 9.2, 4.2 Hz, 1H), 7.92 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.82 (td, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.34–7.24 (m, 4H), 7.22 (d, <i>J</i> = 7.0 Hz, 1H), 6.90 (s, 2H), 4.29 (dd, <i>J</i> = 9.5, 6.5 Hz, 2H), 3.06–2.98 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −114.22; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>15</sub>FN<sub>5</sub>O (M + H), 324.1255; found, 324.1264.</div></div><div id="sec5_1_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 7-Fluoro-1-methyl-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>17</b>)</h5><div class="NLM_p last">6-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. 6-Fluoro-2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one was synthesized according to General Procedure E. Then, 6-fluoro-2-hydrazinyl-3-phenethylquinazolin-4(3<i>H</i>)-one (0.1 g, 0.335 mmol) was stirred in Ac<sub>2</sub>O (16.8 mL) at 100 °C for 5 h. The reaction was concentrated, filtered, and washed with water. The solid was dried and crystallized from EtOH to give 7-fluoro-1-methyl-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (0.0453 g, 42%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.11 (dd, <i>J</i> = 9.2, 4.2 Hz, 1H), 7.95 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.2, 8.0, 3.1 Hz, 1H), 7.29 (td, <i>J</i> = 9.0, 8.4, 6.1 Hz, 4H), 7.21 (td, <i>J</i> = 6.5, 2.2 Hz, 1H), 4.42–4.33 (m, 2H), 3.08–2.99 (m, 2H), 2.84 (s, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −114.29 (td, <i>J</i> = 8.2, 4.0 Hz).</div></div><div id="sec5_1_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 7-Fluoro-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>18</b>)</h5><div class="NLM_p last">6-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. 6-Fluoro-2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one was synthesized according to General Procedure E. Then, 6-fluoro-2-hydrazinyl-3-phenethylquinazolin-4(3<i>H</i>)-one (0.1 g, 0.335 mmol) was stirred in formic acid (16.8 mL) at 100 °C for 5 h. The reaction was concentrated, redissolved, and purified by HPLC to give 7-fluoro-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one, TFA: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.50 (s, 1H), 8.27 (dd, <i>J</i> = 8.8, 4.3 Hz, 1H), 7.89 (ddd, <i>J</i> = 11.0, 7.1, 3.9 Hz, 2H), 7.34–7.25 (m, 4H), 7.25–7.17 (m, 1H), 4.37 (dd, <i>J</i> = 9.2, 6.8 Hz, 2H), 3.09–3.01 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.78 (td, <i>J</i> = 8.3, 4.1 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>4</sub>O (M + H), 309.1146; found, 309.1155.</div></div><div id="sec5_1_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 1-(Methylthio)-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>19</b>)</h5><div class="NLM_p last">3-Phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D. Then, 1-(methylthio)-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one was synthesized as follows: to a solution of 4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(<i>1H</i>)-one (0.092 g, 0.223 mmol) in DMF (1.113 mL) was added K<sub>2</sub>CO<sub>3</sub> (0.037 g, 0.267 mmol) and MeI (0.017 mL, 0.267 mmol). The reaction was quenched with methanol and concentrated. The reaction was stirred for 3 h and quenched with methanol. The crude mixture was concentrated and purified by HPLC to give 1-(methylthio)-4-phenethyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one, TFA.</div></div><div id="sec5_1_7_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 4-Ethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>20</b>)</h5><div class="NLM_p last">3-Ethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-ethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.20 (d, <i>J</i> = 8.5 Hz, 1H), 8.20 (d, <i>J</i> = 7.8 Hz, 1H), 7.87 (t, <i>J</i> = 8.0 Hz, 1H), 7.59 (t, <i>J</i> = 7.7 Hz, 1H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 1.23 (t, <i>J</i> = 7.2 Hz, 3H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>10</sub>N<sub>4</sub>NaOS (M + Na), 269.0468; found, 269.0476.</div></div><div id="sec5_1_7_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 4-Propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>21</b>)</h5><div class="NLM_p last">4-Propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 4-Allyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>22</b>)</h5><div class="NLM_p last">4-Allyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 4-Butyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>23</b>)</h5><div class="NLM_p last">4-Butyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 4-Pentyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>24</b>)</h5><div class="NLM_p last">4-Pentyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 4-Isopentyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>25</b>)</h5><div class="NLM_p last">4-Isopentyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 4-Isopropyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>26</b>)</h5><div class="NLM_p last">4-Isopropyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 1-Thioxo-4-(3,3,3-trifluoropropyl)-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>27</b>)</h5><div class="NLM_p last">2-Thioxo-3-(3,3,3-trifluoropropyl)-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 1-thioxo-4-(3,3,3-trifluoropropyl)-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.19 (d, <i>J</i> = 8.5 Hz, 1H), 8.21 (d, <i>J</i> = 7.8 Hz, 1H), 7.90 (t, <i>J</i> = 8.1 Hz, 1H), 7.61 (t, <i>J</i> = 7.7 Hz, 1H), 4.25 (t, <i>J</i> = 7.3 Hz, 2H), 2.72 (dt, <i>J</i> = 11.5, 7.4 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −64.31 (t, <i>J</i> = 11.3 Hz).</div></div><div id="sec5_1_7_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 4-(3-Methoxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>28</b>)</h5><div class="NLM_p last">4-(3-Methoxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 4-(3-Ethoxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>29</b>)</h5><div class="NLM_p last">4-(3-Ethoxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> <i>N</i>-(<i>sec</i>-Butyl)-3-(5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propenamide (<b>30</b>)</h5><div class="NLM_p last"><i>N</i>-(<i>sec</i>-Butyl)-3-(5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propenamide was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>N</i>-Isopropyl-3-(5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propenamide (<b>31</b>)</h5><div class="NLM_p last"><i>N</i>-Isopropyl-3-(5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propenamide was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>N</i>-Isobutyl-3-(5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propenamide (<b>32</b>)</h5><div class="NLM_p last"><i>N</i>-Isobutyl-3-(5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propenamide was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 4-(2,3-Dimethylphenyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>33</b>)</h5><div class="NLM_p last">4-(2,3-Dimethylphenyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 4-(4-Fluorobenzyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>34</b>)</h5><div class="NLM_p last">4-(4-Fluorobenzyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 2-((Cyclopropyl(methyl)amino)methyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>35</b>)</h5><div class="NLM_p last">2-((Cyclopropyl(methyl)amino)methyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 4-Methyl-2-((methyl(propyl)amino)methyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>36</b>)</h5><div class="NLM_p last">4-Methyl-2-((methyl(propyl)amino)methyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 2-((Methyl(propyl)amino)methyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>37</b>)</h5><div class="NLM_p last">2-((Methyl(propyl)amino)methyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 2-(((Cyclopropylmethyl) (ethyl)amino)methyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>38</b>)</h5><div class="NLM_p last">2-(((Cyclopropylmethyl) (ethyl)amino)methyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from Enamine (Monmouth Jct., NJ).</div></div><div id="sec5_1_7_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 2-(2-Oxo-2-phenylethyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>39</b>)</h5><div class="NLM_p last">2-(2-Oxo-2-phenylethyl)-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 7-Fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>40</b>)</h5><div class="NLM_p">2-Amino-5-fluoro-<i>N</i>-phenethylbenzamide: To a solution of 2-amino-5-fluorobenzoic acid (250 mg, 1.61 mmol), phenethylamine (0.243 mL, 1.93 mmol), dimethylaminopyridine (100 mg, 0.81 mmol), and triethylamine (0.45 mL, 3.22 mmol) in anhydrous dichloromethane (5 mL) was added EDC·HCl (370 mg, 1.93 mmol) and stirred at RT for 18 h. Saturated aq NaHCO<sub>3</sub> solution and dichloromethane were added and stirred. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated under reduced pressure. The residue obtained was purified by silica-gel chromatography to afford the desired product as a white solid (200 mg, 48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.36 (t, <i>J</i> = 7.3 Hz, 2H), 7.27 (q, <i>J</i> = 6.7, 7.6 Hz, 3H), 6.96 (td, <i>J</i> = 2.9, 8.4 Hz, 1H), 6.89 (dd, <i>J</i> = 2.8, 9.2 Hz, 1H), 6.64 (dd, <i>J</i> = 4.6, 9.0 Hz, 1H), 6.01 (s, 1H), 5.24 (s, 2H), 3.69 (q, <i>J</i> = 6.6 Hz, 2H), 2.94 (t, <i>J</i> = 6.9 Hz, 2H); <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −111.91; HRMS: (M + H) for C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>OF calcd, 259.1247; found, 259.1247.</div><div class="NLM_p">6-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one: To a solution of 2-amino-5-fluoro-<i>N</i>-phenethylbenzamide (100 mg, 0.387 mmol) in anhydrous DMF (2 mL) at RT was added carbon disulfide (70 μL, 1.16 mmol) and DBU (127 μL, 0.851 mmol) sequentially. After stirring the reaction mixture for 18 h at RT, cold 1 N aq HCl was added with vigorous stirring. The precipitate was collected by filtration, washed with cold water and hexanes, and dried to give a white solid (110 mg, 95%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.94 (s, 1H), 7.82 (dd, <i>J</i> = 2.9, 8.1 Hz, 1H), 7.40 (d, <i>J</i> = 7.7 Hz, 3H), 7.35 (t, <i>J</i> = 7.3 Hz, 1H), 7.27 (d, <i>J</i> = 4.9 Hz, 2H), 7.19–7.03 (m, 1H), 4.74 (dd, <i>J</i> = 6.4, 10.2 Hz, 2H), 3.11 (t, <i>J</i> = 8.3 Hz, 2H); <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −114.59; HRMS: (M + H) for C<sub>16</sub>H<sub>13</sub>N<sub>2</sub>OSF calcd, 301.0811; found, 301.0813.</div><div class="NLM_p">6-Fluoro-2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one: Following the procedure mentioned for the synthesis of 2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one, 6-fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one (110 mg, 0.366 mmol) gave product 6-fluoro-2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one as a white solid (80 mg, 73%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (dt, <i>J</i> = 1.9, 8.5 Hz, 1H), 7.41–7.20 (m, 8H), 4.20 (t, <i>J</i> = 7.4 Hz, 2H), 3.04 (t, <i>J</i> = 7.4 Hz, 2H); <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −117.99 (td, <i>J</i> = 4.8, 8.3 Hz); HRMS: (M + H) for C<sub>16</sub>H<sub>15</sub>N<sub>4</sub>OF calcd, 299.1308; found, 299.1307.</div><div class="NLM_p last">7-Fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one: Following the procedure described for the synthesis of 4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, 6-fluoro-2-hydrazineyl-3-phenethylquinazolin-4(3<i>H</i>)-one (50 mg, 0.168 mmol) gave product 7-fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one as a white solid (20 mg, 35%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.16 (s, 1H), 10.31 (dd, <i>J</i> = 4.7, 9.3 Hz, 1H), 7.93 (dd, <i>J</i> = 3.1, 8.6 Hz, 1H), 7.83 (td, <i>J</i> = 3.1, 8.6 Hz, 1H), 7.27 (ddt, <i>J</i> = 7.3, 14.2, 19.9 Hz, 4H), 4.34–4.15 (m, 2H), 3.09–2.93 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.99 (td, <i>J</i> = 4.7, 8.3 Hz); HRMS: (M + H) for C<sub>17</sub>H<sub>13</sub>N<sub>4</sub>OSF calcd, 341.0872; found, 341.0871.</div></div><div id="sec5_1_7_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 7-Bromo-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(<i>1H</i>)-one (<b>41</b>)</h5><div class="NLM_p last">6-Bromo-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(<i>1H</i>)-one was synthesized according to General Procedure A. Then, 7-bromo-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.17 (d, <i>J</i> = 9.1 Hz, 1H), 8.25 (d, <i>J</i> = 2.4 Hz, 1H), 8.11 (dd, <i>J</i> = 9.0, 2.5 Hz, 1H), 7.34–7.17 (m, 5H), 4.25–4.17 (m, 2H), 3.02–2.94 (m, 2H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>4</sub>OS (M + H), 403.0046; found, 403.0046.</div></div><div id="sec5_1_7_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 7-Iodo-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>42</b>)</h5><div class="NLM_p last">6-Iodo-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 7-iodo-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.00 (d, <i>J</i> = 8.8 Hz, 1H), 8.41 (d, <i>J</i> = 2.1 Hz, 1H), 8.24 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.32–7.18 (m, 5H), 4.24–4.16 (m, 2H), 3.02–2.93 (m, 2H).</div></div><div id="sec5_1_7_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 7-Methyl-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>43</b>)</h5><div class="NLM_p last">6-Methyl-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 7-methyl-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.06 (d, <i>J</i> = 8.6 Hz, 1H), 8.02–7.97 (m, 1Hl), 7.71 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 7.33–7.16 (m, 5H), 4.26–4.18 (m, 2H), 3.03–2.94 (m, 2H), 2.44 (s, 3H).</div></div><div id="sec5_1_7_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>-(5-Oxo-4-phenethyl-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-7-yl)acetamide (<b>44</b>)</h5><div class="NLM_p last"><i>N</i>-(4-Oxo-3-phenethyl-2-thioxo-1,2,3,4-tetrahydroquinazolin-6-yl)acetamide was synthesized according to General Procedure A. Then, <i>N</i>-(5-oxo-4-phenethyl-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-7-yl)acetamide was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.37 (s, 1H), 10.09 (d, <i>J</i> = 9.1 Hz, 1H), 8.51 (d, <i>J</i> = 2.6 Hz, 1H), 7.96 (dd, <i>J</i> = 9.1, 2.7 Hz, 1H), 7.26 (ddd, <i>J</i> = 19.6, 13.5, 7.3 Hz, 5H), 4.22 (dd, <i>J</i> = 9.4, 6.5 Hz, 2H), 2.99 (t, <i>J</i> = 7.9 Hz, 2H), 2.48 (t, <i>J</i> = 3.0 Hz, 2H), 2.08 (s, 3H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>18</sub>N<sub>5</sub>O<sub>2</sub>S (M + H), 380.1176; found, 380.1174.</div></div><div id="sec5_1_7_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 7-(Dimethylamino)-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>45</b>)</h5><div class="NLM_p last">6-(Dimethylamino)-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 7-(dimethylamino)-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.92 (s, 1H), 9.98 (d, <i>J</i> = 9.3 Hz, 1H), 7.33 (d, <i>J</i> = 3.1 Hz, 1H), 7.32–7.16 (m, 6H), 4.26–4.18 (m, 2H), 2.99 (s, 6H), 3.00–2.94 (m, 2H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>20</sub>N<sub>5</sub>OS (M + H), 366.1383; found, 366.1388; purity (HPLC) 94.83%.</div></div><div id="sec5_1_7_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 7-Morpholino-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>46</b>)</h5><div class="NLM_p last">6-Morpholino-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 7-morpholino-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.97 (s, 1H), 10.02 (d, <i>J</i> = 9.3 Hz, 1H), 7.57 (d, <i>J</i> = 3.0 Hz, 1H), 7.53 (dd, <i>J</i> = 9.3, 3.0 Hz, 1H), 7.31–7.17 (m, 5H), 4.26–4.18 (m, 2H), 3.76 (t, <i>J</i> = 4.8 Hz, 4H), 3.22 (dd, <i>J</i> = 6.1, 3.6 Hz, 4H), 3.02–2.94 (m, 2H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub>S (M + H), 408.1489; found, 408.1490.</div></div><div id="sec5_1_7_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 8-Fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>47</b>)</h5><div class="NLM_p last">7-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 8-fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.11 (dd, <i>J</i> = 11.4, 2.5 Hz, 1H), 8.27 (dd, <i>J</i> = 8.8, 6.3 Hz, 1H), 7.48 (td, <i>J</i> = 8.4, 2.6 Hz, 1H), 7.26 (ddt, <i>J</i> = 13.0, 11.5, 7.1 Hz, 5H), 4.25–4.16 (m, 2H), 3.02–2.94 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −101.36 (dt, <i>J</i> = 11.9, 7.1 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>4</sub>OS (M + H), 341.0867; found, 341.0882.</div></div><div id="sec5_1_7_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 9-Fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>48</b>)</h5><div class="NLM_p last">8-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 9-fluoro-4-phenethyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.88 (s, 1H), 8.01 (d, <i>J</i> = 7.8 Hz, 1H), 7.83–7.73 (m, 1H), 7.62 (td, <i>J</i> = 8.0, 4.0 Hz, 1H), 7.25 (ddd, <i>J</i> = 18.6, 13.0, 7.3 Hz, 5H), 4.16 (dd, <i>J</i> = 9.2, 6.7 Hz, 2H), 3.02–2.94 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −93.38 (dd, <i>J</i> = 11.6, 4.1 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>4</sub>OS (M + H), 341.0867; found, 341.0859.</div></div><div id="sec5_1_7_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 4-Phenethyl-1-thioxo-2,4-dihydropyrido[2,3-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrimidin-5(1<i>H</i>)-one (<b>49</b>)</h5><div class="NLM_p last">3-Phenethyl-2-thioxo-2,3-dihydropyrido[3,2-<i>d</i>]pyrimidin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-phenethyl-1-thioxo-2,4-dihydropyrido[2,3-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrimidin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D.</div></div><div id="sec5_1_7_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 4-Phenethyl-1-thioxo-2,4-dihydropyrido[4,3-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrimidin-5(1<i>H</i>)-one (<b>50</b>)</h5><div class="NLM_p last">3-Phenethyl-2-thioxo-2,3-dihydropyrido[3,4-<i>d</i>]pyrimidin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-phenethyl-1-thioxo-2,4-dihydropyrido[4,3-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrimidin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.36 (s, 1H), 8.82 (d, <i>J</i> = 5.0 Hz, 1H), 8.06 (d, <i>J</i> = 5.0 Hz, 1H), 7.33–7.22 (m, 4H), 7.20 (t, <i>J</i> = 7.1 Hz, 1H), 4.24–4.17 (m, 2H), 2.97 (t, <i>J</i> = 8.0 Hz, 2H).</div></div><div id="sec5_1_7_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 6-Phenethyl-9-thioxo-8,9-dihydropyrido[3,2-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrimidin-5(6<i>H</i>)-one (<b>51</b>)</h5><div class="NLM_p last">3-Phenethyl-2-thioxo-2,3-dihydropyrido[2,3-<i>d</i>]pyrimidin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 6-phenethyl-9-thioxo-8,9-dihydropyrido[3,2-<i>e</i>][1,2,4]triazolo[4,3-<i>a</i>]pyrimidin-5(6<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.84 (s, 1H), 8.83 (dd, <i>J</i> = 4.7, 1.9 Hz, 1H), 8.52 (dd, <i>J</i> = 7.8, 1.9 Hz, 1H), 7.63 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 7.24 (ddt, <i>J</i> = 20.7, 14.0, 7.3 Hz, 5H), 4.23–4.14 (m, 2H), 2.97 (dd, <i>J</i> = 9.4, 6.4 Hz, 2H).</div></div><div id="sec5_1_7_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 4-Benzyl-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>52</b>)</h5><div class="NLM_p last">3-Benzyl-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-benzyl-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D and purified by pouring into ice water and drops of acetic acid were added. The solid was filtered and recrystallized from dioxane to give 4-benzyl-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.0226 g, 25%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.4, 4.7 Hz, 1H), 7.95 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.82 (ddd, <i>J</i> = 9.3, 7.9, 3.1 Hz, 1H), 7.43–7.36 (m, 2H), 7.30 (dd, <i>J</i> = 8.1, 6.2 Hz, 2H), 7.29–7.21 (m, 1H), 5.22 (s, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.06 (td, <i>J</i> = 8.4, 4.9 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>12</sub>FN<sub>4</sub>OS (M + H), 327.0710; found, 327.0716.</div></div><div id="sec5_1_7_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 7-Fluoro-4-(3-phenylpropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>53</b>)</h5><div class="NLM_p last">6-Fluoro-3-(3-phenylpropyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 7-fluoro-4-(3-phenylpropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.79 (td, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.25–7.14 (m, 4H), 7.10 (t, <i>J</i> = 7.0 Hz, 1H), 4.07 (t, <i>J</i> = 7.2 Hz, 2H), 2.67 (t, <i>J</i> = 7.7 Hz, 2H), 2.02 (p, <i>J</i> = 7.4 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19 (td, <i>J</i> = 8.4, 4.9 Hz).</div></div><div id="sec5_1_7_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 7-Chloro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>54</b>)</h5><div class="NLM_p last">7-Chloro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 7-Chloro-1-thioxo-4-(3,3,3-trifluoropropyl)-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>55</b>)</h5><div class="NLM_p last">6-Chloro-2-thioxo-3-(3,3,3-trifluoropropyl)-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-chloro-1-thioxo-4-(3,3,3-trifluoropropyl)-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.23 (d, <i>J</i> = 9.1 Hz, 1H), 8.14 (d, <i>J</i> = 2.5 Hz, 1H), 8.00 (dd, <i>J</i> = 9.1, 2.5 Hz, 1H), 4.25 (t, <i>J</i> = 7.3 Hz, 2H), 2.72 (dt, <i>J</i> = 17.7, 9.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −64.33 (t, <i>J</i> = 11.3 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>9</sub>ClF<sub>3</sub>N<sub>4</sub>OS (M + H), 349.0132; found, 349.0141; purity (HPLC) 91.99%.</div></div><div id="sec5_1_7_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 7-Chloro-4-(3-isopropoxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>56</b>)</h5><div class="NLM_p last">7-Chloro-4-(3-isopropoxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 3-(7-Chloro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-<i>N</i>-isopropylpropanamide (<b>57</b>)</h5><div class="NLM_p last">3-(7-Chloro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-<i>N</i>-isopropylpropanamide one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> <i>N</i>-Isopropyl-3-(7-methyl-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propanamide (<b>58</b>)</h5><div class="NLM_p last"><i>N</i>-Isopropyl-3-(7-methyl-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propanamide one was purchased from ChemDiv (San Diego, CA). Purity (HPLC) 93.49%.</div></div><div id="sec5_1_7_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> <i>N</i>-Isopropyl-5-oxo-4-propyl-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-8-carboxamide (<b>59</b>)</h5><div class="NLM_p last"><i>N</i>-Isopropyl-5-oxo-4-propyl-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-8-carboxamide one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> <i>N</i>-Cyclopentyl-4-isopentyl-5-oxo-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-8-carboxamide (<b>60</b>)</h5><div class="NLM_p last"><i>N</i>-Cyclopentyl-4-isopentyl-5-oxo-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-8-carboxamideone was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> <i>N</i>-Cyclopentyl-4-methyl-5-oxo-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-8-carboxamide (<b>61</b>)</h5><div class="NLM_p last"><i>N</i>-Cyclopentyl-4-methyl-5-oxo-1-thioxo-1,2,4,5-tetrahydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazoline-8-carboxamide one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 6-Fluoro-<i>N</i>-methyl-4-oxo-3-phenethyl-3,4-dihydroquinazoline-1(2<i>H</i>)-carbothioamide (<b>62</b>)</h5><div class="NLM_p">6-Fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 6-fluoro-3-phenethyl-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized as follows: to a solution of 6-fluoro-3-phenethyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one (0.2 g, 0.666 mmol) and nickel(II)chloride (0.604 g, 4.66 mmol) in MeOH (5 mL) was added sodium borohydride (0.529 g, 13.98 mmol) carefully. The reaction was stirred at RT for 30 min. The reaction was then filtered through Celite and the solid washed with MeOH. The filtrate was taken up in EtOAc and washed with water. The organics were dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was recrystallized from EtOH.</div><div class="NLM_p last">6-Fluoro-<i>N</i>-methyl-4-oxo-3-phenethyl-3,4-dihydroquinazoline-1(2<i>H</i>)-carbothioamide, TFA, was synthesized as follows: to a solution of 6-fluoro-3-phenethyl-2,3-dihydroquinazolin-4(1<i>H</i>)-one (0.05 g, 0.185 mmol) in DCM (0.462 mL) was added 1,1′-thiocarbonyldiimidazole (0.049 g, 0.277 mmol) and the reaction was stirred for 2 h at RT. Methylamine hydrochloride (0.125 g, 1.850 mmol) and triethylamine (0.284 mL, 2.035 mmol) were added, and the reaction was stirred for 24 h. The reaction was concentrated under a stream of N<sub>2</sub> and purified by HPLC: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.42 (s, 1H), 7.51 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (d, <i>J</i> = 6.3 Hz, 2H), 7.19 (dq, <i>J</i> = 14.0, 7.2 Hz, 4H), 5.43 (s, 2H), 3.66 (t, <i>J</i> = 7.3 Hz, 2H), 2.93 (d, <i>J</i> = 4.2 Hz, 3H), 2.83 (t, <i>J</i> = 7.4 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −115.99; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>3</sub>NaOS (M + Na), 366.1047; found, 366.1052.</div></div><div id="sec5_1_7_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 4-Ethyl-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>63</b>)</h5><div class="NLM_p last">3-Ethyl-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-ethyl-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.79 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 4.06 (q, <i>J</i> = 7.1 Hz, 2H), 1.24 (t, <i>J</i> = 7.1 Hz, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.15 (td, <i>J</i> = 8.5, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>10</sub>FN<sub>4</sub>OS (M + H), 265.0554; found, 265.0557; purity (HPLC) 91.89%.</div></div><div id="sec5_1_7_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 7-Fluoro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>64</b>)</h5><div class="NLM_p last">7-Fluoro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was purchased from ChemDiv (San Diego, CA).</div></div><div id="sec5_1_7_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 7-Fluoro-1-thioxo-4-(3,3,3-trifluoropropyl)-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>65</b>)</h5><div class="NLM_p last">6-Fluoro-2-thioxo-3-(3,3,3-trifluoropropyl)-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-1-thioxo-4-(3,3,3-trifluoropropyl)-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27 (d, <i>J</i> = 6.5 Hz, 1H), 7.93 (dd, <i>J</i> = 8.6, 3.0 Hz, 1H), 7.82 (td, <i>J</i> = 9.3, 8.7, 3.1 Hz, 1H), 4.26 (t, <i>J</i> = 7.2 Hz, 2H), 2.72 (dtd, <i>J</i> = 18.6, 11.3, 7.7 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −64.33 (t, <i>J</i> = 11.3 Hz), −112.81; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>8</sub>F<sub>4</sub>N<sub>4</sub>NaOS (M + Na), 355.0247; found, 355.0245.</div></div><div id="sec5_1_7_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 7-Fluoro-4-(3-hydroxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>66</b>)</h5><div class="NLM_p last">6-Fluoro-3-(3-hydroxypropyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(3-hydroxypropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (dd, <i>J</i> = 9.4, 4.6 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.78 (td, <i>J</i> = 8.5, 3.0 Hz, 1H), 4.48 (t, <i>J</i> = 5.1 Hz, 1H), 4.08 (t, <i>J</i> = 7.4 Hz, 2H), 3.47 (q, <i>J</i> = 5.8 Hz, 2H), 1.89–1.77 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.18 (q, <i>J</i> = 7.4 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>12</sub>FN<sub>4</sub>O<sub>2</sub>S (M + H), 294.0660; found, 294.0664.</div></div><div id="sec5_1_7_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 4-(2-Aminoethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>67</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (2-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)ethyl)carbamate was synthesized according to General Procedure C. Then, <i>tert</i>-butyl (2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)carbamate was synthesized according to General Procedure D. Then, 4-(2-aminoethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized by treating <i>tert</i>-butyl (2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)carbamate (0.112 g, 0.295 mmol) in DCM (1.230 mL) and MeOH (0.246 mL) with TFA (0.989 mL, 12.84 mmol). The reaction was stirred at RT for 3 h, then blown down, redissolved, and purified by HPLC: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 7.95 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.85 (ddd, <i>J</i> = 9.2, 7.6, 3.2 Hz, 3H), 4.32 (t, <i>J</i> = 5.8 Hz, 2H), 3.20 (t, <i>J</i> = 6.0 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.75 (td, <i>J</i> = 8.3, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>11</sub>H<sub>10</sub>FN<sub>5</sub>NaOS (M + Na), 302.0482; found, 302.0493.</div></div><div id="sec5_1_7_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 4-(3-Aminopropyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>68</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (3-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)propyl)carbamate was synthesized according to General Procedure C. Then, <i>tert</i>-butyl (3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamate was synthesized according to General Procedure D. Then, 4-(3-aminopropyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized by treating a solution of <i>tert</i>-butyl (3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamate (0.056 g, 0.142 mmol) in DCM (0.593 mL), MeOH (0.119 mL) was added to TFA (0.477 mL, 6.19 mmol), and the reaction stirred at RT for 3 h. The reaction was then concentrated, and the product was purified by ISCO (DCM/MeOH +3.3% NH<sub>4</sub>OH, 0–100%): <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.4, 4.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.83 (ddd, <i>J</i> = 9.3, 7.9, 3.1 Hz, 1H), 7.65 (s, 3H), 4.10 (t, <i>J</i> = 6.8 Hz, 2H), 2.89 (q, <i>J</i> = 8.4, 7.3 Hz, 2H), 2.00 (p, <i>J</i> = 7.0 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.06 (td, <i>J</i> = 8.3, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>13</sub>FN<sub>5</sub>OS (M + H), 294.0819; found, 294.0825.</div></div><div id="sec5_1_7_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 4-(3-Aminopropyl)-9-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>69</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (3-(8-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)propyl)carbamate was synthesized according to General Procedure A. Then, <i>tert</i>-butyl (3-(9-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamate was synthesized according to General Procedure D. Then, 4-(3-aminopropyl)-9-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized as follows: <i>tert</i>-butyl (3-(9-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamate (0.170 g, 0.432 mmol) was dissolved in HCl in dioxane (1.512 mL, 6.05 mmol) and the solution stirred at RT for 5 h. The reaction was quenched with triethylamine (0.843 mL, 6.05 mmol), filtered, and concentrated. The product was purified by ISCO (EtOAc/hexanes, 0–100%) to give 4-(3-aminopropyl)-9-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt: <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −93.31 (dd, <i>J</i> = 11.6, 4.2 Hz).</div></div><div id="sec5_1_7_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 4-(2-(Dimethylamino)ethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>70</b>)</h5><div class="NLM_p last">3-(2-(Dimethylamino)ethyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(2-(dimethylamino)ethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 9.10 (s, 1H), 7.95 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.86 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 4.40 (t, <i>J</i> = 5.6 Hz, 2H), 3.50–3.43 (m, 2H), 2.85 (s, 6H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.62 (q, <i>J</i> = 7.5 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>15</sub>FN<sub>5</sub>OS (M + H), 308.0976; found, 308.0989.</div></div><div id="sec5_1_7_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 4-(1-(Dimethylamino)propan-2-yl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>71</b>)</h5><div class="NLM_p last">3-(1-(Dimethylamino)propan-2-yl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(1-(dimethylamino)propan-2-yl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.34 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 9.24 (s, 1H), 7.94 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.85 (td, <i>J</i> = 9.2, 8.7, 3.1 Hz, 1H), 4.05 (t, <i>J</i> = 12.3 Hz, 1H), 3.35 (s, 2H), 2.80 (d, <i>J</i> = 17.7 Hz, 6H), 1.52 (d, <i>J</i> = 6.8 Hz, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.68 (q, <i>J</i> = 7.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>14</sub>H<sub>17</sub>FN<sub>5</sub>OS (M + H), 322.1132; found, 322.1139.</div></div><div id="sec5_1_7_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> <i>N</i>-(2-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)acetamide (<b>72</b>)</h5><div class="NLM_p last"><i>N</i>-(2-(6-Fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)ethyl)acetamide was synthesized according to General Procedure B. Then, <i>N</i>-(2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)acetamide, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.0 Hz, 1H), 7.88–7.76 (m, 2H), 4.08 (t, <i>J</i> = 5.8 Hz, 2H), 3.39 (q, <i>J</i> = 6.1 Hz, 2H), 1.64 (s, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.00 (q, <i>J</i> = 7.6, 6.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>13</sub>FN<sub>5</sub>O<sub>2</sub>S (M + H), 322.0769; found, 322.0780.</div></div><div id="sec5_1_7_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide (<b>73</b>)</h5><div class="NLM_p"><i>tert</i>-Butyl (3-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)propyl)carbamate was synthesized according to General Procedure C.</div><div class="NLM_p">3-(3-Aminopropyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one: TFA (1.476 mL, 19.15 mmol) was added to a solution of crude <i>tert</i>-butyl (3-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)propyl)carbamate (0.1556 g, 0.440 mmol) in DCM (2.201 mL), and the reaction was stirred at RT for 2 h. The reaction was then blown down, the residue dissolved in MeOH, gravity filtered through a PL-HCO<sub>3</sub> SPE cartridge, and concentrated. The crude product was used without further purification.</div><div class="NLM_p"><i>N</i>-(3-(6-Fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)propyl)acetamide: to a solution of 3-(3-aminopropyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one (0.05 g, 0.197 mmol) in pyridine (0.6 mL) was added acetyl chloride (0.021 mL, 0.296 mmol) and the reaction stirred at 0 °C for 2 h. The reaction was then cooled to RT and poured into ice water and filtered, and the solid was washed with water and Et<sub>2</sub>O and dried. The crude product was used without further purification.</div><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.4, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.86–7.75 (m, 2H), 4.02 (dd, <i>J</i> = 8.2, 6.3 Hz, 2H), 3.09 (q, <i>J</i> = 6.6 Hz, 2H), 1.82 (p, <i>J</i> = 7.2 Hz, 2H), 1.76 (s, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.17 (td, <i>J</i> = 8.2, 4.5 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>OS (M + H), 336.0925; found, 336.0929; purity (HPLC) 90.11%.</div></div><div id="sec5_1_7_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)benzamide (<b>74</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)benzamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.46 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.85–7.78 (m, 3H), 7.54–7.49 (m, 1H), 7.48–7.42 (m, 2H), 4.11 (dd, <i>J</i> = 8.1, 6.6 Hz, 2H), 3.36 (q, <i>J</i> = 6.6 Hz, 2H), 1.99 (p, <i>J</i> = 6.9 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.15 (td, <i>J</i> = 8.2, 4.6 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>2</sub>S (M + H), 398.1082; found, 398.1063.</div></div><div id="sec5_1_7_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> <i>N</i>-(2-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)methanesulfonamide (<b>75</b>)</h5><div class="NLM_p last"><i>N</i>-(2-(6-Fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)ethyl)methanesulfonamide was synthesized according to General Procedure C. Then, <i>N</i>-(2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)methanesulfonamide, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.93 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.81 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.17 (t, <i>J</i> = 6.4 Hz, 1H), 4.18 (t, <i>J</i> = 6.2 Hz, 2H), 3.36 (q, <i>J</i> = 6.2 Hz, 2H), 2.88 (s, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.99 (td, <i>J</i> = 8.3, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>12</sub>H<sub>13</sub>FN<sub>5</sub>O<sub>3</sub>S<sub>2</sub> (M + H), 358.0438; found, 358.0441.</div></div><div id="sec5_1_7_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)methanesulfonamide (<b>76</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)methanesulfonamide was synthesized by treating 4-(3-aminopropyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.05 g, 0.170 mmol) in DCM (0.852 mL) at RT with methanesulfonyl chloride (0.015 mL, 0.188 mmol) and triethylamine (0.029 mL, 0.205 mmol). The reaction was stirred at RT for 2 h, concentrated, and purified by HPLC: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.81 (ddd, <i>J</i> = 9.3, 8.0, 3.2 Hz, 1H), 7.00 (t, <i>J</i> = 5.9 Hz, 1H), 4.07 (t, <i>J</i> = 7.1 Hz, 2H), 3.02 (q, <i>J</i> = 6.7 Hz, 2H), 2.86 (s, 3H), 1.89 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.18 (td, <i>J</i> = 8.3, 5.0 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>15</sub>FN<sub>5</sub>O<sub>3</sub>S<sub>2</sub> (M + H), 372.0595; found, 372.0601; purity (HPLC) 94.02%.</div></div><div id="sec5_1_7_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> (2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)phosphonic Acid (<b>77</b>)</h5><div class="NLM_p last">(2-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)phosphonic acid was synthesized by treating a solution of diethyl (2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)phosphonate (0.111 g, 0.277 mmol) in DCM (4.62 mL) at 0 °C with bromotrimethylsilane (0.216 mL, 1.663 mmol) dropwise (fast). The reaction was then warmed to RT, and the solution was stirred for 8 h. The reaction was concentrated, redissolved, and purified by HPLC: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 7.90 (dd, <i>J</i> = 8.7, 3.1 Hz, 1H), 7.79 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 4.24–4.14 (m, 2H), 2.06–1.93 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.10 (q, <i>J</i> = 7.5 Hz); <sup>31</sup>P NMR (162 MHz, DMSO-<i>d</i><sub>6</sub>): δ 20.70.</div></div><div id="sec5_1_7_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Diethyl (2-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)phosphonate (<b>78</b>)</h5><div class="NLM_p last">Diethyl (2-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)ethyl)phosphonate was synthesized according to General Procedure B. Then, diethyl (2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)phosphonate, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.32 (d, <i>J</i> = 7.3 Hz, 1H), 7.92 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.1, 7.9, 3.1 Hz, 1H), 4.25–4.15 (m, 2H), 4.00 (dqd, <i>J</i> = 8.1, 7.0, 3.5 Hz, 4H), 3.26 (s, 1H), 2.28–2.15 (m, 2H), 1.22 (t, <i>J</i> = 7.0 Hz, 6H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.07; <sup>31</sup>P NMR (162 MHz, DMSO-<i>d</i><sub>6</sub>): δ 26.69; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>4</sub>PS (M + H), 401.0843; found, 401.0856.</div></div><div id="sec5_1_7_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 4-(Cyclopropylmethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>79</b>)</h5><div class="NLM_p last">3-(Cyclopropylmethyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(cyclopropylmethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.0 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 7.9, 3.1 Hz, 1H), 3.92 (d, <i>J</i> = 7.1 Hz, 2H), 1.27 (s, 1H), 0.49–0.37 (m, 4H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.02 (td, <i>J</i> = 8.3, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>12</sub>FN<sub>4</sub>OS (M + H), 291.0710; found, 291.0720.</div></div><div id="sec5_1_7_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> 7-Fluoro-4-(<i>trans</i>-2-methylcyclopropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>80</b>)</h5><div class="NLM_p last">6-Fluoro-3-(<i>trans</i>-2-methylcyclopropyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(<i>trans</i>-2-methylcyclopropyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.99 (s, 1H), 10.26 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 7.86 (dd, <i>J</i> = 8.8, 3.1 Hz, 1H), 7.76 (ddd, <i>J</i> = 10.7, 8.2, 3.0 Hz, 1H), 2.56 (dt, <i>J</i> = 7.3, 3.5 Hz, 1H), 1.27–1.19 (m, 1H), 1.15 (d, <i>J</i> = 6.0 Hz, 3H), 1.07 (dt, <i>J</i> = 9.6, 4.8 Hz, 1H), 0.90 (q, <i>J</i> = 6.6 Hz, 1H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.28 (q, <i>J</i> = 7.3, 6.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>13</sub>H<sub>12</sub>FN<sub>4</sub>OS (M + H), 291.0710; found, 291.0717.</div></div><div id="sec5_1_7_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 4-(2-Chlorophenethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>81</b>)</h5><div class="NLM_p last">3-(2-Chlorophenethyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(2-chlorophenethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (s, 1H), 7.88 (dd, <i>J</i> = 8.6, 2.9 Hz, 1H), 7.80 (t, <i>J</i> = 8.7 Hz, 1H), 7.39 (dd, <i>J</i> = 5.6, 3.7 Hz, 1H), 7.36–7.29 (m, 1H), 7.23 (dd, <i>J</i> = 5.9, 3.5 Hz, 2H), 4.27 (t, <i>J</i> = 7.5 Hz, 2H), 3.13 (t, <i>J</i> = 7.3 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.98; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13</sub>ClFN<sub>4</sub>OS (M + H), 375.0477; found, 375.0481.</div></div><div id="sec5_1_7_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 4-(4-Chlorophenethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>82</b>)</h5><div class="NLM_p last">3-(4-Chlorophenethyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(4-chlorophenethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (dd, <i>J</i> = 9.4, 4.6 Hz, 1H), 7.89 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 7.9, 3.1 Hz, 1H), 7.32 (d, <i>J</i> = 8.5 Hz, 2H), 7.27 (d, <i>J</i> = 8.5 Hz, 2H), 4.21 (t, <i>J</i> = 7.7 Hz, 2H), 2.98 (t, <i>J</i> = 7.6 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.00 (td, <i>J</i> = 8.4, 5.0 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>13Cl</sub>FN<sub>4</sub>OS (M + H), 375.0477; found, 375.0480.</div></div><div id="sec5_1_7_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> 7-Fluoro-4-(2-(pyridin-2-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>83</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-(pyridin-2-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-(pyridin-2-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.4, 4.6 Hz, 1H), 8.46 (d, <i>J</i> = 5.0 Hz, 1H), 7.88 (dd, <i>J</i> = 8.6, 3.0 Hz, 1H), 7.80 (td, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.76–7.73 (m, 1H), 7.36 (d, <i>J</i> = 7.7 Hz, 1H), 7.29–7.24 (m, 1H), 4.38 (t, <i>J</i> = 7.6 Hz, 2H), 3.20–3.11 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.97 to −113.04 (m); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>FN<sub>5</sub>OS (M + H), 342.0819; found, 342.0818; purity (HPLC) 94.92%.</div></div><div id="sec5_1_7_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> 7-Fluoro-4-(2-(pyridin-3-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>84</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-(pyridin-3-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-(pyridin-3-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.56 (d, <i>J</i> = 2.2 Hz, 1H), 8.50 (dd, <i>J</i> = 4.9, 1.6 Hz, 1H), 7.92–7.85 (m, 2H), 7.82 (td, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.46 (dd, <i>J</i> = 7.9, 5.0 Hz, 1H), 4.29 (t, <i>J</i> = 7.2 Hz, 2H), 3.08 (t, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.00 (td, <i>J</i> = 8.2, 4.6 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>FN<sub>5</sub>OS (M + H), 342.0819; found, 342.0811.</div></div><div id="sec5_1_7_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 7-Fluoro-4-(2-(pyridin-4-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>85</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-(pyridin-4-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-(pyridin-4-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.65–8.59 (m, 2H), 7.91–7.77 (m, 2H), 7.66 (d, <i>J</i> = 5.6 Hz, 2H), 4.34 (t, <i>J</i> = 7.1 Hz, 2H), 3.17 (t, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.98 (td, <i>J</i> = 8.2, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>13</sub>FN<sub>5</sub>OS (M + H), 342.0819; found, 342.0825.</div></div><div id="sec5_1_7_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> <i>tert</i>-Butyl 3-(2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)azetidine-1-carboxylate (<b>86</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 3-(2-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)ethyl)azetidine-1-carboxylate was synthesized according to General Procedure B. Then, <i>tert</i>-butyl 3-(2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)azetidine-1-carboxylate, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.79 (ddd, <i>J</i> = 9.3, 7.9, 3.1 Hz, 1H), 3.98 (t, <i>J</i> = 6.8 Hz, 2H), 3.84 (s, 2H), 3.47 (s, 2H), 2.59–2.49 (m, 1H), 1.95 (q, <i>J</i> = 7.1 Hz, 2H), 1.33 (s, 8H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.14 (q, <i>J</i> = 7.5 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>22</sub>FN<sub>5</sub>NaO<sub>3</sub>S (M + Na), 442.1320; found, 442.1332.</div></div><div id="sec5_1_7_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> 7-Fluoro-4-(2-(1-methylpyrrolidin-2-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>87</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-(1-methylpyrrolidin-2-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-(1-methylpyrrolidin-2-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 9.43 (s, 1H), 7.92 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.83 (td, <i>J</i> = 8.5, 3.1 Hz, 1H), 4.11 (dp, <i>J</i> = 28.3, 7.4 Hz, 2H), 3.51 (d, <i>J</i> = 11.9 Hz, 1H), 3.01 (d, <i>J</i> = 10.1 Hz, 1H), 2.73 (s, 3H), 2.65 (d, <i>J</i> = 10.2 Hz, 1H), 2.43–2.25 (m, 1H), 2.04–1.79 (m, 3H), 1.72 (dq, <i>J</i> = 16.0, 8.5 Hz, 1H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.96 (dt, <i>J</i> = 12.5, 6.1 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>18</sub>FN<sub>5</sub>NaOS (M + Na), 370.1108; found, 370.1121.</div></div><div id="sec5_1_7_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> 7-Fluoro-4-(2-(piperidin-1-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>88</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-(piperidin-1-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-(piperidin-1-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 8.78 (s, 1H), 7.96 (dd, <i>J</i> = 8.5, 3.0 Hz, 1H), 7.86 (td, <i>J</i> = 8.6, 3.0 Hz, 1H), 4.41 (t, <i>J</i> = 6.1 Hz, 2H), 3.61 (s, 2H), 3.44 (s, 2H), 2.96 (s, 3H), 1.89–1.28 (m, 5H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.56 (q, <i>J</i> = 7.4 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>19</sub>FN<sub>5</sub>OS (M + H), 348.1289; found, 348.1305.</div></div><div id="sec5_1_7_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> 4-(2-(4,4-Difluoropiperidin-1-yl)ethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>89</b>)</h5><div class="NLM_p last">3-(2-(4,4-Difluoropiperidin-1-yl)ethyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(2-(4,4-difluoropiperidin-1-yl)ethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −95.47 (d, <i>J</i> = 213.5 Hz), −100.80 (d, <i>J</i> = 228.4 Hz), −112.68; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>NaOS (M + Na), 406.0920; found, 406.0937.</div></div><div id="sec5_1_7_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 7-Fluoro-4-(2-morpholinoethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>90</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-morpholinoethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-morpholinoethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.4, 4.5 Hz, 1H), 9.48 (s, 1H), 7.95 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.86 (t, <i>J</i> = 8.9 Hz, 1H), 4.41 (s, 2H), 3.98 (s, 2H), 3.57 (dd, <i>J</i> = 25.5, 15.2 Hz, 2H), 3.35 (s, 4H), 3.18 (s, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −112.55; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>2</sub>S (M + H), 350.1082; found, 350.1091.</div></div><div id="sec5_1_7_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 7-Fluoro-4-(2-(4-methylpiperazin-1-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>91</b>)</h5><div class="NLM_p last">6-Fluoro-3-(2-(4-methylpiperazin-1-yl)ethyl)-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 7-fluoro-4-(2-(4-methylpiperazin-1-yl)ethyl)-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, di-TFA salt, was synthesized according to General Procedure D: HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>OS (M + H), 363.1398; found, 363.1384.</div></div><div id="sec5_1_7_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> <i>tert</i>-Butyl 4-(2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)piperazine-1-carboxylate (<b>92</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(2-(6-fluoro-4-oxo-2-thioxo-1,4-dihydroquinazolin-3(2<i>H</i>)-yl)ethyl)piperazine-1-carboxylate was synthesized according to General Procedure B. Then, <i>tert</i>-butyl 4-(2-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)ethyl)piperazine-1-carboxylate, di-TFA salt, was synthesized according to General Procedure D: HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>26</sub>FN<sub>6</sub>O<sub>3</sub>S (M + H), 449.1766; found, 449.1786.</div></div><div id="sec5_1_7_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> 4-(2-(4,4-Difluorocyclohexyl)ethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>93</b>)</h5><div class="NLM_p last">3-(2-(4,4-Difluorocyclohexyl)ethyl)-6-fluoro-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure B. Then, 4-(2-(4,4-difluorocyclohexyl)ethyl)-7-fluoro-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.28 (dd, <i>J</i> = 9.4, 4.6 Hz, 1H), 7.91 (dd, <i>J</i> = 8.7, 3.0 Hz, 1H), 7.84–7.74 (m, 1H), 4.05 (t, <i>J</i> = 7.4 Hz, 2H), 1.96 (d, <i>J</i> = 10.9 Hz, 2H), 1.88–1.58 (m, 6H), 1.46 (s, 1H), 1.16 (q, <i>J</i> = 12.3 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −89.54 (d, <i>J</i> = 231.6 Hz), −99.44 (d, <i>J</i> = 231.4 Hz), −113.14 (q, <i>J</i> = 7.1, 6.2 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>4</sub>OS (M + H), 383.1148; found, 383.1166.</div></div><div id="sec5_1_7_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> 1-Amino-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-3,6,9,12-tetraoxapentadecan-15-amide (<b>94</b>)</h5><div class="NLM_p last">To a solution of <b>95</b> (0.025 g, 0.039 mmol) in DCM (0.195 mL) was added TFA (0.066 mL, 0.858 mmol) and the reaction stirred at RT overnight. The reaction was then blown down and redissolved. The crude material was purified by RP-ISCO (H<sub>2</sub>O/MeCN + 0.2% NH<sub>4</sub>OH, 10–100%) to give 1-amino-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-3,6,9,12-tetraoxapentadecan-15-amide, di-TFA salt: <sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ 13.38 (s, 1H), 10.25 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 8.04 (s, 3H), 7.95 (dd, <i>J</i> = 8.3, 3.0 Hz, 1H), 7.45 (ddd, <i>J</i> = 9.4, 7.5, 3.1 Hz, 1H), 7.40 (s, 1H), 5.53 (s, 1H), 4.21 (t, <i>J</i> = 6.7 Hz, 2H), 3.89–3.55 (m, 16H), 3.27 (d, <i>J</i> = 22.8 Hz, 4H), 2.57 (s, 2H), 2.01 (s, 2H); <sup>19</sup>F NMR (376 MHz, CD<sub>2</sub>Cl<sub>2</sub>): δ −112.54 (td, <i>J</i> = 7.9, 4.4 Hz).</div></div><div id="sec5_1_7_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> <i>tert</i>-Butyl (19-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamate (<b>95</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (19-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-15-oxo-3,6,9,12-tetraoxa-16-azanonadecyl)carbamate, TFA salt, was synthesized according to General Procedure F.</div></div><div id="sec5_1_7_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> (<i>S</i>)-22-Amino-1-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-5,21-dioxo-8,11,14,17-tetraoxa-4,20-diazapentacosan-25-oic Acid (<b>96</b>) and <i>tert</i>-Butyl (<i>S</i>)-22-Amino-1-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-5,21-dioxo-8,11,14,17-tetraoxa-4,20-diazapentacosan-25-oate (<b>97</b>)</h5><div class="NLM_p"><i>tert</i>-Butyl (<i>S</i>)-22-((<i>tert</i>-butoxycarbonyl)amino)-1-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-5,21-dioxo-8,11,14,17-tetraoxa-4,20-diazapentacosan-25-oate: To a solution of <b>95</b> (0.04 g, 0.074 mmol) in DMF (0.190 mL) was added a solution of (<i>S</i>)-5-(<i>tert</i>-butoxy)-2-((<i>tert</i>-butoxycarbonyl)amino)-5-oxopentanoic acid (Boc-<span class="smallcaps smallerCapital">l</span>-Glu-γ-<i>t</i>-Bu-ester, 0.067 g, 0.222 mmol) and COMU (0.063 g, 0.148 mmol) followed by DIPEA (0.013 mL, 0.074 mmol). The reaction was then stirred overnight at RT. The reaction was quenched with water and concentrated. The product was purified by RP-ISCO (H<sub>2</sub>O/MeCN + 3.3% NH<sub>4</sub>OH, 10–75%) to give the protected amino acid intermediate (0.0245 g, 40%): MS (ES-API) found (M + H), 826.2 and (M + Na), 848.1.</div><div class="NLM_p last">Compounds <b>96</b> and <b>97</b> were then prepared according to the following method. TFA (0.022 mL, 0.291 mmol) and triisopropylsilane (5.95 μL, 0.029 mmol) were added to a solution of the protected amino acid intermediate (0.012 g, 0.015 mmol) in DCM (0.145 mL). The reaction was stirred at RT for 2 h and concentrated. The mixture of products was purified by HPLC to give <b>96</b> (2 TFA) and <b>97</b> (2 TFA): <b>96</b>: HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>41</sub>FN<sub>7</sub>O<sub>9</sub>S (M + H), 670.2665; found, 670.2672. <b>97</b>: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.47 (t, <i>J</i> = 5.7 Hz, 1H), 8.07 (s, 3H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.86 (s, 1H), 7.83–7.76 (m, 1H), 4.02 (t, <i>J</i> = 7.3 Hz, 2H), 3.72 (s, 1H), 3.56 (t, <i>J</i> = 6.5 Hz, 2H), 3.46–3.39 (m, 9H), 3.26–3.15 (m, 2H), 3.11 (q, <i>J</i> = 6.7 Hz, 2H), 2.27 (t, <i>J</i> = 7.2 Hz, 3H), 1.85 (dt, <i>J</i> = 23.5, 7.2 Hz, 3H), 1.37 (s, 9H); <sup>19</sup>F NMR (376 MHz, dmso): δ −113.13 (dd, <i>J</i> = 8.2, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>32</sub>H<sub>49</sub>FN<sub>7</sub>O<sub>9</sub>S (M + H), 726.3291; found, 726.3284.</div></div><div id="sec5_1_7_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> 3-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)propenamide (<b>98</b>)</h5><div class="NLM_p last">To a solution of <b>99</b> (0.1496 g, 0.251 mmol) in HCl in dioxane (0.627 mL, 2.507 mmol) was added triisopropylsilane (0.079 g, 0.501 mmol), and the solution was stirred at RT for 2 h and then concentrated. The product was purified by HPLC to give 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)propenamide, di-TFA salt: HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>30</sub>FN<sub>6</sub>O<sub>5</sub>S (M + H), 497.1977; found, 497.1973.</div></div><div id="sec5_1_7_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> <i>tert</i>-Butyl (16-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-12-oxo-3,6,9-trioxa-13-azahexadecyl)carbamate (<b>99</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (16-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)-12-oxo-3,6,9-trioxa-13-azahexadecyl)carbamate, TFA salt, was synthesized according to General Procedure F: HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>37</sub>FN<sub>6</sub>NaO<sub>7</sub>S (M + Na), 619.2321; found, 619.2330.</div></div><div id="sec5_1_7_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> 6-Amino-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)hexanamide (<b>100</b>)</h5><div class="NLM_p last">Triisopropylsilane (0.031 g, 0.193 mmol) was added to a solution of <b>101</b> (0.049 g, 0.097 mmol) in HCl in dioxane (0.242 mL, 0.967 mmol), and the solution was stirred at RT for 2 h. The reaction was concentrated and purified by HPLC to give 6-amino-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)hexanamide, di-TFA salt: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.81 (td, <i>J</i> = 7.9, 2.9 Hz, 2H), 7.61 (s, 3H), 4.02 (t, <i>J</i> = 7.4 Hz, 2H), 3.11 (q, <i>J</i> = 6.6 Hz, 2H), 2.75 (h, <i>J</i> = 6.0 Hz, 2H), 2.03 (t, <i>J</i> = 7.3 Hz, 2H), 1.82 (p, <i>J</i> = 7.2 Hz, 2H), 1.55–1.41 (m, 4H), 1.31–1.19 (m, 2H); <sup>19</sup>F NMR (376 MHz, dmso): δ −113.13 (td, <i>J</i> = 8.3, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>23</sub>FN<sub>6</sub>NaO<sub>2</sub>S (M + Na), 430.1506; found, 430.1512.</div></div><div id="sec5_1_7_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> <i>tert</i>-Butyl (6-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-6-oxohexyl)carbamate (<b>101</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (6-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-6-oxohexyl)carbamate was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.1, 7.8, 2.8 Hz, 2H), 6.73 (t, <i>J</i> = 5.6 Hz, 1H), 4.02 (dd, <i>J</i> = 8.3, 6.3 Hz, 2H), 3.10 (q, <i>J</i> = 6.6 Hz, 2H), 2.86 (q, <i>J</i> = 6.6 Hz, 2H), 2.00 (t, <i>J</i> = 7.4 Hz, 2H), 1.82 (p, <i>J</i> = 7.0 Hz, 2H), 1.44 (p, <i>J</i> = 7.4 Hz, 2H), 1.37–1.27 (m, 11H), 1.24–1.11 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>31</sub>FN<sub>6</sub>NaO<sub>4</sub>S (M + Na), 529.2004; found, 529.1994.</div></div><div id="sec5_1_7_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> <i>tert</i>-Butyl (<i>R</i>)-4-((<i>tert</i>-butoxycarbonyl)amino)-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoate (<b>102</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (<i>R</i>)-4-((<i>tert</i>-butoxycarbonyl)amino)-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoate, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.85–7.76 (m, 2H), 6.82 (d, <i>J</i> = 8.2 Hz, 1H), 4.03 (t, <i>J</i> = 7.2 Hz, 2H), 3.90–3.80 (m, 1H), 3.12 (dp, <i>J</i> = 20.2, 6.6 Hz, 2H), 2.18 (t, <i>J</i> = 7.7 Hz, 2H), 1.83 (dt, <i>J</i> = 13.7, 6.5 Hz, 3H), 1.66 (dt, <i>J</i> = 14.3, 7.6 Hz, 1H), 1.36 (s, 9H), 1.35 (s, 9H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.21 (t, <i>J</i> = 6.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>35</sub>FN<sub>6</sub>NaO<sub>6</sub>S (M + Na), 601.2215; found, 601.2214.</div></div><div id="sec5_1_7_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> <i>tert</i>-Butyl (<i>S</i>)-4-((<i>tert</i>-butoxycarbonyl)amino)-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoate (<b>103</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (<i>S</i>)-4-((<i>tert</i>-butoxycarbonyl)amino)-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoate, TFA salt, was synthesized according to General Procedure F: <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.15 (d, <i>J</i> = 11.0 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>26</sub>H<sub>35</sub>FN<sub>6</sub>NaO<sub>6</sub>S (M + Na), 601.2215; found, 601.2216.</div></div><div id="sec5_1_7_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> <i>tert</i>-Butyl (<i>S</i>)-4-Amino-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoate (<b>104</b>) and (<i>S</i>)-4-Amino-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoic Acid (<b>105</b>)</h5><div class="NLM_p last">TFA (0.041 mL, 0.532 mmol) and triisopropylsilane (10.90 μL, 0.053 mmol) were added to a solution of <b>103</b> (0.0154 g, 0.027 mmol) in DCM (0.266 mL). The reaction was stirred at RT for 2 h and concentrated. The products were purified by HPLC to give <i>tert</i>-butyl (<i>S</i>)-4-amino-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoate, di-TFA salt, and (<i>S</i>)-4-amino-5-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-5-oxopentanoic acid; <b>104</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.8 Hz, 1H), 8.25 (s, 3H), 8.01 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.82 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 4.07–3.99 (m, 2H), 3.92 (t, <i>J</i> = 6.3 Hz, 1H), 3.13 (q, <i>J</i> = 6.7 Hz, 2H), 2.22 (ddt, <i>J</i> = 22.8, 15.3, 7.4 Hz, 2H), 1.95 (q, <i>J</i> = 7.4 Hz, 2H), 1.85 (p, <i>J</i> = 7.1 Hz, 2H), 1.45 (s, 9H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.12 (dt, <i>J</i> = 7.8, 4.1 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>28</sub>FN<sub>6</sub>O<sub>4</sub>S (M + H), 479.1871; found, 479.1866. <b>105</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.26 (s, 3H), 8.02 (t, <i>J</i> = 5.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.83 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 4.05 (dd, <i>J</i> = 8.1, 6.4 Hz, 2H), 3.93 (t, <i>J</i> = 6.6 Hz, 1H), 3.15 (q, <i>J</i> = 6.7 Hz, 2H), 2.54 (s, 0H), 2.24 (ddt, <i>J</i> = 23.0, 15.4, 7.5 Hz, 2H), 1.97 (q, <i>J</i> = 7.4 Hz, 2H), 1.86 (p, <i>J</i> = 7.2 Hz, 2H), 1.46 (s, 9H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.10 (td, <i>J</i> = 8.2, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>17</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>4</sub>S (M + H), 423.1245; found, 423.1232.</div></div><div id="sec5_1_7_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> 4-((3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-4-oxobutanoic Acid (<b>106</b>)</h5><div class="NLM_p last">4-((3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-4-oxobutanoic acid, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.34 (s, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.86 (t, <i>J</i> = 5.6 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 4.05 (t, <i>J</i> = 7.3 Hz, 2H), 3.12 (q, <i>J</i> = 6.7 Hz, 2H), 2.45–2.37 (m, 2H), 2.32–2.24 (m, 3H), 1.84 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.28; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>4</sub>S (M + H), 394.0980; found, 394.0979.</div></div><div id="sec5_1_7_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-4-sulfamoylbutanamide (<b>107</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-4-sulfamoylbutanamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.93 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.87 (t, <i>J</i> = 5.6 Hz, 1H), 7.85–7.78 (m, 1H), 6.75 (s, 2H), 4.05 (dd, <i>J</i> = 8.1, 6.3 Hz, 2H), 3.13 (q, <i>J</i> = 6.6 Hz, 2H), 3.00–2.92 (m, 2H), 2.20 (t, <i>J</i> = 7.4 Hz, 2H), 1.94–1.81 (m, 4H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.14; HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>16</sub>H<sub>20</sub>FN<sub>6</sub>O<sub>4</sub>S<sub>2</sub> (M + H), 443.0966; found, 443.0977.</div></div><div id="sec5_1_7_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)cyclopentanecarboxamide (<b>108</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)cyclopentanecarboxamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.75 (t, <i>J</i> = 5.6 Hz, 1H), 4.02 (dd, <i>J</i> = 8.2, 6.5 Hz, 2H), 3.10 (q, <i>J</i> = 6.6 Hz, 2H), 1.82 (p, <i>J</i> = 7.0 Hz, 2H), 1.73–1.63 (m, 2H), 1.63–1.51 (m, 4H), 1.50–1.40 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19 (td, <i>J</i> = 8.2, 4.6 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>2</sub>S (M + H), 390.1395; found, 390.1387.</div></div><div id="sec5_1_7_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> <i>trans</i>-4-(<i>tert</i>-Butyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)cyclohexane-1-carboxamide (<b>109</b>)</h5><div class="NLM_p last"><i>trans</i>-4-(<i>tert</i>-Butyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)cyclohexane-1-carboxamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.67 (t, <i>J</i> = 5.7 Hz, 1H), 4.01 (dd, <i>J</i> = 8.4, 6.4 Hz, 2H), 3.09 (q, <i>J</i> = 6.5 Hz, 2H), 1.93 (td, <i>J</i> = 12.2, 2.9 Hz, 1H), 1.81 (p, <i>J</i> = 6.9 Hz, 2H), 1.73 (d, <i>J</i> = 9.8 Hz, 4H), 1.26 (q, <i>J</i> = 12.2 Hz, 2H), 0.97–0.87 (m, 3H), 0.80 (s, 9H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.21 (td, <i>J</i> = 8.3, 4.6 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>31</sub>FN<sub>5</sub>O<sub>2</sub>S (M + H), 460.2177; found, 460.2177.</div></div><div id="sec5_1_7_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> <i>tert</i>-Butyl (4-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)cyclohexyl)carbamate (<b>110</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (4-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)cyclohexyl)carbamate, di-TFA salt was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.4, 8.0, 3.2 Hz, 1H), 7.67 (t, <i>J</i> = 5.7 Hz, 1H), 6.65 (d, <i>J</i> = 6.5 Hz, 1H), 4.06–3.98 (m, 2H), 3.43 (s, 1H), 3.11 (q, <i>J</i> = 6.5 Hz, 2H), 2.10 (dq, <i>J</i> = 12.2, 3.8 Hz, 1H), 1.82 (p, <i>J</i> = 7.7, 7.3 Hz, 2H), 1.77–1.68 (m, 1H), 1.64–1.53 (m, 2H), 1.47–1.37 (m, 5H), 1.36 (s, 9H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.17 (td, <i>J</i> = 8.3, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>24</sub>H<sub>31</sub>FN<sub>6</sub>NaO<sub>4</sub>S (M + Na), 541.2004; found, 541.2011.</div></div><div id="sec5_1_7_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 4-Amino-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)cyclohexane-1-carboxamide (<b>111</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (4-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)cyclohexyl)carbamate (0.0282 g, 0.054 mmol) was dissolved in HCl in dioxane (0.136 mL, 0.544 mmol) and the solution stirred at RT for 2 h. The reaction was concentrated and purified by HPLC to give 4-amino-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)cyclohexane-1-carboxamide, di-TFA salt: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.93 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.88–7.76 (m, 2H), 7.71 (s, 3H), 4.04 (dd, <i>J</i> = 8.3, 6.4 Hz, 2H), 3.14 (q, <i>J</i> = 6.6 Hz, 2H), 2.33–2.23 (m, 0H), 1.91–1.78 (m, 5H), 1.72–1.63 (m, 6H), 1.58–1.47 (m, 1H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.09 (td, <i>J</i> = 8.4, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>24</sub>FN<sub>6</sub>O<sub>2</sub>S (M + H), 419.1660; found, 419.1642.</div></div><div id="sec5_1_7_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-2-carboxamide (<b>112</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 2-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)piperidine-1-carboxylate was synthesized according to General Procedure F. Then, <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-2-carboxamide was synthesized as follows: <i>tert</i>-butyl 2-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)piperidine-1-carboxylate (0.172 g, 0.341 mmol) was dissolved in HCl in dioxane (0.852 mL, 3.41 mmol) and the solution stirred at RT for 2 h. The reaction was concentrated and purified by HPLC (H<sub>2</sub>O + 0.1% NH<sub>4</sub>OH/MeCN, 10–50%, 8 min, Waters XBridge Prep C18 OBD, 5 μm, 30 × 75 mm) to give <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-2-carboxamide: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.46 (dd, <i>J</i> = 9.3, 4.8 Hz, 1H), 8.28–8.22 (m, 1H), 7.87 (dd, <i>J</i> = 8.6, 3.2 Hz, 1H), 7.77 (td, <i>J</i> = 8.7, 3.1 Hz, 1H), 4.07 (t, <i>J</i> = 7.2 Hz, 2H), 3.49 (s, 1H), 3.22–3.06 (m, 3H), 2.79 (t, <i>J</i> = 11.8 Hz, 1H), 2.00–1.93 (m, 1H), 1.91–1.82 (m, 2H), 1.76–1.71 (m, 1H), 1.61 (d, <i>J</i> = 12.4 Hz, 1H), 1.49–1.37 (m, 4H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>2</sub>S (M + H), 405.1503; found, 405.1517.</div></div><div id="sec5_1_7_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-3-carboxamide (<b>113</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 2-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)piperidine-1-carboxylate was synthesized according to General Procedure F. Then, <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-3-carboxamide was synthesized as follows: <i>tert</i>-butyl 3-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)piperidine-1-carboxylate (0.172 g, 0.341 mmol) was dissolved in HCl in dioxane (0.852 mL, 3.41 mmol) and the solution stirred at RT for 2 h. The reaction was concentrated and purified by HPLC (H<sub>2</sub>O + 0.1% NH<sub>4</sub>OH/MeCN, 10–50%, 8 min, Waters XBridge Prep C18 OBD, 5 μm, 30 × 75 mm) to give <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-3-carboxamide: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.43 (s, 1H), 8.14 (t, <i>J</i> = 5.8 Hz, 1H), 7.87 (dd, <i>J</i> = 8.6, 3.2 Hz, 1H), 7.82–7.73 (m, 1H), 4.05 (t, <i>J</i> = 7.5 Hz, 2H), 3.11 (dq, <i>J</i> = 19.6, 7.8, 6.2 Hz, 5H), 2.96–2.90 (m, 1H), 2.89–2.80 (m, 2H), 1.84 (p, <i>J</i> = 7.1 Hz, 4H), 1.74 (app s, 1H), 1.56 (t, <i>J</i> = 9.7 Hz, 2H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>2</sub>S (M + H), 405.1503; found, 405.1491.</div></div><div id="sec5_1_7_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-4-carboxamide (<b>114</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)piperidine-1-carboxylate was synthesized according to General Procedure F. Then, <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-4-carboxamide was synthesized as follows: <i>tert</i>-butyl 4-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)carbamoyl)piperidine-1-carboxylate (0.172 g, 0.341 mmol) was dissolved in HCl in dioxane (0.852 mL, 3.41 mmol) and the solution stirred at RT for 2 h. The reaction was concentrated and purified by HPLC (H<sub>2</sub>O + 0.1% NH<sub>4</sub>OH/MeCN, 10–50%, 8 min, Waters XBridge Prep C18 OBD, 5 μm, 30 × 75 mm) to give <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)piperidine-4-carboxamide: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.34 (s, 1H), 7.96 (t, <i>J</i> = 5.5 Hz, 1H), 7.91–7.87 (m, 1H), 7.83–7.76 (m, 1H), 4.02 (t, <i>J</i> = 7.4 Hz, 2H), 3.12 (dd, <i>J</i> = 12.4, 6.1 Hz, 2H), 2.87 (t, <i>J</i> = 12.2 Hz, 2H), 2.41–2.32 (m, 1H), 1.81 (d, <i>J</i> = 12.4 Hz, 5H), 1.69 (d, <i>J</i> = 13.1 Hz, 2H); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>2</sub>S (M + H), 405.1503; found, 405.1511; purity (HPLC) 93.09%.</div></div><div id="sec5_1_7_100" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)tetrahydro-2H-pyran-4-carboxamide (<b>115</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)tetrahydro-2H-pyran-4-carboxamide, TFA salt, was synthesized according to General Procedure F: HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>3</sub>S (M + H), 406.1344; found, 406.1355.</div></div><div id="sec5_1_7_101" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(piperidin-4-yl)acetamide (<b>116</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 4-(2-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-2-oxoethyl)piperidine-1-carboxylate was synthesized according to General Procedure F. Then, <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(piperidin-4-yl)acetamide was synthesized as follows: <i>tert</i>-butyl 4-(2-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-2-oxoethyl)piperidine-1-carboxylate (0.0209 g, 0.040 mmol) was dissolved in HCl in dioxane (0.101 mL, 0.403 mmol) and the solution stirred at RT for 2 h. The reaction was concentrated and purified by HPLC to give <i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(piperidin-4-yl)acetamide, TFA: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.43 (s, 1H), 8.12 (s, 1H), 7.96–7.89 (m, 2H), 7.83 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 4.08–4.00 (m, 2H), 3.24 (d, <i>J</i> = 13.1 Hz, 2H), 3.13 (q, <i>J</i> = 6.6 Hz, 2H), 2.86 (dd, <i>J</i> = 21.5, 10.8 Hz, 3H), 2.02 (d, <i>J</i> = 7.0 Hz, 2H), 1.97–1.89 (m, 1H), 1.84 (p, <i>J</i> = 7.0 Hz, 2H), 1.77 (d, <i>J</i> = 14.0 Hz, 2H), 1.35–1.22 (m, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.06 to −113.17 (m).</div></div><div id="sec5_1_7_102" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-methylpiperazin-1-yl)acetamide (<b>117</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-methylpiperazin-1-yl)acetamide, di-TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 9.49 (s, 1H), 7.97 (t, <i>J</i> = 5.5 Hz, 1H), 7.93 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.82 (ddd, <i>J</i> = 9.3, 8.0, 3.2 Hz, 1H), 4.02 (t, <i>J</i> = 7.2 Hz, 2H), 3.40 (d, <i>J</i> = 10.2 Hz, 1H), 3.21–3.11 (m, 2H), 3.08 (s, 4H), 2.99 (d, <i>J</i> = 13.1 Hz, 3H), 2.78 (s, 3H), 1.84 (p, <i>J</i> = 6.8 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.07 (td, <i>J</i> = 8.2, 4.6 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>25</sub>FN<sub>7</sub>O<sub>2</sub>S (M + H), 434.1769; found, 434.1763.</div></div><div id="sec5_1_7_103" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-morpholinoacetamide (<b>118</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-morpholinoacetamide, di-TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 10.18 (s, 1H), 8.55 (s, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.82 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 4.05 (t, <i>J</i> = 7.1 Hz, 2H), 3.97–3.67 (m, 8H), 3.22 (q, <i>J</i> = 6.6 Hz, 2H), 1.89 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.07 (td, <i>J</i> = 8.3, 4.6 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>18</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>3</sub>S (M + H), 421.1453; found, 421.1449.</div></div><div id="sec5_1_7_104" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> 4-((1<i>H</i>-Imidazole-1-yl)methyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)benzamide (<b>119</b>)</h5><div class="NLM_p last">4-((1<i>H</i>-Imidazole-1-yl)methyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)benzamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 9.13 (t, <i>J</i> = 1.5 Hz, 1H), 8.52 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.5, 3.1 Hz, 1H), 7.86–7.77 (m, 3H), 7.75 (t, <i>J</i> = 1.7 Hz, 1H), 7.64 (t, <i>J</i> = 1.6 Hz, 1H), 7.57–7.45 (m, 2H), 5.46 (s, 2H), 4.11 (dd, <i>J</i> = 8.3, 6.3 Hz, 2H), 3.37–3.33 (m, 2H), 1.99 (p, <i>J</i> = 7.0 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.10 (td, <i>J</i> = 8.3, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>21</sub>FN<sub>7</sub>O<sub>2</sub>S (M + H), 478.1456; found, 478.1454.</div></div><div id="sec5_1_7_105" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-phenylacetamide (<b>120</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-phenylacetamide was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.05 (t, <i>J</i> = 5.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.81 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.33–7.15 (m, 5H), 4.04 (dd, <i>J</i> = 8.2, 6.4 Hz, 2H), 3.38 (s, 2H), 3.14 (q, <i>J</i> = 6.7 Hz, 2H), 1.86 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.17 (td, <i>J</i> = 8.3, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>19</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>2</sub>S (M + H), 398.1082; found, 398.1063.</div></div><div id="sec5_1_7_106" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> 3-(3,5-Dimethylisoxazol-4-yl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)propenamide (<b>121</b>)</h5><div class="NLM_p last">3-(3,5-Dimethylisoxazol-4-yl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)propenamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.0 Hz, 1H), 7.85–7.78 (m, 2H), 4.01 (t, <i>J</i> = 7.2 Hz, 2H), 3.32–3.23 (m, 2H), 3.10 (q, <i>J</i> = 6.7 Hz, 2H), 2.25 (s, 3H), 2.19 (dd, <i>J</i> = 7.9, 7.0 Hz, 2H), 2.13 (s, 3H), 1.81 (p, <i>J</i> = 7.0 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.14 (dd, <i>J</i> = 8.3, 5.0 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>3</sub>S (M + H), 445.1453; found, 445.1475.</div></div><div id="sec5_1_7_107" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(3-fluorophenyl)acetamide (<b>122</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(3-fluorophenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.08 (t, <i>J</i> = 5.6 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.31 (td, <i>J</i> = 8.1, 6.5 Hz, 1H), 7.08–6.99 (m, 3H), 4.03 (t, <i>J</i> = 7.3 Hz, 2H), 3.40 (s, 2H), 3.13 (q, <i>J</i> = 6.6 Hz, 2H), 1.84 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19 (q, <i>J</i> = 7.7, 7.1 Hz), −113.86 to −113.98 (m); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>18</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S (M + H), 430.1144; found, 430.1153.</div></div><div id="sec5_1_7_108" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-fluorophenyl)acetamide (<b>123</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-fluorophenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.4, 4.7 Hz, 1H), 8.05 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.30–7.22 (m, 2H), 7.14–7.05 (m, 2H), 4.02 (t, <i>J</i> = 7.3 Hz, 2H), 3.36 (s, 2H), 3.12 (q, <i>J</i> = 6.6 Hz, 2H), 1.84 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.18 (td, <i>J</i> = 8.3, 4.8 Hz), −116.95 (ddd, <i>J</i> = 14.6, 9.1, 5.5 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>18</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S (M + H), 430.1144; found, 430.1141; purity (HPLC) 93.64%.</div></div><div id="sec5_1_7_109" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> 2-(3-Chlorophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide (<b>124</b>)</h5><div class="NLM_p last">2-(3-Chlorophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.09 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.33–7.24 (m, 3H), 7.19 (dt, <i>J</i> = 7.5, 1.5 Hz, 1H), 4.03 (t, <i>J</i> = 7.2 Hz, 2H), 3.39 (s, 2H), 3.27 (s, 1H), 3.12 (q, <i>J</i> = 6.7 Hz, 2H), 1.85 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19 (d, <i>J</i> = 10.0 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>20</sub>H<sub>18</sub>ClFN<sub>5</sub>O<sub>2</sub>S (M + H), 446.0848; found, 446.0867; purity (HPLC) 94.66%.</div></div><div id="sec5_1_7_110" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> 2-(4-Bromophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide (<b>125</b>)</h5><div class="NLM_p last">2-(4-Bromophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 8.08 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.2, 7.9, 3.1 Hz, 1H), 7.50–7.42 (m, 2H), 7.22–7.15 (m, 2H), 4.02 (t, <i>J</i> = 7.3 Hz, 2H), 3.36 (s, 2H), 3.12 (q, <i>J</i> = 6.6 Hz, 2H), 1.84 (p, <i>J</i> = 7.0 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19; purity (HPLC) 88.26%.</div></div><div id="sec5_1_7_111" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(<i>p</i>-tolyl)acetamide (<b>126</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(<i>p</i>-tolyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.4, 4.6 Hz, 1H), 7.99 (t, <i>J</i> = 5.8 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 10.9, 8.0, 3.1 Hz, 1H), 7.09 (q, <i>J</i> = 8.0 Hz, 4H), 4.02 (t, <i>J</i> = 7.3 Hz, 2H), 3.11 (q, <i>J</i> = 6.6 Hz, 2H), 2.24 (s, 3H), 1.83 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.20; purity (HPLC) 89.66%.</div></div><div id="sec5_1_7_112" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-hydroxyphenyl)acetamide (<b>127</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-hydroxyphenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 9.16 (s, 1H), 7.94–7.87 (m, 2H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.04–6.98 (m, 2H), 6.69–6.60 (m, 2H), 4.06–3.98 (m, 2H), 3.23 (s, 2H), 3.10 (q, <i>J</i> = 6.6 Hz, 2H), 1.83 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19; purity (HPLC) 90.60%.</div></div><div id="sec5_1_7_113" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(2-methoxyphenyl)acetamide (<b>128</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(2-methoxyphenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.2, 7.8, 3.0 Hz, 2H), 7.22–7.16 (m, 1H), 7.13 (dd, <i>J</i> = 7.5, 1.7 Hz, 1H), 6.92 (dd, <i>J</i> = 8.2, 1.1 Hz, 1H), 6.86 (td, <i>J</i> = 7.4, 1.1 Hz, 1H), 4.03 (t, <i>J</i> = 7.3 Hz, 2H), 3.74 (s, 3H), 3.34 (s, 2H), 3.13 (q, <i>J</i> = 6.6 Hz, 2H), 1.84 (p, <i>J</i> = 7.0 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.18 (td, <i>J</i> = 8.3, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>3</sub>S (M + H), 442.1344; found, 442.1360.</div></div><div id="sec5_1_7_114" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(3-methoxyphenyl)acetamide (<b>129</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(3-methoxyphenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.6 Hz, 1H), 8.01 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.22–7.13 (m, 1H), 6.82–6.73 (m, 3H), 4.03 (t, <i>J</i> = 7.2 Hz, 2H), 3.71 (s, 3H), 3.33 (s, 2H), 3.12 (q, <i>J</i> = 6.7 Hz, 2H), 1.84 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19.</div></div><div id="sec5_1_7_115" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-methoxyphenyl)acetamide (<b>130</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(4-methoxyphenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 7.96 (t, <i>J</i> = 5.8 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.17–7.09 (m, 2H), 6.87–6.79 (m, 2H), 4.02 (t, <i>J</i> = 7.3 Hz, 2H), 3.69 (s, 3H), 3.29 (s, 2H), 3.11 (q, <i>J</i> = 6.6 Hz, 2H), 1.83 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.19 (td, <i>J</i> = 8.2, 4.7 Hz).</div></div><div id="sec5_1_7_116" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(2-(trifluoromethyl)phenyl)acetamide (<b>131</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(2-(trifluoromethyl)phenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.05 (t, <i>J</i> = 5.7 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.2, 7.9, 3.1 Hz, 1H), 7.65 (d, <i>J</i> = 7.7 Hz, 1H), 7.60 (t, <i>J</i> = 7.6 Hz, 1H), 7.44 (d, <i>J</i> = 7.8 Hz, 2H), 4.04 (t, <i>J</i> = 7.3 Hz, 2H), 3.61 (s, 2H), 3.15 (q, <i>J</i> = 6.7 Hz, 2H), 1.85 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −58.53, −113.20 (td, <i>J</i> = 8.3, 4.8 Hz).</div></div><div id="sec5_1_7_117" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(3-(trifluoromethyl)phenyl)acetamide (<b>132</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(3-(trifluoromethyl)phenyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.14 (t, <i>J</i> = 5.6 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.61–7.49 (m, 4H), 4.03 (dd, <i>J</i> = 8.1, 6.3 Hz, 2H), 3.50 (s, 2H), 3.13 (q, <i>J</i> = 6.8 Hz, 2H), 1.85 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −61.01, −113.20 (td, <i>J</i> = 8.2, 4.7 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>18</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub>S (M + H), 480.1112; found, 480.1126.</div></div><div id="sec5_1_7_118" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> 2-(2-Cyanophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide (<b>133</b>)</h5><div class="NLM_p last">2-(2-Cyanophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.20 (t, <i>J</i> = 5.6 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.85–7.73 (m, 2H), 7.63 (td, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.46 (d, <i>J</i> = 7.8 Hz, 1H), 7.42 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 4.05 (t, <i>J</i> = 7.2 Hz, 2H), 3.65 (s, 2H), 3.16 (q, <i>J</i> = 6.7 Hz, 2H), 1.87 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.18 (td, <i>J</i> = 8.4, 4.8 Hz); HRMS (ES-API) <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>6</sub>O<sub>2</sub>S (M + H) 437.1190; found, 437.1194.</div></div><div id="sec5_1_7_119" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> 2-(4-Cyanophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide (<b>134</b>)</h5><div class="NLM_p last">2-(4-Cyanophenyl)-<i>N</i>-(3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)acetamide, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.16 (t, <i>J</i> = 5.6 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.77–7.73 (m, 2H), 7.47–7.40 (m, 2H), 4.02 (t, <i>J</i> = 7.3 Hz, 2H), 3.50 (s, 2H), 3.18–3.09 (m, 2H), 1.84 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.17.</div></div><div id="sec5_1_7_120" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> <i>tert</i>-Butyl (4-(2-((3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-2-oxoethyl)phenyl)carbamate (<b>135</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl (4-(2-((3-(7-fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)amino)-2-oxoethyl)phenyl)carbamate, TFA salt, was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.30 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 9.23 (s, 1H), 7.98 (t, <i>J</i> = 5.7 Hz, 1H), 7.92 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.81 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.34 (d, <i>J</i> = 8.5 Hz, 2H), 7.15–7.05 (m, 2H), 4.03 (dd, <i>J</i> = 8.1, 6.5 Hz, 2H), 3.30 (s, 2H), 3.12 (q, <i>J</i> = 6.7 Hz, 2H), 1.84 (p, <i>J</i> = 7.1 Hz, 2H), 1.46 (s, 9H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.16 (td, <i>J</i> = 8.2, 4.8 Hz).</div></div><div id="sec5_1_7_121" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(pyridine-2-yl)acetamide (<b>136</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(pyridine-2-yl)acetamide was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.48–8.42 (m, 1H), 8.13 (t, <i>J</i> = 5.8 Hz, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.2 Hz, 1H), 7.80 (td, <i>J</i> = 8.6, 3.2 Hz, 1H), 7.71 (td, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.31 (d, <i>J</i> = 7.8 Hz, 1H), 7.22 (dd, <i>J</i> = 7.5, 5.0 Hz, 1H), 4.04 (t, <i>J</i> = 7.2 Hz, 2H), 3.57 (s, 2H), 3.14 (q, <i>J</i> = 6.7 Hz, 2H), 2.52 (s, 1H), 1.85 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, dmso): δ −113.14 to −113.23 (m).</div></div><div id="sec5_1_7_122" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(pyridine-3-yl)acetamide (<b>137</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(pyridine-3-yl)acetamide was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.44–8.37 (m, 2H), 8.14 (t, <i>J</i> = 5.7 Hz, 1H), 7.90 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (ddd, <i>J</i> = 9.3, 8.0, 3.1 Hz, 1H), 7.64 (dt, <i>J</i> = 7.8, 2.0 Hz, 1H), 7.31 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 4.03 (dd, <i>J</i> = 8.3, 6.3 Hz, 2H), 3.42 (s, 2H), 3.13 (q, <i>J</i> = 6.5 Hz, 2H), 1.85 (p, <i>J</i> = 7.1 Hz, 2H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −113.20 (d, <i>J</i> = 9.2 Hz).</div></div><div id="sec5_1_7_123" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> <i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(pyridine-4-yl)acetamide (<b>138</b>)</h5><div class="NLM_p last"><i>N</i>-(3-(7-Fluoro-5-oxo-1-thioxo-1,2-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-4(5<i>H</i>)-yl)propyl)-2-(pyridine-4-yl)acetamide was synthesized according to General Procedure F: <sup>1</sup>H NMR (400 MHz, dmso): δ 10.29 (dd, <i>J</i> = 9.3, 4.7 Hz, 1H), 8.51–8.44 (m, 2H), 8.23–8.16 (m, 1H), 7.91 (dd, <i>J</i> = 8.6, 3.1 Hz, 1H), 7.80 (td, <i>J</i> = 8.6, 3.2 Hz, 1H), 7.28 (s, 2H), 4.03 (t, <i>J</i> = 7.3 Hz, 2H), 3.44 (d, <i>J</i> = 4.1 Hz, 2H), 3.14 (q, <i>J</i> = 6.6 Hz, 2H), 1.85 (p, <i>J</i> = 7.2 Hz, 2H); <sup>19</sup>F NMR (376 MHz, dmso): δ −113.17 (td, <i>J</i> = 8.3, 4.7 Hz).</div></div><div id="sec5_1_7_124" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> 9-Fluoro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>139</b>)</h5><div class="NLM_p last">8-Fluoro-3-propyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure A. Then, 9-fluoro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.83 (s, 1H), 8.02 (dd, <i>J</i> = 7.9, 1.5 Hz, 1H), 7.77 (ddd, <i>J</i> = 11.5, 8.3, 1.5 Hz, 1H), 7.61 (td, <i>J</i> = 8.0, 4.1 Hz, 1H), 3.97–3.89 (m, 2H), 1.70 (sext, <i>J</i> = 7.5 Hz, 2H), 0.89 (t, <i>J</i> = 7.5 Hz, 3H); <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −93.30 (dd, <i>J</i> = 11.5, 4.2 Hz).</div></div><div id="sec5_1_7_125" class="NLM_sec NLM_sec_level_4"><div id="ac_i159" class="anchor-spacer"></div><h5 class="article-section__title" id="_i159"> 9-Chloro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>140</b>)</h5><div class="NLM_p last">8-Chloro-3-propyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure A. Then, 9-chloro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.78 (s, 1H), 8.10 (dd, <i>J</i> = 7.7, 1.5 Hz, 1H), 7.91 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.60 (t, <i>J</i> = 7.9 Hz, 1H), 3.94–3.86 (m, 2H), 1.70 (sext, <i>J</i> = 7.5 Hz, 2H), 0.89 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec5_1_7_126" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> 9-Methoxy-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (<b>141</b>)</h5><div class="NLM_p last">8-Methoxy-3-propyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 9-methoxy-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized according to General Procedure D: <sup>1</sup>H NMR (400 MHz, dmso): δ 13.67 (s, 1H), 7.71 (dd, <i>J</i> = 7.3, 1.7 Hz, 1H), 7.62–7.50 (m, 2H), 3.95–3.87 (m, 5H), 1.68 (sext, <i>J</i> = 7.5 Hz, 2H), 0.87 (t, <i>J</i> = 7.5 Hz, 3H).</div></div><div id="sec5_1_7_127" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> S-(5-Oxo-4-propyl-4,5-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-1-yl) Ethanethioate (<b>142</b>)</h5><div class="NLM_p last">3-Propyl-2-thioxo-2,3-dihydroquinazolin-4(1<i>H</i>)-one was synthesized according to General Procedure A. Then, 4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one, TFA salt, was synthesized according to General Procedure D. Then, S-(5-oxo-4-propyl-4,5-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-1-yl) ethanethioate was synthesized by the following method. Triethylamine (0.054 mL, 0.384 mmol) and acetic anhydride (0.022 mL, 0.230 mmol) were added to a solution of 4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.05 g, 0.192 mmol) in acetonitrile (0.549 mL). The reaction was stirred for 2 h and quenched with water. The crude mixture was concentrated and purified by HPLC to give S-(5-oxo-4-propyl-4,5-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-1-yl) ethanethioate, TFA: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.32 (dd, <i>J</i> = 8.6, 1.0 Hz, 1H), 8.24 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.90 (ddd, <i>J</i> = 8.8, 7.3, 1.7 Hz, 1H), 7.64 (td, <i>J</i> = 7.6, 1.1 Hz, 1H), 4.06–4.00 (m, 2H), 2.65 (s, 3H), 1.77 (sext, <i>J</i> = 7.4 Hz, 2H), 0.93 (t, <i>J</i> = 7.5 Hz, 3H).</div></div><div id="sec5_1_7_128" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162"> 1-(Methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>143</b>)</h5><div class="NLM_p last">4-Propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one was synthesized as described above. Then, 1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one was synthesized by the following method. K<sub>2</sub>CO<sub>3</sub> (0.032 g, 0.230 mmol) and MeI (0.012 mL, 0.192 mmol) were added to a solution of 4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.05 g, 0.192 mmol) in DMF (0.549 mL). The reaction was stirred for 2 h and quenched with methanol. The crude mixture was concentrated and purified by HPLC (conditions) to give 1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one, TFA.</div></div><div id="sec5_1_7_129" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163"> 7-Fluoro-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>144</b>)</h5><div class="NLM_p last">To a solution of 7-fluoro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.05 g, 0.180 mmol) in DMF (0.513 mL) was added K<sub>2</sub>CO<sub>3</sub> (0.030 g, 0.216 mmol) and MeI (0.011 mL, 0.180 mmol). The reaction was stirred for 2 h and quenched with methanol. The crude mixture was concentrated and purified by HPLC (conditions) to give 7-fluoro-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one, TFA.</div></div><div id="sec5_1_7_130" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> 9-Fluoro-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>145</b>)</h5><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (0.027 g, 0.199 mmol) and MeI (10.36 μL, 0.166 mmol) were added to a solution of 9-fluoro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.0461 g, 0.166 mmol) in DMF (0.473 mL). The reaction was stirred for 3 h and quenched with methanol. The crude mixture was concentrated and purified by HPLC to give 9-fluoro-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one, TFA.</div></div><div id="sec5_1_7_131" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> 9-Chloro-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>146</b>)</h5><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (0.066 g, 0.480 mmol) and MeI (0.030 mL, 0.480 mmol) were added to a solution of 9-chloro-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.1179 g, 0.400 mmol) in DMF (2.000 mL). The reaction was stirred for 3 h and quenched with methanol. The crude mixture was concentrated and purified by ISCO (EtOAc/hexanes, 0–75%) to give 9-chloro-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one.</div></div><div id="sec5_1_7_132" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> 9-Methoxy-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one (<b>147</b>)</h5><div class="NLM_p last">K<sub>2</sub>CO<sub>3</sub> (0.059 g, 0.426 mmol) and MeI (0.027 mL, 0.426 mmol) were added to a solution of 9-methoxy-4-propyl-1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one (0.103 g, 0.355 mmol) in DMF (1.774 mL). The reaction was stirred for 3 h and quenched with methanol. The crude mixture was concentrated and purified by ISCO (EtOAc/hexanes, 0–90%) to give 9-methoxy-1-(methylthio)-4-propyl-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(4<i>H</i>)-one.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i167" class="anchor-spacer"></div><h3 class="article-section__title" id="_i167"> Biochemical Assays</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> ELISA-Based PBD-Binding Inhibition Assay</h4><div class="NLM_p last">The assay was performed essentially as described previously. Briefly, a biotinylated PBIP1 p-T78 peptide (i.e., Biotin-Ahx-C-ETFDPPLHSpTAI-NH<sub>2</sub>) was first diluted with 1× coating solution (SeraCare, Gaithersburg, MD) to the final concentration of 0.3 μM, and then 100 μL of the resulting solution was immobilized onto a 96-well streptavidin-coated plate (Nalgene Nunc, Rochester, NY). The wells were washed once with PBS + 0.05% Tween 20 (PBST) and incubated with 200 μL of PBS plus 1% BSA (blocking buffer) for 1 h to prevent nonspecific binding. HEK293A lysates expressing HA-EGFP-Plk1 were prepared in a TBSN [20 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.5% NP-40, 5 mM EGTA, 2 mM MgCl<sub>2</sub>, 1.5 mM EDTA, and protease inhibitor cocktail (Roche)] + 20% DMSO buffer (∼20 μg total lysates in 100 μL buffer), mixed with the indicated amount of the competitors (p-T78 peptide and its derivative compounds) for 30 min, provided onto the biotinylated peptide-coated ELISA wells, and then incubated with constant rocking for 1 h at 25 °C. Following the incubation, ELISA plates were washed five times with PBST. To detect bound HA-EGFP-Plk1, the plates were probed for 2 h with 100 μL/well of anti-HA antibody at a concentration of 0.5 μg/mL in the blocking buffer and then washed five times. The plates were further probed for 1 h with 100 μL/well of HRP-conjugated secondary antibody (GE Healthcare) at a 1:1000 dilution in the blocking buffer. The plates were washed five times with PBST and incubated with 100 μL/well of 3,3′,5,5′-tetramethylbenzidine solution (Sigma-Aldrich, St. Louis, MO) as a substrate until a desired absorbance was reached. The reactions were stopped by the addition of 100 μL/well of stop solution (Cell Signaling Technology, Danvers, MA). The optical density was measured at 450 nm by using a PerkinElmer Enspire Multimode Plate reader (PerkinElmer, Inc., Boston, MA). Data obtained from more than three independent experiments were analyzed by GraphPad (San Diego, CA) Prism software version 7.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> PBD FP Binding Assays for Plk1 Specificity</h4><div class="NLM_p last">FP assays were carried out essentially as described previously.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Briefly, an appropriate 5-carboxyfluorescein-labeled PBD-binding peptide for Plk1, Plk2, or Plk3 was incubated at a final concentration of 5 nM with various concentrations of the bacterially expressed and purified PBD of Plk1, Plk2 or Plk3, respectively, in a binding buffer [10 mM Tris (pH 8.0), 1 mM EDTA, 50 mM NaCl, and 0.01% Nonidet P-40]. Samples were analyzed 30 min after mixing all components in a 384-well format using the Molecular Devices (San Jose, CA). To eliminate the possibility that the apparent anti-Plk1 PBD activity is not the result of the compounds’ ability to inhibit the ligand peptide used for the Plk1 FP assay above (i.e., FITC-Ahx-DPPLHSpTAI-NH<sub>2</sub>), a second Plk1 PBD-binding peptide (FITC-Ahx-GPMQSpTPLNG-NH<sub>2</sub>)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> was used to confirm the activity (Figure S3B, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">Supporting Information</a>). SpectraMax Paradigm multimode microplate detection platform. All experiments were performed in triplicate for each sample. The obtained data were plotted using GraphPad Prism software version 7.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> ADME Measurements</h4><div class="NLM_p last">PAMPA permeability was measured using a high-throughput protocol, as previously reported.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Aqueous solubility was determined by a published procedure.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Microsomal metabolic stability assays were performed as reported previously.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i171" class="anchor-spacer"></div><h3 class="article-section__title" id="_i171"> Cell-Based Assays</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> Culture, Immunostaining, and Confocal Microscopy</h4><div class="NLM_p">HeLa cells were cultured as recommended by the American Type Culture Collection (ATCC). Asynchronously growing cells were treated with control DMSO or the indicated concentration of <b>143</b>. To reveal chromosome morphologies, cells were treated with DAPI, fixed, and subjected to confocal microscopy.</div><div class="NLM_p last">Immunostaining was carried out using anti-Plk1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Cep63 (MilliporeSigma), anti-CREST (Antibodies Incorp, Davis, CA), and anti-α-tubulin (Sigma) antibodies. Confocal images were acquired using a Zeiss LSM780 equipped with a plan-apochromat 63× (N.A. 1.4) oil-immersion objective lens, 34-channel GaAsP spectral detector (Carl Zeiss Microscopy, LLC.), and 8-bit, 0.5 μm z-steps.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> Image Quantification and Statistical Analysis</h4><div class="NLM_p last">To quantify fluorescence signal intensities, images were acquired under the same settings and the images obtained after the maximum-intensity projection of z-stacks were analyzed using the Zeiss ZEN v2.1 software (Carl Zeiss Microscopy, LLC). All the quantifications were performed with randomly chosen fields from at least three independent experiments. All values are given as mean ± s. d. <i>P</i> values were calculated by an unpaired <i>t</i>-test from the mean data of each group in GraphPad Prism (***<i>P</i> < 0.001). The statistical details including the definitions and value of n (e.g., number of experimental replicates, cells, etc.) and standard deviations are provided in the figure legends.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i174" class="anchor-spacer"></div><h3 class="article-section__title" id="_i174"> Metabolism Study</h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i175" class="anchor-spacer"></div><h4 class="article-section__title" id="_i175"> Animals</h4><div class="NLM_p last">Male C57BL/6 mice from Charles River Laboratories (Wilmington, MA) were housed in the National Cancer Institute animal facility that is a pathogen-free environment controlled for temperature, light (25 °C, 12 h light/dark cycle), and humidity (45–65%) with free access to food and water. The National Cancer Institute Animal Care and Use Committee approved all animal experiments conducted in this study.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i176" class="anchor-spacer"></div><h4 class="article-section__title" id="_i176"> In Vivo Mouse Pharmacokinetics Study</h4><div class="NLM_p last">6–8-week-old male C57BL/6 mice were selected for metabolite profiling. In brief, 200 μL/20 g mice of WA (20 mg/kg dissolved in 5% DMSO and 5% Tween 80-contained saline) was administered intraperitoneally to mice. Control mice were treated with saline containing 5% DMSO and 5% Tween 80 alone. Each group consisted of three mice. Blood samples were collected by retro-orbital bleeding at 4 h postdose. After centrifugation for 10 min at 14,000<i>g</i>, serum was obtained and prepared by mixing 20 μL serum with 180 μL 50% aqueous acetonitrile. After centrifugation at 14,000<i>g</i> for 20 min, a 5 μL aliquot of the supernatants was injected into a Waters UPLC-ESI-QTOFMS system (Waters Corporation, Milford, MA).</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i177" class="anchor-spacer"></div><h4 class="article-section__title" id="_i177"> In Vitro MLM Assay</h4><div class="NLM_p last">The incubation system (200 μL) contained 100 mM phosphate buffer solution (pH = 7.4), 1.0 mg·mL<sup>–1</sup> MLMs, 5 mM MgCl<sub>2</sub>, and 20 μM test compound. The mixture was preincubated at 37 °C for 3 min and initiated with 2 mM NADPH or 2 mM UDPGA. The reaction was stopped by an aliquot of 200 μL of ice-cold acetonitrile after 60 min. After centrifugation at 14,000<i>g</i> for 10 min, a 5 μL aliquot of the supernatant was injected into a UHPLC-ESIQTOFMS.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i178" class="anchor-spacer"></div><h4 class="article-section__title" id="_i178"> UHPLC-ESI-QTOFMS and UHPLC-ESI-TQMS Analysis</h4><div class="NLM_p last">Metabolite profiling and identification were performed on an Acquity UPLC/Synapt HDMS Q-TOF MS system (Waters Corp., Milford, MA) with an ESI source. Separation was achieved on an Acquity C18 BEH UPLC column (1.7 mm, 2.1 × 50 mm; Waters Corp.). The mobile phase consisted of water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). The initial condition of 2% B was held for 0.5 min, with the following linear gradient employed: 20% B at 4 min, 95% B at 8 min, to 99% B at 9 min, held for 1 min for column flushing, then returning to initial conditions for 2 min for column equilibration before the next injection. The flow rate of the mobile phase was set at 0.4 mL/min. Column temperature was maintained at 40 °C throughout the run. Data were collected in positive ion mode, which was operated in full-scan mode at 50–950 <i>m</i>/<i>z</i>. Nitrogen was used as both cone gas (50 L/h) and desolvation gas (950 L/h). Source temperature and desolvation temperature were set at 150 and 400 °C, respectively. The capillary voltage and cone voltage were 3000 and 30 V, respectively. The structures of metabolites of interest were elucidated by tandem MS fragmentography with collision energies ramping from 15 to 40 eV, employing the same chromatographic conditions described above.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i179"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01669" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34812" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34812" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01669?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01669</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Extracted ion chromatograms of selected compounds and their glucuronides in MLM incubations with UDPGA after 60 min; MS/MS spectrum of selected compounds and their glucuronides; comparative FP-based assays showing the ability of additional triazoloquinazolinone-derived compounds (<b>20</b>, <b>27</b>, <b>89</b>, and <b>90</b>) to specifically inhibit Plk1 PBD; acyl-transfer from <b>142</b>; extracted ion chromatograms of <b>143</b> and its metabolites in MLM incubations with NADPH and UDPGA after 60 min, MS/MS spectrum of <b>143</b>, its hydroxylated metabolite, and its demethylated metabolite, and proposed metabolic pathways of <b>143</b> in mice; extracted ion chromatograms of <b>143</b> and its metabolites from MS after 20 mg/kg IP injection of C57BL/6 mice analyzed 4 h post injection and extracted ion chromatograms of <b>145</b> and its metabolites from MS after 20 mg/kg IP injection of C57BL/6 mice analyzed 4 h post injection; inactive S-alkylated compounds; multispecies microsome and cytosol stability of selected compounds; and in vitro and in vivo stability of selected prodrugs (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf">jm0c01669_si_001.pdf (8.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_002.csv">jm0c01669_si_002.csv (9.53 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01669" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth A. Jacobson</span> - <span class="hlFld-Affiliation affiliation">Molecular
Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8104-1493" title="Orcid link">http://orcid.org/0000-0001-8104-1493</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2c47494242495844466c424548484702424544024b435a"><span class="__cf_email__" data-cfemail="96fdf3f8f8f3e2fefcd6f8fff2f2fdb8f8fffeb8f1f9e0">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyung S. Lee</span> - <span class="hlFld-Affiliation affiliation">Chemistry
Section, Laboratory of Metabolism, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8326-7162" title="Orcid link">http://orcid.org/0000-0001-8326-7162</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1972606c777e757c7c597478707537777071377e766f"><span class="__cf_email__" data-cfemail="d3b8aaa6bdb4bfb6b693beb2babffdbdbabbfdb4bca5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celeste N. Alverez</span> - <span class="hlFld-Affiliation affiliation">Chemistry
Section, Laboratory of Metabolism, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Preclinical Innovation, National Center
for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jung-Eun Park</span> - <span class="hlFld-Affiliation affiliation">Chemistry
Section, Laboratory of Metabolism, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kiran S. Toti</span> - <span class="hlFld-Affiliation affiliation">Molecular
Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney
Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4528-4858" title="Orcid link">http://orcid.org/0000-0002-4528-4858</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yangliu Xia</span> - <span class="hlFld-Affiliation affiliation">Chemistry
Section, Laboratory of Metabolism, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristopher W. Krausz</span> - <span class="hlFld-Affiliation affiliation">Chemistry
Section, Laboratory of Metabolism, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ganesha Rai</span> - <span class="hlFld-Affiliation affiliation">Division
of Preclinical Innovation, National Center
for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9763-9641" title="Orcid link">http://orcid.org/0000-0001-9763-9641</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeong K. Bang</span> - <span class="hlFld-Affiliation affiliation">Division
of Magnetic Resonance, Korea Basic Science
Institute, Cheongju 28119, Republic of Korea</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5916-0912" title="Orcid link">http://orcid.org/0000-0001-5916-0912</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank J. Gonzalez</span> - <span class="hlFld-Affiliation affiliation">Chemistry
Section, Laboratory of Metabolism, National
Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.N.A. and J.-E.P. contributed equally to this work. C.N.A. and K.S.T. carried out the chemical synthesis under the supervision of K.A.J.; J.-E.P. performed ELISA, FP, and cell-based assays under the guidance of K.S.L.; Y.X. and K.W.K. executed mouse PK analyses; G.R. and J.K.B. assisted in the synthetic chemistry and provided in vitro assay reagents, respectively. C.N.A., J.-E.P., Y.X., K.S.T., F.J.G., K.A.J., and K.S.L. designed the experiments and wrote the paper.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i181">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Robert O’Connor and Stewart R. Durell for structural assistance and Juan Marugan and Anton Simeonov for helpful advice. This research was supported by the Intramural Research Program of the National Institutes of Health NCI FLEX (K.S.L.), NIDDK ZIADK31117 (K.A.J.), and NCI ZIA BC005562 (F.J.G.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism excretion</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">COMU</td><td class="NLM_def"><p class="first last">(1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein-5-isothiocyanate</p></td></tr><tr><td class="NLM_term">FP</td><td class="NLM_def"><p class="first last">fluorescence polarization assay</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">H-bond acceptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">IP</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">MS/MS</td><td class="NLM_def"><p class="first last">tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">MT</td><td class="NLM_def"><p class="first last">microtubule</p></td></tr><tr><td class="NLM_term">NAPDH</td><td class="NLM_def"><p class="first last">reduced nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">PBD</td><td class="NLM_def"><p class="first last">polo-box domain</p></td></tr><tr><td class="NLM_term">PBIP1</td><td class="NLM_def"><p class="first last">centromeric protein U</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">pyr</td><td class="NLM_def"><p class="first last">pyridine</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">UDPGA</td><td class="NLM_def"><p class="first last">uridine 5′-diphosphoglucuronic acid</p></td></tr><tr><td class="NLM_term">UGT</td><td class="NLM_def"><p class="first last">uridine diphosphate glucuronosyltransferase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i183">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 77 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zitouni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt-Dias, M.</span></span> <span> </span><span class="NLM_article-title">Polo-like Kinases: Structural Variations Lead to Multiple Functions</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1038/nrm3819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnrm3819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24954208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=433-452&author=S.+Zitouniauthor=C.+Nabaisauthor=S.+C.+Janaauthor=A.+Guerreroauthor=M.+Bettencourt-Dias&title=Polo-like+Kinases%3A+Structural+Variations+Lead+to+Multiple+Functions&doi=10.1038%2Fnrm3819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases: structural variations lead to multiple functions</span></div><div class="casAuthors">Zitouni, Sihem; Nabais, Catarina; Jana, Swadhin Chandra; Guerrero, Adan; Bettencourt-Dias, Monica</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">433-452</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Members of the polo-like kinase (PLK) family are crucial regulators of cell cycle progression, centriole duplication, mitosis, cytokinesis and the DNA damage response.  PLKs undergo major changes in abundance, activity, localization and structure at different stages of the cell cycle.  They interact with other proteins in a tightly controlled spatiotemporal manner as part of a network that coordinates key cell cycle events.  Their essential roles are highlighted by the fact that alterations in PLK function are assocd. with cancers and other diseases.  Recent knowledge gained from PLK crystal structures, evolution and interacting mols. offers important insights into the mechanisms that underlie their regulation and activity, and suggests novel functions unrelated to cell cycle control for this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaF-mmmGZrt7Vg90H21EOLACvtfcHk0lgxUxezlLvKDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P&md5=c4201eea6cece3b31094e823e188ce10</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm3819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3819%26sid%3Dliteratum%253Aachs%26aulast%3DZitouni%26aufirst%3DS.%26aulast%3DNabais%26aufirst%3DC.%26aulast%3DJana%26aufirst%3DS.%2BC.%26aulast%3DGuerrero%26aufirst%3DA.%26aulast%3DBettencourt-Dias%26aufirst%3DM.%26atitle%3DPolo-like%2520Kinases%253A%2520Structural%2520Variations%2520Lead%2520to%2520Multiple%2520Functions%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D433%26epage%3D452%26doi%3D10.1038%2Fnrm3819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span> <span> </span><span class="NLM_article-title">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.tips.2015.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26478211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=858-877&author=K.+S.+Leeauthor=T.+R.+Burkeauthor=J.-E.+Parkauthor=J.+K.+Bangauthor=E.+Lee&title=Recent+Advances+and+New+Strategies+in+Targeting+Plk1+for+Anticancer+Therapy&doi=10.1016%2Fj.tips.2015.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span></div><div class="casAuthors">Lee, Kyung S.; Burke, Terrence R.; Park, Jung-Eun; Bang, Jeong K.; Lee, Eunhye</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">858-877</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) plays key roles in regulating mitotic processes that are crucial for cellular proliferation.  Overexpression of Plk1 is tightly assocd. with the development of particular cancers in humans, and a large body of evidence suggests that Plk1 is an attractive target for anticancer therapeutic development.  Drugs targeting Plk1 can potentially be directed at two distinct sites: the N-terminal catalytic kinase domain (KD), which phosphorylates substrates, and the C-terminal polo-box domain (PBD) which is essential for protein-protein interactions.  In this review we summarize recent advances and new challenges in the development of Plk1 inhibitors targeting these two domains.  We also discuss novel strategies for designing and developing next-generation inhibitors to effectively treat Plk1-assocd. human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7P4zqY1Q4BLVg90H21EOLACvtfcHk0lgxUxezlLvKDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO&md5=4e5110c5022c2bf0f5fc8846a91b2d87</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DE.%26atitle%3DRecent%2520Advances%2520and%2520New%2520Strategies%2520in%2520Targeting%2520Plk1%2520for%2520Anticancer%2520Therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D858%26epage%3D877%26doi%3D10.1016%2Fj.tips.2015.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span> <span> </span><span class="NLM_article-title">Multifaceted Polo-like Kinases: Drug Targets and Antitargets for Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1038/nrd3184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnrd3184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=20671765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=643-660&author=K.+Strebhardt&title=Multifaceted+Polo-like+Kinases%3A+Drug+Targets+and+Antitargets+for+Cancer+Therapy&doi=10.1038%2Fnrd3184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">643-660</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of crit. cell cycle events.  Because PLK1 has been preclinically validated as a cancer target, small-mol. inhibitors of PLK1 have become attractive candidates for anticancer drug development.  Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumor suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals.  In this article, recent insights into the biol. of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-mol. PLK1 inhibitors will be examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaWCrqfphwErVg90H21EOLACvtfcHk0lgxUxezlLvKDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D&md5=62ab87ce3392ce187d7d62ac5f7c2679</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3184%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DMultifaceted%2520Polo-like%2520Kinases%253A%2520Drug%2520Targets%2520and%2520Antitargets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D643%26epage%3D660%26doi%3D10.1038%2Fnrd3184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Cárcer, G.</span></span> <span> </span><span class="NLM_article-title">The Mitotic Cancer Target Polo-like Kinase 1: Oncogene or Tumor Suppressor?</span>. <i>Genes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.3390/genes10030208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.3390%2Fgenes10030208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ajtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=208-221&author=G.+de%0AC%C3%A1rcer&title=The+Mitotic+Cancer+Target+Polo-like+Kinase+1%3A+Oncogene+or+Tumor+Suppressor%3F&doi=10.3390%2Fgenes10030208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The mitotic cancer target polo-like kinase 1: oncogene or tumor suppressor?</span></div><div class="casAuthors">de Carcer, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">Genes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208</span>CODEN:
                <span class="NLM_cas:coden">GENEG9</span>;
        ISSN:<span class="NLM_cas:issn">2073-4425</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The master mitotic regulator, Polo-like kinase 1 (Plk1), is an essential gene for the correct execution of cell division.  Plk1 has strong clin. relevance, as it is considered a bona fide cancer target, it is found overexpressed in a large collection of different cancer types and this tumoral overexpression often correlates with poor patient prognosis.  All these data led the scientific community to historically consider Plk1 as an oncogene.  Although there is a collection of scientific reports showing how Plk1 can contribute to tumor progression, recent data from different labs. using mouse models, show that Plk1 can surprisingly play as a tumor suppressor.  Therefore, the fact that Plk1 is an oncogene is now under debate.  This review summarizes the proposed mechanisms by which Plk1 can play as an oncogene or as a tumor suppressor, and extrapolates this information to clin. features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp8NowpHPelLVg90H21EOLACvtfcHk0lgAAp6Bx9FmqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ajtL%252FP&md5=475cddfb428995bbacdf7326bb7ad133</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fgenes10030208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fgenes10030208%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BC%25C3%25A1rcer%26aufirst%3DG.%26atitle%3DThe%2520Mitotic%2520Cancer%2520Target%2520Polo-like%2520Kinase%25201%253A%2520Oncogene%2520or%2520Tumor%2520Suppressor%253F%26jtitle%3DGenes%26date%3D2019%26volume%3D10%26spage%3D208%26epage%3D221%26doi%3D10.3390%2Fgenes10030208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanuele, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span> <span> </span><span class="NLM_article-title">A Genome-Wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cell.2009.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19490893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=835-848&author=J.+Luoauthor=M.+J.+Emanueleauthor=D.+Liauthor=C.+J.+Creightonauthor=M.+R.+Schlabachauthor=T.+F.+Westbrookauthor=K.-K.+Wongauthor=S.+J.+Elledge&title=A+Genome-Wide+RNAi+Screen+Identifies+Multiple+Synthetic+Lethal+Interactions+with+the+Ras+Oncogene&doi=10.1016%2Fj.cell.2009.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</span></div><div class="casAuthors">Luo, Ji; Emanuele, Michael J.; Li, Danan; Creighton, Chad J.; Schlabach, Michael R.; Westbrook, Thomas F.; Wong, Kwok-Kin; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">835-848</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understanding of the vulnerabilities of these cancers is lacking.  We undertook a genome-wide RNAi screen to identify synthetic lethal interactions with the KRAS oncogene.  We discovered a diverse set of proteins whose depletion selectively impaired the viability of Ras mutant cells.  Among these we obsd. a strong enrichment for genes with mitotic functions.  We describe a pathway involving the mitotic kinase PLK1, the anaphase-promoting complex/cyclosome, and the proteasome that, when inhibited, results in prometaphase accumulation and the subsequent death of Ras mutant cells.  Gene expression anal. indicates that reduced expression of genes in this pathway correlates with increased survival of patients bearing tumors with a Ras transcriptional signature.  Our results suggest a previously underappreciated role for Ras in mitotic progression and demonstrate a pharmacol. tractable pathway for the potential treatment of cancers harboring Ras mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmWFKW3XYaabVg90H21EOLACvtfcHk0lgAAp6Bx9FmqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D&md5=f06fd1f1c469495489ad2ac7f0cab090</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DEmanuele%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Genome-Wide%2520RNAi%2520Screen%2520Identifies%2520Multiple%2520Synthetic%2520Lethal%2520Interactions%2520with%2520the%2520Ras%2520Oncogene%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D835%26epage%3D848%26doi%3D10.1016%2Fj.cell.2009.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rago, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span> <span> </span><span class="NLM_article-title">A Panel of Isogenic Human Cancer Cells Suggests a Therapeutic Approach for Cancers with Inactivated p53</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3964</span>– <span class="NLM_lpage">3969</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813333106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1073%2Fpnas.0813333106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19225112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1Gkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=3964-3969&author=S.+Surauthor=R.+Pagliariniauthor=F.+Bunzauthor=C.+Ragoauthor=L.+A.+Diazauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=N.+Papadopoulos&title=A+Panel+of+Isogenic+Human+Cancer+Cells+Suggests+a+Therapeutic+Approach+for+Cancers+with+Inactivated+p53&doi=10.1073%2Fpnas.0813333106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53</span></div><div class="casAuthors">Sur, Surojit; Pagliarini, Raymond; Bunz, Fred; Rago, Carlo; Diaz, Luis A., Jr.; Kinzler, Kenneth W.; Vogelstein, Bert; Papadopoulos, Nickolas</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3964-3969</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status.  We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation.  Transcriptome analyses revealed a consistent upregulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G2/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes.  This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1.  This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_tZtZSiSY2LVg90H21EOLACvtfcHk0lgAAp6Bx9FmqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1Gkt74%253D&md5=4703f4df3e7280d2efb56ae7ecb2ecc6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813333106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813333106%26sid%3Dliteratum%253Aachs%26aulast%3DSur%26aufirst%3DS.%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DBunz%26aufirst%3DF.%26aulast%3DRago%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DPapadopoulos%26aufirst%3DN.%26atitle%3DA%2520Panel%2520of%2520Isogenic%2520Human%2520Cancer%2520Cells%2520Suggests%2520a%2520Therapeutic%2520Approach%2520for%2520Cancers%2520with%2520Inactivated%2520p53%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D3964%26epage%3D3969%26doi%3D10.1073%2Fpnas.0813333106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Selective Blockade of Cancer Cell Proliferation and Anchorage-Independent Growth by Plk1 Activity–Dependent Suicidal Inhibition of its Polo-Box Domain</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3624</span>– <span class="NLM_lpage">3634</span>, <span class="refDoi"> DOI: 10.1080/15384101.2015.1104435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1080%2F15384101.2015.1104435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26513691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSqur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3624-3634&author=J.-E.+Parkauthor=T.-S.+Kimauthor=B.+Y.+Kimauthor=K.+S.+Lee&title=Selective+Blockade+of+Cancer+Cell+Proliferation+and+Anchorage-Independent+Growth+by+Plk1+Activity%E2%80%93Dependent+Suicidal+Inhibition+of+its+Polo-Box+Domain&doi=10.1080%2F15384101.2015.1104435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain</span></div><div class="casAuthors">Park, Jung-Eun; Kim, Tae-Sung; Kim, Bo Yeon; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3624-3634</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) plays a crit. role in proper M-phase progression and cell proliferation.  Plk1 is overexpressed in a broad spectrum of human cancers and is considered an attractive anticancer drug target.  Although a large no. of inhibitors targeting the catalytic domain of Plk1 have been developed, these inhibitors commonly exhibit a substantial level of cross-reactivity with other structurally related kinases, thus narrowing their applicable dose for patient treatment.  Plk1 contains a C-terminal polo-box domain (PBD) that is essentially required for interacting with its binding targets.  However, largely due to the lack of both specific and membrane-permeable inhibitors, whether PBD serves as an alternative target for the development of anticancer therapeutics has not been rigorously examd.  Here, we used an intracellularly expressed 29-mer-long PBIP1-derived peptide (i.e., PBIPtide), which can be converted into a "suicidal" PBD inhibitor via Plk1-dependent self-priming and binding.  Using this highly specific and potent system, we showed that Plk1 PBD inhibition alone is sufficient for inducing mitotic arrest and apoptotic cell death in cancer cells but not in normal cells, and that cancer cell-selective killing can occur regardless of the presence or absence of oncogenic RAS mutation.  Intriguingly, PBD inhibition also effectively prevented anchorage-independent growth of malignant cancer cells.  Thus, targeting PBD represents an appealing strategy for anti-Plk1 inhibitor development.  Addnl., PBD inhibition-induced cancer cell-selective killing may not simply stem from activated RAS alone but, rather, from multiple altered biochem. and physiol. mechanisms, which may have collectively contributed to Plk1 addiction in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmxo7qMZcEFbVg90H21EOLACvtfcHk0lh00-ffPlswWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSqur3P&md5=1ed9033801a84d16c42477fe82558ddb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1104435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1104435%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DSelective%2520Blockade%2520of%2520Cancer%2520Cell%2520Proliferation%2520and%2520Anchorage-Independent%2520Growth%2520by%2520Plk1%2520Activity%25E2%2580%2593Dependent%2520Suicidal%2520Inhibition%2520of%2520its%2520Polo-Box%2520Domain%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D3624%26epage%3D3634%26doi%3D10.1080%2F15384101.2015.1104435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, I. B.</span></span> <span> </span><span class="NLM_article-title">Addiction to Oncogenes – The Achilles Heal of Cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1126/science.1073096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1126%2Fscience.1073096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=12098689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFGgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=63-64&author=I.+B.+Weinstein&title=Addiction+to+Oncogenes+%E2%80%93+The+Achilles+Heal+of+Cancer&doi=10.1126%2Fscience.1073096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives: Cancer: Addiction to oncogenes - the Achilles heal of cancer</span></div><div class="casAuthors">Weinstein, I. Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5578</span>),
    <span class="NLM_cas:pages">63-64</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review perspective focusing on the accompanying article by M. Jain et al. (ibid. 102-104) that evaluates whether an oncogene that is crucial for the initial development of a specific tumor is required for maintaining the malignant phenotype of the tumor.  Jain et al. engineered a conditional transgenic mouse to overexpress the myc oncogene, which induced formation of highly malignant osteogenic sarcoma.  Jain et al. discovered that brief loss of myc overexpression caused the tumor cells to differentiate into mature osteocytes that formed histol. normal bone.  These findings are in agreement with other data showing that cancer cells are often addicted to the continued activity of specific activated or overexpressed oncogenes for maintenance of their malignant phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7J2rsral7ELVg90H21EOLACvtfcHk0lh00-ffPlswWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFGgsbc%253D&md5=d6eb8b78ea39ee6a0f7aefd3bbe7edc9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1073096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1073096%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DI.%2BB.%26atitle%3DAddiction%2520to%2520Oncogenes%2520%25E2%2580%2593%2520The%2520Achilles%2520Heal%2520of%2520Cancer%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D63%26epage%3D64%26doi%3D10.1126%2Fscience.1073096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compitello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebanov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakovlev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, H.</span></span> <span> </span><span class="NLM_article-title">Synergistic Response to Oncogenic Mutations Defines Gene Class Critical to Cancer Phenotype</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>453</i></span>,  <span class="NLM_fpage">1112</span>– <span class="NLM_lpage">1116</span>, <span class="refDoi"> DOI: 10.1038/nature06973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnature06973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18500333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlGjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2008&pages=1112-1116&author=H.+R.+McMurrayauthor=E.+R.+Sampsonauthor=G.+Compitelloauthor=C.+Kinseyauthor=L.+Newmanauthor=B.+Smithauthor=S.-R.+Chenauthor=L.+Klebanovauthor=P.+Salzmanauthor=A.+Yakovlevauthor=H.+Land&title=Synergistic+Response+to+Oncogenic+Mutations+Defines+Gene+Class+Critical+to+Cancer+Phenotype&doi=10.1038%2Fnature06973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype</span></div><div class="casAuthors">McMurray, Helene R.; Sampson, Erik R.; Compitello, George; Kinsey, Conan; Newman, Laurel; Smith, Bradley; Chen, Shaw-Ree; Klebanov, Lev; Salzman, Peter; Yakovlev, Andrei; Land, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">453</span>
        (<span class="NLM_cas:issue">7198</span>),
    <span class="NLM_cas:pages">1112-1116</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Understanding the mol. underpinnings of cancer is of crit. importance to the development of targeted intervention strategies.  Identification of such targets, however, is notoriously difficult and unpredictable.  Malignant cell transformation requires the cooperation of a few oncogenic mutations that cause substantial reorganization of many cell features and induce complex changes in gene expression patterns.  Genes crit. to this multifaceted cellular phenotype have therefore only been identified after signaling pathway anal. or on an ad hoc basis.  Our observations that cell transformation by cooperating oncogenic lesions depends on synergistic modulation of downstream signaling circuitry suggest that malignant transformation is a highly cooperative process, involving synergy at multiple levels of regulation, including gene expression.  Here we show that a large proportion of genes controlled synergistically by loss-of-function p53 and Ras activation are crit. to the malignant state of murine and human colon cells.  Notably, 14 out of 24 cooperation response genes' were found to contribute to tumor formation in gene perturbation expts.  In contrast, only 1 in 14 perturbations of the genes responding in a non-synergistic manner had a similar effect.  Synergistic control of gene expression by oncogenic mutations thus emerges as an underlying key to malignancy, and provides an attractive rationale for identifying intervention targets in gene networks downstream of oncogenic gain- and loss-of-function mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgkRVUSrZtgrVg90H21EOLACvtfcHk0liX93O7AlOtFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlGjtb8%253D&md5=aadeb4cd635a1153825be0ca1717433d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature06973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06973%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurray%26aufirst%3DH.%2BR.%26aulast%3DSampson%26aufirst%3DE.%2BR.%26aulast%3DCompitello%26aufirst%3DG.%26aulast%3DKinsey%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DS.-R.%26aulast%3DKlebanov%26aufirst%3DL.%26aulast%3DSalzman%26aufirst%3DP.%26aulast%3DYakovlev%26aufirst%3DA.%26aulast%3DLand%26aufirst%3DH.%26atitle%3DSynergistic%2520Response%2520to%2520Oncogenic%2520Mutations%2520Defines%2520Gene%2520Class%2520Critical%2520to%2520Cancer%2520Phenotype%26jtitle%3DNature%26date%3D2008%26volume%3D453%26spage%3D1112%26epage%3D1116%26doi%3D10.1038%2Fnature06973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solimini, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span> <span> </span><span class="NLM_article-title">Principles of Cancer Therapy: Oncogene and Non-Oncogene Addiction</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">837</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cell.2009.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19269363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=823-837&author=J.+Luoauthor=N.+L.+Soliminiauthor=S.+J.+Elledge&title=Principles+of+Cancer+Therapy%3A+Oncogene+and+Non-Oncogene+Addiction&doi=10.1016%2Fj.cell.2009.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of cancer therapy: oncogene and non-oncogene addiction</span></div><div class="casAuthors">Luo, Ji; Solimini, Nicole L.; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-837</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cancer is a complex collection of distinct genetic diseases united by common hallmarks.  Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis.  We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells.  In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets.  Finally, we discuss the path ahead to therapeutic discovery and provide theor. considerations for combining orthogonal cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrH3NH_D9W6LVg90H21EOLACvtfcHk0liX93O7AlOtFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D&md5=dfbc7a874dcad44f8af947083dab8c33</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSolimini%26aufirst%3DN.%2BL.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DPrinciples%2520of%2520Cancer%2520Therapy%253A%2520Oncogene%2520and%2520Non-Oncogene%2520Addiction%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D823%26epage%3D837%26doi%3D10.1016%2Fj.cell.2009.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elia, A. E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rellos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haire, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivins, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smerdon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span> <span> </span><span class="NLM_article-title">The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(03)00725-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2FS0092-8674%2803%2900725-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=14532005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFSltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2003&pages=83-95&author=A.+E.+H.+Eliaauthor=P.+Rellosauthor=L.+F.+Haireauthor=J.+W.+Chaoauthor=F.+J.+Ivinsauthor=K.+Hoepkerauthor=D.+Mohammadauthor=L.+C.+Cantleyauthor=S.+J.+Smerdonauthor=M.+B.+Yaffe&title=The+Molecular+Basis+for+Phosphodependent+Substrate+Targeting+and+Regulation+of+Plks+by+the+Polo-Box+Domain&doi=10.1016%2Fs0092-8674%2803%2900725-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain</span></div><div class="casAuthors">Elia, Andrew E. H.; Rellos, Peter; Haire, Lesley F.; Chao, Jerry W.; Ivins, Frank J.; Hoepker, Katja; Mohammad, Duaa; Cantley, Lewis C.; Smerdon, Stephen J.; Yaffe, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-95</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polo-like kinases (Plks) perform crucial functions in cell-cycle progression and multiple stages of mitosis.  Plks are characterized by a C-terminal noncatalytic region contg. two tandem Polo boxes, termed the Polo-box domain (PBD), which has recently been implicated in phosphodependent substrate targeting.  We show that the PBDs of human, Xenopus, and yeast Plks all recognize similar phosphoserine/threonine-contg. motifs.  The 1.9 Å X-ray structure of a human Plk1 PBD-phosphopeptide complex shows that the Polo boxes each comprise β6α structures that assoc. to form a 12-stranded β sandwich domain.  The phosphopeptide binds along a conserved, pos. charged cleft located at the edge of the Polo-box interface.  Mutations that specifically disrupt phosphodependent interactions abolish cell-cycle-dependent localization and provide compelling phenotypic evidence that PBD-phospholigand binding is necessary for proper mitotic progression.  In addn., phosphopeptide binding to the PBD stimulates kinase activity in full-length Plk1, suggesting a conformational switching mechanism for Plk regulation and a dual functionality for the PBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwyNVczSqmSrVg90H21EOLACvtfcHk0ljhDzcKy-YWaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFSltb4%253D&md5=6efe7693e3b1f398eacc98263dcf04c6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900725-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900725-6%26sid%3Dliteratum%253Aachs%26aulast%3DElia%26aufirst%3DA.%2BE.%2BH.%26aulast%3DRellos%26aufirst%3DP.%26aulast%3DHaire%26aufirst%3DL.%2BF.%26aulast%3DChao%26aufirst%3DJ.%2BW.%26aulast%3DIvins%26aufirst%3DF.%2BJ.%26aulast%3DHoepker%26aufirst%3DK.%26aulast%3DMohammad%26aufirst%3DD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DSmerdon%26aufirst%3DS.%2BJ.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26atitle%3DThe%2520Molecular%2520Basis%2520for%2520Phosphodependent%2520Substrate%2520Targeting%2520and%2520Regulation%2520of%2520Plks%2520by%2520the%2520Polo-Box%2520Domain%26jtitle%3DCell%26date%3D2003%26volume%3D115%26spage%3D83%26epage%3D95%26doi%3D10.1016%2Fs0092-8674%2803%2900725-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenfell, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarm, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erikson, R. L.</span></span> <span> </span><span class="NLM_article-title">Mutation of the Polo-Box Disrupts Localization and Mitotic Functions of the Mammalian Polo Kinase Plk</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">9301</span>– <span class="NLM_lpage">9306</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.16.9301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1073%2Fpnas.95.16.9301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=9689075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=9301-9306&author=K.+S.+Leeauthor=T.+Z.+Grenfellauthor=F.+R.+Yarmauthor=R.+L.+Erikson&title=Mutation+of+the+Polo-Box+Disrupts+Localization+and+Mitotic+Functions+of+the+Mammalian+Polo+Kinase+Plk&doi=10.1073%2Fpnas.95.16.9301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk</span></div><div class="casAuthors">Lee, Kyung S.; Grenfell, Tallessyn Z.; Yarm, Frederic R.; Erikson, Raymond L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">9301-9306</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Members of the polo subfamily of protein kinases play pivotal roles in cell proliferation.  In addn. to the kinase domain, polo kinases have a strikingly conserved sequence in the noncatalytic domain, termed the polo-box.  The function of the polo-box is currently undefined.  The mammalian polo-like kinase Plk is a functional homolog of Saccharomyces cerevisiae Cdc5.  Here, we show that Plk localizes at the spindle poles and cytokinetic neck filaments.  Without impairing kinase activity, a conservative mutation in the polo-box disrupts the capacity of Plk to complement the defect assocd. with a cdc5-1 temp.-sensitive mutation and to localize to these subcellular structures.  Our data provide evidence that the polo-box plays a crit. role in Plk function, likely by directing its subcellular localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdff34tDzSE7Vg90H21EOLACvtfcHk0ljhDzcKy-YWaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCmurs%253D&md5=cce706613217de3dd76f91a9050eec44</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.16.9301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.16.9301%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DGrenfell%26aufirst%3DT.%2BZ.%26aulast%3DYarm%26aufirst%3DF.%2BR.%26aulast%3DErikson%26aufirst%3DR.%2BL.%26atitle%3DMutation%2520of%2520the%2520Polo-Box%2520Disrupts%2520Localization%2520and%2520Mitotic%2520Functions%2520of%2520the%2520Mammalian%2520Polo%2520Kinase%2520Plk%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D9301%26epage%3D9306%26doi%3D10.1073%2Fpnas.95.16.9301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seong, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">A Spindle Checkpoint Arrest and a Cytokinesis Failure by the Dominant-Negative Polo-Box Domain of Plk1 in U-2 OS Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">32282</span>– <span class="NLM_lpage">32293</span>, <span class="refDoi"> DOI: 10.1074/jbc.m202602200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1074%2Fjbc.M202602200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=12034729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32282-32293&author=Y.-S.+Seongauthor=K.+Kamijoauthor=J.-S.+Leeauthor=E.+Fernandezauthor=R.+Kuriyamaauthor=T.+Mikiauthor=K.+S.+Lee&title=A+Spindle+Checkpoint+Arrest+and+a+Cytokinesis+Failure+by+the+Dominant-Negative+Polo-Box+Domain+of+Plk1+in+U-2+OS+Cells&doi=10.1074%2Fjbc.m202602200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells</span></div><div class="casAuthors">Seong, Yeon-Sun; Kamijo, Keiju; Lee, Jae-Seon; Fernandez, Ester; Kuriyama, Ryoko; Miki, Toru; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">32282-32293</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Polo kinases play crit. roles for proper M-phase progression.  They are characterized by the presence of two regions of homol. in the C-terminal non-catalytic domain, termed polo-box 1 (PB1) and polo-box 2 (PB2).  Here we demonstrate that both PB1 and PB2 are required for targeting the catalytic activity of Plk1 to centrosomes, midbody, and kinetochores.  Expression of either kinase-inactive PLK1/K82M or the C-terminal plk1ΔN induced a pre-anaphase arrest with elevated Cdc2 and Plk1 activity.  Prophase-arrested cells exhibited randomly oriented spindle structures, whereas metaphase cells exhibited aberrant bipolar spindles with Mad2 localization at kinetochores of misaligned chromosomes.  Microtubule nucleation activity of centrosomes was not compromised.  In vivo time-lapse studies revealed that expression of plk1ΔN resulted in repeated cycles of bipolar spindle formation and disruption, suggestive of a defect in spindle stability.  A prolonged arrest frequently led to the generation of micronucleated cells in the absence of sister chromatid sepn. and centrosome duplication, indicating that micronucleation is not a result of accumulated cytokinesis failures.  Interestingly, bypass of the mitotic arrest by dominant-neg. spindle checkpoint components led to a failure in completion of cytokinesis.  We propose that, in mammalian cells, the polo-box-dependent Plk1 activity is required for proper metaphase/anaphase transition and for cytokinesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrruzMG9X3l0rVg90H21EOLACvtfcHk0ljhDzcKy-YWaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyjsLY%253D&md5=e6ed028c69d0a7548f9671235a724755</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202602200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202602200%26sid%3Dliteratum%253Aachs%26aulast%3DSeong%26aufirst%3DY.-S.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DFernandez%26aufirst%3DE.%26aulast%3DKuriyama%26aufirst%3DR.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DA%2520Spindle%2520Checkpoint%2520Arrest%2520and%2520a%2520Cytokinesis%2520Failure%2520by%2520the%2520Dominant-Negative%2520Polo-Box%2520Domain%2520of%2520Plk1%2520in%2520U-2%2520OS%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D32282%26epage%3D32293%26doi%3D10.1074%2Fjbc.m202602200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">BI 6727, a Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3094</span>– <span class="NLM_lpage">3102</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1158%2F1078-0432.CCR-08-2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19383823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3094-3102&author=D.+Rudolphauthor=M.+Steegmaierauthor=M.+Hoffmannauthor=M.+Grauertauthor=A.+Baumauthor=J.+Quantauthor=C.+Haslingerauthor=P.+Garin-Chesaauthor=G.+R.+Adolf&title=BI+6727%2C+a+Polo-like+Kinase+Inhibitor+with+Improved+Pharmacokinetic+Profile+and+Broad+Antitumor+Activity&doi=10.1158%2F1078-0432.ccr-08-2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span></div><div class="casAuthors">Rudolph, Dorothea; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias; Baum, Anke; Quant, Jens; Haslinger, Christian; Garin-Chesa, Pilar; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3094-3102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers.  To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.  The first compd. in this series, suitable for i.v. administration, has entered clin. development.  To fully explore the potential of Polo-like kinase 1 inhibition in oncol., we have profiled addnl. compds. and now describe a novel clin. candidate.  BI 6727 is a highly potent (enzyme IC50 = 0.87 nmol/L, EC50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties.  First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high vol. of distribution and a long terminal half-life in mice (Vss = 7.6 L/kg, t1/2 = 46 h) and rats (Vss = 22 L/kg, t1/2 = 54 h).  Second, BI 6727 has physicochem. and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules.  Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.  With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.  These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clin. studies have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YEX91EOHHLVg90H21EOLACvtfcHk0liGFFvw3obLyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D&md5=daed550be9d9b99ac6797c359039d295</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2445%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DBI%25206727%252C%2520a%2520Polo-like%2520Kinase%2520Inhibitor%2520with%2520Improved%2520Pharmacokinetic%2520Profile%2520and%2520Broad%2520Antitumor%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3094%26epage%3D3102%26doi%3D10.1158%2F1078-0432.ccr-08-2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lénárt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krššák, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürtler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth in Vivo</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Kr%C5%A1%C5%A1%C3%A1kauthor=U.+G%C3%BCrtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.-M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinase+1%2C+Inhibits+Tumor+Growth+in+Vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0liGFFvw3obLyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKr%25C5%25A1%25C5%25A1%25C3%25A1k%26aufirst%3DM.%26aulast%3DG%25C3%25BCrtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%252C%2520Inhibits%2520Tumor%2520Growth%2520in%2520Vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cristofano, A.</span></span> <span> </span><span class="NLM_article-title">The PLK1 Inhibitor GSK461364A is Effective in Poorly Differentiated and Anaplastic Thyroid Carcinoma Cells, Independent of the Nature of Their Driver Mutations</span>. <i>Thyroid</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1284</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1089/thy.2013.0037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1089%2Fthy.2013.0037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23509868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFerurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1284-1293&author=M.+A.+Russoauthor=K.+S.+Kangauthor=A.+Di+Cristofano&title=The+PLK1+Inhibitor+GSK461364A+is+Effective+in+Poorly+Differentiated+and+Anaplastic+Thyroid+Carcinoma+Cells%2C+Independent+of+the+Nature+of+Their+Driver+Mutations&doi=10.1089%2Fthy.2013.0037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The PLK1 Inhibitor GSK461364A Is Effective in Poorly Differentiated and Anaplastic Thyroid Carcinoma Cells, Independent of the Nature of Their Driver Mutations</span></div><div class="casAuthors">Russo, Marika A.; Kang, Kristy S.; Di Cristofano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Thyroid</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1284-1293</span>CODEN:
                <span class="NLM_cas:coden">THYRER</span>;
        ISSN:<span class="NLM_cas:issn">1050-7256</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Background: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are the most aggressive forms of thyroid cancer.  Despite their low incidence, they account for a disproportionate no. of thyroid cancer-related deaths because of their resistance to most therapeutic approaches.  We have generated mouse models that develop ATC ([Pten, p53]thyr-/- mice) and follicular thyroid cancer with areas of poor differentiation (Ptenthyr-/-,KrasG12D mice).  Comparative gene expression profiling of human and mouse ATCs reveals a common "mitotic signature" in which mitotic kinases, including Polo-like kinase-1 (PLK1), are found deregulated in both species.  Most genes from this signature are also upregulated in poorly differentiated tumors developing in Ptenthyr-/-,KrasG12D mice.  PLK1 is a crucial driving force for normal mitotic spindle formation, centrosome maturation, and sepn., and its overexpression has been demonstrated in a wide range of tumors.  Methods: Human and mouse ATC and PDTC cell lines were treated with the PLK1 inhibitor GSK461364A, and proliferation, apoptosis, and mitotic spindle alterations were analyzed.  Furthermore, immunocompetent mice were injected in the flank with mouse ATC cells, and treated with placebo or GSK461364A.  Results: We show that the PLK1 inhibitor GSK461364A inhibits cell proliferation and induces cell death in both mouse ATC- and PDTC-derived cell lines and in several human ATC cell lines carrying different driver mutations.  Dose-dependent changes in chromosome alignment and spindle assembly during mitosis are obsd. after treatment, together with changes in the mitotic index.  FACS anal. reveals a G2/M phase arrest, followed by apoptosis, and mitotic slippage in cells with PI3K activation.  GSK461364A is also effective in vivo, in an allograft model of ATC.  Conclusions: Taken together, these data suggest that PLK1 targeting is a promising and effective therapeutic approach against PDTC cells and undifferentiated thyroid carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorUfpD5u472LVg90H21EOLACvtfcHk0lgmR208aAkxHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFerurrM&md5=64f1ba9bd46ffcf074aa8e423c2316b1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1089%2Fthy.2013.0037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fthy.2013.0037%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%2BA.%26aulast%3DKang%26aufirst%3DK.%2BS.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26atitle%3DThe%2520PLK1%2520Inhibitor%2520GSK461364A%2520is%2520Effective%2520in%2520Poorly%2520Differentiated%2520and%2520Anaplastic%2520Thyroid%2520Carcinoma%2520Cells%252C%2520Independent%2520of%2520the%2520Nature%2520of%2520Their%2520Driver%2520Mutations%26jtitle%3DThyroid%26date%3D2013%26volume%3D23%26spage%3D1284%26epage%3D1293%26doi%3D10.1089%2Fthy.2013.0037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarelli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fachin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posteri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depaolini, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsasina, B.</span></span> <span> </span><span class="NLM_article-title">NMS-P937, a 4,5-dihydro-1H-Pyrazolo[4,3-h]Quinazoline Derivative as Potent and Selective Polo-like Kinase 1 Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2969</span>– <span class="NLM_lpage">2974</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmcl.2011.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=21470862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2969-2974&author=I.+Beriaauthor=R.+T.+Bossiauthor=M.+G.+Brascaauthor=M.+Carusoauthor=W.+Ceccarelliauthor=G.+Fachinauthor=M.+Fasoliniauthor=B.+Forteauthor=F.+Fiorentiniauthor=E.+Pesentiauthor=D.+Pezzettaauthor=H.+Posteriauthor=A.+Scolaroauthor=S.+R.+Depaoliniauthor=B.+Valsasina&title=NMS-P937%2C+a+4%2C5-dihydro-1H-Pyrazolo%5B4%2C3-h%5DQuinazoline+Derivative+as+Potent+and+Selective+Polo-like+Kinase+1+Inhibitor&doi=10.1016%2Fj.bmcl.2011.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor</span></div><div class="casAuthors">Beria, Italo; Bossi, Roberto T.; Brasca, Maria Gabriella; Caruso, Michele; Ceccarelli, Walter; Fachin, Gabriele; Fasolini, Marina; Forte, Barbara; Fiorentini, Francesco; Pesenti, Enrico; Pezzetta, Daniele; Posteri, Helena; Scolaro, Alessandra; Depaolini, Stefania Re; Valsasina, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2969-2974</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivs. as PLK1 inhibitors.  We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 inhibitor.  Also, in order to understand the source of PLK1 selectivity, we detd. the crystal structure of PLK1 with NMS-P937.  The compd. was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clin. trials evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtzzXBLt7b_rVg90H21EOLACvtfcHk0lgmR208aAkxHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtbg%253D&md5=ec905c6a918e920d830e50a5a53e5cab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DBeria%26aufirst%3DI.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DCeccarelli%26aufirst%3DW.%26aulast%3DFachin%26aufirst%3DG.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPezzetta%26aufirst%3DD.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DDepaolini%26aufirst%3DS.%2BR.%26aulast%3DValsasina%26aufirst%3DB.%26atitle%3DNMS-P937%252C%2520a%25204%252C5-dihydro-1H-Pyrazolo%255B4%252C3-h%255DQuinazoline%2520Derivative%2520as%2520Potent%2520and%2520Selective%2520Polo-like%2520Kinase%25201%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2969%26epage%3D2974%26doi%3D10.1016%2Fj.bmcl.2011.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiryanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of TAK-960: An Orally Available Small Molecule Inhibitor of Polo-like Kinase 1 (PLK1)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3662</span>– <span class="NLM_lpage">3666</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmcl.2013.02.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23664874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3662-3666&author=Z.+Nieauthor=V.+Feherauthor=S.+Natalaauthor=C.+McBrideauthor=A.+Kiryanovauthor=B.+Jonesauthor=B.+Lamauthor=Y.+Liuauthor=S.+Kaldorauthor=J.+Staffordauthor=K.+Hikamiauthor=N.+Uchiyamaauthor=T.+Kawamotoauthor=Y.+Hikichiauthor=S.-i.+Matsumotoauthor=N.+Amanoauthor=L.+Zhangauthor=D.+Hosfieldauthor=R.+Skeneauthor=H.+Zouauthor=X.+Caoauthor=T.+Ichikawa&title=Discovery+of+TAK-960%3A+An+Orally+Available+Small+Molecule+Inhibitor+of+Polo-like+Kinase+1+%28PLK1%29&doi=10.1016%2Fj.bmcl.2013.02.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)</span></div><div class="casAuthors">Nie, Zhe; Feher, Victoria; Natala, Srinivasa; McBride, Christopher; Kiryanov, Andre; Jones, Benjamin; Lam, Betty; Liu, Yan; Kaldor, Stephen; Stafford, Jeffrey; Hikami, Kouki; Uchiyama, Noriko; Kawamoto, Tomohiro; Hikichi, Yuichi; Matsumoto, Shin-ichi; Amano, Nobuyuki; Zhang, Lilly; Hosfield, David; Skene, Robert; Zou, Hua; Cao, Xiaodong; Ichikawa, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3662-3666</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using structure-based drug design, the authors identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960 (I).  TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo06c_HY-gD-LVg90H21EOLACvtfcHk0lhXdZu9xkBj9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D&md5=25dca079405c47098fd261a77ceccf53</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.083%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DZ.%26aulast%3DFeher%26aufirst%3DV.%26aulast%3DNatala%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKaldor%26aufirst%3DS.%26aulast%3DStafford%26aufirst%3DJ.%26aulast%3DHikami%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DHikichi%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DS.-i.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHosfield%26aufirst%3DD.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DIchikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520TAK-960%253A%2520An%2520Orally%2520Available%2520Small%2520Molecule%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%2520%2528PLK1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3662%26epage%3D3666%26doi%3D10.1016%2Fj.bmcl.2013.02.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhXdZu9xkBj9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span> <span> </span><span class="NLM_article-title">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.tips.2015.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26478211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=858-877&author=K.+S.+Leeauthor=T.+R.+Burkeauthor=J.-E.+Parkauthor=J.+K.+Bangauthor=E.+Lee&title=Recent+Advances+and+New+Strategies+in+Targeting+Plk1+for+Anticancer+Therapy&doi=10.1016%2Fj.tips.2015.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span></div><div class="casAuthors">Lee, Kyung S.; Burke, Terrence R.; Park, Jung-Eun; Bang, Jeong K.; Lee, Eunhye</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">858-877</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) plays key roles in regulating mitotic processes that are crucial for cellular proliferation.  Overexpression of Plk1 is tightly assocd. with the development of particular cancers in humans, and a large body of evidence suggests that Plk1 is an attractive target for anticancer therapeutic development.  Drugs targeting Plk1 can potentially be directed at two distinct sites: the N-terminal catalytic kinase domain (KD), which phosphorylates substrates, and the C-terminal polo-box domain (PBD) which is essential for protein-protein interactions.  In this review we summarize recent advances and new challenges in the development of Plk1 inhibitors targeting these two domains.  We also discuss novel strategies for designing and developing next-generation inhibitors to effectively treat Plk1-assocd. human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7P4zqY1Q4BLVg90H21EOLACvtfcHk0ljt8FNh7xaA0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO&md5=4e5110c5022c2bf0f5fc8846a91b2d87</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DE.%26atitle%3DRecent%2520Advances%2520and%2520New%2520Strategies%2520in%2520Targeting%2520Plk1%2520for%2520Anticancer%2520Therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D858%26epage%3D877%26doi%3D10.1016%2Fj.tips.2015.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Current Progress and Future Perspectives in the Development of Anti-Polo-like Kinase 1 Therapeutic Agents</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1024</span>, <span class="refDoi"> DOI: 10.12688/f1000research.11398.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.12688%2Ff1000research.11398.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28721210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2nu7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=1024&author=J.-E.+Parkauthor=D.+Hymelauthor=T.+R.+Burkeauthor=K.+S.+Lee&title=Current+Progress+and+Future+Perspectives+in+the+Development+of+Anti-Polo-like+Kinase+1+Therapeutic+Agents&doi=10.12688%2Ff1000research.11398.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents</span></div><div class="casAuthors">Park, Jung-Eun; Hymel, David; Burke, Terrence R., Jr.; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1024/1-1024/10</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">Although significant levels of side effects are often assocd. with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics.  With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression.  As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery.  To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clin. trials.  Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH2fa4WqHh4bVg90H21EOLACvtfcHk0ljt8FNh7xaA0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2nu7jJ&md5=3f62aea80e2067b19a293e7680603de3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.11398.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.11398.1%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DHymel%26aufirst%3DD.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DCurrent%2520Progress%2520and%2520Future%2520Perspectives%2520in%2520the%2520Development%2520of%2520Anti-Polo-like%2520Kinase%25201%2520Therapeutic%2520Agents%26jtitle%3DF1000Research%26date%3D2017%26volume%3D6%26spage%3D1024%26doi%3D10.12688%2Ff1000research.11398.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spender, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Nions, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allday, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, T.</span></span> <span> </span><span class="NLM_article-title">Transcriptional Silencing of Polo-like Kinase 2 (SNK/PLK2) is a Frequent Event in B-cell Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-03-1194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1182%2Fblood-2005-03-1194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=16160013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=250-256&author=N.+Syedauthor=P.+Smithauthor=A.+Sullivanauthor=L.+C.+Spenderauthor=M.+Dyerauthor=L.+Karranauthor=J.+O%E2%80%99Nionsauthor=M.+Alldayauthor=I.+Hoffmannauthor=D.+Crawfordauthor=B.+Griffinauthor=P.+J.+Farrellauthor=T.+Crook&title=Transcriptional+Silencing+of+Polo-like+Kinase+2+%28SNK%2FPLK2%29+is+a+Frequent+Event+in+B-cell+Malignancies&doi=10.1182%2Fblood-2005-03-1194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional silencing of polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies</span></div><div class="casAuthors">Syed, Nelofer; Smith, Paul; Sullivan, Alexandra; Spender, Lindsay C.; Dyer, Martin; Karran, Lorraine; O'Nions, Jenny; Allday, Martin; Hoffmann, Ingrid; Crawford, Dorothy; Griffin, Beverley; Farrell, Paul J.; Crook, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-256</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Polo-like kinases (Plks) are a highly conserved family of protein kinases that function in regulation of cell cycle and DNA damage-induced checkpoints.  Evidence of a tumor suppressor function for the Plks in human neoplasia is lacking.  Here, the authors report that Snk/Plk2 is transcriptionally down-regulated in B-cell neoplasms.  Silencing occurs with very high frequency in Burkitt lymphoma (BL) but is also detected in B-cell neoplasms of other types and is assocd. with aberrant cytosine methylation in the CpG island located at the 5' end of the SNK/PLK2 gene.  Silencing is specific to malignant B cells because SNK/PLK2 was unmethylated (and expressed) in primary B lymphocytes, in EBV-immortalized B lymphoblastoid cell lines (LCLs), and in adenocarcinomas (of the breast) and squamous-cell carcinomas (of the head and neck).  Expression of Snk/Plk2 in BL cell lines was restored by demethylating agents.  The related PLK1 and PLK3 (FNK/PRK) genes were overexpressed in BL cell lines lacking Snk/Plk2 expression, consistent with functional degeneracy among the Plk family.  Ectopic expression of Snk/Plk2 in BL cells resulted in apoptosis, a potential mechanistic basis underlying the strong selective pressure for abrogation of Snk/Plk2 function in B-cell neoplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn5sn40EHXebVg90H21EOLACvtfcHk0lj9jwy5Ka1kJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVGmug%253D%253D&md5=694a1118b993b38868a89cc3312d0646</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-03-1194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-03-1194%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DSpender%26aufirst%3DL.%2BC.%26aulast%3DDyer%26aufirst%3DM.%26aulast%3DKarran%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Nions%26aufirst%3DJ.%26aulast%3DAllday%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DI.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DB.%26aulast%3DFarrell%26aufirst%3DP.%2BJ.%26aulast%3DCrook%26aufirst%3DT.%26atitle%3DTranscriptional%2520Silencing%2520of%2520Polo-like%2520Kinase%25202%2520%2528SNK%252FPLK2%2529%2520is%2520a%2520Frequent%2520Event%2520in%2520B-cell%2520Malignancies%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D250%26epage%3D256%26doi%3D10.1182%2Fblood-2005-03-1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komissarova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkles, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span> <span> </span><span class="NLM_article-title">Polo-like Kinase 3 Functions as a Tumor Suppressor and is a Negative Regulator of Hypoxia-Inducible Factor-1 Alpha Under Hypoxic Conditions</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">4077</span>– <span class="NLM_lpage">4085</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-07-6182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1158%2F0008-5472.CAN-07-6182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18519666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4077-4085&author=Y.+Yangauthor=J.+Baiauthor=R.+Shenauthor=S.+A.+N.+Brownauthor=E.+Komissarovaauthor=Y.+Huangauthor=N.+Jiangauthor=G.+F.+Albertsauthor=M.+Costaauthor=L.+Luauthor=J.+A.+Winklesauthor=W.+Dai&title=Polo-like+Kinase+3+Functions+as+a+Tumor+Suppressor+and+is+a+Negative+Regulator+of+Hypoxia-Inducible+Factor-1+Alpha+Under+Hypoxic+Conditions&doi=10.1158%2F0008-5472.can-07-6182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like Kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1α under hypoxic conditions</span></div><div class="casAuthors">Yang, Yali; Bai, Jingxiang; Shen, Rulong; Brown, Sharron A. N.; Komissarova, Elena; Huang, Ying; Jiang, Ning; Alberts, Gregory F.; Costa, Max; Lu, Luo; Winkles, Jeffrey A.; Dai, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4077-4085</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Polo-like kinase 3 (Plk3) is an important mediator of the cellular responses to genotoxic stresses.  In this study, we examd. the physiol. function of Plk3 by generating Plk3-deficient mice.  Plk3-/- mice displayed an increase in wt. and developed tumors in various organs at advanced age.  Many tumors in Plk3-/- mice were large in size, exhibiting enhanced angiogenesis.  Plk3-/- mouse embryonic fibroblasts were hypersensitive to the induction of hypoxia-inducible factor-1α (HIF-1α) under hypoxic conditions or by nickel and cobalt ion treatments.  Ectopic expression of the Plk3-kinase domain (Plk3 kDa), but not its Polo-box domain or a Plk3 kDa mutant, suppressed the nuclear accumulation of HIF-1α induced by nickel or cobalt ions.  Moreover, hypoxia-induced HIF-1α expression was tightly assocd. with a significant down-regulation of Plk3 expression in HeLa cells.  Given the importance of HIF-1α in mediating the activation of the "survival machinery" in cancer cells, these studies strongly suggest that enhanced tumorigenesis in Plk3-null mice is at least partially mediated by a deregulated HIF-1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbqUM2u8RALVg90H21EOLACvtfcHk0lj9jwy5Ka1kJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKmt7c%253D&md5=7ee59d18a7cde4989890a7422d65b7fe</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6182%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DS.%2BA.%2BN.%26aulast%3DKomissarova%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DAlberts%26aufirst%3DG.%2BF.%26aulast%3DCosta%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWinkles%26aufirst%3DJ.%2BA.%26aulast%3DDai%26aufirst%3DW.%26atitle%3DPolo-like%2520Kinase%25203%2520Functions%2520as%2520a%2520Tumor%2520Suppressor%2520and%2520is%2520a%2520Negative%2520Regulator%2520of%2520Hypoxia-Inducible%2520Factor-1%2520Alpha%2520Under%2520Hypoxic%2520Conditions%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4077%26epage%3D4085%26doi%3D10.1158%2F0008-5472.can-07-6182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigg, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silljé, H. H. W.</span></span> <span> </span><span class="NLM_article-title">Different Plk1 Functions Show Distinct Dependencies on Polo-Box Domain-Mediated Targeting</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1091/mbc.e05-08-0801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1091%2Fmbc.e05-08-0801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=16267267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnpt1CktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=448-459&author=A.+Hanischauthor=A.+Wehnerauthor=E.+A.+Niggauthor=H.+H.+W.+Sillj%C3%A9&title=Different+Plk1+Functions+Show+Distinct+Dependencies+on+Polo-Box+Domain-Mediated+Targeting&doi=10.1091%2Fmbc.e05-08-0801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting</span></div><div class="casAuthors">Hanisch Anja; Wehner Anja; Nigg Erich A; Sillje Herman H W</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology of the cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">448-59</span>
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    </div><div class="casAbstract">Polo-like kinase 1 (Plk1) has multiple important functions during M-phase progression.  In addition to a catalytic domain, Plk1 possesses a phosphopeptide-binding motif, the polo-box domain (PBD), which is required for proper localization.  Here, we have explored the importance of correct Plk1 subcellular targeting for its mitotic functions.  We either displaced endogenous Plk1 through overexpression of the PBD or introduced the catalytic domain of Plk1, lacking the PBD, into Plk1-depleted cells.  Both treatments resulted in remarkably similar phenotypes, which were distinct from the Plk1 depletion phenotype.  Cells depleted of Plk1 mostly arrested with monoastral spindles, because of inhibition of centrosome maturation and separation.  In contrast, these functions were not impaired in cells with mislocalized Plk1.  Instead, these latter cells showed a checkpoint-dependent mitotic arrest characterized by impaired chromosome congression.  Thus, whereas chromosome congression requires localized Plk1 activity, other investigated Plk1 functions are less dependent on correct PBD-mediated targeting.  This opens the possibility that PBD-directed drugs might be developed to selectively interfere with a subset of Plk1 functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPXdNL0FVCSq91pGlMMoT5fW6udTcc2ebfuaVY3VYtFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnpt1CktQ%253D%253D&md5=d8752dd98fb17f573d9ea4bbf5097f73</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e05-08-0801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e05-08-0801%26sid%3Dliteratum%253Aachs%26aulast%3DHanisch%26aufirst%3DA.%26aulast%3DWehner%26aufirst%3DA.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26aulast%3DSillj%25C3%25A9%26aufirst%3DH.%2BH.%2BW.%26atitle%3DDifferent%2520Plk1%2520Functions%2520Show%2520Distinct%2520Dependencies%2520on%2520Polo-Box%2520Domain-Mediated%2520Targeting%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2006%26volume%3D17%26spage%3D448%26epage%3D459%26doi%3D10.1091%2Fmbc.e05-08-0801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gräber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Serendipitous Alkylation of a Plk1 Ligand Uncovers a New Binding Channel</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.1038/nchembio.614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnchembio.614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=21765407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFyhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=595-601&author=F.+Liuauthor=J.-E.+Parkauthor=W.-J.+Qianauthor=D.+Limauthor=M.+Gr%C3%A4berauthor=T.+Bergauthor=M.+B.+Yaffeauthor=K.+S.+Leeauthor=T.+R.+Burke&title=Serendipitous+Alkylation+of+a+Plk1+Ligand+Uncovers+a+New+Binding+Channel&doi=10.1038%2Fnchembio.614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel</span></div><div class="casAuthors">Liu, Fa; Park, Jung-Eun; Qian, Wen-Jian; Lim, Dan; Graber, Martin; Berg, Thorsten; Yaffe, Michael B.; Lee, Kyung-S.; Burke, Terrence R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">595-601</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We obtained unanticipated synthetic byproducts from alkylation of the δ1 nitrogen (N3) of the histidineimidazole ring of the polo-like kinase-1 (Plk1) polo-box domain (PBD)-binding peptide PLHSpT.  For the highest-affinity byproduct, bearing a C6H5(CH2)8- group, a Plk1 PBD cocrystal structure revealed a new binding channel that had previously been occluded.  An N-terminal PEGylated version of this peptide contg. a hydrolytically stable phosphothreonyl residue (pT) bound the Plk1 PBD with affinity equal to that of the non-PEGylated parent but showed markedly less interaction with the PBDs of the two closely related proteins Plk2 and Plk3.  Treatment of cultured cells with this PEGylated peptide resulted in delocalization of Plk1 from centrosomes and kinetochores and in chromosome misalignment that effectively induced mitotic block and apoptotic cell death.  This work provides insights that might advance efforts to develop Plk1 PBD-binding inhibitors as potential Plk1-specific anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mKHC1CmiMrVg90H21EOLACvtfcHk0liauEIaqsk8lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFyhtL8%253D&md5=42ff203cdf3d912f97dc748a4659a81f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.614%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DGr%25C3%25A4ber%26aufirst%3DM.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26atitle%3DSerendipitous%2520Alkylation%2520of%2520a%2520Plk1%2520Ligand%2520Uncovers%2520a%2520New%2520Binding%2520Channel%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D595%26epage%3D601%26doi%3D10.1038%2Fnchembio.614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Mono-anionic Phosphopeptides Produced by Unexpected Histidine Alkylation Exhibit High Plk1 Polo-Box Domain-Binding Affinities and Enhanced Antiproliferative Effects in HeLa Cells</span>. <i>Biopolymers</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1002/bip.22569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fbip.22569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25283071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2014&pages=444-455&author=W.-J.+Qianauthor=J.-E.+Parkauthor=D.+Limauthor=C.+C.+Laiauthor=J.+A.+Kelleyauthor=S.-Y.+Parkauthor=K.+W.+Leeauthor=M.+B.+Yaffeauthor=K.+S.+Leeauthor=T.+R.+Burke&title=Mono-anionic+Phosphopeptides+Produced+by+Unexpected+Histidine+Alkylation+Exhibit+High+Plk1+Polo-Box+Domain-Binding+Affinities+and+Enhanced+Antiproliferative+Effects+in+HeLa+Cells&doi=10.1002%2Fbip.22569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells</span></div><div class="casAuthors">Qian, Wen-Jian; Park, Jung-Eun; Lim, Dan; Lai, Christopher C.; Kelley, James A.; Park, Suk-Youl; Lee, Ki Won; Yaffe, Michael B.; Lee, Kyung S.; Burke, Terrence R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">444-455</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Binding of polo-like kinase 1 (Plk1) polo-box domains (PBDs) to phosphothreonine (pThr)/phosphoserine (pSer)-contg. sequences is crit. for the proper function of Plk1.  Although high-affinity synthetic pThr-contg. peptides provide starting points for developing PBD-directed inhibitors, to date the efficacy of such peptides in whole cell assays has been poor.  This potentially reflects limited cell membrane permeability arising, in part, from the di-anionic nature of the phosphoryl group or its mimetics.  In our current article we report the unanticipated on-resin N(τ)-alkylation of histidine residues already bearing a N(π)- alkyl group.  This resulted in cationic imidazolium-contg. pThr peptides, several of which exhibit single-digit nanomolar PBD-binding affinities in extracellular assays and improved antimitotic efficacies in intact cells.  We enhanced the cellular efficacies of these peptides further by applying bio-reversible pivaloyloxymethyl (POM) phosphoryl protection.  New structural insights presented in our current study, including the potential utility of intramol. charge masking, may be useful for the further development of PBD-binding peptides and peptide mimetics. © 2014 Wiley Periodicals, Inc.  Biopolymers (Pept Sci) 102: 444-455, 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpj60b8IBsXrVg90H21EOLACvtfcHk0liauEIaqsk8lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksb3P&md5=a763d14198e9d304f0eb876cc933350f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fbip.22569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22569%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DLai%26aufirst%3DC.%2BC.%26aulast%3DKelley%26aufirst%3DJ.%2BA.%26aulast%3DPark%26aufirst%3DS.-Y.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26atitle%3DMono-anionic%2520Phosphopeptides%2520Produced%2520by%2520Unexpected%2520Histidine%2520Alkylation%2520Exhibit%2520High%2520Plk1%2520Polo-Box%2520Domain-Binding%2520Affinities%2520and%2520Enhanced%2520Antiproliferative%2520Effects%2520in%2520HeLa%2520Cells%26jtitle%3DBiopolymers%26date%3D2014%26volume%3D102%26spage%3D444%26epage%3D455%26doi%3D10.1002%2Fbip.22569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulaei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicklaus, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Analyses of Minimal Phosphopeptides Targeting the Polo-Box Domain of Polo-Like Kinase 1</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnsmb.1628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19597481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=876-882&author=S.-M.+Yunauthor=T.+Moulaeiauthor=D.+Limauthor=J.+K.+Bangauthor=J.-E.+Parkauthor=S.+R.+Shenoyauthor=F.+Liuauthor=Y.+H.+Kangauthor=C.+Liaoauthor=N.-K.+Soungauthor=S.+Leeauthor=D.-Y.+Yoonauthor=Y.+Limauthor=D.-H.+Leeauthor=A.+Otakaauthor=E.+Appellaauthor=J.+B.+McMahonauthor=M.+C.+Nicklausauthor=T.+R.+Burkeauthor=M.+B.+Yaffeauthor=A.+Wlodawerauthor=K.+S.+Lee&title=Structural+and+Functional+Analyses+of+Minimal+Phosphopeptides+Targeting+the+Polo-Box+Domain+of+Polo-Like+Kinase+1&doi=10.1038%2Fnsmb.1628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1</span></div><div class="casAuthors">Yun, Sang-Moon; Moulaei, Tinoush; Lim, Dan; Bang, Jeong K.; Park, Jung-Eun; Shenoy, Shilpa R.; Liu, Fa; Kang, Young H.; Liao, Chenzhong; Soung, Nak-Kyun; Lee, Sunhee; Yoon, Do-Young; Lim, Yoongho; Lee, Dong-Hee; Otaka, Akira; Appella, Ettore; McMahon, James B.; Nicklaus, Marc C.; Burke, Terrence R., Jr.; Yaffe, Michael B.; Wlodawer, Alexander; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">876-882</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polo-like kinase-1 (Plk1) has a pivotal role in cell proliferation and is considered a potential target for anticancer therapy.  The noncatalytic polo-box domain (PBD) of Plk1 forms a phosphoepitope binding module for protein-protein interaction.  Here, we report the identification of minimal phosphopeptides that specifically interact with the PBD of human PLK1, but not those of the closely related PLK2 and PLK3.  Comparative binding studies and analyses of crystal structures of the PLK1 PBD in complex with the minimal phosphopeptides revealed that the C-terminal SpT dipeptide functions as a high-affinity anchor, whereas the N-terminal residues are crucial for providing specificity and affinity to the interaction.  Inhibition of the PLK1 PBD by phosphothreonine mimetic peptides was sufficient to induce mitotic arrest and apoptotic cell death.  The mode of interaction between the minimal peptide and PBD may provide a template for designing therapeutic agents that target PLK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooHCw-v0d9drVg90H21EOLACvtfcHk0lhoFCTOd8U57g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsrk%253D&md5=3f275f41856641fbadbe8c7e54322855</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1628%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DS.-M.%26aulast%3DMoulaei%26aufirst%3DT.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DShenoy%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DKang%26aufirst%3DY.%2BH.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DSoung%26aufirst%3DN.-K.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DD.-Y.%26aulast%3DLim%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DD.-H.%26aulast%3DOtaka%26aufirst%3DA.%26aulast%3DAppella%26aufirst%3DE.%26aulast%3DMcMahon%26aufirst%3DJ.%2BB.%26aulast%3DNicklaus%26aufirst%3DM.%2BC.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DWlodawer%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DStructural%2520and%2520Functional%2520Analyses%2520of%2520Minimal%2520Phosphopeptides%2520Targeting%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-Like%2520Kinase%25201%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D876%26epage%3D882%26doi%3D10.1038%2Fnsmb.1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huggins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laraia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narvaez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts-Thomson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span> <span> </span><span class="NLM_article-title">Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b03626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b03626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKms7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=822-831&author=D.+J.+Hugginsauthor=B.+S.+Hardwickauthor=P.+Sharmaauthor=A.+Emeryauthor=L.+Laraiaauthor=F.+Zhangauthor=A.+J.+Narvaezauthor=M.+Roberts-Thomsonauthor=A.+T.+Crooksauthor=R.+G.+Boyleauthor=R.+Boyceauthor=D.+W.+Walkerauthor=N.+Mateuauthor=G.+J.+McKenzieauthor=D.+R.+Springauthor=A.+R.+Venkitaraman&title=Development+of+a+Novel+Cell-Permeable+Protein-Protein+Interaction+Inhibitor+for+the+Polo-box+Domain+of+Polo-like+Kinase+1&doi=10.1021%2Facsomega.9b03626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1</span></div><div class="casAuthors">Huggins, David J.; Hardwick, Bryn S.; Sharma, Pooja; Emery, Amy; Laraia, Luca; Zhang, Fengzhi; Narvaez, Ana J.; Roberts-Thomson, Meredith; Crooks, Alex T.; Boyle, Robert G.; Boyce, Richard; Walker, David W.; Mateu, Natalia; McKenzie, Grahame J.; Spring, David R.; Venkitaraman, Ashok R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">822-831</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (PLK1) is a key regulator of mitosis and a recognized drug target for cancer therapy.  Inhibiting the polo-box domain of PLK1 offers potential advantages of increased selectivity and subsequently reduced toxicity compared with targeting the kinase domain.  However, many if not all existing polo-box domain inhibitors have been shown to be unsuitable for further development.  In this paper, we describe a novel compd. series, which inhibits the protein-protein interactions of PLK1 via the polo-box domain.  We combine high throughput screening with mol. modeling and computer-aided design, synthetic chem., and cell biol. to address some of the common problems with protein-protein interaction inhibitors, such as soly. and potency.  We use mol. modeling to improve the soly. of a hit series with initially poor physicochem. properties, enabling biophys. and biochem. characterization.  We isolate and characterize enantiomers to improve potency and demonstrate on-target activity in both cell-free and cell-based assays, entirely consistent with the proposed binding model.  The resulting compd. series represents a promising starting point for further progression along the drug discovery pipeline and a new tool compd. to study kinase-independent PLK functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWFhsrh2HYrVg90H21EOLACvtfcHk0lgf0Agl8em6wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKms7%252FF&md5=f1582278a5175d17fa488eb9cc37b799</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b03626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b03626%26sid%3Dliteratum%253Aachs%26aulast%3DHuggins%26aufirst%3DD.%2BJ.%26aulast%3DHardwick%26aufirst%3DB.%2BS.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DEmery%26aufirst%3DA.%26aulast%3DLaraia%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNarvaez%26aufirst%3DA.%2BJ.%26aulast%3DRoberts-Thomson%26aufirst%3DM.%26aulast%3DCrooks%26aufirst%3DA.%2BT.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DBoyce%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DD.%2BW.%26aulast%3DMateu%26aufirst%3DN.%26aulast%3DMcKenzie%26aufirst%3DG.%2BJ.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DDevelopment%2520of%2520a%2520Novel%2520Cell-Permeable%2520Protein-Protein%2520Interaction%2520Inhibitor%2520for%2520the%2520Polo-box%2520Domain%2520of%2520Polo-like%2520Kinase%25201%26jtitle%3DACS%2520Omega%26date%3D2020%26volume%3D5%26spage%3D822%26epage%3D831%26doi%3D10.1021%2Facsomega.9b03626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huggins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunciw, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span> <span> </span><span class="NLM_article-title">A Cryptic Hydrophobic Pocket in the Polo-Box Domain of the Polo-like Kinase PLK1 Regulates Substrate Recognition and Mitotic Chromosome Segregation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">15930</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-50702-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fs41598-019-50702-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=31685831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BB3MjltVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=15930&author=P.+Sharmaauthor=R.+Mahenauthor=M.+Rossmannauthor=J.+E.+Stokesauthor=B.+Hardwickauthor=D.+J.+Hugginsauthor=A.+Emeryauthor=D.+L.+Kunciwauthor=M.+Hyvonenauthor=D.+R.+Springauthor=G.+J.+McKenzieauthor=A.+R.+Venkitaraman&title=A+Cryptic+Hydrophobic+Pocket+in+the+Polo-Box+Domain+of+the+Polo-like+Kinase+PLK1+Regulates+Substrate+Recognition+and+Mitotic+Chromosome+Segregation&doi=10.1038%2Fs41598-019-50702-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation</span></div><div class="casAuthors">Sharma Pooja; Mahen Robert; Hardwick Bryn; Emery Amy; McKenzie Grahame J; Venkitaraman Ashok R; Rossmann Maxim; Hyvonen Marko; Stokes Jamie E; Kunciw Dominique L; Spring David R; Huggins David J</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15930</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human polo-like kinase PLK1 coordinates mitotic chromosome segregation by phosphorylating multiple chromatin- and kinetochore-binding proteins.  How PLK1 activity is directed to specific substrates via phosphopeptide recognition by its carboxyl-terminal polo-box domain (PBD) is poorly understood.  Here, we combine molecular, structural and chemical biology to identify a determinant for PLK1 substrate recognition that is essential for proper chromosome segregation.  We show that mutations ablating an evolutionarily conserved, Tyr-lined pocket in human PLK1 PBD trigger cellular anomalies in mitotic progression and timing.  Tyr pocket mutations selectively impair PLK1 binding to the kinetochore phosphoprotein substrate PBIP1, but not to the centrosomal substrate NEDD1.  Through a structure-guided approach, we develop a small-molecule inhibitor, Polotyrin, which occupies the Tyr pocket.  Polotyrin recapitulates the mitotic defects caused by mutations in the Tyr pocket, further evidencing its essential function, and exemplifying a new approach for selective PLK1 inhibition.  Thus, our findings support a model wherein substrate discrimination via the Tyr pocket in the human PLK1 PBD regulates mitotic chromosome segregation to preserve genome integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmE_81mdt7jLqxQ2mb9Pu8fW6udTcc2eaio1Ze-XSqYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjltVKqtw%253D%253D&md5=39d6fd4ff6c560ee5256956716d1bd39</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-50702-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-50702-2%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DMahen%26aufirst%3DR.%26aulast%3DRossmann%26aufirst%3DM.%26aulast%3DStokes%26aufirst%3DJ.%2BE.%26aulast%3DHardwick%26aufirst%3DB.%26aulast%3DHuggins%26aufirst%3DD.%2BJ.%26aulast%3DEmery%26aufirst%3DA.%26aulast%3DKunciw%26aufirst%3DD.%2BL.%26aulast%3DHyvonen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26aulast%3DMcKenzie%26aufirst%3DG.%2BJ.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DA%2520Cryptic%2520Hydrophobic%2520Pocket%2520in%2520the%2520Polo-Box%2520Domain%2520of%2520the%2520Polo-like%2520Kinase%2520PLK1%2520Regulates%2520Substrate%2520Recognition%2520and%2520Mitotic%2520Chromosome%2520Segregation%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D15930%26doi%3D10.1038%2Fs41598-019-50702-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">17043</span>– <span class="NLM_lpage">17047</span>, <span class="refDoi"> DOI: 10.1002/anie.201809640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fanie.201809640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlCmu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=17043-17047&author=S.+Rubnerauthor=A.+Scharowauthor=S.+Schubertauthor=T.+Berg&title=Selective+Degradation+of+Polo-like+Kinase+1+by+a+Hydrophobically+Tagged+Inhibitor+of+the+Polo-Box+Domain&doi=10.1002%2Fanie.201809640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain</span></div><div class="casAuthors">Rubner, Stefan; Scharow, Andrej; Schubert, Sabine; Berg, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">17043-17047</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hydrophobic tagging (HT) of bioactive compds. can induce target degrdn. via the proteasomal pathway.  The first application of hydrophobic tagging to an existing inhibitor of protein-protein interactions is now presented.  We developed Poloxin-2HT by fusing an adamantyl tag to Poloxin-2, an inhibitor of the polo-box domain (PBD) of the protein kinase Plk1, which is a target for tumor therapy.  Poloxin-2HT selectively reduced the protein levels of Plk1 in HeLa cells and had a significantly stronger effect on cell viability and the induction of apoptosis than the untagged PBD inhibitor Poloxin-2.  The change in cellular phenotype assocd. with the addn. of the hydrophobic tag to Poloxin-2 demonstrated that Poloxin-2HT targets Plk1 in living cells.  Our data validate hydrophobic tagging of selective inhibitors of protein-protein interactions as a novel strategy to target and destroy disease-relevant proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_u-8CJlq93rVg90H21EOLACvtfcHk0lixNX1zro7AMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlCmu7nO&md5=4fc1c52c673ab5636d3bc78c40d90fc2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201809640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201809640%26sid%3Dliteratum%253Aachs%26aulast%3DRubner%26aufirst%3DS.%26aulast%3DScharow%26aufirst%3DA.%26aulast%3DSchubert%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DSelective%2520Degradation%2520of%2520Polo-like%2520Kinase%25201%2520by%2520a%2520Hydrophobically%2520Tagged%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domain%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D17043%26epage%3D17047%26doi%3D10.1002%2Fanie.201809640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelfatah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdoun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">MCC1019, a Selective Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 as Novel, Potent Anticancer Candidate</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.apsb.2019.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=31649851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BB3MjhsVyiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1021-1034&author=S.+Abdelfatahauthor=A.+Bergauthor=Q.+Huangauthor=L.+J.+Yangauthor=S.+Hamdounauthor=A.+Klingerauthor=H.+J.+Gretenauthor=E.+Fleischerauthor=T.+Bergauthor=V.+K.+W.+Wongauthor=T.+Efferth&title=MCC1019%2C+a+Selective+Inhibitor+of+the+Polo-Box+Domain+of+Polo-like+Kinase+1+as+Novel%2C+Potent+Anticancer+Candidate&doi=10.1016%2Fj.apsb.2019.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate</span></div><div class="casAuthors">Abdelfatah Sara; Hamdoun Sami; Efferth Thomas; Berg Angela; Berg Thorsten; Huang Qi; Yang Li Jun; Wong Vincent K W; Klinger Anette; Fleischer Edmond; Greten Henry J</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1034</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment.  Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity.  PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition.  We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD.  Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD.  The activity of compound MC1019 against the PLK1 PBD was confirmed using fluorescence polarization and microscale thermophoresis.  This compound exerted specificity towards PLK1 over PLK2 and PLK3.  MCC1019 showed cytotoxic activity in a panel of different cancer cell lines.  Mechanistic investigations in A549 lung adenocarcinoma cells revealed that MCC1019 induced cell growth inhibition through inactivation of AKT signaling pathway, it also induced prolonged mitotic arrest-a phenomenon known as mitotic catastrophe, which is followed by immediate cell death via apoptosis and necroptosis.  MCC1019 significantly inhibited tumor growth in vivo in a murine lung cancer model without affecting body weight or vital organ size, and reduced the growth of metastatic lesions in the lung.  We propose MCC1019 as promising anti-cancer drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvkjWQNLMrdtts4TFFB11gfW6udTcc2eZS90FJ2rNS97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjhsVyiug%253D%253D&md5=018084162f99502d13b93ae90757af77</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelfatah%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DL.%2BJ.%26aulast%3DHamdoun%26aufirst%3DS.%26aulast%3DKlinger%26aufirst%3DA.%26aulast%3DGreten%26aufirst%3DH.%2BJ.%26aulast%3DFleischer%26aufirst%3DE.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DMCC1019%252C%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-like%2520Kinase%25201%2520as%2520Novel%252C%2520Potent%2520Anticancer%2520Candidate%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D1021%26epage%3D1034%26doi%3D10.1016%2Fj.apsb.2019.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.1002/cbic.200900059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fcbic.200900059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19350612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVOnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1145-1148&author=W.+Reindlauthor=J.+Yuanauthor=A.+Kr%C3%A4merauthor=K.+Strebhardtauthor=T.+Berg&title=A+Pan-Specific+Inhibitor+of+the+Polo-Box+Domains+of+Polo-like+Kinases+Arrests+Cancer+Cells+in+Mitosis&doi=10.1002%2Fcbic.200900059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis</span></div><div class="casAuthors">Reindl, Wolfgang; Yuan, Juping; Kraemer, Andrea; Strebhardt, Klaus; Berg, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1145-1148</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Playing polo: Small-mol. inhibitors of polo-like kinase 1 are mostly ATP-competitive, and thus face enormous specificity hurdles.  This communication explores the concept of inhibiting Plk1 with a small-mol. inhibitor of the protein-protein interactions required for Plk1 function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxCZKviUmvb7Vg90H21EOLACvtfcHk0lj6m1_c00ZDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVOnt74%253D&md5=0eed2290f271030a44edaf04a45a370d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200900059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200900059%26sid%3Dliteratum%253Aachs%26aulast%3DReindl%26aufirst%3DW.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DA%2520Pan-Specific%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domains%2520of%2520Polo-like%2520Kinases%2520Arrests%2520Cancer%2520Cells%2520in%2520Mitosis%26jtitle%3DChemBioChem%26date%3D2009%26volume%3D10%26spage%3D1145%26epage%3D1148%26doi%3D10.1002%2Fcbic.200900059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Polo-Like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2008.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.chembiol.2008.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18482698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVSjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=459-466&author=W.+Reindlauthor=J.+Yuanauthor=A.+Kr%C3%A4merauthor=K.+Strebhardtauthor=T.+Berg&title=Inhibition+of+Polo-Like+Kinase+1+by+Blocking+Polo-Box+Domain-Dependent+Protein-Protein+Interactions&doi=10.1016%2Fj.chembiol.2008.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions</span></div><div class="casAuthors">Reindl, Wolfgang; Yuan, Juping; Kraemer, Andrea; Strebhardt, Klaus; Berg, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">459-466</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Ser/Thr kinase Polo-like kinase 1 (Plk1) is overexpressed in many types of human cancers, and was implicated as an adverse prognostic marker for cancer patients.  Plk1 localizes to its intracellular anchoring sites via its polo-box domain (PBD).  Here we show that Plk1 can be inhibited by small mols. which interfere with its intracellular localization by inhibiting the function of the PBD.  We report the natural product thymoquinone and, esp., the synthetic thymoquinone deriv. Poloxin as inhibitors of the Plk1 PBD.  Both compds. inhibit the function of the Plk1 PBD in vitro, and cause Plk1 mislocalization, chromosome congression defects, mitotic arrest, and apoptosis in HeLa cells.  These data validate the Plk1 PBD as an anticancer target and provide a rationale for developing thymoquinone derivs. as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVCWgVzGi04rVg90H21EOLACvtfcHk0lj6m1_c00ZDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVSjsL8%253D&md5=cb8a592799b8ac1a1d08868d1f0b7033</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DReindl%26aufirst%3DW.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520Polo-Like%2520Kinase%25201%2520by%2520Blocking%2520Polo-Box%2520Domain-Dependent%2520Protein-Protein%2520Interactions%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D459%26epage%3D466%26doi%3D10.1016%2Fj.chembiol.2008.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, H.</span></span> <span> </span><span class="NLM_article-title">Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-Dependent Recognition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">2344</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1074/jbc.m805308200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1074%2Fjbc.M805308200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19033445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=2344-2353&author=N.+Watanabeauthor=T.+Sekineauthor=M.+Takagiauthor=J.-i.+Iwasakiauthor=N.+Imamotoauthor=H.+Kawasakiauthor=H.+Osada&title=Deficiency+in+Chromosome+Congression+by+the+Inhibition+of+Plk1+Polo+Box+Domain-Dependent+Recognition&doi=10.1074%2Fjbc.m805308200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency in chromosome congression by the inhibition of Plk1 Polo box domain-dependent recognition</span></div><div class="casAuthors">Watanabe, Nobumoto; Sekine, Tomomi; Takagi, Masatoshi; Iwasaki, Jun-ichi; Imamoto, Naoko; Kawasaki, Hisashi; Osada, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) is one of the key regulators of mitotic cell division.  In addn. to an N-terminal protein kinase catalytic domain, Plk1 possesses a phosphopeptide binding domain named polo box domain (PBD) at its C terminus.  PBD is postulated to be essential for Plk1 localization and substrate targeting.  Here, we developed a high-throughput screening system to identify inhibitors of PBD-dependent binding and screened a chem. library.  We isolated a benzotropolone-contg. natural compd. derived from nutgalls (purpurogallin (PPG)) that inhibited PBD-dependent binding in vitro and in vivo.  PPG not only delayed the onset of mitosis but also prolonged the progression of mitosis in HeLa cells.  Although apparently normal bipolar spindles were formed even in the presence of PPG, the perturbation of chromosome alignment at metaphase plates activated the spindle assembly checkpoint pathway.  These results demonstrate the predominant role of PBD-dependent binding on smooth chromosome congression at metaphase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSwEPlVFENJ7Vg90H21EOLACvtfcHk0lj6m1_c00ZDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFeisg%253D%253D&md5=21d5ea87349844035483599db5e1f2b9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805308200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805308200%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSekine%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DJ.-i.%26aulast%3DImamoto%26aufirst%3DN.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DH.%26atitle%3DDeficiency%2520in%2520Chromosome%2520Congression%2520by%2520the%2520Inhibition%2520of%2520Plk1%2520Polo%2520Box%2520Domain-Dependent%2520Recognition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D2344%26epage%3D2353%26doi%3D10.1074%2Fjbc.m805308200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavallee, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beautrait, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archambault, V.</span></span> <span> </span><span class="NLM_article-title">Identification of Polo-like Kinase 1 Interaction Inhibitors Using a Novel Cell-Based Assay</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">37581</span>, <span class="refDoi"> DOI: 10.1038/srep37581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fsrep37581" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=37581&author=K.+Normandinauthor=J.+F.+Lavalleeauthor=M.+Futterauthor=A.+Beautraitauthor=J.+Duchaineauthor=S.+Guiralauthor=A.+Marinierauthor=V.+Archambault&title=Identification+of+Polo-like+Kinase+1+Interaction+Inhibitors+Using+a+Novel+Cell-Based+Assay&doi=10.1038%2Fsrep37581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fsrep37581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep37581%26sid%3Dliteratum%253Aachs%26aulast%3DNormandin%26aufirst%3DK.%26aulast%3DLavallee%26aufirst%3DJ.%2BF.%26aulast%3DFutter%26aufirst%3DM.%26aulast%3DBeautrait%26aufirst%3DA.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DArchambault%26aufirst%3DV.%26atitle%3DIdentification%2520of%2520Polo-like%2520Kinase%25201%2520Interaction%2520Inhibitors%2520Using%2520a%2520Novel%2520Cell-Based%2520Assay%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D37581%26doi%3D10.1038%2Fsrep37581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scharow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knappe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Development of Bifunctional Inhibitors of Polo-like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">767</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fcbic.201500535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26634982" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=759-767&author=A.+Scharowauthor=D.+Knappeauthor=W.+Reindlauthor=R.+Hoffmannauthor=T.+Berg&title=Development+of+Bifunctional+Inhibitors+of+Polo-like+Kinase+1+with+Low-Nanomolar+Activities+Against+the+Polo-Box+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500535%26sid%3Dliteratum%253Aachs%26aulast%3DScharow%26aufirst%3DA.%26aulast%3DKnappe%26aufirst%3DD.%26aulast%3DReindl%26aufirst%3DW.%26aulast%3DHoffmann%26aufirst%3DR.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520Bifunctional%2520Inhibitors%2520of%2520Polo-like%2520Kinase%25201%2520with%2520Low-Nanomolar%2520Activities%2520Against%2520the%2520Polo-Box%2520Domain%26jtitle%3DChemBioChem%26date%3D2015%26volume%3D17%26spage%3D759%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a Novel Polo-like Kinase 1 Inhibitor that Specifically Blocks the Functions of Polo-Box Domain</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1234</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.18632%2Foncotarget.13603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=27902479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhvFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1234-1246&author=Y.+Chenauthor=J.+Zhangauthor=D.+Liauthor=J.+Jiangauthor=Y.+Wangauthor=S.+Si&title=Identification+of+a+Novel+Polo-like+Kinase+1+Inhibitor+that+Specifically+Blocks+the+Functions+of+Polo-Box+Domain&doi=10.18632%2Foncotarget.13603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain</span></div><div class="casAuthors">Chen Yunyu; Zhang Jing; Li Dongsheng; Jiang Jiandong; Wang Yanchang; Si Shuyi; Wang Yanchang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1234-1246</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polo-like kinase 1 (Plk1) is a promising target for cancer therapy due to its essential role in cell division.  In addition to a highly conserved kinase domain, Plk1 also contains a Polo-Box domain (PBD), which is essential for Plk1's subcellular localization and mitotic functions.  We adopted a fluorescence polarization assay and identified a new Plk1 PBD inhibitor T521 from a small-molecule compound library.  T521 specifically inhibits the PBD of Plk1, but not those of Plk2-3.  T521 exhibits covalent binding to some lysine residues of Plk1 PBD, which causes significant changes in the secondary structure of Plk1 PBD.  Using a cell-based assay, we showed that T521 impedes the interaction between Plk1 and Bub1, a mitotic checkpoint protein.  Moreover, HeLa cells treated with T521 exhibited dramatic mitotic defects.  Importantly, T521 suppresses the growth of A549 cells in xenograft nude mice.  Taken together, we have identified a novel Plk1 inhibitor that specifically disrupts the functions of Plk1 PBD and shows anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcaWAdrH758FHFYivNCdPRfW6udTcc2ebTOH2nbIWgMLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhvFGgsA%253D%253D&md5=709ae17e7357c8cdc3047014b65daf37</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13603%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Polo-like%2520Kinase%25201%2520Inhibitor%2520that%2520Specifically%2520Blocks%2520the%2520Functions%2520of%2520Polo-Box%2520Domain%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D1234%26epage%3D1246%26doi%3D10.18632%2Foncotarget.13603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, K.-S.</span></span> <span> </span><span class="NLM_article-title">Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1462</span>, <span class="refDoi"> DOI: 10.1248/bpb.b17-00283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1248%2Fbpb.b17-00283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28867728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2rsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2017&pages=1454-1462&author=T.+G.+Kimauthor=J.+H.+Leeauthor=M.+Y.+Leeauthor=K.-U.+Kimauthor=J.+H.+Leeauthor=C.+H.+Parkauthor=B.+H.+Leeauthor=K.-S.+Oh&title=Development+of+a+High-Throughput+Assay+for+Inhibitors+of+the+Polo-Box+Domain+of+Polo-Like+Kinase+1+Based+on+Time-Resolved+Fluorescence+Energy+Transfer&doi=10.1248%2Fbpb.b17-00283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-throughput assay for inhibitors of the polo-box domain of polo-like kinase 1 based on time-resolved fluorescence energy transfer</span></div><div class="casAuthors">Kim, Tae Gi; Lee, Ju Hee; Lee, Mi Young; Kim, Ka-Ul; Lee, Jeong Hyun; Park, Chi Hoon; Lee, Byung Ho; Oh, Kwang-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1454-1462</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Although ELISA (ELISA) technol. has been widely accepted for binding assays against the polo-box domain (PBD) of polo-like kinase-1 (Plk1), these assays have a limitation-related heterogeneous procedure, such as multiple incubations and washing steps to apply high-throughput screenings (HTSs).  In the present study, a Plk1-PBD binding assay based on time-resolved fluorescence energy transfer (TR-FRET) was developed for HTS of PBD-binding inhibitors.  The TR-FRET-based Plk1-PBD binding assay is sensitive and robust and can be miniaturized into the 384-well plate-based format.  Compared with the ELISA-based Plk1-PBD binding assay (Z' factor, 0.53; signal-to-background ratio, 4.19), the TR-FRET-based Plk1-PBD binding assay improved the Z' factor (0.72) and signal-to-background ratio (8.16).  Using TR-FRET based Plk1-PBD binding assay, pilot library screening of 1019 natural compds. was conducted and five hit compds. such as haematoxylin, verbascoside, menadione, lithospermic acid and (1,3-dioxolo[4,5-g]isoquinolinium 5,6,7,8-tetrahydro-4-methoxy-6,6-dimethyl-5-[2-oxo-2-(2-pyridinyl)ethyl]-iodide) (DITMD) were identified as Plk1-PBD inhibitor.  In a functional assay to validate the hit compds., five hit compds. exhibited suppression of HeLa cells proliferation.  These results suggest that TR-FRET-based Plk1-PBD binding assay can be applied for an efficient and less time-consuming HTS of compd. libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT5YDFNeDJ9bVg90H21EOLACvtfcHk0lgWQ_eSYkFfHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2rsLnN&md5=f6f8b400d4bd45f1f8139c613f904a72</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b17-00283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b17-00283%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DKim%26aufirst%3DK.-U.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DOh%26aufirst%3DK.-S.%26atitle%3DDevelopment%2520of%2520a%2520High-Throughput%2520Assay%2520for%2520Inhibitors%2520of%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-Like%2520Kinase%25201%2520Based%2520on%2520Time-Resolved%2520Fluorescence%2520Energy%2520Transfer%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2017%26volume%3D40%26spage%3D1454%26epage%3D1462%26doi%3D10.1248%2Fbpb.b17-00283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel and Selective Non-Peptide Inhibitors Targeting the Polo-Box Domain of Polo-Like Kinase 1</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bioorg.2018.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=30170276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Smsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=278-288&author=Y.+Chenauthor=Z.+Liauthor=Y.+Liuauthor=T.+Linauthor=H.+Sunauthor=D.+Yangauthor=C.+Jiang&title=Identification+of+Novel+and+Selective+Non-Peptide+Inhibitors+Targeting+the+Polo-Box+Domain+of+Polo-Like+Kinase+1&doi=10.1016%2Fj.bioorg.2018.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1</span></div><div class="casAuthors">Chen, Yanhong; Li, Zhiyan; Liu, Yu; Lin, Tongyuan; Sun, Huiyong; Yang, Dasong; Jiang, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">278-288</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of non-peptide inhibitors targeting the polo-box domain (PBD) of polo-like kinase 1 (Plk1) was designed based on the potent and selective minimal tripeptide Plk1 PBD inhibitor.  Seven compds. were designed, synthesized and evaluated for fluorescence polarization (FP) assay.  The most promising compd. 10 bound to Plk1 PBD with IC50 of 3.37 μM and had no binding to Plk2 PBD or Plk3 PBD at 100 μM.  Mol. docking study was performed and possible binding mode was proposed.  MM/GBSA binding free energy calcn. were in agreement with the obsd. exptl. results.  These novel non-peptide selective Plk1 PBD inhibitors provided new lead compds. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKrHsqzfkRRbVg90H21EOLACvtfcHk0lgWQ_eSYkFfHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Smsb%252FM&md5=7d4e1b7c50e73280dfdf0159a58fa507</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520Novel%2520and%2520Selective%2520Non-Peptide%2520Inhibitors%2520Targeting%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-Like%2520Kinase%25201%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D278%26epage%3D288%26doi%3D10.1016%2Fj.bioorg.2018.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelfatah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böckers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 Identified by Virtual Screening</span>. <i>J. Adv. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.jare.2018.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.jare.2018.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=30899597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKktr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=145-156&author=S.+Abdelfatahauthor=A.+Bergauthor=M.+B%C3%B6ckersauthor=T.+Efferth&title=A+Selective+Inhibitor+of+the+Polo-Box+Domain+of+Polo-like+Kinase+1+Identified+by+Virtual+Screening&doi=10.1016%2Fj.jare.2018.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening</span></div><div class="casAuthors">Abdelfatah, Sara; Berg, Angela; Boeckers, Madeleine; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Advanced Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145-156</span>CODEN:
                <span class="NLM_cas:coden">JAROES</span>;
        ISSN:<span class="NLM_cas:issn">2090-1224</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study, in silico virtual drug screening, fluorescence polarization and microscale thermophoresis to identify new scaffolds targeting the polo-box domain of PLK1 was applied.  One compd., 3-{[(1R,9S)-3-(naphthalen-2-yl)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-11-yl]methyl}benzonitrile (designated compd. (1)), out of a total of 30,793 natural product derivs., inhibited the PLK1 PBD with high selectivity (IC50: 17.9 ± 0.5 μM).  This compd. inhibited the growth of cultured leukemia cells (CCRF-CEM and CEM/ADR5000) and arrested the cell cycle in the G2/M phase, which is characteristic for PLK1 inhibitors.  Immunofluorescence analyses showed that treatment with compd. (1) disrupted spindle formation due to the aberrant localization of PLK1 during the mitotic process, leading to G2/M arrest and ultimately cell death.  In conclusion, compd. (1) is a selective PLK1 inhibitor that inhibits cancer cell growth.  It represents a chem. scaffold for the future synthesis of new selective PLK1 inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh1DdqorQSvbVg90H21EOLACvtfcHk0lgWQ_eSYkFfHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKktr7L&md5=afd5eead207c623b4407258ad55fe798</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.jare.2018.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jare.2018.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelfatah%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DA.%26aulast%3DB%25C3%25B6ckers%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-like%2520Kinase%25201%2520Identified%2520by%2520Virtual%2520Screening%26jtitle%3DJ.%2520Adv.%2520Res.%26date%3D2019%26volume%3D16%26spage%3D145%26epage%3D156%26doi%3D10.1016%2Fj.jare.2018.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, M.-M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate Through Structure-Based Design</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4351</span>– <span class="NLM_lpage">4360</span>, <span class="refDoi"> DOI: 10.3390/molecules24234351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.3390%2Fmolecules24234351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4351-4360&author=Y.+Zhouauthor=F.+Yanauthor=X.+Huoauthor=M.-M.+Niu&title=Discovery+of+a+Potent+PLK1-PBD+Small-Molecule+Inhibitor+as+an+Anticancer+Drug+Candidate+Through+Structure-Based+Design&doi=10.3390%2Fmolecules24234351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent PLK1-PBD small-molecule inhibitor as an anticancer drug candidate through structure-based design</span></div><div class="casAuthors">Zhou, Yunjiang; Yan, Fang; Huo, Xiangyun; Niu, Miao-Miao</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4351</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Polo-box domain of polo-like kinase 1 (PLK1-PBD) has a pivotal role in cell proliferation and could be implicated as a potential anticancer target.  Although some small-mol. inhibitors have been developed, their clin. application has been restricted by the poor selectivity.  Therefore, there is an urgent need to develop effective PLK1-PBD inhibitors.  Herein, we have developed a virtual screening protocol to find PLK1-PBD inhibitors by using combination of structure-based pharmacophore modeling and mol. docking.  This protocol was successfully applied to screen PLK1-PBD inhibitors from specs database.  MTT assay indicated that five screened hits suppressed the growth of HeLa cells.  Particularly, hit-5, as a selective PLK1 inhibitor targeting PLK1-PBD, significantly inhibited the progression of HeLa cells-derived xenograft, with no obvious side effects.  This work demonstrates that hit-5 may be a potential anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV69vyNCDdSLVg90H21EOLACvtfcHk0lglvt9NXW6woQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisr3N&md5=19a897e8cd7d6c03ab20ced979366e32</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24234351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24234351%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DF.%26aulast%3DHuo%26aufirst%3DX.%26aulast%3DNiu%26aufirst%3DM.-M.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520PLK1-PBD%2520Small-Molecule%2520Inhibitor%2520as%2520an%2520Anticancer%2520Drug%2520Candidate%2520Through%2520Structure-Based%2520Design%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D4351%26epage%3D4360%26doi%3D10.3390%2Fmolecules24234351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idle, J. R.</span></span> <span> </span><span class="NLM_article-title">Pinning Down the Polo-Box Domain</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2008.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.chembiol.2008.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18482691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVSjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=415-416&author=K.+S.+Leeauthor=J.+R.+Idle&title=Pinning+Down+the+Polo-Box+Domain&doi=10.1016%2Fj.chembiol.2008.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pinning Down the Polo-Box Domain</span></div><div class="casAuthors">Lee, Kyung S.; Idle, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-416</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Polo-like kinase 1 (Plk1) appears to be an attractive target for anticancer therapy.  In this issue of Chem. & Biol., the identification of a small mol. called Poloxin is described that appears to interfere with the function of the polo-box domain (PBD) of Plk1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFS4t_tT8iWLVg90H21EOLACvtfcHk0lglvt9NXW6woQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVSjs70%253D&md5=b913229af35a2992cc0fd44248d6f01c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DIdle%26aufirst%3DJ.%2BR.%26atitle%3DPinning%2520Down%2520the%2520Polo-Box%2520Domain%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D415%26epage%3D416%26doi%3D10.1016%2Fj.chembiol.2008.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Archambault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, K.</span></span> <span> </span><span class="NLM_article-title">Several Inhibitors of the Plk1 Polo-Box Domain Turn Out to Be Non-Specific Protein Alkylators</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1220</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1080/15384101.2017.1325043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1080%2F15384101.2017.1325043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28521657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptlSgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1220-1224&author=V.+Archambaultauthor=K.+Normandin&title=Several+Inhibitors+of+the+Plk1+Polo-Box+Domain+Turn+Out+to+Be+Non-Specific+Protein+Alkylators&doi=10.1080%2F15384101.2017.1325043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators</span></div><div class="casAuthors">Archambault, Vincent; Normandin, Karine</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1220-1224</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">For almost a decade, there has been much interest in the development of chem. inhibitors of Polo-like kinase 1 (Plk1) protein interactions.  Plk1 is a master regulator of the cell division cycle that controls numerous substrates.  It is a promising target for cancer drug development.  Inhibitors of the kinase domain of Plk1 had some success in clin. trials.  However, they are not perfectly selective.  In principle, Plk1 can also be inhibited by interfering with its protein interaction domain, the Polo-Box Domain (PBD).  Selective chem. inhibitors of the PBD would constitute tools to probe for PBD-dependent functions of Plk1 and could be advantageous in cancer therapy.  The discovery of Poloxin and thymoquinone as PBD inhibitors indicated that small, cell-permeable chem. inhibitors could be identified.  Other efforts followed, including ours, reporting addnl. mols. capable of blocking the PBD.  It is now clear that, unfortunately, most of these compds. are non-specific protein alkylators (defined here as groups covalently added via a carbon) that have little or no potential for the development of real Plk1 PBD-specific drugs.  This situation should be minded by biologists potentially interested in using these compds. to study Plk1.  Further efforts are needed to develop selective, cell-permeable PBD inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK-O1l-4MHz7Vg90H21EOLACvtfcHk0lhzgs6YUNIjRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptlSgtbs%253D&md5=5f3a695bd266cc7eb9ebbb089de143b5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F15384101.2017.1325043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2017.1325043%26sid%3Dliteratum%253Aachs%26aulast%3DArchambault%26aufirst%3DV.%26aulast%3DNormandin%26aufirst%3DK.%26atitle%3DSeveral%2520Inhibitors%2520of%2520the%2520Plk1%2520Polo-Box%2520Domain%2520Turn%2520Out%2520to%2520Be%2520Non-Specific%2520Protein%2520Alkylators%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26spage%3D1220%26epage%3D1224%26doi%3D10.1080%2F15384101.2017.1325043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seong, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Self-regulated Plk1 Recruitment to Kinetochores by the Plk1-PBIP1 Interaction Is Critical for Proper Chromosome Segregation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2006.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.molcel.2006.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17081991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtF2qs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=409-422&author=Y.+H.+Kangauthor=J.-E.+Parkauthor=L.-R.+Yuauthor=N.-K.+Soungauthor=S.-M.+Yunauthor=J.+K.+Bangauthor=Y.-S.+Seongauthor=H.+Yuauthor=S.+Garfieldauthor=T.+D.+Veenstraauthor=K.+S.+Lee&title=Self-regulated+Plk1+Recruitment+to+Kinetochores+by+the+Plk1-PBIP1+Interaction+Is+Critical+for+Proper+Chromosome+Segregation&doi=10.1016%2Fj.molcel.2006.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation</span></div><div class="casAuthors">Kang, Young H.; Park, Jung-Eun; Yu, Li-Rong; Soung, Nak-Kyun; Yun, Sang-Moon; Bang, Jeong K.; Seong, Yeon-Sun; Yu, Hongtao; Garfield, Susan; Veenstra, Timothy D.; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-422</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The polo-box domain (PBD) of mammalian polo-like kinase 1 (Plk1) is essential in targeting its catalytic activity to specific subcellular structures crit. for mitosis.  The mechanism underlying Plk1 recruitment to the kinetochores and the role of Plk1 at this site remain elusive.  Here, we demonstrate that a PBD-binding protein, PBIP1, is crucial for recruiting Plk1 to the interphase and mitotic kinetochores.  Unprecedentedly, Plk1 phosphorylated PBIP1 at T78, creating a self-tethering site that specifically interacted with the PBD of Plk1, but not Plk2 or Plk3.  Later in mitosis, Plk1 also induced PBIP1 degrdn. in a T78-dependent manner, thereby enabling itself to interact with other components crit. for proper kinetochore functions.  Absence of the p-T78-dependent Plk1 localization induced a chromosome congression defect and compromised the spindle checkpoint, ultimately leading to aneuploidy.  Thus, Plk1 self-regulates the Plk1-PBIP1 interaction to localize to the kinetochores in a timely fashion and to promote proper chromosome segregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlddiJGIfzrVg90H21EOLACvtfcHk0ljiXvHRO_feVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtF2qs7jE&md5=db1bb5711b4dd5c83288cf5e88a524e7</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2006.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2006.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BH.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DYu%26aufirst%3DL.-R.%26aulast%3DSoung%26aufirst%3DN.-K.%26aulast%3DYun%26aufirst%3DS.-M.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DSeong%26aufirst%3DY.-S.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGarfield%26aufirst%3DS.%26aulast%3DVeenstra%26aufirst%3DT.%2BD.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DSelf-regulated%2520Plk1%2520Recruitment%2520to%2520Kinetochores%2520by%2520the%2520Plk1-PBIP1%2520Interaction%2520Is%2520Critical%2520for%2520Proper%2520Chromosome%2520Segregation%26jtitle%3DMol.%2520Cell%26date%3D2006%26volume%3D24%26spage%3D409%26epage%3D422%26doi%3D10.1016%2Fj.molcel.2006.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Discovery of A<sub>2A</sub> Adenosine Receptor Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3748</span>– <span class="NLM_lpage">3755</span>, <span class="refDoi"> DOI: 10.1021/jm100240h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100240h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3748-3755&author=J.+Carlssonauthor=L.+Yooauthor=Z.-G.+Gaoauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=K.+A.+Jacobson&title=Structure-Based+Discovery+of+A2A+Adenosine+Receptor+Ligands&doi=10.1021%2Fjm100240h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span></div><div class="casAuthors">Carlsson, Jens; Yoo, Lena; Gao, Zhan-Guo; Irwin, John J.; Shoichet, Brian K.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3748-3755</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent detn. of X-ray structures of pharmacol. relevant GPCRs has made these targets accessible to structure-based ligand discovery.  Here we explore whether novel chemotypes may be discovered for the A2A adenosine receptor, based on complementarity to its recently detd. structure.  The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as anti-inflammatory drugs and antagonists explored for neurodegenerative diseases.  We used mol. docking to screen a 1.4 million compd. database against the X-ray structure computationally and tested 20 high-ranking, previously unknown mols. exptl.  Of these 35% showed substantial activity with affinities between 200 nM and 9 μM.  For the most potent of these new inhibitors, over 50-fold specificity was obsd. for the A2A vs. the related A1 and A3 subtypes.  These high hit rates and affinities at least partly reflect the bias of com. libraries toward GPCR-like chemotypes, an issue that we attempt to investigate quant.  Despite this bias, many of the most potent new ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this medically important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvS6-9T9bd7Vg90H21EOLACvtfcHk0ljiXvHRO_feVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D&md5=c36c941d52d2cec06387d79c4c423d46</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm100240h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100240h%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DYoo%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-Based%2520Discovery%2520of%2520A2A%2520Adenosine%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3748%26epage%3D3755%26doi%3D10.1021%2Fjm100240h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimacombe, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheff, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karavadhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span> <span> </span><span class="NLM_article-title">Assessing Inhibitors of Mutant Isocitrate Dehydrogenase Using a Suite of Pre-Clinical Discovery Assays</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12758</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-12630-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fs41598-017-12630-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28986582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FmtFKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=12758&author=D.+J.+Urbanauthor=N.+J.+Martinezauthor=M.+I.+Davisauthor=K.+R.+Brimacombeauthor=D.+M.+Cheffauthor=T.+D.+Leeauthor=M.+J.+Hendersonauthor=S.+A.+Titusauthor=R.+Praganiauthor=J.+M.+Rohdeauthor=L.+Liuauthor=Y.+Fangauthor=S.+Karavadhiauthor=P.+Shahauthor=O.+W.+Leeauthor=A.+Wangauthor=A.+McIverauthor=H.+Zhengauthor=X.+Wangauthor=X.+Xuauthor=A.+Jadhavauthor=A.+Simeonovauthor=M.+Shenauthor=M.+B.+Boxerauthor=M.+D.+Hall&title=Assessing+Inhibitors+of+Mutant+Isocitrate+Dehydrogenase+Using+a+Suite+of+Pre-Clinical+Discovery+Assays&doi=10.1038%2Fs41598-017-12630-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays</span></div><div class="casAuthors">Urban Daniel J; Martinez Natalia J; Davis Mindy I; Brimacombe Kyle R; Cheff Dorian M; Lee Tobie D; Henderson Mark J; Titus Steven A; Pragani Rajan; Rohde Jason M; Liu Li; Fang Yuhong; Karavadhi Surendra; Shah Pranav; Lee Olivia W; Wang Amy; Xu Xin; Jadhav Ajit; Simeonov Anton; Shen Min; Boxer Matthew B; Hall Matthew D; McIver Andrew; Zheng Hongchao; Wang Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12758</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that are mutated in a variety of cancers to confer a gain-of-function activity resulting in the accumulation of an oncometabolite, D-2-hydroxyglutarate (2-HG).  Accumulation of 2-HG can result in epigenetic dysregulation and a block in cellular differentiation, suggesting these mutations play a role in neoplasia.  Based on its potential as a cancer target, a number of small molecule inhibitors have been developed to specifically inhibit mutant forms of IDH (mIDH1 and mIDH2).  We present a comprehensive suite of in vitro preclinical drug development assays that can be used as a tool-box to identify lead compounds for mIDH drug discovery programs, as well as what we believe is the most comprehensive publically available dataset on the top mIDH inhibitors.  This involved biochemical, cell-based, and tier-one ADME techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVx3wC5R7hFEodMGTatQ7LfW6udTcc2ebApfr0tjF60Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FmtFKitA%253D%253D&md5=0e9c5c76a90bd7575413735e7ca1a5e9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-12630-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-12630-x%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DD.%2BJ.%26aulast%3DMartinez%26aufirst%3DN.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DBrimacombe%26aufirst%3DK.%2BR.%26aulast%3DCheff%26aufirst%3DD.%2BM.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DTitus%26aufirst%3DS.%2BA.%26aulast%3DPragani%26aufirst%3DR.%26aulast%3DRohde%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DKaravadhi%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DO.%2BW.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DMcIver%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DAssessing%2520Inhibitors%2520of%2520Mutant%2520Isocitrate%2520Dehydrogenase%2520Using%2520a%2520Suite%2520of%2520Pre-Clinical%2520Discovery%2520Assays%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D12758%26doi%3D10.1038%2Fs41598-017-12630-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Highly Predictive and Interpretable Models for PAMPA Permeability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmc.2016.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28082071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1266-1276&author=H.+Sunauthor=K.+Nguyenauthor=E.+Kernsauthor=Z.+Yanauthor=K.+R.+Yuauthor=P.+Shahauthor=A.+Jadhavauthor=X.+Xu&title=Highly+Predictive+and+Interpretable+Models+for+PAMPA+Permeability&doi=10.1016%2Fj.bmc.2016.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Highly predictive and interpretable models for PAMPA permeability</span></div><div class="casAuthors">Sun, Hongmao; Nguyen, Kimloan; Kerns, Edward; Yan, Zhengyin; Yu, Kyeong Ri; Shah, Pranav; Jadhav, Ajit; Xu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug mol.  An in silico model predicting drug permeability is described, which is built based on a large permeability dataset of 7488 compd. entries or 5435 structurally unique mols. measured by the same lab using parallel artificial membrane permeability assay (PAMPA).  On the basis of customized mol. descriptors, the support vector regression (SVR) model trained with 4071 compds. with quant. data is able to predict the remaining 1364 compds. with the qual. data with an area under the curve of receiver operating characteristic (AUC-ROC) of 0.90.  The support vector classification (SVC) model trained with half of the whole dataset comprised of both the quant. and the qual. data produced accurate predictions to the remaining data with the AUC-ROC of 0.88.  The results suggest that the developed SVR model is highly predictive and provides medicinal chemists a useful in silico tool to facilitate design and synthesis of novel compds. with optimal drug-like properties, and thus accelerate the lead optimization in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y8FhTLLqbrVg90H21EOLACvtfcHk0liVkIQOMRCN_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlOhsA%253D%253D&md5=2f6b60dfcd168b5bf837405ca52457b2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DKerns%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DK.%2BR.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DHighly%2520Predictive%2520and%2520Interpretable%2520Models%2520for%2520PAMPA%2520Permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D1266%26epage%3D1276%26doi%3D10.1016%2Fj.bmc.2016.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Predictive Models of Aqueous Solubility of Organic Compounds Built on a Large Dataset of High Integrity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3110</span>– <span class="NLM_lpage">3114</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.05.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmc.2019.05.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=31176566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFClsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3110-3114&author=H.+Sunauthor=P.+Shahauthor=K.+Nguyenauthor=K.+R.+Yuauthor=E.+Kernsauthor=M.+Kabirauthor=Y.+Wangauthor=X.+Xu&title=Predictive+Models+of+Aqueous+Solubility+of+Organic+Compounds+Built+on+a+Large+Dataset+of+High+Integrity&doi=10.1016%2Fj.bmc.2019.05.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity</span></div><div class="casAuthors">Sun, Hongmao; Shah, Pranav; Nguyen, Kimloan; Yu, Katherine; Kerns, Ed; Kabir, Md; Wang, Yuhong; Xu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3110-3114</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aq. soly. is one of the most important properties in drug discovery, as it has profound impact on various drug properties, including biol. activity, pharmacokinetics (PK), toxicity, and in vivo efficacy.  Both kinetic and thermodn. solubilities are detd. during different stages of drug discovery and development.  Since kinetic soly. is more relevant in preclin. drug discovery research, esp. during the structure optimization process, the authors have developed predictive models for kinetic soly. with inhouse data generated from 11,780 compds. collected from over 200 NCATS intramural research projects.  This represents one of the largest kinetic soly. datasets of high quality and integrity.  Based on the customized atom type descriptors, the support vector classification (SVC) models were trained on 80% of the whole dataset, and exhibited high predictive performance for estg. the soly. of the remaining 20% compds. within the test set.  The values of the area under the receiver operating characteristic curve (AUC-ROC) for the compds. in the test sets reached 0.93 and 0.91, when the threshold for insol. compds. was set to 10 and 50 μg/mL, resp.  The predictive models of aq. soly. can be used to identify insol. compds. in drug discovery pipeline, provide design ideas for improving soly. by analyzing the atom types assocd. with poor soly. and prioritize compd. libraries to be purchased or synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfBZqnazp8KLVg90H21EOLACvtfcHk0liVkIQOMRCN_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFClsrnN&md5=8981617a93473ab5bc1112fc96e2c9fa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.05.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.05.037%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DK.%2BR.%26aulast%3DKerns%26aufirst%3DE.%26aulast%3DKabir%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DPredictive%2520Models%2520of%2520Aqueous%2520Solubility%2520of%2520Organic%2520Compounds%2520Built%2520on%2520a%2520Large%2520Dataset%2520of%2520High%2520Integrity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D3110%26epage%3D3114%26doi%3D10.1016%2Fj.bmc.2019.05.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lénárt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fiore, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipp, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-M.</span></span> <span> </span><span class="NLM_article-title">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights Into Mitotic Roles of Polo-Like Kinase 1</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cub.2006.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17291761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=304-315&author=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Steegmaierauthor=B.+Di+Fioreauthor=J.+J.+Lippauthor=M.+Hoffmannauthor=W.+J.+Rettigauthor=N.+Krautauthor=J.-M.+Peters&title=The+Small-Molecule+Inhibitor+BI+2536+Reveals+Novel+Insights+Into+Mitotic+Roles+of+Polo-Like+Kinase+1&doi=10.1016%2Fj.cub.2006.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1</span></div><div class="casAuthors">Lenart, Peter; Petronczki, Mark; Steegmaier, Martin; Di Fiore, Barbara; Lipp, Jesse J.; Hoffmann, Matthias; Rettig, Wolfgang J.; Kraut, Norbert; Peters, Jan-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-315</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensively to further understanding of mitotic mechanisms and as potential targets for cancer therapy.  Cdk1 and Aurora kinase studies have been facilitated by small-mol. inhibitors, but few if any potent Plk1 inhibitors have been identified.  We describe the cellular effects of a novel compd., BI 2536, a potent and selective inhibitor of Plk1.  The fact that BI 2536 blocks Plk1 activity fully and instantaneously enabled us to study controversial and unknown functions of Plk1.  Cells treated with BI 2536 are delayed in prophase but eventually import Cdk1-cyclin B into the nucleus, enter prometaphase, and degrade cyclin A, although BI 2536 prevents degrdn. of the APC/C inhibitor Emi1.  BI 2536-treated cells lack prophase microtubule asters and thus polymerize mitotic microtubules only after nuclear-envelope breakdown and form monopolar spindles that do not stably attach to kinetochores.  Mad2 accumulates at kinetochores, and cells arrest with an activated spindle-assembly checkpoint.  BI 2536 prevents Plk1's enrichment at kinetochores and centrosomes, and when added to metaphase cells, it induces detachment of microtubules from kinetochores and leads to spindle collapse.  Our results suggest that Plk1's accumulation at centrosomes and kinetochores depends on its own activity and that this activity is required for maintaining centrosome and kinetochore function.  Our data also show that Plk1 is not required for prophase entry, but delays transition to prometaphase, and that Emi1 destruction in prometaphase is not essential for APC/C-mediated cyclin A degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCmCcyKwjrX7Vg90H21EOLACvtfcHk0lhABvwG-5_pOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D&md5=4f0bc426138f64db93e17bf10a5f4db9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DDi%2BFiore%26aufirst%3DB.%26aulast%3DLipp%26aufirst%3DJ.%2BJ.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26atitle%3DThe%2520Small-Molecule%2520Inhibitor%2520BI%25202536%2520Reveals%2520Novel%2520Insights%2520Into%2520Mitotic%2520Roles%2520of%2520Polo-Like%2520Kinase%25201%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.cub.2006.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. S.</span></span> <span> </span><span class="NLM_article-title">Targeted Anti-Mitotic Therapies: Can We Improve on Tubulin Agents?</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1038/nrc2049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnrc2049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17251917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFOjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=107-117&author=J.+R.+Jacksonauthor=D.+R.+Patrickauthor=M.+M.+Darauthor=P.+S.+Huang&title=Targeted+Anti-Mitotic+Therapies%3A+Can+We+Improve+on+Tubulin+Agents%3F&doi=10.1038%2Fnrc2049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted anti-mitotic therapies: can we improve on tubulin agents?</span></div><div class="casAuthors">Jackson, Jeffrey R.; Patrick, Denis R.; Dar, Mohammed M.; Huang, Pearl S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-117</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The advent of molecularly targeted drug discovery has facilitated the identification of a new generation of anti-mitotic therapies that target proteins with specific functions in mitosis.  The exquisite selectivity for mitosis and the distinct ways in which these new agents interfere with mitosis provides the potential to not only overcome certain limitations of current tubulin-targeted anti-mitotic drugs, but to expand the scope of clin. efficacy that those drugs have established.  The development of these new anti-mitotic drugs as targeted therapies faces significant challenges; nevertheless, these potential therapies also serve as unique tools to dissect the mol. mechanisms of the mitotic-checkpoint response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEI9t3GggVrVg90H21EOLACvtfcHk0lhABvwG-5_pOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFOjtA%253D%253D&md5=67a94114629154b9be66428e697835bc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc2049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2049%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DTargeted%2520Anti-Mitotic%2520Therapies%253A%2520Can%2520We%2520Improve%2520on%2520Tubulin%2520Agents%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D107%26epage%3D117%26doi%3D10.1038%2Fnrc2049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Münch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, A.-V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wäsch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogatyreva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, A. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Polo-Like Kinase 1 Inhibition Results in Mitotic Arrest and Subsequent Cell Death of Blasts in the Bone Marrow of AML Patients and Has Similar Effects in Non-Neoplastic Cell Lines</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2015.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.leukres.2015.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25697066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFygt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=462-470&author=C.+M%C3%BCnchauthor=D.+Dragoiauthor=A.-V.+Freyauthor=K.+Thurigauthor=M.+L%C3%BCbbertauthor=R.+W%C3%A4schauthor=L.+Bogatyrevaauthor=D.+Hauschkeauthor=S.+Lassmannauthor=M.+Wernerauthor=A.+M.+May&title=Therapeutic+Polo-Like+Kinase+1+Inhibition+Results+in+Mitotic+Arrest+and+Subsequent+Cell+Death+of+Blasts+in+the+Bone+Marrow+of+AML+Patients+and+Has+Similar+Effects+in+Non-Neoplastic+Cell+Lines&doi=10.1016%2Fj.leukres.2015.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines</span></div><div class="casAuthors">Muench, Claudia; Dragoi, Diana; Frey, Anna-Verena; Thurig, Katja; Luebbert, Michael; Waesch, Ralph; Bogatyreva, Lioudmila; Hauschke, Dieter; Lassmann, Silke; Werner, Martin; May, Annette M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-470</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (PLK1) is an important regulator of the cell cycle and is overexpressed in various solid and hematol. malignancies.  Small mol. inhibitors targeting PLK1, such as BI2536 or BI6727 (Volasertib) are a promising therapeutic approach in such malignancies.  Here, we show a loss of specifically localized PLK1 in AML blasts in vivo, accompanied by mitotic arrest with transition into apoptosis, in bone marrow biopsies of AML patients after treatment with BI2536.  We verify these results in live cell imaging expts. with the AML cell line HL-60, and demonstrate that non-neoplastic, immortalized lymphoblastoid cells are also sensitive to PLK1 inhibition.  It is demonstrated that normal granulopoietic precursors have similar PLK1 expression levels as leukemic blasts.  These results are in line with the adverse effects of PLK1 inhibition and underline the great potential of PLK1 inhibitors in the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouncr8B53VwLVg90H21EOLACvtfcHk0lgD5PDyCjzjPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFygt7s%253D&md5=41b58df73efc6e8f3a63d6810b8fc1cd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCnch%26aufirst%3DC.%26aulast%3DDragoi%26aufirst%3DD.%26aulast%3DFrey%26aufirst%3DA.-V.%26aulast%3DThurig%26aufirst%3DK.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DW%25C3%25A4sch%26aufirst%3DR.%26aulast%3DBogatyreva%26aufirst%3DL.%26aulast%3DHauschke%26aufirst%3DD.%26aulast%3DLassmann%26aufirst%3DS.%26aulast%3DWerner%26aufirst%3DM.%26aulast%3DMay%26aufirst%3DA.%2BM.%26atitle%3DTherapeutic%2520Polo-Like%2520Kinase%25201%2520Inhibition%2520Results%2520in%2520Mitotic%2520Arrest%2520and%2520Subsequent%2520Cell%2520Death%2520of%2520Blasts%2520in%2520the%2520Bone%2520Marrow%2520of%2520AML%2520Patients%2520and%2520Has%2520Similar%2520Effects%2520in%2520Non-Neoplastic%2520Cell%2520Lines%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D462%26epage%3D470%26doi%3D10.1016%2Fj.leukres.2015.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandwein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepretre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Tidow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span> <span> </span><span class="NLM_article-title">Randomized, Phase 2 Trial of Low-Dose Cytarabine With or Without Volasertib in AML Patients Not Suitable for Induction Therapy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1426</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-03-560557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1182%2Fblood-2014-03-560557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25006120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgsFKksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1426-1433&author=H.+D%C3%B6hnerauthor=M.+L%C3%BCbbertauthor=W.+Fiedlerauthor=L.+Fouillardauthor=A.+Haalandauthor=J.+M.+Brandweinauthor=S.+Lepretreauthor=O.+Remanauthor=P.+Turlureauthor=O.+G.+Ottmannauthor=C.+M%C3%BCller-Tidowauthor=A.+Kr%C3%A4merauthor=E.+Raffouxauthor=K.+D%C3%B6hnerauthor=R.+F.+Schlenkauthor=F.+Vossauthor=T.+Taubeauthor=H.+Fritschauthor=J.+Maertens&title=Randomized%2C+Phase+2+Trial+of+Low-Dose+Cytarabine+With+or+Without+Volasertib+in+AML+Patients+Not+Suitable+for+Induction+Therapy&doi=10.1182%2Fblood-2014-03-560557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy</span></div><div class="casAuthors">Dohner Hartmut; Dohner Konstanze; Schlenk Richard F; Lubbert Michael; Fiedler Walter; Fouillard Loic; Haaland Alf; Brandwein Joseph M; Lepretre Stephane; Reman Oumedaly; Turlure Pascal; Ottmann Oliver G; Muller-Tidow Carsten; Kramer Alwin; Raffoux Emmanuel; Voss Florian; Taube Tillmann; Fritsch Holger; Maertens Johan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1426-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal.  This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor of polo-like kinases.  Eighty-seven patients (median age 75 years) received LDAC 20 mg twice daily subcutaneously days 1-10 or LDAC + volasertib 350 mg IV days 1 + 15 every 4 weeks.  Response rate (complete remission and complete remission with incomplete blood count recovery) was higher for LDAC + volasertib vs LDAC (31.0% vs 13.3%; odds ratio, 2.91; P = .052).  Responses in the LDAC + volasertib arm were observed across all genetic groups, including 5 of 14 patients with adverse cytogenetics.  Median event-free survival was significantly prolonged by LDAC + volasertib compared with LDAC (5.6 vs 2.3 months; hazard ratio, 0.57; 95% confidence interval, 0.35-0.92; P = .021); median overall survival was 8.0 vs 5.2 months, respectively (hazard ratio, 0.63; 95% confidence interval, 0.40-1.00; P = .047).  LDAC + volasertib led to an increased frequency of adverse events that was most pronounced for neutropenic fever/infections and gastrointestinal events; there was no increase in the death rate at days 60 + 90.  This study was registered at www.clinicaltrials.gov as #NCT00804856.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS913fFJ9KQsu2mnZh2OgS0fW6udTcc2eY8DiP9UWevyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgsFKksg%253D%253D&md5=b749d6547cea7f559c51559fb5f0add2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-03-560557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-03-560557%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DFouillard%26aufirst%3DL.%26aulast%3DHaaland%26aufirst%3DA.%26aulast%3DBrandwein%26aufirst%3DJ.%2BM.%26aulast%3DLepretre%26aufirst%3DS.%26aulast%3DReman%26aufirst%3DO.%26aulast%3DTurlure%26aufirst%3DP.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DM%25C3%25BCller-Tidow%26aufirst%3DC.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DVoss%26aufirst%3DF.%26aulast%3DTaube%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DMaertens%26aufirst%3DJ.%26atitle%3DRandomized%252C%2520Phase%25202%2520Trial%2520of%2520Low-Dose%2520Cytarabine%2520With%2520or%2520Without%2520Volasertib%2520in%2520AML%2520Patients%2520Not%2520Suitable%2520for%2520Induction%2520Therapy%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1426%26epage%3D1433%26doi%3D10.1182%2Fblood-2014-03-560557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span> <span> </span><span class="NLM_article-title">Volasertib for the Treatment of Acute Myeloid Leukemia: A Review of Preclinical and Clinical Development</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1165</span>, <span class="refDoi"> DOI: 10.2217/fon.14.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.2217%2Ffon.14.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24947257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1157-1165&author=M.+Janningauthor=W.+Fiedler&title=Volasertib+for+the+Treatment+of+Acute+Myeloid+Leukemia%3A+A+Review+of+Preclinical+and+Clinical+Development&doi=10.2217%2Ffon.14.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development</span></div><div class="casAuthors">Janning, Melanie; Fiedler, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1157-1165</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and PLK3.  PLKs are key regulators of the cell cycle and volasertib blocks cells in G2-M phase of the cell cycle.  The compd. has been evaluated in Phase I and II studies in acute myeloid leukemia and solid tumors.  Side effects are mainly hematol.  In acute myeloid leukemia (AML), a randomized Phase II study has been conducted in elderly patients unfit for intensive chemotherapy.  Patients have been randomized to a combination of volarsetib and low-dose cytarabine vs. low-dose cytarabine alone.  Preliminary results show significantly higher rates of complete remission and of complete remission with incomplete hematol. recovery in the combination vs. the monotherapy arm, with 31% and 13%, resp.  Longer event-free survival was obsd. with the combination with 5.6 vs. 2.3 mo, resp. (p = 0.0237).  These encouraging data supported the initiation of an international Phase III trial, which currently underway, to confirm these results.  Volasertib has not yet been approved for regular clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhCAxXOP3iebVg90H21EOLACvtfcHk0liBXBPVTqasTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjJ&md5=3a820e3d98b5bc9695aa67c5801e383e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.53%26sid%3Dliteratum%253Aachs%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26atitle%3DVolasertib%2520for%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%253A%2520A%2520Review%2520of%2520Preclinical%2520and%2520Clinical%2520Development%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D1157%26epage%3D1165%26doi%3D10.2217%2Ffon.14.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftimos, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costermans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forceville, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeus, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span> <span> </span><span class="NLM_article-title">Phase I Trial of Volasertib, a Polo-like Kinase Inhibitor, Plus Platinum Agents in Solid Tumors: Safety, Pharmacokinetics and Activity</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0223-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1007%2Fs10637-015-0223-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25794535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFentrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=611-620&author=A.+Awadaauthor=H.+Dumezauthor=P.+G.+Aftimosauthor=J.+Costermansauthor=S.+Bartholomeusauthor=K.+Forcevilleauthor=T.+Berghmansauthor=M.-A.+Meeusauthor=J.+Cescuttiauthor=G.+Munzertauthor=K.+Pilzauthor=D.+Liuauthor=P.+Sch%C3%B6ffski&title=Phase+I+Trial+of+Volasertib%2C+a+Polo-like+Kinase+Inhibitor%2C+Plus+Platinum+Agents+in+Solid+Tumors%3A+Safety%2C+Pharmacokinetics+and+Activity&doi=10.1007%2Fs10637-015-0223-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity</span></div><div class="casAuthors">Awada, Ahmad; Dumez, Herlinde; Aftimos, Philippe G.; Costermans, Jo; Bartholomeus, Sylvie; Forceville, Kathleen; Berghmans, Thierry; Meeus, Marie-Anne; Cescutti, Jessica; Munzert, Gerd; Pilz, Korinna; Liu, Dan; Schoffski, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">611-620</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background This trial evaluated the max. tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1 inhibitor that induces mitotic arrest and apoptosis, combined with cisplatin or carboplatin in patients with advanced/metastatic solid tumors (NCT00969761; 1230.6).  Methods Sequential patient cohorts (3 + 3 dose-escalation design) received a single infusion of volasertib (100-350 mg) with cisplatin (60-100 mg/m2) or carboplatin (area under the concn. vs. time curve [AUC]4-AUC6) on day 1 every 3 wk for up to six cycles.  Sixty-one patients received volasertib/cisplatin (n = 30) or volasertib/carboplatin (n = 31) for a median of 3.5 (range, 1-6) and 2.0 (range, 1-6) treatment cycles, resp.  Results The most common cycle 1 dose-limiting toxicities (DLTs) were thrombocytopenia, neutropenia and fatigue.  MTDs (based on cycle 1 DLTs) were detd. to be volasertib 300 mg plus cisplatin 100 mg/m2 and volasertib 300 mg plus carboplatin AUC6.  Co-administration did not affect the pharmacokinetics of each drug.  Partial responses were obsd. in two patients in each arm.  Stable disease was achieved in 11 and six patients treated with volasertib/cisplatin and volasertib/carboplatin, resp.  Conclusions Volasertib plus cisplatin or carboplatin at full single-agent doses was generally manageable and demonstrated activity in heavily pretreated patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_OcICZV1kyLVg90H21EOLACvtfcHk0lhvxxphIK1gug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFentrg%253D&md5=42ad57a310c9369b071600dc76391719</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0223-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0223-9%26sid%3Dliteratum%253Aachs%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DAftimos%26aufirst%3DP.%2BG.%26aulast%3DCostermans%26aufirst%3DJ.%26aulast%3DBartholomeus%26aufirst%3DS.%26aulast%3DForceville%26aufirst%3DK.%26aulast%3DBerghmans%26aufirst%3DT.%26aulast%3DMeeus%26aufirst%3DM.-A.%26aulast%3DCescutti%26aufirst%3DJ.%26aulast%3DMunzert%26aufirst%3DG.%26aulast%3DPilz%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26atitle%3DPhase%2520I%2520Trial%2520of%2520Volasertib%252C%2520a%2520Polo-like%2520Kinase%2520Inhibitor%252C%2520Plus%2520Platinum%2520Agents%2520in%2520Solid%2520Tumors%253A%2520Safety%252C%2520Pharmacokinetics%2520and%2520Activity%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D611%26epage%3D620%26doi%3D10.1007%2Fs10637-015-0223-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willemze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suciu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marie, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halkes, C. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistrik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specchia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbiano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sborgia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D. L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefrère, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beksac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berneman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luppi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marijt, E. W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venditti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilloni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisolini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span> <span> </span><span class="NLM_article-title">High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.51.8571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1200%2FJCO.2013.51.8571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24297940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFWnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=219-228&author=R.+Willemzeauthor=S.+Suciuauthor=G.+Meloniauthor=B.+Labarauthor=J.-P.+Marieauthor=C.+J.+M.+Halkesauthor=P.+Muusauthor=M.+Mistrikauthor=S.+Amadoriauthor=G.+Specchiaauthor=F.+Fabbianoauthor=F.+Nobileauthor=M.+Sborgiaauthor=A.+Cameraauthor=D.+L.+D.+Selleslagauthor=F.+Lefr%C3%A8reauthor=D.+Magroauthor=S.+Sicaauthor=N.+Cantoreauthor=M.+Beksacauthor=Z.+Bernemanauthor=X.+Thomasauthor=L.+Melilloauthor=J.+E.+Guimaraesauthor=P.+Leoniauthor=M.+Luppiauthor=M.+E.+Mitraauthor=D.+Mitraauthor=G.+Bronauthor=E.+W.+A.+Marijtauthor=A.+Vendittiauthor=A.+Hagemeijerauthor=M.+Manciniauthor=J.+Jansenauthor=D.+Cilloniauthor=L.+Meertauthor=P.+Faziauthor=M.+Vignettiauthor=S.+M.+Trisoliniauthor=F.+Mandelliauthor=T.+de+Witteauthor=T.+de+Witte&title=High-Dose+Cytarabine+in+Induction+Treatment+Improves+the+Outcome+of+Adult+Patients+Younger+Than+Age+46+Years+With+Acute+Myeloid+Leukemia%3A+Results+of+the+EORTC-GIMEMA+AML-12+Trial&doi=10.1200%2Fjco.2013.51.8571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial</span></div><div class="casAuthors">Willemze, Roelof; Suciu, Stefan; Meloni, Giovanna; Labar, Boris; Marie, Jean-Pierre; Halkes, Constantijn J. M.; Muus, Petra; Mistrik, Martin; Amadori, Sergio; Specchia, Giorgina; Fabbiano, Francesco; Nobile, Francesco; Sborgia, Marco; Camera, Andrea; Selleslag, Dominik L. D.; Lefrere, Francois, Sr.; Magro, Domenico; Sica, Simona; Cantore, Nicola; Beksac, Meral; Berneman, Zwi; Thomas, Xavier; Melillo, Lorella; Guimaraes, Jose E.; Leoni, Pietro; Luppi, Mario; Mitra, Maria E.; Bron, Dominique; Fillet, Georges; Marijt, Erik W. A.; Venditti, Adriano; Hagemeijer, Anne; Mancini, Marco; Jansen, Joop; Cilloni, Daniela; Meert, Liv; Fazi, Paola; Vignetti, Marco; Trisolini, Silvia M.; Mandelli, Franco; de Witte, Theo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML).  Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m2 for remission induction.  Consensus has not been reached on the benefit of higher dosages of cytarabine.  Patients and Methods: The European Organization for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment contg. daunorubicin, etoposide, and either std.-dose (SD) cytarabine (100 mg/m2 per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m2 every 12 h by 3-h infusion on days 1, 3, 5, and 7).  Patients in complete remission (CR) received a single consolidation cycle contg. daunorubicin and intermediate-dose cytarabine (500 mg/m2 every 12 h for 6 days).  Subsequently, a stem-cell transplantation was planned.  The primary end point was survival.  Results: At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable anal. P = .009).  For patients younger than age 46 years, survival was 43.3% and 51.9%, resp. (P = .009; multivariable anal. P = .003), and for patients age 46 to 60 years, survival was 33.9% and 32.9%, resp. (P = .91).  CR rates were 72.0% and 78.7%, resp. (P < .001) and were 75.6% and 82.4% for patients younger than age 46 years (P = .01) and 68.3% and 74.8% for patients age 46 years and older (P = .03).  Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with secondary AML benefitted from HD cytarabine.  Conclusion: HD cytarabine produces higher remission and survival rates than SD cytarabine, esp. in patients younger than age 46 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Iny8nPust7Vg90H21EOLACvtfcHk0lhvxxphIK1gug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFWnsro%253D&md5=7fcedb1679c242f077a192966e5b1dfd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.51.8571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.51.8571%26sid%3Dliteratum%253Aachs%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DSuciu%26aufirst%3DS.%26aulast%3DMeloni%26aufirst%3DG.%26aulast%3DLabar%26aufirst%3DB.%26aulast%3DMarie%26aufirst%3DJ.-P.%26aulast%3DHalkes%26aufirst%3DC.%2BJ.%2BM.%26aulast%3DMuus%26aufirst%3DP.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DSpecchia%26aufirst%3DG.%26aulast%3DFabbiano%26aufirst%3DF.%26aulast%3DNobile%26aufirst%3DF.%26aulast%3DSborgia%26aufirst%3DM.%26aulast%3DCamera%26aufirst%3DA.%26aulast%3DSelleslag%26aufirst%3DD.%2BL.%2BD.%26aulast%3DLefr%25C3%25A8re%26aufirst%3DF.%26aulast%3DMagro%26aufirst%3DD.%26aulast%3DSica%26aufirst%3DS.%26aulast%3DCantore%26aufirst%3DN.%26aulast%3DBeksac%26aufirst%3DM.%26aulast%3DBerneman%26aufirst%3DZ.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DMelillo%26aufirst%3DL.%26aulast%3DGuimaraes%26aufirst%3DJ.%2BE.%26aulast%3DLeoni%26aufirst%3DP.%26aulast%3DLuppi%26aufirst%3DM.%26aulast%3DMitra%26aufirst%3DM.%2BE.%26aulast%3DMitra%26aufirst%3DD.%26aulast%3DBron%26aufirst%3DG.%26aulast%3DMarijt%26aufirst%3DE.%2BW.%2BA.%26aulast%3DVenditti%26aufirst%3DA.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DMancini%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DMeert%26aufirst%3DL.%26aulast%3DFazi%26aufirst%3DP.%26aulast%3DVignetti%26aufirst%3DM.%26aulast%3DTrisolini%26aufirst%3DS.%2BM.%26aulast%3DMandelli%26aufirst%3DF.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26atitle%3DHigh-Dose%2520Cytarabine%2520in%2520Induction%2520Treatment%2520Improves%2520the%2520Outcome%2520of%2520Adult%2520Patients%2520Younger%2520Than%2520Age%252046%2520Years%2520With%2520Acute%2520Myeloid%2520Leukemia%253A%2520Results%2520of%2520the%2520EORTC-GIMEMA%2520AML-12%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D219%26epage%3D228%26doi%3D10.1200%2Fjco.2013.51.8571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Two Dosing Schedules of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Patients With Advanced Solid Malignancies</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2440</span>, <span class="refDoi"> DOI: 10.1038/bjc.2014.195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fbjc.2014.195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24755882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntVShs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=2434-2440&author=C.-C.+Linauthor=W.-C.+Suauthor=C.-J.+Yenauthor=C.-H.+Hsuauthor=W.-P.+Suauthor=K.-H.+Yehauthor=Y.-S.+Luauthor=A.-L.+Chengauthor=D.+C.-L.+Huangauthor=H.+Fritschauthor=F.+Vossauthor=T.+Taubeauthor=J.+C.-H.+Yang&title=A+Phase+I+Study+of+Two+Dosing+Schedules+of+Volasertib+%28BI+6727%29%2C+an+Intravenous+Polo-Like+Kinase+Inhibitor%2C+in+Patients+With+Advanced+Solid+Malignancies&doi=10.1038%2Fbjc.2014.195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies</span></div><div class="casAuthors">Lin, C.-C.; Su, W.-C.; Yen, C.-J.; Hsu, C.-H.; Su, W.-P.; Yeh, K.-H.; Lu, Y.-S.; Cheng, A.-L.; Huang, D. C.-L.; Fritsch, H.; Voss, F.; Taube, T.; Yang, J. C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2434-2440</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Polo-like kinase 1 (Plk1) has an important role in mitosis.  Volasertib (BI 6727), a potent and selective cell cycle kinase inhibitor, induces mitotic arrest and apoptosis by targeting Plk; this phase I study sought to det. its max. tolerated dose (MTD) in Asian patients with advanced solid tumors.  Methods: Patients were enrolled simultaneously into two 3-wk schedules of volasertib: a 2-h infusion on day 1 (schedule A) or days 1 and 8 (schedule B).  Dose escalation followed a 3+3 design.  The MTD was detd. based on dose-limiting toxicities (DLT) in the first treatment course.  Results: Among 59 treated patients, the most common first course DLTs were reversible thrombocytopenia, neutropenia and febrile neutropenia; MTDs were 300 mg for schedule A and 150 mg for schedule B.  Volasertib exhibited multi-exponential pharmacokinetics (PK), a long terminal half-life of ∼135 h, a large vol. of distribution (>3000 l), and a moderate clearance.  Partial responses were obsd. in two pre-treated patients (ureteral cancer; melanoma).  Volasertib was generally well tolerated, with an adverse event profile consistent with its antimitotic mode of action and a favorable PK profile.  Conclusions: These data support further development of volasertib and a harmonized dosing for Asian and Caucasian patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oPJHGDc887Vg90H21EOLACvtfcHk0lhvxxphIK1gug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntVShs7Y%253D&md5=c9007f0690e8034f62a9af551a64e5d7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.195%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DYen%26aufirst%3DC.-J.%26aulast%3DHsu%26aufirst%3DC.-H.%26aulast%3DSu%26aufirst%3DW.-P.%26aulast%3DYeh%26aufirst%3DK.-H.%26aulast%3DLu%26aufirst%3DY.-S.%26aulast%3DCheng%26aufirst%3DA.-L.%26aulast%3DHuang%26aufirst%3DD.%2BC.-L.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DVoss%26aufirst%3DF.%26aulast%3DTaube%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Two%2520Dosing%2520Schedules%2520of%2520Volasertib%2520%2528BI%25206727%2529%252C%2520an%2520Intravenous%2520Polo-Like%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520With%2520Advanced%2520Solid%2520Malignancies%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D110%26spage%3D2434%26epage%3D2440%26doi%3D10.1038%2Fbjc.2014.195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machiels, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herremans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specenier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Smet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelkowa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottey, S.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Volasertib Combined With Afatinib, in Advanced Solid Tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1007/s00280-015-2860-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1007%2Fs00280-015-2860-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26349473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=843-851&author=J.-P.+Machielsauthor=M.+Peetersauthor=C.+Herremansauthor=V.+Surmontauthor=P.+Specenierauthor=M.+De+Smetauthor=K.+Pilzauthor=N.+Strelkowaauthor=D.+Liuauthor=S.+Rottey&title=A+Phase+I+Study+of+Volasertib+Combined+With+Afatinib%2C+in+Advanced+Solid+Tumors&doi=10.1007%2Fs00280-015-2860-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of volasertib combined with afatinib, in advanced solid tumors</span></div><div class="casAuthors">Machiels, Jean-Pascal; Peeters, Marc; Herremans, Catherine; Surmont, Veerle; Specenier, Pol; De Smet, Marina; Pilz, Korinna; Strelkowa, Natalja; Liu, Dan; Rottey, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843-851</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To det. the max. tolerated dose (MTD) of volasertib, a Polo-like kinase inhibitor, combined with afatinib, an oral irreversible ErbB family blocker, in patients with advanced solid tumors (NCT01206816; Study 1230.20).  Methods: Patients with advanced non-resectable and/or metastatic disease following failure of conventional treatment received i.v. volasertib 150-300 mg on day 1 every 21 days, combined with oral afatinib 30-40 mg on days 2-21 of a 3-wk cycle (Schedule A), or 50-90 mg on days 2-6 of a 3-wk cycle (Schedule B).  The primary objective was to det. the MTD of volasertib in combination with afatinib.  Results: Fifty-seven patients (Schedule A, N = 29; Schedule B, N = 28) were treated.  The MTDs were volasertib 300 mg plus afatinib 30 mg days 2-21 and 70 mg days 2-6 of a 3-wk cycle for Schedules A and B, resp.  The most common Grade 3/4 adverse events were neutropenia (31.0 %), diarrhea (13.8 %), and thrombocytopenia (10.3 %) in Schedule A; neutropenia (39.3 %), thrombocytopenia (35.7 %), hypokalemia (14.3 %), febrile neutropenia, and nausea (each 10.7 %) in Schedule B.  The best overall response was two partial responses (6.9 %; both in Schedule A); eight patients in each schedule achieved stable disease.  Volasertib showed multi-exponential pharmacokinetic (PK) behavior; co-administration of volasertib and afatinib had no significant effects on the PK profile of either drug.  Conclusions: Volasertib combined with afatinib had manageable adverse effects and limited antitumor activity in this heavily pretreated population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWgk2_lwPvbVg90H21EOLACvtfcHk0lik3pV3gl1OSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbzP&md5=efbb81662f63d69d7508b5dd35486eb0</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00280-015-2860-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-015-2860-2%26sid%3Dliteratum%253Aachs%26aulast%3DMachiels%26aufirst%3DJ.-P.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DHerremans%26aufirst%3DC.%26aulast%3DSurmont%26aufirst%3DV.%26aulast%3DSpecenier%26aufirst%3DP.%26aulast%3DDe%2BSmet%26aufirst%3DM.%26aulast%3DPilz%26aufirst%3DK.%26aulast%3DStrelkowa%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DRottey%26aufirst%3DS.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Volasertib%2520Combined%2520With%2520Afatinib%252C%2520in%2520Advanced%2520Solid%2520Tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2015%26volume%3D76%26spage%3D843%26epage%3D851%26doi%3D10.1007%2Fs00280-015-2860-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascinu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitaleri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clementi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pas, T.</span></span> <span> </span><span class="NLM_article-title">A Phase I, Dose-Escalation Study of Volasertib Combined With Nintedanib in Advanced Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2341</span>– <span class="NLM_lpage">2346</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1093%2Fannonc%2Fmdv354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26395347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC283kslSisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2341-2346&author=F.+de%0ABraudauthor=S.+Cascinuauthor=G.+Spitaleriauthor=K.+Pilzauthor=L.+Clementiauthor=D.+Liuauthor=P.+Sikkenauthor=T.+De+Pas&title=A+Phase+I%2C+Dose-Escalation+Study+of+Volasertib+Combined+With+Nintedanib+in+Advanced+Solid+Tumors&doi=10.1093%2Fannonc%2Fmdv354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors</span></div><div class="casAuthors">de Braud F; Cascinu S; Spitaleri G; De Pas T; Pilz K; Liu D; Sikken P; Clementi L</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2341-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases.  This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors.  PATIENTS AND METHODS:  This open-label, dose-escalation trial recruited patients with advanced metastatic solid tumors following failure of conventional treatment (NCT01022853; Study 1230.7).  Volasertib was administered by intravenous infusion over 2 h, starting at 100 mg in the first dose cohort.  Nintedanib was administered orally at a dose of 200 mg twice daily.  The first treatment cycle comprised 28 days (days 1-7 and days 9-28: nintedanib; day 8: volasertib).  From cycle 2 onwards, volasertib was administered on day 1 of a 21-day cycle and nintedanib was administered days 2-21.  The primary objective was the MTD of volasertib in combination with nintedanib.  RESULTS:  Thirty patients were treated.  The MTD of volasertib plus fixed-dose nintedanib was 300 mg once every 3 weeks, the same as the recommended single-agent dose of volasertib in solid tumors.  Two of 12 assessable patients treated with the MTD experienced dose-limiting toxicities [grade 3 increased alanine aminotransferase (ALT); grade 3 ALT increase and grade 3 increased aspartate aminotransferase].  Disease control [stable disease (SD)/partial response (PR)/complete response (CR)] was achieved in 18 patients (60%): 1 CR (breast cancer), 1 PR (nonsmall-cell lung cancer), and 16 patients with SD.  Volasertib showed that multiexponential pharmacokinetic behavior and co-administration of nintedanib had no significant effects on its exposure.  CONCLUSIONS:  Volasertib could be combined with fixed-dose nintedanib at the recommended single-agent dose.  At this dose, the combination had a manageable safety profile without unexpected or overlapping adverse events, and showed antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRChqUf96U1lrGbPKh4T9eAfW6udTcc2eZrnixVHUZlEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283kslSisA%253D%253D&md5=afbd9117a3d69caf440aa0909fe8c2b3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv354%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DCascinu%26aufirst%3DS.%26aulast%3DSpitaleri%26aufirst%3DG.%26aulast%3DPilz%26aufirst%3DK.%26aulast%3DClementi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSikken%26aufirst%3DP.%26aulast%3DDe%2BPas%26aufirst%3DT.%26atitle%3DA%2520Phase%2520I%252C%2520Dose-Escalation%2520Study%2520of%2520Volasertib%2520Combined%2520With%2520Nintedanib%2520in%2520Advanced%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D2341%26epage%3D2346%26doi%3D10.1093%2Fannonc%2Fmdv354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetto, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taegtmeyer, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriuso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampkin, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients With Advanced Solid Malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3430</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-10-2946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1158%2F1078-0432.CCR-10-2946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=21459796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3420-3430&author=D.+Olmosauthor=D.+Barkerauthor=R.+Sharmaauthor=A.+T.+Brunettoauthor=T.+A.+Yapauthor=A.+B.+Taegtmeyerauthor=J.+Barriusoauthor=H.+Medaniauthor=Y.+Y.+Degenhardtauthor=A.+J.+Allredauthor=D.+A.+Smithauthor=S.+C.+Murrayauthor=T.+A.+Lampkinauthor=M.+M.+Darauthor=R.+Wilsonauthor=J.+S.+de+Bonoauthor=S.+P.+Blagden&title=Phase+I+Study+of+GSK461364%2C+a+Specific+and+Competitive+Polo-like+Kinase+1+Inhibitor%2C+in+Patients+With+Advanced+Solid+Malignancies&doi=10.1158%2F1078-0432.ccr-10-2946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Olmos, David; Barker, Douglas; Sharma, Rohini; Brunetto, Andre T.; Yap, Timothy A.; Taegtmeyer, Anne B.; Barriuso, Jorge; Medani, Hanine; Degenhardt, Yan Y.; Allred, Alicia J.; Smith, Deborah A.; Murray, Sharon C.; Lampkin, Thomas A.; Dar, Mohammed M.; Wilson, Richard; de Bono, Johann S.; Blagden, Sarah P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3420-3430</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1).  A phase I study of two schedules of i.v. GSK461364 was conducted.  Exptl. Design: GSK461364 was administered in escalating doses to patients with solid malignancies by two schedules, either on days 1, 8, and 15 of 28-day cycles (schedule A) or on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (schedule B).  Assessments included pharmacokinetic and pharmacodynamic profiles, as well as marker expression studies in pretreatment tumor biopsies.  RESULTS: Forty patients received GSK461364: 23 patients in schedule A and 17 in schedule B. Dose-limiting toxicities (DLT) in schedule A at 300 mg (2 of 7 patients) and 225 mg (1 of 8 patients) cohorts included grade 4 neutropenia and/or grade 3-4 thrombocytopenia.  In schedule B, DLTs of grade 4 pulmonary emboli and grade 4 neutropenia occurred at 7 or more days at 100 mg dose level.  Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3-4, drug-related events.  Pharmacokinetic data indicated that AUC (area under the curve) and Cmax (max. concn.) were proportional across doses, with a half-life of 9 to 13 h.  Pharmacodynamic studies in circulating tumor cells revealed an increase in phosphorylated histone H3 (pHH3) following drug administration.  A best response of prolonged stable disease of more than 16 wk occurred in 6 (15%) patients, including 4 esophageal cancer patients.  Those with prolonged stable disease had greater expression of Ki-67, pHH3, and Plk1 in archived tumor biopsies.  CONCLUSIONS: The final recommended phase II dose for GSK461364 was 225 mg administered i.v. in schedule A. Because of the high incidence (20%) of VTE, for further clin. evaluation, GSK461364 should involve coadministration of prophylactic anticoagulation.  Clin Cancer Res; 17(10); 3420-30.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOJ4inVI09-rVg90H21EOLACvtfcHk0lgZmlfG5BxiGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D&md5=3cf3213934f3a34aaeee469dc9cb6529</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2946%26sid%3Dliteratum%253Aachs%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DBarker%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DBrunetto%26aufirst%3DA.%2BT.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTaegtmeyer%26aufirst%3DA.%2BB.%26aulast%3DBarriuso%26aufirst%3DJ.%26aulast%3DMedani%26aufirst%3DH.%26aulast%3DDegenhardt%26aufirst%3DY.%2BY.%26aulast%3DAllred%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DMurray%26aufirst%3DS.%2BC.%26aulast%3DLampkin%26aufirst%3DT.%2BA.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26atitle%3DPhase%2520I%2520Study%2520of%2520GSK461364%252C%2520a%2520Specific%2520and%2520Competitive%2520Polo-like%2520Kinase%25201%2520Inhibitor%252C%2520in%2520Patients%2520With%2520Advanced%2520Solid%2520Malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D3420%26epage%3D3430%26doi%3D10.1158%2F1078-0432.ccr-10-2946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glomb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzert, G.</span></span> <span> </span><span class="NLM_article-title">A Phase I, Dose-Escalation Study of the Novel Polo-like Kinase Inhibitor Volasertib (BI 6727) In Patients With Advanced Solid Tumours</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2011.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.ejca.2011.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=22119200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC387gs1Oitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=179-186&author=P.+Sch%C3%B6ffskiauthor=A.+Awadaauthor=H.+Dumezauthor=T.+Gilauthor=S.+Bartholomeusauthor=P.+Wolterauthor=M.+Tatonauthor=H.+Fritschauthor=P.+Glombauthor=G.+Munzert&title=A+Phase+I%2C+Dose-Escalation+Study+of+the+Novel+Polo-like+Kinase+Inhibitor+Volasertib+%28BI+6727%29+In+Patients+With+Advanced+Solid+Tumours&doi=10.1016%2Fj.ejca.2011.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours</span></div><div class="casAuthors">Schoffski Patrick; Awada Ahmad; Dumez Herlinde; Gil Thierry; Bartholomeus Sylvie; Wolter Pascal; Taton Martine; Fritsch Holger; Glomb Patricia; Munzert Gerd</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer (Oxford, England : 1990)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk).  This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of volasertib, safety and efficacy, and pharmacokinetic (PK) parameters.  METHODS:  This trial followed an open-label, toxicity-guided dose-titration design.  Patients with progressive advanced or metastatic solid tumours received a single 1-h infusion of volasertib every 3 weeks.  A total of 65 patients were treated at doses of 12-450 mg.  RESULTS:  Reversible haematological toxicity was the main side-effect; thrombocytopenia, neutropenia, and febrile neutropenia constituting the main dose-limiting events.  Anaemia (all grades 22%; grade 3: 8%), neutropenia (15%; grade 3/4: 14%), fatigue (15%; grade 3: 2%), and thrombocytopenia (14%; grade 3/4: 14%) were the most frequent drug-related adverse events.  The MTD was 400mg; however, 300 mg was the recommended dose for further development based on overall tolerability.  Three patients achieved confirmed partial response.  Stable disease as best response was reported in 40% of patients.  Two patients remained progression free for >1 year.  PK analysis showed no indication of deviation from 'dose-linear PK' behaviour, a large volume of distribution (>4000 l), moderate clearance and a long half-life (~111 h).  CONCLUSION:  This first-in-man trial demonstrated a favourable PK profile of volasertib, with manageable toxicities.  As expected, the most common events were haematological.  Encouraging preliminary antitumour activity has been observed, supporting Plk inhibition as a therapeutic approach.  Clinical development of volasertib in phase II monotherapy and combination trials is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2sE1eVKpQRHRxY89Cm6SyfW6udTcc2eaUZkZ2NVtLN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387gs1Oitg%253D%253D&md5=ca4316cf6705a2cb92ab243c1c151c35</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2011.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2011.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DGil%26aufirst%3DT.%26aulast%3DBartholomeus%26aufirst%3DS.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DTaton%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DGlomb%26aufirst%3DP.%26aulast%3DMunzert%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%252C%2520Dose-Escalation%2520Study%2520of%2520the%2520Novel%2520Polo-like%2520Kinase%2520Inhibitor%2520Volasertib%2520%2528BI%25206727%2529%2520In%2520Patients%2520With%2520Advanced%2520Solid%2520Tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2012%26volume%3D48%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.ejca.2011.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bojadzic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180531092503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.2174%2F1568026618666180531092503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=29848279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=674-699&author=D.+Bojadzicauthor=P.+Buchwald&title=Toward+Small-Molecule+Inhibition+of+Protein-Protein+Interactions%3A+General+Aspects+and+Recent+Progress+in+Targeting+Costimulatory+and+Coinhibitory+%28Immune+Checkpoint%29+Interactions&doi=10.2174%2F1568026618666180531092503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions</span></div><div class="casAuthors">Bojadzic, Damir; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">674-699</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein-Protein Interactions (PPIs) that are part of the costimulatory and coinhibitory (immune checkpoint) signaling are crit. for adequate T cell response and are important therapeutic targets for immunomodulation.  Biologics targeting them have already achieved considerable clin. success in the treatment of autoimmune diseases or transplant recipients (e.g., abatacept, belatacept, and belimumab) as well as cancer (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab).  In view of such progress, there have been only relatively limited efforts toward developing small-mol. PPI inhibitors (SMPPIIs) targeting these cosignaling interactions, possibly because they, as all other PPIs, are difficult to target by small mols. and were not considered druggable.  Nevertheless, substantial progress has been achieved during the last decade.  SMPPIIs proving the feasibility of such approaches have been identified through various strategies for a no. of cosignaling interactions including CD40-CD40L, OX40-OX40L, BAFFR-BAFF, CD80-CD28, and PD-1-PD-L1s.  Here, after an overview of the general aspects and challenges of SMPPII-focused drug discovery, we review them briefly together with relevant structural, immune-signaling, physicochem., and medicinal chem. aspects.  While so far only a few of these SMPPIIs have shown activity in animal models (DRI-C21045 for CD40-D40L, KR33426 for BAFFR-BAFF) or reached clin. development (RhuDex for CD80-CD28, CA-170 for PD-1-PD-L1), there is proof-of-principle evidence for the feasibility of such approaches in immunomodulation.  They can result in products that are easier to develop/ manuf. and are less likely to be immunogenic or encounter postmarket safety events than corresponding biologics, and, contrary to them, can even become orally bioavailable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxFgcfDDFwirVg90H21EOLACvtfcHk0lgZmlfG5BxiGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM&md5=0c3c3adbf37198bf3db786209abb5892</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180531092503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180531092503%26sid%3Dliteratum%253Aachs%26aulast%3DBojadzic%26aufirst%3DD.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DToward%2520Small-Molecule%2520Inhibition%2520of%2520Protein-Protein%2520Interactions%253A%2520General%2520Aspects%2520and%2520Recent%2520Progress%2520in%2520Targeting%2520Costimulatory%2520and%2520Coinhibitory%2520%2528Immune%2520Checkpoint%2529%2520Interactions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D674%26epage%3D699%26doi%3D10.2174%2F1568026618666180531092503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Rational design of protein–protein interaction inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1039/c4md00328d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1039%2FC4MD00328D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=51-60&author=D.+Rognan&title=Rational+design+of+protein%E2%80%93protein+interaction+inhibitors&doi=10.1039%2Fc4md00328d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of protein-protein interaction inhibitors</span></div><div class="casAuthors">Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions are at the heart of most physiopathol. processes.  As such, they have attracted considerable attention for designing drugs of the future.  Although initially considered as high-value but difficult to identify, low mol. wt. compds. able to selectively and potently modulate protein-protein interactions have recently reached clin. trials.  Along with high-throughput screening of compd. libraries, combining structural and computational approaches has boosted this formerly minor area of research into a currently tremendously active field.  This review highlights the very recent developments in the rational design of protein-protein interaction inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrLT1KBf_9U7Vg90H21EOLACvtfcHk0lh45enVHDTrtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsLzF&md5=dc97477ed0e63d4338af4a7af59ac374</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1039%2FC4MD00328D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00328D%26sid%3Dliteratum%253Aachs%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DRational%2520design%2520of%2520protein%25E2%2580%2593protein%2520interaction%2520inhibitors%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D51%26epage%3D60%26doi%3D10.1039%2Fc4md00328d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceesay, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couchman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, A.</span></span> <span> </span><span class="NLM_article-title">Triazole Antifungals Used for Prophylaxis and Treatment of Invasive Fungal Disease in Adult Haematology Patients: Trough Serum Concentrations in Relation to Outcome</span>. <i>Med. Mycol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1093/mmy/myw031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1093%2Fmmy%2Fmyw031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=27161786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1Wmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2016&pages=691-698&author=M.+M.+Ceesayauthor=L.+Couchmanauthor=M.+Smithauthor=J.+Wadeauthor=R.+J.+Flanaganauthor=A.+Pagliuca&title=Triazole+Antifungals+Used+for+Prophylaxis+and+Treatment+of+Invasive+Fungal+Disease+in+Adult+Haematology+Patients%3A+Trough+Serum+Concentrations+in+Relation+to+Outcome&doi=10.1093%2Fmmy%2Fmyw031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: trough serum concentrations in relation to outcome</span></div><div class="casAuthors">Ceesay, M. Mansour; Couchman, Lewis; Smith, Melvyn; Wade, Jim; Flanagan, Robert J.; Pagliuca, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Medical Mycology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">691-698</span>CODEN:
                <span class="NLM_cas:coden">MEMYFR</span>;
        ISSN:<span class="NLM_cas:issn">1369-3786</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Triazole antifungal drugs are widely used for the prophylaxis and treatment of invasive fungal disease (IFD).  Efficacy may depend on attaining min. effective plasma concns.  The aim of this study was to ascertain the proportion of samples in which the recommended concns. were achieved in patients given these drugs in relation to outcome.  In-patients prescribed std. doses of fluconazole, itraconazole soln., posaconazole suspension, or oral voriconazole for at least one week were studied.  Pre-dose serum triazole concns. were measured using validated methods.  There were 359 samples from 90 patients.  The median (range) no. of samples per patient was 3 (1-13), and the median (range) fluconazole, itraconazole, posaconazole (prophylaxis), posaconazole (treatment), and voriconazole serum concns. were 5.64 (0.11-18), 0.57 (0-5.3), 0.31 (0.02-2.5), 0.65 (0.02-2.5), and 0.95 (0.10-5.4) mg/l, resp.  The no. of samples in which the recommended pre-dose concns. were achieved was 98 (54%), 9 (20%), 2 (18%), and 29 (49%) for itraconazole, posaconazole (>0.7 mg/l prophylaxis), posaconazole (treatment), and voriconazole, resp.  No significant differences were detected in the median triazole trough concns. between patients with proven/probable IFD compared to those with no evidence of IFD.  However, itraconazole was not detected in 10 samples (7 patients).  The small no. of patients who achieved the recommended trough posaconazole concns. may explain the high rate of break-through IFD obsd. in patients prescribed this drug.  Except for fluconazole, the no. of patients prescribed std. doses of triazoles who achieved recommended trough triazole concns. was low.  The prospective use of serum triazole measurements assay may have improved outcomes with itraconazole, posaconazole, and with voriconazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOpa98pzPvG7Vg90H21EOLACvtfcHk0lh45enVHDTrtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1Wmuro%253D&md5=a019097c496b15d3291dc90c6e69e883</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fmmy%2Fmyw031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmmy%252Fmyw031%26sid%3Dliteratum%253Aachs%26aulast%3DCeesay%26aufirst%3DM.%2BM.%26aulast%3DCouchman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DWade%26aufirst%3DJ.%26aulast%3DFlanagan%26aufirst%3DR.%2BJ.%26aulast%3DPagliuca%26aufirst%3DA.%26atitle%3DTriazole%2520Antifungals%2520Used%2520for%2520Prophylaxis%2520and%2520Treatment%2520of%2520Invasive%2520Fungal%2520Disease%2520in%2520Adult%2520Haematology%2520Patients%253A%2520Trough%2520Serum%2520Concentrations%2520in%2520Relation%2520to%2520Outcome%26jtitle%3DMed.%2520Mycol.%26date%3D2016%26volume%3D54%26spage%3D691%26epage%3D698%26doi%3D10.1093%2Fmmy%2Fmyw031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lass-Flörl, C.</span></span> <span> </span><span class="NLM_article-title">Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2419</span>, <span class="refDoi"> DOI: 10.2165/11596540-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.2165%2F11596540-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=22141384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FltFajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2405-2419&author=C.+Lass-Fl%C3%B6rl&title=Triazole+Antifungal+Agents+in+Invasive+Fungal+Infections%3A+A+Comparative+Review&doi=10.2165%2F11596540-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole antifungal agents in invasive fungal infections: a comparative review</span></div><div class="casAuthors">Lass-Florl Cornelia</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2405-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Invasive fungal disease continues to be a problem associated with significant morbidity and high mortality in immunocompromised and, to a lesser extent, immunocompetent individuals.  Triazole antifungals have emerged as front-line drugs for the treatment and prophylaxis of many systemic mycoses.  Fluconazole plays an excellent role in prophylaxis, empirical therapy, and the treatment of both superficial and invasive yeast fungal infections.  Voriconazole is strongly recommended for pulmonary invasive aspergillosis.  Posaconazole shows a very wide spectrum of activity and its primary clinical indications are as salvage therapy for patients with invasive aspergillosis and prophylaxis for patients with neutropenia and haematopoietic stem-cell transplant recipients.  Itraconazole also has a role in the treatment of fungal skin and nail infections as well as dematiaceous fungi and endemic mycoses.  Fluconazole and voriconazole are well absorbed and exhibit high oral bioavailability, whereas the oral bioavailability of itraconazole and posaconazole is lower and more variable.  Posaconazole absorption depends on administration with a high-fat meal or nutritional supplements.  Itraconazole and voriconazole undergo extensive hepatic metabolism involving the cytochrome P450 system.  The therapeutic window for triazoles is narrow, and inattention to their pharmacokinetic properties can lead to drug levels too low for efficacy or too high for good tolerability or safety.  This makes these agents prime candidates for therapeutic drug monitoring (TDM).  Target drug concentrations for voriconazole and itraconazole should be >1 μg/mL and for posaconazole >1.5 μg/mL for treatment.  Blood should be drawn once the patient reaches steady state, which occurs after 5 and 7 days of triazole therapy.  Routine TDM of fluconazole is not required given its highly favourable pharmacokinetic profile and wide therapeutic index.  The aim of this review is to provide a brief update on the pharmacology, activity, clinical efficacy, safety and cost of triazole agents (itraconazole, fluconazole, voriconazole and posaconazole) and highlight the clinical implications of similarities and differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdDzNfOIknD4IRAdBLKY41fW6udTcc2eZpSnxvd9Day7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FltFajsw%253D%253D&md5=7f032dbd61751d93e10358852c7b89bb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2165%2F11596540-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596540-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DLass-Fl%25C3%25B6rl%26aufirst%3DC.%26atitle%3DTriazole%2520Antifungal%2520Agents%2520in%2520Invasive%2520Fungal%2520Infections%253A%2520A%2520Comparative%2520Review%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D2405%26epage%3D2419%26doi%3D10.2165%2F11596540-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shagufta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span> <span> </span><span class="NLM_article-title">An Insight Into the Therapeutic Potential of Quinazoline Derivatives as Anticancer Agents</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1039/c7md00097a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1039%2FC7MD00097A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=30108803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslCrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=871-885&author=S.+Shaguftaauthor=I.+Ahmad&title=An+Insight+Into+the+Therapeutic+Potential+of+Quinazoline+Derivatives+as+Anticancer+Agents&doi=10.1039%2Fc7md00097a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">An insight into the therapeutic potential of quinazoline derivatives as anticancer agents</span></div><div class="casAuthors">Shagufta; Ahmad, Irshad</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">871-885</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cancer is one of the major causes of worldwide human mortality.  A wide range of cytotoxic drugs are available on the market, and several compds. are in different phases of clin. trials.  Many studies suggest that these cytotoxic mols. are also assocd. with different types of adverse side effects; therefore researchers around the globe are involved in the development of more efficient and safer anticancer drugs.  In recent years, quinazoline and its derivs. have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors.  The aim of this article is to comprehensively review and highlight the recent developments concerning the anticancer activity of quinazoline derivs. as well as offer perspectives on the development of novel quinazoline derivs. as anticancer agents in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ0qD4nxDYQLVg90H21EOLACvtfcHk0ljMlpPGHWvltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslCrtbw%253D&md5=2b5e331baaa9beb7e6dc14e7e439add3</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1039%2FC7MD00097A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00097A%26sid%3Dliteratum%253Aachs%26aulast%3DShagufta%26aufirst%3DS.%26aulast%3DAhmad%26aufirst%3DI.%26atitle%3DAn%2520Insight%2520Into%2520the%2520Therapeutic%2520Potential%2520of%2520Quinazoline%2520Derivatives%2520as%2520Anticancer%2520Agents%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D871%26epage%3D885%26doi%3D10.1039%2Fc7md00097a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritschel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, S. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreurs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Heuvel, J. J. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderink, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greupink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G. M.</span></span> <span> </span><span class="NLM_article-title">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds Through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1021/tx5000393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5000393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=873-881&author=T.+Ritschelauthor=S.+M.+A.+Hermansauthor=M.+Schreursauthor=J.+J.+M.+W.+van+den+Heuvelauthor=J.+B.+Koenderinkauthor=R.+Greupinkauthor=F.+G.+M.+Russel&title=In+Silico+Identification+and+in+Vitro+Validation+of+Potential+Cholestatic+Compounds+Through+3D+Ligand-Based+Pharmacophore+Modeling+of+BSEP+Inhibitors&doi=10.1021%2Ftx5000393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span></div><div class="casAuthors">Ritschel, Tina; Hermans, Susanne M. A.; Schreurs, Marieke; van den Heuvel, Jeroen J. M. W.; Koenderink, Jan B.; Greupink, Rick; Russel, Frans G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">873-881</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced cholestasis is a frequently obsd. side effect of drugs and is often caused by an unexpected interaction with the bile salt export pump (BSEP/ABCB11).  BSEP is the key membrane transporter responsible for the transport of bile acids from hepatocytes into bile.  Here, we developed a pharmacophore model that describes the mol. features of compds. assocd. with BSEP inhibitory activity.  To generate input and validation data sets, in vitro expts. with membrane vesicles overexpressing human BSEP were used to assess the effect of compds. (50 μM) on BSEP-mediated 3H-taurocholic acid transport.  The model contains two hydrogen bond acceptor/anionic features, two hydrogen bond acceptor vector features, four hydrophobic/arom. features, and exclusion vols.  The pharmacophore was validated against a set of 59 compds., including registered drugs.  The model recognized 9 out of 12 inhibitors (75%), which could not be identified based on general parameters, such as mol. wt. or SlogP, alone.  Finally, the model was used to screen a virtual compd. database.  A no. of compds. found via virtual screening were tested and displayed statistically significant BSEP inhibition, ranging from 13±1% to 67±7% of control (P < 0.05).  In conclusion, we developed and validated a pharmacophore model that describes mol. features found in BSEP inhibitors.  The model may be used as an in silico screening tool to identify potentially harmful drug candidates at an early stage in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhv5ltUmvILVg90H21EOLACvtfcHk0ljMlpPGHWvltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D&md5=95ecfad2ba7f4cd40dc2ed2f064ed7fb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Ftx5000393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5000393%26sid%3Dliteratum%253Aachs%26aulast%3DRitschel%26aufirst%3DT.%26aulast%3DHermans%26aufirst%3DS.%2BM.%2BA.%26aulast%3DSchreurs%26aufirst%3DM.%26aulast%3Dvan%2Bden%2BHeuvel%26aufirst%3DJ.%2BJ.%2BM.%2BW.%26aulast%3DKoenderink%26aufirst%3DJ.%2BB.%26aulast%3DGreupink%26aufirst%3DR.%26aulast%3DRussel%26aufirst%3DF.%2BG.%2BM.%26atitle%3DIn%2520Silico%2520Identification%2520and%2520in%2520Vitro%2520Validation%2520of%2520Potential%2520Cholestatic%2520Compounds%2520Through%25203D%2520Ligand-Based%2520Pharmacophore%2520Modeling%2520of%2520BSEP%2520Inhibitors%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D873%26epage%3D881%26doi%3D10.1021%2Ftx5000393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one and Its Derivatives</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1002/ardp.201500115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fardp.201500115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26053879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Wgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=564-574&author=H.-J.+Zhangauthor=P.+Jinauthor=S.-B.+Wangauthor=F.-N.+Liauthor=L.-P.+Guanauthor=Z.-S.+Quan&title=Synthesis+and+Anticonvulsant+Activity+Evaluation+of+4-Phenyl-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dquinazolin-5%284H%29-one+and+Its+Derivatives&doi=10.1002%2Fardp.201500115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one and Its Derivatives</span></div><div class="casAuthors">Zhang, Hong-Jian; Jin, Peng; Wang, Shi-Ben; Li, Fu-Nan; Guan, Li-Ping; Quan, Zhe-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">564-574</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of 4-(substituted-phenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones I [R = H, 4-Cl, 2-F, 3,4-Me2, etc.] and other heterocyclic compds., e.g., II, were synthesized and evaluated for their anticonvulsant activity and neurotoxicity by maximal electroshock (MES) and rotarod neurotoxicity tests.  Among the compds. studied, I [R = 4-Cl, 4-Br] (III) showed wide margins of safety with protective indexes (PIs) that were much higher than those of currently used drugs (PI6o >25.5, PI6q >26.0).  III showed significant oral activity against MES-induced seizures in mice, with ED50 values of 88.02 and 94.6 mg/kg, resp.  Moreover, these two compds. were also found to have potent activity against seizures that were induced by pentylenetetrazole and bicuculline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpECw9881KEoLVg90H21EOLACvtfcHk0ljMlpPGHWvltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Wgtbk%253D&md5=0fe407922af8fcefd5fc924bafaa3252</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fardp.201500115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201500115%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DLi%26aufirst%3DF.-N.%26aulast%3DGuan%26aufirst%3DL.-P.%26aulast%3DQuan%26aufirst%3DZ.-S.%26atitle%3DSynthesis%2520and%2520Anticonvulsant%2520Activity%2520Evaluation%2520of%25204-Phenyl-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dquinazolin-5%25284H%2529-one%2520and%2520Its%2520Derivatives%26jtitle%3DArch.%2520Pharm.%26date%3D2015%26volume%3D348%26spage%3D564%26epage%3D574%26doi%3D10.1002%2Fardp.201500115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antidepressant Activities of 4-(substituted-phenyl)tetrazolo[1,5-a]quinazolin-5(4H)-ones and Their Derivatives</span>. <i>Mol. Divers.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1007/s11030-015-9623-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1007%2Fs11030-015-9623-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26251313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12lsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=817-828&author=H.-J.+Zhangauthor=S.-B.+Wangauthor=Z.-S.+Quan&title=Synthesis+and+Antidepressant+Activities+of+4-%28substituted-phenyl%29tetrazolo%5B1%2C5-a%5Dquinazolin-5%284H%29-ones+and+Their+Derivatives&doi=10.1007%2Fs11030-015-9623-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antidepressant activities of 4-(substituted-phenyl)tetrazolo[1,5-a]quinazolin-5(4H)-ones and their derivatives</span></div><div class="casAuthors">Zhang, Hong-Jian; Wang, Shi-Ben; Quan, Zhe-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Diversity</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">817-828</span>CODEN:
                <span class="NLM_cas:coden">MODIF4</span>;
        ISSN:<span class="NLM_cas:issn">1381-1991</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A series of novel 4-(substituted-phenyl) tetrazolo[1,5-a]quinazolin-5(4H)-ones (6a-x) and their derivs. with tetrazole and other heterocyclic substituents (7-14) were designed, synthesized, and evaluated for antidepressant activities in mice.  Pharmacol. tests showed that three compds. (6l, 6u, and 6v) at a dose of 50 mg/kg significantly reduced the immobility time in the forced swimming test.  The most active compd. was 4-(p-tolyl)tetrazolo[1,5-a]quinazolin-5(4H)-one (6v), which decreased the immobility time by 82.69 % at 50 mg/kg.  Moreover, 6v did not affect spontaneous activity in the open-field test, and this effect was comparable to the antidepressant effect of fluoxetine.  Noradrenaline (NE) and 5-hydroxytryptamine (5-HT) levels in the brains of mice in the test sample groups significantly increased at a dose of 50 mg/kg compared with that in the control group.  The monoamine oxidase (MAO) level of all test groups was reduced, but this result was not significantly different between the groups.  Therefore, we can infer that their underlying mechanisms may involve the regulation of brain monoamine neurotransmitter homeostasis, based on the detected content of NE, 5-HT, and MAO in mouse brain tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsF4abAq8MGbVg90H21EOLACvtfcHk0lj0FXW5prBT4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12lsr7L&md5=4bf045c4170c367d78076f5522c15a2a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs11030-015-9623-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-015-9623-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DQuan%26aufirst%3DZ.-S.%26atitle%3DSynthesis%2520and%2520Antidepressant%2520Activities%2520of%25204-%2528substituted-phenyl%2529tetrazolo%255B1%252C5-a%255Dquinazolin-5%25284H%2529-ones%2520and%2520Their%2520Derivatives%26jtitle%3DMol.%2520Divers.%26date%3D2015%26volume%3D19%26spage%3D817%26epage%3D828%26doi%3D10.1007%2Fs11030-015-9623-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span>; <span class="NLM_string-name">Nagpal, N.</span>; <span class="NLM_string-name">Fong, Y.</span></span> <span> </span><span class="NLM_article-title">PAPD5 Inhibitors and Methods of Use Thereof</span>. U.S. Patent <span class="NLM_patent">WO 2019084271 A1</span>, May 2, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Agarwal&author=N.+Nagpal&author=Y.+Fong&title=PAPD5+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26atitle%3DPAPD5%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ram, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srimal, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushwaha, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, L.</span></span> <span> </span><span class="NLM_article-title">Chemoterapeutic Agents. XIX. Synthesis of [1,2,4]-Triazoloquinazolinones and Related Compounds as Antihypertensive Agents</span>. <i>J. Prakt. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1002/prac.19903320507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fprac.19903320507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADyaK3MXhs1Citrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1990&pages=629-639&author=V.+J.+Ramauthor=R.+C.+Srimalauthor=D.+S.+Kushwahaauthor=L.+Mishra&title=Chemoterapeutic+Agents.+XIX.+Synthesis+of+%5B1%2C2%2C4%5D-Triazoloquinazolinones+and+Related+Compounds+as+Antihypertensive+Agents&doi=10.1002%2Fprac.19903320507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapeutic agents.  XIX.  Synthesis of [1,2,4]triazoloquinazolinones and related compounds as antihypertensive agents</span></div><div class="casAuthors">Ram, V. J.; Srimal, R. C.; Kushwaha, D. S.; Mishra, L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal fuer Praktische Chemie (Leipzig)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-39</span>CODEN:
                <span class="NLM_cas:coden">JPCEAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-8383</span>.
    </div><div class="casAbstract">A series of [1,2,4]triazolo[4,3-a]quinazolin-5-ones, e.g. I (R = Me, Et, R4 = H, Me, R5 = Me, aryl, R6 = H, Me), were prepd. starting from appropriate quinazolinones.  Only II (R = Me) and I (R = Me, R4 = R6 = H, R5 = Me) exhibited antihypertensive activity in mice; all others were inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLD5rs3Ek2-rVg90H21EOLACvtfcHk0lj0FXW5prBT4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhs1Citrs%253D&md5=0d9f5fdb3ae1e0a09aa613d9f6495f37</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fprac.19903320507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.19903320507%26sid%3Dliteratum%253Aachs%26aulast%3DRam%26aufirst%3DV.%2BJ.%26aulast%3DSrimal%26aufirst%3DR.%2BC.%26aulast%3DKushwaha%26aufirst%3DD.%2BS.%26aulast%3DMishra%26aufirst%3DL.%26atitle%3DChemoterapeutic%2520Agents.%2520XIX.%2520Synthesis%2520of%2520%255B1%252C2%252C4%255D-Triazoloquinazolinones%2520and%2520Related%2520Compounds%2520as%2520Antihypertensive%2520Agents%26jtitle%3DJ.%2520Prakt.%2520Chem.%26date%3D1990%26volume%3D332%26spage%3D629%26epage%3D639%26doi%3D10.1002%2Fprac.19903320507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ram, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapil, A.</span></span> <span> </span><span class="NLM_article-title">Latent Leishmanicidal Activity of Quinazolinones and 1,2,4-Triazoloquinazolinones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2090</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(01)80107-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2FS0960-894X%2801%2980107-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADyaK2MXovVyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=2087-2090&author=V.+J.+Ramauthor=A.+Goelauthor=M.+Vermaauthor=I.+B.+Kaulauthor=A.+Kapil&title=Latent+Leishmanicidal+Activity+of+Quinazolinones+and+1%2C2%2C4-Triazoloquinazolinones&doi=10.1016%2Fs0960-894x%2801%2980107-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Latent leishmanicidal activity of quinazolinones and 1,2,4-triazoloquinazolinones</span></div><div class="casAuthors">Ram, Vishnu Ji; Goel, Atul; Verma, Monika; Kaul, Indu Bala; Kapil, Aruna</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2087-90</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    </div><div class="casAbstract">Derivs. of quinazolinones (I, e.g., R = 6-OMe, or 7-Cl, R1 = Me or Et, R2 = H or Me) and various 1,2,4-triazoloquinazolinones were prepd. and evaluated for in vitro leishmanicidal activity against Leishmania donovani promastigotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxzDlAZfgjKLVg90H21EOLACvtfcHk0lj0FXW5prBT4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVyisg%253D%253D&md5=a4ccc2798af97690c83a5bd510b0a962</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980107-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980107-4%26sid%3Dliteratum%253Aachs%26aulast%3DRam%26aufirst%3DV.%2BJ.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DVerma%26aufirst%3DM.%26aulast%3DKaul%26aufirst%3DI.%2BB.%26aulast%3DKapil%26aufirst%3DA.%26atitle%3DLatent%2520Leishmanicidal%2520Activity%2520of%2520Quinazolinones%2520and%25201%252C2%252C4-Triazoloquinazolinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D2087%26epage%3D2090%26doi%3D10.1016%2Fs0960-894x%2801%2980107-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated Design of Ligands to Polypharmacological Profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+Design+of+Ligands+to+Polypharmacological+Profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lhy6ox1ZkVvAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520Design%2520of%2520Ligands%2520to%2520Polypharmacological%2520Profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brassesco, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezuk, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho de Oliveira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberto, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicioli da Silva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco de Oliveira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrideli, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, L. G.</span></span> <span> </span><span class="NLM_article-title">In Vitro Targeting of Polo-like Kinase 1 in Bladder Carcinoma: Comparative Effects of Four Potent Inhibitors</span>. <i>Canc. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.4161/cbt.25087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.4161%2Fcbt.25087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23792639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=648-657&author=M.+S.+Brassescoauthor=J.+A.+Pezukauthor=A.+G.+Moralesauthor=J.+Carvalho+de+Oliveiraauthor=G.+M.+Robertoauthor=G.+Nicioli+da+Silvaauthor=H.+Francisco+de+Oliveiraauthor=C.+A.+Scrideliauthor=L.+G.+Tone&title=In+Vitro+Targeting+of+Polo-like+Kinase+1+in+Bladder+Carcinoma%3A+Comparative+Effects+of+Four+Potent+Inhibitors&doi=10.4161%2Fcbt.25087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors</span></div><div class="casAuthors">Brassesco, Maria Sol; Pezuk, Julia Alejandra; Morales, Andressa Gois; Carvalho de Oliveira, Jaqueline; Roberto, Gabriela Molinari; Nicioli da Silva, Glenda; Francisco de Oliveira, Harley; Scrideli, Carlos Alberto; Tone, Luiz Gonzaga</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">648-657</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Despite the improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little over the past 30 years.  In the present study we tested and compared the in vitro antitumor activities of four different inhibitors of Polo-like kinase 1 (PLK1) (BI 2536, BI 6727, GW843682X, and GSK461364), against 3 bladder carcinoma cell lines RT4, 5637 and T24.  The impact on radiosensitivity and drug interactions in simultaneous treatments with cisplatin, methotrexate, and doxorubicin were also investigated.  Our results showed that PLK1 inhibition prevented cell proliferation and clonogenicity, causing significant inhibition of invasion of tumor cells, though modest differences were obsd. between drugs.  Moreover, all PLK1 inhibitors induced G2/M arrest, with the subsequent induction of death in all 3 cell lines.  Drug interactions studies showed auspicious results for all PLK1 inhibitors when combined with the commonly used cisplatin and methotrexate, though combinations with doxorubicin showed mostly antagonistic effects.  Comparably, the four PLK1 inhibitors efficiently sensitized cells to ionizing radiation.  Our findings demonstrate that irresp. of the inhibitor used, the pharmacol. inhibition of PLK1 constrains bladder cancer growth and dissemination, providing new opportunities for future therapeutic intervention.  However, further laboratorial and preclin. tests are still needed to corroborate the usefulness of using them in combination with other commonly used chemotherapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSY13bvs2NQbVg90H21EOLACvtfcHk0lhy6ox1ZkVvAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1yit74%253D&md5=cc07290ff65e479d69518edd7cc7b606</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4161%2Fcbt.25087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.25087%26sid%3Dliteratum%253Aachs%26aulast%3DBrassesco%26aufirst%3DM.%2BS.%26aulast%3DPezuk%26aufirst%3DJ.%2BA.%26aulast%3DMorales%26aufirst%3DA.%2BG.%26aulast%3DCarvalho%2Bde%2BOliveira%26aufirst%3DJ.%26aulast%3DRoberto%26aufirst%3DG.%2BM.%26aulast%3DNicioli%2Bda%2BSilva%26aufirst%3DG.%26aulast%3DFrancisco%2Bde%2BOliveira%26aufirst%3DH.%26aulast%3DScrideli%26aufirst%3DC.%2BA.%26aulast%3DTone%26aufirst%3DL.%2BG.%26atitle%3DIn%2520Vitro%2520Targeting%2520of%2520Polo-like%2520Kinase%25201%2520in%2520Bladder%2520Carcinoma%253A%2520Comparative%2520Effects%2520of%2520Four%2520Potent%2520Inhibitors%26jtitle%3DCanc.%2520Biol.%2520Ther.%26date%3D2013%26volume%3D14%26spage%3D648%26epage%3D657%26doi%3D10.4161%2Fcbt.25087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogado, R. F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezuk, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassesco, M. S.</span></span> <span> </span><span class="NLM_article-title">6727 and GSK461364 Suppress Growth and Radiosensitize Osteosarcoma Cells, but Show Limited Cytotoxic Effects When Combined With Conventional Treatments</span>. <i>Anticancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1097/cad.0000000000000157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1097%2FCAD.0000000000000157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC2cbosVKntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=56-63&author=R.+F.+E.+Bogadoauthor=J.+A.+Pezukauthor=H.+F.+de+Oliveiraauthor=L.+G.+Toneauthor=M.+S.+Brassesco&title=6727+and+GSK461364+Suppress+Growth+and+Radiosensitize+Osteosarcoma+Cells%2C+but+Show+Limited+Cytotoxic+Effects+When+Combined+With+Conventional+Treatments&doi=10.1097%2Fcad.0000000000000157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments</span></div><div class="casAuthors">Bogado Rodrigo F E; Pezuk Julia A; de Oliveira Harley F; Tone Luiz G; Brassesco Maria S</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polo-like kinase 1 (PLK1), a key regulator of mitosis, is often overexpressed in childhood cancers and is associated with poor prognosis.  Previous reports have shown that inhibition of PLK1 might serve as a promising anticancer treatment for osteosarcoma.  In this study, we tested the second-generation PLK1 inhibitors BI 6727 and GSK461364 in HOS and MG-63 cell lines, both as a single agent and in combination with methotrexate, cisplatin, vinblastine, doxorubicin, or ionizing radiation.  Both PLK1 inhibitors worked equally in terms of cell growth arrest, apoptosis induction, and radiosensitization.  Combining BI 6727 or GSK461364 with conventional treatments, however, showed trivial synergistic antitumor effects in vitro.  Our results reinforce the potential use of PLK1 inhibitors for a pharmacologic intervention in osteosarcoma, although their applicability in polychemotherapeutic regimens deserves further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZTZEKqodBsijiVMCqkKxVfW6udTcc2eaPzUpE1zK1tLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbosVKntA%253D%253D&md5=00ebcecda322493e8b92b1e83bb8f855</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000157%26sid%3Dliteratum%253Aachs%26aulast%3DBogado%26aufirst%3DR.%2BF.%2BE.%26aulast%3DPezuk%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BOliveira%26aufirst%3DH.%2BF.%26aulast%3DTone%26aufirst%3DL.%2BG.%26aulast%3DBrassesco%26aufirst%3DM.%2BS.%26atitle%3D6727%2520and%2520GSK461364%2520Suppress%2520Growth%2520and%2520Radiosensitize%2520Osteosarcoma%2520Cells%252C%2520but%2520Show%2520Limited%2520Cytotoxic%2520Effects%2520When%2520Combined%2520With%2520Conventional%2520Treatments%26jtitle%3DAnticancer%2520Drugs%26date%3D2015%26volume%3D26%26spage%3D56%26epage%3D63%26doi%3D10.1097%2Fcad.0000000000000157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlich, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernitznig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savarese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiselmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-like Kinases, in Preclinical Models of Acute Myeloid Leukemia</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.221150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1124%2Fjpet.114.221150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25576074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=579-589&author=D.+Rudolphauthor=M.+A.+Impagnatielloauthor=C.+Blaukopfauthor=C.+Sommerauthor=D.+W.+Gerlichauthor=M.+Rothauthor=U.+Tontsch-Gruntauthor=A.+Wernitznigauthor=F.+Savareseauthor=M.+H.+Hofmannauthor=C.+Albrechtauthor=L.+Geiselmannauthor=M.+Reschkeauthor=P.+Garin-Chesaauthor=J.+Zuberauthor=J.+Mollauthor=G.+R.+Adolfauthor=N.+Kraut&title=Efficacy+and+Mechanism+of+Action+of+Volasertib%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinases%2C+in+Preclinical+Models+of+Acute+Myeloid+Leukemia&doi=10.1124%2Fjpet.114.221150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of polo-like kinases, in preclinical models of acute myeloid leukemia</span></div><div class="casAuthors">Rudolph, Dorothea; Impagnatiello, Maria Antonietta; Blaukopf, Claudia; Sommer, Christoph; Gerlich, Daniel W.; Roth, Mareike; Tontsch-Grunt, Ulrike; Wernitznig, Andreas; Savarese, Fabio; Hofmann, Marco H.; Albrecht, Christoph; Geiselmann, Lena; Reschke, Markus; Pilar, Garin-Chesa; Zuber, Johannes; Moll, Juergen; Adolf, Guenther R.; Krauf, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">579-589, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family of serine/threonine kinases, is a key regulator of multiple steps in mitosis.  Here we report on the pharmacol. profile of volasertib, a potent and selective Plk inhibitor, in multiple preclin. models of acute myeloid leukemia (AML) including established cell lines, bone marrow samples from AML patients in short-term culture, and s.c. as well as disseminated in vivo models in immune-deficient mice.  Our results indicate that volasertib is highly efficacious as a single agent and in combination with established and emerging AML drugs, including the antimetabolite cytarabine, hypomethylating agents (decitabine, azacitidine), and quizartinib, a signal transduction inhibitor targeting FLT3.  Collectively, these preclin. data support the use of volasertib as a new therapeutic approach for the treatment of AML patients, and provide a foundation for combination approaches that may further improve and prolong clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD6Oj8vQUjU7Vg90H21EOLACvtfcHk0lgwb1q6VdSTtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omur8%253D&md5=da04fc2f3bea64606b938c4f9518b78f</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221150%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DImpagnatiello%26aufirst%3DM.%2BA.%26aulast%3DBlaukopf%26aufirst%3DC.%26aulast%3DSommer%26aufirst%3DC.%26aulast%3DGerlich%26aufirst%3DD.%2BW.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWernitznig%26aufirst%3DA.%26aulast%3DSavarese%26aufirst%3DF.%26aulast%3DHofmann%26aufirst%3DM.%2BH.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DGeiselmann%26aufirst%3DL.%26aulast%3DReschke%26aufirst%3DM.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26atitle%3DEfficacy%2520and%2520Mechanism%2520of%2520Action%2520of%2520Volasertib%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinases%252C%2520in%2520Preclinical%2520Models%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D579%26epage%3D589%26doi%3D10.1124%2Fjpet.114.221150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of the Polo-like Kinase Inhibitor Volasertib in Cancer Therapy</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fleu.2014.222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25027517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=11-19&author=B.+T.+Gjertsenauthor=P.+Sch%C3%B6ffski&title=Discovery+and+Development+of+the+Polo-like+Kinase+Inhibitor+Volasertib+in+Cancer+Therapy&doi=10.1038%2Fleu.2014.222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy</span></div><div class="casAuthors">Gjertsen, B. T.; Schoffski, P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Owing to their integral involvement in cell cycle regulation, the Polo-like kinase (Plk) family, particularly Plk1, has emerged as an attractive therapeutic target in oncol.  In recent years, several Plk1 inhibitors have been developed, with some agents showing encouraging results in early-phase clin. trials.  This review focuses on volasertib (BI 6727; an investigational agent), a potent and selective Plk inhibitor.  Volasertib has shown promising activity in various cancer cell lines and xenograft models of human cancer.  Trials performed to date suggest that volasertib has clin. efficacy in a range of malignancies, with the most promising results seen in patients with acute myeloid leukemia (AML).  Encouragingly, recent phase II data have demonstrated that volasertib combined with low-dose cytarabine (LDAC) was assocd. with higher response rates and improved event-free survival than LDAC alone in patients with previously untreated AML.  Based on these observations, and its presumably manageable safety profile, volasertib is currently in phase III development as a potential treatment for patients with AML who are ineligible for intensive remission induction therapy.  Given that many patients with AML are of an older age and frail, this constitutes an area of major unmet need.  In this review, we discuss the biol. rationale for Plk1 inhibitors in cancer, the clin. development of volasertib to date in solid tumors and AML, and the future identification of biomarkers that might predict response to volasertib and help det. the role of this agent in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9D-SO9pn3cbVg90H21EOLACvtfcHk0lgwb1q6VdSTtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7%252FE&md5=cabf0c81a92b210b09c4bdc23150c5bb</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.222%26sid%3Dliteratum%253Aachs%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520the%2520Polo-like%2520Kinase%2520Inhibitor%2520Volasertib%2520in%2520Cancer%2520Therapy%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D11%26epage%3D19%26doi%3D10.1038%2Fleu.2014.222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span> <span> </span><span class="NLM_article-title">Finding the Optimal Combination Therapy for the Treatment of Newly Diagnosed AML in Older Patients Unfit for Intensive Therapy</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2014.11.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.leukres.2014.11.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25577399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFShsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=183-191&author=H.+P.+Erba&title=Finding+the+Optimal+Combination+Therapy+for+the+Treatment+of+Newly+Diagnosed+AML+in+Older+Patients+Unfit+for+Intensive+Therapy&doi=10.1016%2Fj.leukres.2014.11.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy</span></div><div class="casAuthors">Erba, Harry P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-191</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  There is no std. of care for older patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity therapies (decitabine, azacitidine, and low-dose cytarabine [LDAC]) remains poor.  One promising strategy is to combine low-intensity treatments with novel agents.  Gemtuzumab ozogamicin, tipifarnib, and barasertib have been investigated in phase 2/3 or 3 trials combined with LDAC, and phase 3 trials are currently investigating sapacitabine plus decitabine, and volasertib plus LDAC in AML.  This review discusses current treatment recommendations and the development of combination therapies for older patients unfit for intensive therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU81UBDc5q_7Vg90H21EOLACvtfcHk0lgwb1q6VdSTtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFShsrfN&md5=a295426b269466ec140c7fe5074effdc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2014.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2014.11.027%26sid%3Dliteratum%253Aachs%26aulast%3DErba%26aufirst%3DH.%2BP.%26atitle%3DFinding%2520the%2520Optimal%2520Combination%2520Therapy%2520for%2520the%2520Treatment%2520of%2520Newly%2520Diagnosed%2520AML%2520in%2520Older%2520Patients%2520Unfit%2520for%2520Intensive%2520Therapy%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D183%26epage%3D191%26doi%3D10.1016%2Fj.leukres.2014.11.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaolan  Xing</span>, <span class="hlFld-ContribAuthor ">Peng  Guan</span>, <span class="hlFld-ContribAuthor ">Shubin  Song</span>, <span class="hlFld-ContribAuthor ">Guirong  You</span>, <span class="hlFld-ContribAuthor ">Chengcai  Xia</span>, <span class="hlFld-ContribAuthor ">Tingting  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113314. <a href="https://doi.org/10.1016/j.ejmech.2021.113314" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113314%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bagents%252Btargeting%252Bpolo-like%252Bkinases%25253A%252BPromising%252Btherapeutic%252Bstrategies%26aulast%3DZhang%26aufirst%3DZheng%26date%3D2021%26volume%3D217%26spage%3D113314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dazhong  Xu</span>, <span class="hlFld-ContribAuthor ">Cen  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of the SIAH2-HIF-1 Axis by Protein Kinases and Its Implication in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.646687" title="DOI URL">https://doi.org/10.3389/fcell.2021.646687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.646687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.646687%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DRegulation%252Bof%252Bthe%252BSIAH2-HIF-1%252BAxis%252Bby%252BProtein%252BKinases%252Band%252BIts%252BImplication%252Bin%252BCancer%252BTherapy%26aulast%3DXu%26aufirst%3DDazhong%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Structures of Inhibitors of the KD (<b>1–5</b>) and the PBD (<b>6</b>) of Plk1</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Delineation of zones of SAR focus in the triazoloquinazolinone series.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of 7-Fluoro Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Zone 4 Amides</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Representative inhibition curves in the ELISA assay. A previously characterized phosphopeptide, PLHSpT <b>6a</b> (<i>K</i><sub>d</sub> of ∼450 nM<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>), is included for comparison. The curve numbers correspond to compound numbers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparative FP-based assays showing that compound <b>79</b> potently inhibits the PBD of Plk1 but not Plk2 and Plk3 with an IC<sub>50</sub> of 0.47 μM. Under the same experimental conditions, PLHSpT <b>6a</b> shows an IC<sub>50</sub> of 22 μM, whereas its control nonphosphorylated form, PLHST <b>6b</b>, exhibits no detectable activity. Bars, mean ± standard deviation (s.d.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Antiproliferative effect of <b>143</b> in HeLa cells. (A) Asynchronously growing HeLa cells were treated with 100 μM of compound <b>143</b> for 12 h, subjected to phase-contrast micrography (cells with a rounded morphology are marked with barbed arrows) and stained with DAPI. Cells exhibiting mitotic and apoptotic DNA morphologies (arrows in DAPI) (bottom left) and abnormally misaligned or lagging chromosomes (bottom right) were quantified from three independent experiments (<i>n</i> > 515 cells/sample/experiment). Bars, mean ± s.d., ***, <i>P</i> < 0.001 (unpaired two-tailed <i>t</i>-test). (B) Cell numbers at the indicated time points were quantified from three independent experiments (<i>n</i> = an average of 2547 cells/experiment for DMSO and 1673 cells/experiment for <b>143</b>). Bars, mean ± s.d. (C,D) Cells in (A) were immunostained with the indicated antibodies to reveal delocalized Plk1 signals from centrosomes (marker: Cep63) and kinetochores (marker: CREST) (C) and abnormal spindle morphologies (marker: α-tubulin) (D). Asterisks, centrosome-localized Plk1; brackets, kinetochore-associated Plk1. Arrowheads in (C), delocalized Plk1 aggregates in the cytosol. Quantification was carried out from three independent experiments [≥20 (DMSO) or 32 (<b>143</b>) centrosomes/sample/experiment and ≥42 (DMSO) or 64 (<b>143</b>) kinetochores (∼4 kinetochores per cell)/sample/experiment for (C); ≥106 (DMSO) or 102 (<b>143</b>) cells/sample/experiment for (D)]. Bars, means ± s.d., ***, <i>P</i> < 0.001 (unpaired two-tailed <i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/medium/jm0c01669_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Summary of SAR studies on a 1-thioxo-2,4-dihydro-[1,2,4]triazolo[4,3-<i>a</i>]quinazolin-5(1<i>H</i>)-one scaffold for inhibition of Plk1 PBD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01669/20201120/images/large/jm0c01669_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01669&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i183">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50803" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50803" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 77 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zitouni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettencourt-Dias, M.</span></span> <span> </span><span class="NLM_article-title">Polo-like Kinases: Structural Variations Lead to Multiple Functions</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1038/nrm3819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnrm3819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24954208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=433-452&author=S.+Zitouniauthor=C.+Nabaisauthor=S.+C.+Janaauthor=A.+Guerreroauthor=M.+Bettencourt-Dias&title=Polo-like+Kinases%3A+Structural+Variations+Lead+to+Multiple+Functions&doi=10.1038%2Fnrm3819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like kinases: structural variations lead to multiple functions</span></div><div class="casAuthors">Zitouni, Sihem; Nabais, Catarina; Jana, Swadhin Chandra; Guerrero, Adan; Bettencourt-Dias, Monica</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">433-452</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Members of the polo-like kinase (PLK) family are crucial regulators of cell cycle progression, centriole duplication, mitosis, cytokinesis and the DNA damage response.  PLKs undergo major changes in abundance, activity, localization and structure at different stages of the cell cycle.  They interact with other proteins in a tightly controlled spatiotemporal manner as part of a network that coordinates key cell cycle events.  Their essential roles are highlighted by the fact that alterations in PLK function are assocd. with cancers and other diseases.  Recent knowledge gained from PLK crystal structures, evolution and interacting mols. offers important insights into the mechanisms that underlie their regulation and activity, and suggests novel functions unrelated to cell cycle control for this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaF-mmmGZrt7Vg90H21EOLACvtfcHk0lghVhFFV1RIzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaisL7P&md5=c4201eea6cece3b31094e823e188ce10</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm3819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3819%26sid%3Dliteratum%253Aachs%26aulast%3DZitouni%26aufirst%3DS.%26aulast%3DNabais%26aufirst%3DC.%26aulast%3DJana%26aufirst%3DS.%2BC.%26aulast%3DGuerrero%26aufirst%3DA.%26aulast%3DBettencourt-Dias%26aufirst%3DM.%26atitle%3DPolo-like%2520Kinases%253A%2520Structural%2520Variations%2520Lead%2520to%2520Multiple%2520Functions%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D433%26epage%3D452%26doi%3D10.1038%2Fnrm3819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span> <span> </span><span class="NLM_article-title">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.tips.2015.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26478211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=858-877&author=K.+S.+Leeauthor=T.+R.+Burkeauthor=J.-E.+Parkauthor=J.+K.+Bangauthor=E.+Lee&title=Recent+Advances+and+New+Strategies+in+Targeting+Plk1+for+Anticancer+Therapy&doi=10.1016%2Fj.tips.2015.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span></div><div class="casAuthors">Lee, Kyung S.; Burke, Terrence R.; Park, Jung-Eun; Bang, Jeong K.; Lee, Eunhye</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">858-877</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) plays key roles in regulating mitotic processes that are crucial for cellular proliferation.  Overexpression of Plk1 is tightly assocd. with the development of particular cancers in humans, and a large body of evidence suggests that Plk1 is an attractive target for anticancer therapeutic development.  Drugs targeting Plk1 can potentially be directed at two distinct sites: the N-terminal catalytic kinase domain (KD), which phosphorylates substrates, and the C-terminal polo-box domain (PBD) which is essential for protein-protein interactions.  In this review we summarize recent advances and new challenges in the development of Plk1 inhibitors targeting these two domains.  We also discuss novel strategies for designing and developing next-generation inhibitors to effectively treat Plk1-assocd. human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7P4zqY1Q4BLVg90H21EOLACvtfcHk0lh2ZEwBaUgDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO&md5=4e5110c5022c2bf0f5fc8846a91b2d87</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DE.%26atitle%3DRecent%2520Advances%2520and%2520New%2520Strategies%2520in%2520Targeting%2520Plk1%2520for%2520Anticancer%2520Therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D858%26epage%3D877%26doi%3D10.1016%2Fj.tips.2015.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span> <span> </span><span class="NLM_article-title">Multifaceted Polo-like Kinases: Drug Targets and Antitargets for Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1038/nrd3184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnrd3184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=20671765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=643-660&author=K.+Strebhardt&title=Multifaceted+Polo-like+Kinases%3A+Drug+Targets+and+Antitargets+for+Cancer+Therapy&doi=10.1038%2Fnrd3184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy</span></div><div class="casAuthors">Strebhardt, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">643-660</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The polo-like kinase 1 (PLK1) acts in concert with cyclin-dependent kinase 1-cyclin B1 and Aurora kinases to orchestrate a wide range of crit. cell cycle events.  Because PLK1 has been preclinically validated as a cancer target, small-mol. inhibitors of PLK1 have become attractive candidates for anticancer drug development.  Although the roles of the closely related PLK2, PLK3 and PLK4 in cancer are less well understood, there is evidence showing that PLK2 and PLK3 act as tumor suppressors through their functions in the p53 signalling network, which guards the cell against various stress signals.  In this article, recent insights into the biol. of PLKs will be reviewed, with an emphasis on their role in malignant transformation, and progress in the development of small-mol. PLK1 inhibitors will be examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaWCrqfphwErVg90H21EOLACvtfcHk0lh2ZEwBaUgDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCktrw%253D&md5=62ab87ce3392ce187d7d62ac5f7c2679</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3184%26sid%3Dliteratum%253Aachs%26aulast%3DStrebhardt%26aufirst%3DK.%26atitle%3DMultifaceted%2520Polo-like%2520Kinases%253A%2520Drug%2520Targets%2520and%2520Antitargets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D643%26epage%3D660%26doi%3D10.1038%2Fnrd3184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Cárcer, G.</span></span> <span> </span><span class="NLM_article-title">The Mitotic Cancer Target Polo-like Kinase 1: Oncogene or Tumor Suppressor?</span>. <i>Genes</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.3390/genes10030208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.3390%2Fgenes10030208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ajtL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=208-221&author=G.+de%0AC%C3%A1rcer&title=The+Mitotic+Cancer+Target+Polo-like+Kinase+1%3A+Oncogene+or+Tumor+Suppressor%3F&doi=10.3390%2Fgenes10030208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The mitotic cancer target polo-like kinase 1: oncogene or tumor suppressor?</span></div><div class="casAuthors">de Carcer, Guillermo</div><div class="citationInfo"><span class="NLM_cas:title">Genes</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208</span>CODEN:
                <span class="NLM_cas:coden">GENEG9</span>;
        ISSN:<span class="NLM_cas:issn">2073-4425</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The master mitotic regulator, Polo-like kinase 1 (Plk1), is an essential gene for the correct execution of cell division.  Plk1 has strong clin. relevance, as it is considered a bona fide cancer target, it is found overexpressed in a large collection of different cancer types and this tumoral overexpression often correlates with poor patient prognosis.  All these data led the scientific community to historically consider Plk1 as an oncogene.  Although there is a collection of scientific reports showing how Plk1 can contribute to tumor progression, recent data from different labs. using mouse models, show that Plk1 can surprisingly play as a tumor suppressor.  Therefore, the fact that Plk1 is an oncogene is now under debate.  This review summarizes the proposed mechanisms by which Plk1 can play as an oncogene or as a tumor suppressor, and extrapolates this information to clin. features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqp8NowpHPelLVg90H21EOLACvtfcHk0lh2ZEwBaUgDrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ajtL%252FP&md5=475cddfb428995bbacdf7326bb7ad133</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3390%2Fgenes10030208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fgenes10030208%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BC%25C3%25A1rcer%26aufirst%3DG.%26atitle%3DThe%2520Mitotic%2520Cancer%2520Target%2520Polo-like%2520Kinase%25201%253A%2520Oncogene%2520or%2520Tumor%2520Suppressor%253F%26jtitle%3DGenes%26date%3D2019%26volume%3D10%26spage%3D208%26epage%3D221%26doi%3D10.3390%2Fgenes10030208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emanuele, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlabach, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span> <span> </span><span class="NLM_article-title">A Genome-Wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">835</span>– <span class="NLM_lpage">848</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cell.2009.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19490893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=835-848&author=J.+Luoauthor=M.+J.+Emanueleauthor=D.+Liauthor=C.+J.+Creightonauthor=M.+R.+Schlabachauthor=T.+F.+Westbrookauthor=K.-K.+Wongauthor=S.+J.+Elledge&title=A+Genome-Wide+RNAi+Screen+Identifies+Multiple+Synthetic+Lethal+Interactions+with+the+Ras+Oncogene&doi=10.1016%2Fj.cell.2009.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</span></div><div class="casAuthors">Luo, Ji; Emanuele, Michael J.; Li, Danan; Creighton, Chad J.; Schlabach, Michael R.; Westbrook, Thomas F.; Wong, Kwok-Kin; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">835-848</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Oncogenic mutations in the small GTPase Ras are highly prevalent in cancer, but an understanding of the vulnerabilities of these cancers is lacking.  We undertook a genome-wide RNAi screen to identify synthetic lethal interactions with the KRAS oncogene.  We discovered a diverse set of proteins whose depletion selectively impaired the viability of Ras mutant cells.  Among these we obsd. a strong enrichment for genes with mitotic functions.  We describe a pathway involving the mitotic kinase PLK1, the anaphase-promoting complex/cyclosome, and the proteasome that, when inhibited, results in prometaphase accumulation and the subsequent death of Ras mutant cells.  Gene expression anal. indicates that reduced expression of genes in this pathway correlates with increased survival of patients bearing tumors with a Ras transcriptional signature.  Our results suggest a previously underappreciated role for Ras in mitotic progression and demonstrate a pharmacol. tractable pathway for the potential treatment of cancers harboring Ras mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmWFKW3XYaabVg90H21EOLACvtfcHk0lhlvtQNujoB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVCltb4%253D&md5=f06fd1f1c469495489ad2ac7f0cab090</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DEmanuele%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DSchlabach%26aufirst%3DM.%2BR.%26aulast%3DWestbrook%26aufirst%3DT.%2BF.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Genome-Wide%2520RNAi%2520Screen%2520Identifies%2520Multiple%2520Synthetic%2520Lethal%2520Interactions%2520with%2520the%2520Ras%2520Oncogene%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D835%26epage%3D848%26doi%3D10.1016%2Fj.cell.2009.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rago, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span> <span> </span><span class="NLM_article-title">A Panel of Isogenic Human Cancer Cells Suggests a Therapeutic Approach for Cancers with Inactivated p53</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">3964</span>– <span class="NLM_lpage">3969</span>, <span class="refDoi"> DOI: 10.1073/pnas.0813333106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1073%2Fpnas.0813333106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19225112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1Gkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=3964-3969&author=S.+Surauthor=R.+Pagliariniauthor=F.+Bunzauthor=C.+Ragoauthor=L.+A.+Diazauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=N.+Papadopoulos&title=A+Panel+of+Isogenic+Human+Cancer+Cells+Suggests+a+Therapeutic+Approach+for+Cancers+with+Inactivated+p53&doi=10.1073%2Fpnas.0813333106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53</span></div><div class="casAuthors">Sur, Surojit; Pagliarini, Raymond; Bunz, Fred; Rago, Carlo; Diaz, Luis A., Jr.; Kinzler, Kenneth W.; Vogelstein, Bert; Papadopoulos, Nickolas</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3964-3969</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status.  We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation.  Transcriptome analyses revealed a consistent upregulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G2/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes.  This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1.  This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_tZtZSiSY2LVg90H21EOLACvtfcHk0lhlvtQNujoB3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1Gkt74%253D&md5=4703f4df3e7280d2efb56ae7ecb2ecc6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0813333106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0813333106%26sid%3Dliteratum%253Aachs%26aulast%3DSur%26aufirst%3DS.%26aulast%3DPagliarini%26aufirst%3DR.%26aulast%3DBunz%26aufirst%3DF.%26aulast%3DRago%26aufirst%3DC.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DPapadopoulos%26aufirst%3DN.%26atitle%3DA%2520Panel%2520of%2520Isogenic%2520Human%2520Cancer%2520Cells%2520Suggests%2520a%2520Therapeutic%2520Approach%2520for%2520Cancers%2520with%2520Inactivated%2520p53%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D3964%26epage%3D3969%26doi%3D10.1073%2Fpnas.0813333106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Selective Blockade of Cancer Cell Proliferation and Anchorage-Independent Growth by Plk1 Activity–Dependent Suicidal Inhibition of its Polo-Box Domain</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3624</span>– <span class="NLM_lpage">3634</span>, <span class="refDoi"> DOI: 10.1080/15384101.2015.1104435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1080%2F15384101.2015.1104435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26513691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVSqur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3624-3634&author=J.-E.+Parkauthor=T.-S.+Kimauthor=B.+Y.+Kimauthor=K.+S.+Lee&title=Selective+Blockade+of+Cancer+Cell+Proliferation+and+Anchorage-Independent+Growth+by+Plk1+Activity%E2%80%93Dependent+Suicidal+Inhibition+of+its+Polo-Box+Domain&doi=10.1080%2F15384101.2015.1104435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain</span></div><div class="casAuthors">Park, Jung-Eun; Kim, Tae-Sung; Kim, Bo Yeon; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3624-3634</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) plays a crit. role in proper M-phase progression and cell proliferation.  Plk1 is overexpressed in a broad spectrum of human cancers and is considered an attractive anticancer drug target.  Although a large no. of inhibitors targeting the catalytic domain of Plk1 have been developed, these inhibitors commonly exhibit a substantial level of cross-reactivity with other structurally related kinases, thus narrowing their applicable dose for patient treatment.  Plk1 contains a C-terminal polo-box domain (PBD) that is essentially required for interacting with its binding targets.  However, largely due to the lack of both specific and membrane-permeable inhibitors, whether PBD serves as an alternative target for the development of anticancer therapeutics has not been rigorously examd.  Here, we used an intracellularly expressed 29-mer-long PBIP1-derived peptide (i.e., PBIPtide), which can be converted into a "suicidal" PBD inhibitor via Plk1-dependent self-priming and binding.  Using this highly specific and potent system, we showed that Plk1 PBD inhibition alone is sufficient for inducing mitotic arrest and apoptotic cell death in cancer cells but not in normal cells, and that cancer cell-selective killing can occur regardless of the presence or absence of oncogenic RAS mutation.  Intriguingly, PBD inhibition also effectively prevented anchorage-independent growth of malignant cancer cells.  Thus, targeting PBD represents an appealing strategy for anti-Plk1 inhibitor development.  Addnl., PBD inhibition-induced cancer cell-selective killing may not simply stem from activated RAS alone but, rather, from multiple altered biochem. and physiol. mechanisms, which may have collectively contributed to Plk1 addiction in cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmxo7qMZcEFbVg90H21EOLACvtfcHk0lh4vrPlwyvBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVSqur3P&md5=1ed9033801a84d16c42477fe82558ddb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1104435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1104435%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DKim%26aufirst%3DT.-S.%26aulast%3DKim%26aufirst%3DB.%2BY.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DSelective%2520Blockade%2520of%2520Cancer%2520Cell%2520Proliferation%2520and%2520Anchorage-Independent%2520Growth%2520by%2520Plk1%2520Activity%25E2%2580%2593Dependent%2520Suicidal%2520Inhibition%2520of%2520its%2520Polo-Box%2520Domain%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D3624%26epage%3D3634%26doi%3D10.1080%2F15384101.2015.1104435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, I. B.</span></span> <span> </span><span class="NLM_article-title">Addiction to Oncogenes – The Achilles Heal of Cancer</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>297</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1126/science.1073096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1126%2Fscience.1073096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=12098689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD38XltFGgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2002&pages=63-64&author=I.+B.+Weinstein&title=Addiction+to+Oncogenes+%E2%80%93+The+Achilles+Heal+of+Cancer&doi=10.1126%2Fscience.1073096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives: Cancer: Addiction to oncogenes - the Achilles heal of cancer</span></div><div class="casAuthors">Weinstein, I. Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">297</span>
        (<span class="NLM_cas:issue">5578</span>),
    <span class="NLM_cas:pages">63-64</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review perspective focusing on the accompanying article by M. Jain et al. (ibid. 102-104) that evaluates whether an oncogene that is crucial for the initial development of a specific tumor is required for maintaining the malignant phenotype of the tumor.  Jain et al. engineered a conditional transgenic mouse to overexpress the myc oncogene, which induced formation of highly malignant osteogenic sarcoma.  Jain et al. discovered that brief loss of myc overexpression caused the tumor cells to differentiate into mature osteocytes that formed histol. normal bone.  These findings are in agreement with other data showing that cancer cells are often addicted to the continued activity of specific activated or overexpressed oncogenes for maintenance of their malignant phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7J2rsral7ELVg90H21EOLACvtfcHk0lh4vrPlwyvBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltFGgsbc%253D&md5=d6eb8b78ea39ee6a0f7aefd3bbe7edc9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1073096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1073096%26sid%3Dliteratum%253Aachs%26aulast%3DWeinstein%26aufirst%3DI.%2BB.%26atitle%3DAddiction%2520to%2520Oncogenes%2520%25E2%2580%2593%2520The%2520Achilles%2520Heal%2520of%2520Cancer%26jtitle%3DScience%26date%3D2002%26volume%3D297%26spage%3D63%26epage%3D64%26doi%3D10.1126%2Fscience.1073096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compitello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebanov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salzman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakovlev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, H.</span></span> <span> </span><span class="NLM_article-title">Synergistic Response to Oncogenic Mutations Defines Gene Class Critical to Cancer Phenotype</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>453</i></span>,  <span class="NLM_fpage">1112</span>– <span class="NLM_lpage">1116</span>, <span class="refDoi"> DOI: 10.1038/nature06973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnature06973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18500333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlGjtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2008&pages=1112-1116&author=H.+R.+McMurrayauthor=E.+R.+Sampsonauthor=G.+Compitelloauthor=C.+Kinseyauthor=L.+Newmanauthor=B.+Smithauthor=S.-R.+Chenauthor=L.+Klebanovauthor=P.+Salzmanauthor=A.+Yakovlevauthor=H.+Land&title=Synergistic+Response+to+Oncogenic+Mutations+Defines+Gene+Class+Critical+to+Cancer+Phenotype&doi=10.1038%2Fnature06973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype</span></div><div class="casAuthors">McMurray, Helene R.; Sampson, Erik R.; Compitello, George; Kinsey, Conan; Newman, Laurel; Smith, Bradley; Chen, Shaw-Ree; Klebanov, Lev; Salzman, Peter; Yakovlev, Andrei; Land, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">453</span>
        (<span class="NLM_cas:issue">7198</span>),
    <span class="NLM_cas:pages">1112-1116</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Understanding the mol. underpinnings of cancer is of crit. importance to the development of targeted intervention strategies.  Identification of such targets, however, is notoriously difficult and unpredictable.  Malignant cell transformation requires the cooperation of a few oncogenic mutations that cause substantial reorganization of many cell features and induce complex changes in gene expression patterns.  Genes crit. to this multifaceted cellular phenotype have therefore only been identified after signaling pathway anal. or on an ad hoc basis.  Our observations that cell transformation by cooperating oncogenic lesions depends on synergistic modulation of downstream signaling circuitry suggest that malignant transformation is a highly cooperative process, involving synergy at multiple levels of regulation, including gene expression.  Here we show that a large proportion of genes controlled synergistically by loss-of-function p53 and Ras activation are crit. to the malignant state of murine and human colon cells.  Notably, 14 out of 24 cooperation response genes' were found to contribute to tumor formation in gene perturbation expts.  In contrast, only 1 in 14 perturbations of the genes responding in a non-synergistic manner had a similar effect.  Synergistic control of gene expression by oncogenic mutations thus emerges as an underlying key to malignancy, and provides an attractive rationale for identifying intervention targets in gene networks downstream of oncogenic gain- and loss-of-function mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgkRVUSrZtgrVg90H21EOLACvtfcHk0lh4vrPlwyvBUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlGjtb8%253D&md5=aadeb4cd635a1153825be0ca1717433d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnature06973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature06973%26sid%3Dliteratum%253Aachs%26aulast%3DMcMurray%26aufirst%3DH.%2BR.%26aulast%3DSampson%26aufirst%3DE.%2BR.%26aulast%3DCompitello%26aufirst%3DG.%26aulast%3DKinsey%26aufirst%3DC.%26aulast%3DNewman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DS.-R.%26aulast%3DKlebanov%26aufirst%3DL.%26aulast%3DSalzman%26aufirst%3DP.%26aulast%3DYakovlev%26aufirst%3DA.%26aulast%3DLand%26aufirst%3DH.%26atitle%3DSynergistic%2520Response%2520to%2520Oncogenic%2520Mutations%2520Defines%2520Gene%2520Class%2520Critical%2520to%2520Cancer%2520Phenotype%26jtitle%3DNature%26date%3D2008%26volume%3D453%26spage%3D1112%26epage%3D1116%26doi%3D10.1038%2Fnature06973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solimini, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S. J.</span></span> <span> </span><span class="NLM_article-title">Principles of Cancer Therapy: Oncogene and Non-Oncogene Addiction</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">837</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cell.2009.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19269363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=823-837&author=J.+Luoauthor=N.+L.+Soliminiauthor=S.+J.+Elledge&title=Principles+of+Cancer+Therapy%3A+Oncogene+and+Non-Oncogene+Addiction&doi=10.1016%2Fj.cell.2009.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of cancer therapy: oncogene and non-oncogene addiction</span></div><div class="casAuthors">Luo, Ji; Solimini, Nicole L.; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">823-837</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Cancer is a complex collection of distinct genetic diseases united by common hallmarks.  Here, we expand upon the classic hallmarks to include the stress phenotypes of tumorigenesis.  We describe a conceptual framework of how oncogene and non-oncogene addictions contribute to these hallmarks and how they can be exploited through stress sensitization and stress overload to selectively kill cancer cells.  In particular, we present evidence for a large class of non-oncogenes that are essential for cancer cell survival and present attractive drug targets.  Finally, we discuss the path ahead to therapeutic discovery and provide theor. considerations for combining orthogonal cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrH3NH_D9W6LVg90H21EOLACvtfcHk0ljA27jmV15_xQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnsLw%253D&md5=dfbc7a874dcad44f8af947083dab8c33</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSolimini%26aufirst%3DN.%2BL.%26aulast%3DElledge%26aufirst%3DS.%2BJ.%26atitle%3DPrinciples%2520of%2520Cancer%2520Therapy%253A%2520Oncogene%2520and%2520Non-Oncogene%2520Addiction%26jtitle%3DCell%26date%3D2009%26volume%3D136%26spage%3D823%26epage%3D837%26doi%3D10.1016%2Fj.cell.2009.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elia, A. E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rellos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haire, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivins, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smerdon, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span> <span> </span><span class="NLM_article-title">The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(03)00725-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2FS0092-8674%2803%2900725-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=14532005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotFSltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2003&pages=83-95&author=A.+E.+H.+Eliaauthor=P.+Rellosauthor=L.+F.+Haireauthor=J.+W.+Chaoauthor=F.+J.+Ivinsauthor=K.+Hoepkerauthor=D.+Mohammadauthor=L.+C.+Cantleyauthor=S.+J.+Smerdonauthor=M.+B.+Yaffe&title=The+Molecular+Basis+for+Phosphodependent+Substrate+Targeting+and+Regulation+of+Plks+by+the+Polo-Box+Domain&doi=10.1016%2Fs0092-8674%2803%2900725-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain</span></div><div class="casAuthors">Elia, Andrew E. H.; Rellos, Peter; Haire, Lesley F.; Chao, Jerry W.; Ivins, Frank J.; Hoepker, Katja; Mohammad, Duaa; Cantley, Lewis C.; Smerdon, Stephen J.; Yaffe, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-95</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Polo-like kinases (Plks) perform crucial functions in cell-cycle progression and multiple stages of mitosis.  Plks are characterized by a C-terminal noncatalytic region contg. two tandem Polo boxes, termed the Polo-box domain (PBD), which has recently been implicated in phosphodependent substrate targeting.  We show that the PBDs of human, Xenopus, and yeast Plks all recognize similar phosphoserine/threonine-contg. motifs.  The 1.9 Å X-ray structure of a human Plk1 PBD-phosphopeptide complex shows that the Polo boxes each comprise β6α structures that assoc. to form a 12-stranded β sandwich domain.  The phosphopeptide binds along a conserved, pos. charged cleft located at the edge of the Polo-box interface.  Mutations that specifically disrupt phosphodependent interactions abolish cell-cycle-dependent localization and provide compelling phenotypic evidence that PBD-phospholigand binding is necessary for proper mitotic progression.  In addn., phosphopeptide binding to the PBD stimulates kinase activity in full-length Plk1, suggesting a conformational switching mechanism for Plk regulation and a dual functionality for the PBD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwyNVczSqmSrVg90H21EOLACvtfcHk0li4KXq42O_rCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotFSltb4%253D&md5=6efe7693e3b1f398eacc98263dcf04c6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2803%2900725-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252803%252900725-6%26sid%3Dliteratum%253Aachs%26aulast%3DElia%26aufirst%3DA.%2BE.%2BH.%26aulast%3DRellos%26aufirst%3DP.%26aulast%3DHaire%26aufirst%3DL.%2BF.%26aulast%3DChao%26aufirst%3DJ.%2BW.%26aulast%3DIvins%26aufirst%3DF.%2BJ.%26aulast%3DHoepker%26aufirst%3DK.%26aulast%3DMohammad%26aufirst%3DD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DSmerdon%26aufirst%3DS.%2BJ.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26atitle%3DThe%2520Molecular%2520Basis%2520for%2520Phosphodependent%2520Substrate%2520Targeting%2520and%2520Regulation%2520of%2520Plks%2520by%2520the%2520Polo-Box%2520Domain%26jtitle%3DCell%26date%3D2003%26volume%3D115%26spage%3D83%26epage%3D95%26doi%3D10.1016%2Fs0092-8674%2803%2900725-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenfell, T. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarm, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erikson, R. L.</span></span> <span> </span><span class="NLM_article-title">Mutation of the Polo-Box Disrupts Localization and Mitotic Functions of the Mammalian Polo Kinase Plk</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">9301</span>– <span class="NLM_lpage">9306</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.16.9301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1073%2Fpnas.95.16.9301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=9689075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=9301-9306&author=K.+S.+Leeauthor=T.+Z.+Grenfellauthor=F.+R.+Yarmauthor=R.+L.+Erikson&title=Mutation+of+the+Polo-Box+Disrupts+Localization+and+Mitotic+Functions+of+the+Mammalian+Polo+Kinase+Plk&doi=10.1073%2Fpnas.95.16.9301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk</span></div><div class="casAuthors">Lee, Kyung S.; Grenfell, Tallessyn Z.; Yarm, Frederic R.; Erikson, Raymond L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">9301-9306</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Members of the polo subfamily of protein kinases play pivotal roles in cell proliferation.  In addn. to the kinase domain, polo kinases have a strikingly conserved sequence in the noncatalytic domain, termed the polo-box.  The function of the polo-box is currently undefined.  The mammalian polo-like kinase Plk is a functional homolog of Saccharomyces cerevisiae Cdc5.  Here, we show that Plk localizes at the spindle poles and cytokinetic neck filaments.  Without impairing kinase activity, a conservative mutation in the polo-box disrupts the capacity of Plk to complement the defect assocd. with a cdc5-1 temp.-sensitive mutation and to localize to these subcellular structures.  Our data provide evidence that the polo-box plays a crit. role in Plk function, likely by directing its subcellular localization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdff34tDzSE7Vg90H21EOLACvtfcHk0li4KXq42O_rCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCmurs%253D&md5=cce706613217de3dd76f91a9050eec44</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.16.9301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.16.9301%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DGrenfell%26aufirst%3DT.%2BZ.%26aulast%3DYarm%26aufirst%3DF.%2BR.%26aulast%3DErikson%26aufirst%3DR.%2BL.%26atitle%3DMutation%2520of%2520the%2520Polo-Box%2520Disrupts%2520Localization%2520and%2520Mitotic%2520Functions%2520of%2520the%2520Mammalian%2520Polo%2520Kinase%2520Plk%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D9301%26epage%3D9306%26doi%3D10.1073%2Fpnas.95.16.9301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seong, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamijo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">A Spindle Checkpoint Arrest and a Cytokinesis Failure by the Dominant-Negative Polo-Box Domain of Plk1 in U-2 OS Cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">32282</span>– <span class="NLM_lpage">32293</span>, <span class="refDoi"> DOI: 10.1074/jbc.m202602200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1074%2Fjbc.M202602200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=12034729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD38XmslyjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=32282-32293&author=Y.-S.+Seongauthor=K.+Kamijoauthor=J.-S.+Leeauthor=E.+Fernandezauthor=R.+Kuriyamaauthor=T.+Mikiauthor=K.+S.+Lee&title=A+Spindle+Checkpoint+Arrest+and+a+Cytokinesis+Failure+by+the+Dominant-Negative+Polo-Box+Domain+of+Plk1+in+U-2+OS+Cells&doi=10.1074%2Fjbc.m202602200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells</span></div><div class="casAuthors">Seong, Yeon-Sun; Kamijo, Keiju; Lee, Jae-Seon; Fernandez, Ester; Kuriyama, Ryoko; Miki, Toru; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">32282-32293</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Polo kinases play crit. roles for proper M-phase progression.  They are characterized by the presence of two regions of homol. in the C-terminal non-catalytic domain, termed polo-box 1 (PB1) and polo-box 2 (PB2).  Here we demonstrate that both PB1 and PB2 are required for targeting the catalytic activity of Plk1 to centrosomes, midbody, and kinetochores.  Expression of either kinase-inactive PLK1/K82M or the C-terminal plk1ΔN induced a pre-anaphase arrest with elevated Cdc2 and Plk1 activity.  Prophase-arrested cells exhibited randomly oriented spindle structures, whereas metaphase cells exhibited aberrant bipolar spindles with Mad2 localization at kinetochores of misaligned chromosomes.  Microtubule nucleation activity of centrosomes was not compromised.  In vivo time-lapse studies revealed that expression of plk1ΔN resulted in repeated cycles of bipolar spindle formation and disruption, suggestive of a defect in spindle stability.  A prolonged arrest frequently led to the generation of micronucleated cells in the absence of sister chromatid sepn. and centrosome duplication, indicating that micronucleation is not a result of accumulated cytokinesis failures.  Interestingly, bypass of the mitotic arrest by dominant-neg. spindle checkpoint components led to a failure in completion of cytokinesis.  We propose that, in mammalian cells, the polo-box-dependent Plk1 activity is required for proper metaphase/anaphase transition and for cytokinesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrruzMG9X3l0rVg90H21EOLACvtfcHk0li4KXq42O_rCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmslyjsLY%253D&md5=e6ed028c69d0a7548f9671235a724755</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M202602200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M202602200%26sid%3Dliteratum%253Aachs%26aulast%3DSeong%26aufirst%3DY.-S.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.-S.%26aulast%3DFernandez%26aufirst%3DE.%26aulast%3DKuriyama%26aufirst%3DR.%26aulast%3DMiki%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DA%2520Spindle%2520Checkpoint%2520Arrest%2520and%2520a%2520Cytokinesis%2520Failure%2520by%2520the%2520Dominant-Negative%2520Polo-Box%2520Domain%2520of%2520Plk1%2520in%2520U-2%2520OS%2520Cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D32282%26epage%3D32293%26doi%3D10.1074%2Fjbc.m202602200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">BI 6727, a Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3094</span>– <span class="NLM_lpage">3102</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1158%2F1078-0432.CCR-08-2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19383823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=3094-3102&author=D.+Rudolphauthor=M.+Steegmaierauthor=M.+Hoffmannauthor=M.+Grauertauthor=A.+Baumauthor=J.+Quantauthor=C.+Haslingerauthor=P.+Garin-Chesaauthor=G.+R.+Adolf&title=BI+6727%2C+a+Polo-like+Kinase+Inhibitor+with+Improved+Pharmacokinetic+Profile+and+Broad+Antitumor+Activity&doi=10.1158%2F1078-0432.ccr-08-2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity</span></div><div class="casAuthors">Rudolph, Dorothea; Steegmaier, Martin; Hoffmann, Matthias; Grauert, Matthias; Baum, Anke; Quant, Jens; Haslinger, Christian; Garin-Chesa, Pilar; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3094-3102</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers.  To identify novel mitosis-specific agents with higher selectivity than approved tubulin-binding agents (taxanes, Vinca alkaloids), we have generated inhibitors of Polo-like kinase 1, a target that functions predominantly in mitosis.  The first compd. in this series, suitable for i.v. administration, has entered clin. development.  To fully explore the potential of Polo-like kinase 1 inhibition in oncol., we have profiled addnl. compds. and now describe a novel clin. candidate.  BI 6727 is a highly potent (enzyme IC50 = 0.87 nmol/L, EC50 = 11-37 nmol/L on a panel of cancer cell lines) and selective dihydropteridinone with distinct properties.  First, BI 6727 has a pharmacokinetic profile favoring sustained exposure of tumor tissues with a high vol. of distribution and a long terminal half-life in mice (Vss = 7.6 L/kg, t1/2 = 46 h) and rats (Vss = 22 L/kg, t1/2 = 54 h).  Second, BI 6727 has physicochem. and pharmacokinetic properties that allow in vivo testing of i.v. as well as oral formulations, adding flexibility to dosing schedules.  Finally, BI 6727 shows marked antitumor activity in multiple cancer models, including a model of taxane-resistant colorectal cancer.  With oral and i.v. routes of administration, the total weekly dose of BI 6727 is most relevant for efficacy, supporting the use of a variety of well-tolerated dosing schedules.  These findings warrant further investigation of BI 6727 as a tailored antimitotic agent; clin. studies have been initiated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-YEX91EOHHLVg90H21EOLACvtfcHk0li4KXq42O_rCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFOrtbo%253D&md5=daed550be9d9b99ac6797c359039d295</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2445%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DBI%25206727%252C%2520a%2520Polo-like%2520Kinase%2520Inhibitor%2520with%2520Improved%2520Pharmacokinetic%2520Profile%2520and%2520Broad%2520Antitumor%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D3094%26epage%3D3102%26doi%3D10.1158%2F1078-0432.ccr-08-2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lénárt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krššák, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gürtler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieb, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span> <span> </span><span class="NLM_article-title">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth in Vivo</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.12.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cub.2006.12.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17291758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=316-322&author=M.+Steegmaierauthor=M.+Hoffmannauthor=A.+Baumauthor=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Kr%C5%A1%C5%A1%C3%A1kauthor=U.+G%C3%BCrtlerauthor=P.+Garin-Chesaauthor=S.+Liebauthor=J.+Quantauthor=M.+Grauertauthor=G.+R.+Adolfauthor=N.+Krautauthor=J.-M.+Petersauthor=W.+J.+Rettig&title=BI+2536%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinase+1%2C+Inhibits+Tumor+Growth+in+Vivo&doi=10.1016%2Fj.cub.2006.12.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo</span></div><div class="casAuthors">Steegmaier, Martin; Hoffmann, Matthias; Baum, Anke; Lenart, Peter; Petronczki, Mark; Krssak, Martin; Guertler, Ulrich; Garin-Chesa, Pilar; Lieb, Simone; Quant, Jens; Grauert, Matthias; Adolf, Guenther R.; Kraut, Norbert; Peters, Jan-Michael; Rettig, Wolfgang J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">316-322</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Fine-mapping of the cell-division cycle, notably the identification of mitotic kinase signaling pathways, provides novel opportunities for cancer-drug discovery.  As a key regulator of multiple steps during mitotic progression across eukaryotic species, the serine/threonine-specific Polo-like kinase 1 (Plk1) is highly expressed in malignant cells and serves as a neg. prognostic marker in specific human cancer types .  Here, we report the discovery of a potent small-mol. inhibitor of mammalian Plk1, BI 2536, which inhibits Plk1 enzyme activity at low nanomolar concns.  The compd. potently causes a mitotic arrest and induces apoptosis in human cancer cell lines of diverse tissue origin and oncogenome signature.  BI 2536 inhibits growth of human tumor xenografts in nude mice and induces regression of large tumors with well-tolerated i.v. dose regimens.  In treated tumors, cells arrest in prometaphase, accumulate phosphohistone H3, and contain aberrant mitotic spindles.  This mitotic arrest is followed by a surge in apoptosis, detectable by immunohistochem. and noninvasive optical and magnetic resonance imaging.  For addressing the therapeutic potential of Plk1 inhibition, BI 2536 has progressed into clin. studies in patients with locally advanced or metastatic cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-eEWnSYWORbVg90H21EOLACvtfcHk0lilTVuiegQgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbg%253D&md5=49807e335b4ab8cf8209b55597fc7b4e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.037%26sid%3Dliteratum%253Aachs%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DKr%25C5%25A1%25C5%25A1%25C3%25A1k%26aufirst%3DM.%26aulast%3DG%25C3%25BCrtler%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DLieb%26aufirst%3DS.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DGrauert%26aufirst%3DM.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBI%25202536%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%252C%2520Inhibits%2520Tumor%2520Growth%2520in%2520Vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D316%26epage%3D322%26doi%3D10.1016%2Fj.cub.2006.12.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Cristofano, A.</span></span> <span> </span><span class="NLM_article-title">The PLK1 Inhibitor GSK461364A is Effective in Poorly Differentiated and Anaplastic Thyroid Carcinoma Cells, Independent of the Nature of Their Driver Mutations</span>. <i>Thyroid</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1284</span>– <span class="NLM_lpage">1293</span>, <span class="refDoi"> DOI: 10.1089/thy.2013.0037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1089%2Fthy.2013.0037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23509868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFerurrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1284-1293&author=M.+A.+Russoauthor=K.+S.+Kangauthor=A.+Di+Cristofano&title=The+PLK1+Inhibitor+GSK461364A+is+Effective+in+Poorly+Differentiated+and+Anaplastic+Thyroid+Carcinoma+Cells%2C+Independent+of+the+Nature+of+Their+Driver+Mutations&doi=10.1089%2Fthy.2013.0037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The PLK1 Inhibitor GSK461364A Is Effective in Poorly Differentiated and Anaplastic Thyroid Carcinoma Cells, Independent of the Nature of Their Driver Mutations</span></div><div class="casAuthors">Russo, Marika A.; Kang, Kristy S.; Di Cristofano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Thyroid</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1284-1293</span>CODEN:
                <span class="NLM_cas:coden">THYRER</span>;
        ISSN:<span class="NLM_cas:issn">1050-7256</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Background: Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are the most aggressive forms of thyroid cancer.  Despite their low incidence, they account for a disproportionate no. of thyroid cancer-related deaths because of their resistance to most therapeutic approaches.  We have generated mouse models that develop ATC ([Pten, p53]thyr-/- mice) and follicular thyroid cancer with areas of poor differentiation (Ptenthyr-/-,KrasG12D mice).  Comparative gene expression profiling of human and mouse ATCs reveals a common "mitotic signature" in which mitotic kinases, including Polo-like kinase-1 (PLK1), are found deregulated in both species.  Most genes from this signature are also upregulated in poorly differentiated tumors developing in Ptenthyr-/-,KrasG12D mice.  PLK1 is a crucial driving force for normal mitotic spindle formation, centrosome maturation, and sepn., and its overexpression has been demonstrated in a wide range of tumors.  Methods: Human and mouse ATC and PDTC cell lines were treated with the PLK1 inhibitor GSK461364A, and proliferation, apoptosis, and mitotic spindle alterations were analyzed.  Furthermore, immunocompetent mice were injected in the flank with mouse ATC cells, and treated with placebo or GSK461364A.  Results: We show that the PLK1 inhibitor GSK461364A inhibits cell proliferation and induces cell death in both mouse ATC- and PDTC-derived cell lines and in several human ATC cell lines carrying different driver mutations.  Dose-dependent changes in chromosome alignment and spindle assembly during mitosis are obsd. after treatment, together with changes in the mitotic index.  FACS anal. reveals a G2/M phase arrest, followed by apoptosis, and mitotic slippage in cells with PI3K activation.  GSK461364A is also effective in vivo, in an allograft model of ATC.  Conclusions: Taken together, these data suggest that PLK1 targeting is a promising and effective therapeutic approach against PDTC cells and undifferentiated thyroid carcinoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorUfpD5u472LVg90H21EOLACvtfcHk0lilTVuiegQgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFerurrM&md5=64f1ba9bd46ffcf074aa8e423c2316b1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1089%2Fthy.2013.0037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fthy.2013.0037%26sid%3Dliteratum%253Aachs%26aulast%3DRusso%26aufirst%3DM.%2BA.%26aulast%3DKang%26aufirst%3DK.%2BS.%26aulast%3DDi%2BCristofano%26aufirst%3DA.%26atitle%3DThe%2520PLK1%2520Inhibitor%2520GSK461364A%2520is%2520Effective%2520in%2520Poorly%2520Differentiated%2520and%2520Anaplastic%2520Thyroid%2520Carcinoma%2520Cells%252C%2520Independent%2520of%2520the%2520Nature%2520of%2520Their%2520Driver%2520Mutations%26jtitle%3DThyroid%26date%3D2013%26volume%3D23%26spage%3D1284%26epage%3D1293%26doi%3D10.1089%2Fthy.2013.0037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brasca, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccarelli, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fachin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forte, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzetta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posteri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scolaro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depaolini, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsasina, B.</span></span> <span> </span><span class="NLM_article-title">NMS-P937, a 4,5-dihydro-1H-Pyrazolo[4,3-h]Quinazoline Derivative as Potent and Selective Polo-like Kinase 1 Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2969</span>– <span class="NLM_lpage">2974</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmcl.2011.03.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=21470862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2969-2974&author=I.+Beriaauthor=R.+T.+Bossiauthor=M.+G.+Brascaauthor=M.+Carusoauthor=W.+Ceccarelliauthor=G.+Fachinauthor=M.+Fasoliniauthor=B.+Forteauthor=F.+Fiorentiniauthor=E.+Pesentiauthor=D.+Pezzettaauthor=H.+Posteriauthor=A.+Scolaroauthor=S.+R.+Depaoliniauthor=B.+Valsasina&title=NMS-P937%2C+a+4%2C5-dihydro-1H-Pyrazolo%5B4%2C3-h%5DQuinazoline+Derivative+as+Potent+and+Selective+Polo-like+Kinase+1+Inhibitor&doi=10.1016%2Fj.bmcl.2011.03.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor</span></div><div class="casAuthors">Beria, Italo; Bossi, Roberto T.; Brasca, Maria Gabriella; Caruso, Michele; Ceccarelli, Walter; Fachin, Gabriele; Fasolini, Marina; Forte, Barbara; Fiorentini, Francesco; Pesenti, Enrico; Pezzetta, Daniele; Posteri, Helena; Scolaro, Alessandra; Depaolini, Stefania Re; Valsasina, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2969-2974</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivs. as PLK1 inhibitors.  We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 inhibitor.  Also, in order to understand the source of PLK1 selectivity, we detd. the crystal structure of PLK1 with NMS-P937.  The compd. was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clin. trials evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtzzXBLt7b_rVg90H21EOLACvtfcHk0lilTVuiegQgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtbg%253D&md5=ec905c6a918e920d830e50a5a53e5cab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.054%26sid%3Dliteratum%253Aachs%26aulast%3DBeria%26aufirst%3DI.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DCeccarelli%26aufirst%3DW.%26aulast%3DFachin%26aufirst%3DG.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DForte%26aufirst%3DB.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPezzetta%26aufirst%3DD.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DScolaro%26aufirst%3DA.%26aulast%3DDepaolini%26aufirst%3DS.%2BR.%26aulast%3DValsasina%26aufirst%3DB.%26atitle%3DNMS-P937%252C%2520a%25204%252C5-dihydro-1H-Pyrazolo%255B4%252C3-h%255DQuinazoline%2520Derivative%2520as%2520Potent%2520and%2520Selective%2520Polo-like%2520Kinase%25201%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2969%26epage%3D2974%26doi%3D10.1016%2Fj.bmcl.2011.03.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiryanov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaldor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stafford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchiyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hikichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, S.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosfield, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of TAK-960: An Orally Available Small Molecule Inhibitor of Polo-like Kinase 1 (PLK1)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3662</span>– <span class="NLM_lpage">3666</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmcl.2013.02.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23664874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3662-3666&author=Z.+Nieauthor=V.+Feherauthor=S.+Natalaauthor=C.+McBrideauthor=A.+Kiryanovauthor=B.+Jonesauthor=B.+Lamauthor=Y.+Liuauthor=S.+Kaldorauthor=J.+Staffordauthor=K.+Hikamiauthor=N.+Uchiyamaauthor=T.+Kawamotoauthor=Y.+Hikichiauthor=S.-i.+Matsumotoauthor=N.+Amanoauthor=L.+Zhangauthor=D.+Hosfieldauthor=R.+Skeneauthor=H.+Zouauthor=X.+Caoauthor=T.+Ichikawa&title=Discovery+of+TAK-960%3A+An+Orally+Available+Small+Molecule+Inhibitor+of+Polo-like+Kinase+1+%28PLK1%29&doi=10.1016%2Fj.bmcl.2013.02.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)</span></div><div class="casAuthors">Nie, Zhe; Feher, Victoria; Natala, Srinivasa; McBride, Christopher; Kiryanov, Andre; Jones, Benjamin; Lam, Betty; Liu, Yan; Kaldor, Stephen; Stafford, Jeffrey; Hikami, Kouki; Uchiyama, Noriko; Kawamoto, Tomohiro; Hikichi, Yuichi; Matsumoto, Shin-ichi; Amano, Nobuyuki; Zhang, Lilly; Hosfield, David; Skene, Robert; Zou, Hua; Cao, Xiaodong; Ichikawa, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3662-3666</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using structure-based drug design, the authors identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960 (I).  TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo06c_HY-gD-LVg90H21EOLACvtfcHk0lhaAW1tIuCYDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D&md5=25dca079405c47098fd261a77ceccf53</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.083%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DZ.%26aulast%3DFeher%26aufirst%3DV.%26aulast%3DNatala%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKaldor%26aufirst%3DS.%26aulast%3DStafford%26aufirst%3DJ.%26aulast%3DHikami%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DHikichi%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DS.-i.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHosfield%26aufirst%3DD.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DIchikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520TAK-960%253A%2520An%2520Orally%2520Available%2520Small%2520Molecule%2520Inhibitor%2520of%2520Polo-like%2520Kinase%25201%2520%2528PLK1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3662%26epage%3D3666%26doi%3D10.1016%2Fj.bmcl.2013.02.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A Quantitative Analysis of Kinase Inhibitor Selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+Quantitative+Analysis+of+Kinase+Inhibitor+Selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhaAW1tIuCYDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520Quantitative%2520Analysis%2520of%2520Kinase%2520Inhibitor%2520Selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span> <span> </span><span class="NLM_article-title">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">858</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2015.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.tips.2015.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26478211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=858-877&author=K.+S.+Leeauthor=T.+R.+Burkeauthor=J.-E.+Parkauthor=J.+K.+Bangauthor=E.+Lee&title=Recent+Advances+and+New+Strategies+in+Targeting+Plk1+for+Anticancer+Therapy&doi=10.1016%2Fj.tips.2015.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy</span></div><div class="casAuthors">Lee, Kyung S.; Burke, Terrence R.; Park, Jung-Eun; Bang, Jeong K.; Lee, Eunhye</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">858-877</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) plays key roles in regulating mitotic processes that are crucial for cellular proliferation.  Overexpression of Plk1 is tightly assocd. with the development of particular cancers in humans, and a large body of evidence suggests that Plk1 is an attractive target for anticancer therapeutic development.  Drugs targeting Plk1 can potentially be directed at two distinct sites: the N-terminal catalytic kinase domain (KD), which phosphorylates substrates, and the C-terminal polo-box domain (PBD) which is essential for protein-protein interactions.  In this review we summarize recent advances and new challenges in the development of Plk1 inhibitors targeting these two domains.  We also discuss novel strategies for designing and developing next-generation inhibitors to effectively treat Plk1-assocd. human disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7P4zqY1Q4BLVg90H21EOLACvtfcHk0lit9kLahTTUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Orsb%252FO&md5=4e5110c5022c2bf0f5fc8846a91b2d87</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DE.%26atitle%3DRecent%2520Advances%2520and%2520New%2520Strategies%2520in%2520Targeting%2520Plk1%2520for%2520Anticancer%2520Therapy%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D858%26epage%3D877%26doi%3D10.1016%2Fj.tips.2015.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Current Progress and Future Perspectives in the Development of Anti-Polo-like Kinase 1 Therapeutic Agents</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1024</span>, <span class="refDoi"> DOI: 10.12688/f1000research.11398.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.12688%2Ff1000research.11398.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28721210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2nu7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=1024&author=J.-E.+Parkauthor=D.+Hymelauthor=T.+R.+Burkeauthor=K.+S.+Lee&title=Current+Progress+and+Future+Perspectives+in+the+Development+of+Anti-Polo-like+Kinase+1+Therapeutic+Agents&doi=10.12688%2Ff1000research.11398.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents</span></div><div class="casAuthors">Park, Jung-Eun; Hymel, David; Burke, Terrence R., Jr.; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1024/1-1024/10</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">Although significant levels of side effects are often assocd. with their use, microtubule-directed agents that primarily target fast-growing mitotic cells have been considered to be some of the most effective anti-cancer therapeutics.  With the hope of developing new-generation anti-mitotic agents with reduced side effects and enhanced tumor specificity, researchers have targeted various proteins whose functions are critically required for mitotic progression.  As one of the highly attractive mitotic targets, polo-like kinase 1 (Plk1) has been the subject of an extensive effort for anti-cancer drug discovery.  To date, a variety of anti-Plk1 agents have been developed, and several of them are presently in clin. trials.  Here, we will discuss the current status of generating anti-Plk1 agents as well as future strategies for designing and developing more efficacious anti-Plk1 therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH2fa4WqHh4bVg90H21EOLACvtfcHk0lit9kLahTTUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2nu7jJ&md5=3f62aea80e2067b19a293e7680603de3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.11398.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.11398.1%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DHymel%26aufirst%3DD.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DCurrent%2520Progress%2520and%2520Future%2520Perspectives%2520in%2520the%2520Development%2520of%2520Anti-Polo-like%2520Kinase%25201%2520Therapeutic%2520Agents%26jtitle%3DF1000Research%26date%3D2017%26volume%3D6%26spage%3D1024%26doi%3D10.12688%2Ff1000research.11398.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Syed, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spender, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karran, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Nions, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allday, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crook, T.</span></span> <span> </span><span class="NLM_article-title">Transcriptional Silencing of Polo-like Kinase 2 (SNK/PLK2) is a Frequent Event in B-cell Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1182/blood-2005-03-1194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1182%2Fblood-2005-03-1194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=16160013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVGmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=250-256&author=N.+Syedauthor=P.+Smithauthor=A.+Sullivanauthor=L.+C.+Spenderauthor=M.+Dyerauthor=L.+Karranauthor=J.+O%E2%80%99Nionsauthor=M.+Alldayauthor=I.+Hoffmannauthor=D.+Crawfordauthor=B.+Griffinauthor=P.+J.+Farrellauthor=T.+Crook&title=Transcriptional+Silencing+of+Polo-like+Kinase+2+%28SNK%2FPLK2%29+is+a+Frequent+Event+in+B-cell+Malignancies&doi=10.1182%2Fblood-2005-03-1194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional silencing of polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies</span></div><div class="casAuthors">Syed, Nelofer; Smith, Paul; Sullivan, Alexandra; Spender, Lindsay C.; Dyer, Martin; Karran, Lorraine; O'Nions, Jenny; Allday, Martin; Hoffmann, Ingrid; Crawford, Dorothy; Griffin, Beverley; Farrell, Paul J.; Crook, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-256</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The Polo-like kinases (Plks) are a highly conserved family of protein kinases that function in regulation of cell cycle and DNA damage-induced checkpoints.  Evidence of a tumor suppressor function for the Plks in human neoplasia is lacking.  Here, the authors report that Snk/Plk2 is transcriptionally down-regulated in B-cell neoplasms.  Silencing occurs with very high frequency in Burkitt lymphoma (BL) but is also detected in B-cell neoplasms of other types and is assocd. with aberrant cytosine methylation in the CpG island located at the 5' end of the SNK/PLK2 gene.  Silencing is specific to malignant B cells because SNK/PLK2 was unmethylated (and expressed) in primary B lymphocytes, in EBV-immortalized B lymphoblastoid cell lines (LCLs), and in adenocarcinomas (of the breast) and squamous-cell carcinomas (of the head and neck).  Expression of Snk/Plk2 in BL cell lines was restored by demethylating agents.  The related PLK1 and PLK3 (FNK/PRK) genes were overexpressed in BL cell lines lacking Snk/Plk2 expression, consistent with functional degeneracy among the Plk family.  Ectopic expression of Snk/Plk2 in BL cells resulted in apoptosis, a potential mechanistic basis underlying the strong selective pressure for abrogation of Snk/Plk2 function in B-cell neoplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn5sn40EHXebVg90H21EOLACvtfcHk0lit9kLahTTUxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVGmug%253D%253D&md5=694a1118b993b38868a89cc3312d0646</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2005-03-1194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2005-03-1194%26sid%3Dliteratum%253Aachs%26aulast%3DSyed%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DSpender%26aufirst%3DL.%2BC.%26aulast%3DDyer%26aufirst%3DM.%26aulast%3DKarran%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Nions%26aufirst%3DJ.%26aulast%3DAllday%26aufirst%3DM.%26aulast%3DHoffmann%26aufirst%3DI.%26aulast%3DCrawford%26aufirst%3DD.%26aulast%3DGriffin%26aufirst%3DB.%26aulast%3DFarrell%26aufirst%3DP.%2BJ.%26aulast%3DCrook%26aufirst%3DT.%26atitle%3DTranscriptional%2520Silencing%2520of%2520Polo-like%2520Kinase%25202%2520%2528SNK%252FPLK2%2529%2520is%2520a%2520Frequent%2520Event%2520in%2520B-cell%2520Malignancies%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D250%26epage%3D256%26doi%3D10.1182%2Fblood-2005-03-1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komissarova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkles, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span> <span> </span><span class="NLM_article-title">Polo-like Kinase 3 Functions as a Tumor Suppressor and is a Negative Regulator of Hypoxia-Inducible Factor-1 Alpha Under Hypoxic Conditions</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">4077</span>– <span class="NLM_lpage">4085</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-07-6182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1158%2F0008-5472.CAN-07-6182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18519666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFKmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4077-4085&author=Y.+Yangauthor=J.+Baiauthor=R.+Shenauthor=S.+A.+N.+Brownauthor=E.+Komissarovaauthor=Y.+Huangauthor=N.+Jiangauthor=G.+F.+Albertsauthor=M.+Costaauthor=L.+Luauthor=J.+A.+Winklesauthor=W.+Dai&title=Polo-like+Kinase+3+Functions+as+a+Tumor+Suppressor+and+is+a+Negative+Regulator+of+Hypoxia-Inducible+Factor-1+Alpha+Under+Hypoxic+Conditions&doi=10.1158%2F0008-5472.can-07-6182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Polo-like Kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1α under hypoxic conditions</span></div><div class="casAuthors">Yang, Yali; Bai, Jingxiang; Shen, Rulong; Brown, Sharron A. N.; Komissarova, Elena; Huang, Ying; Jiang, Ning; Alberts, Gregory F.; Costa, Max; Lu, Luo; Winkles, Jeffrey A.; Dai, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4077-4085</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Polo-like kinase 3 (Plk3) is an important mediator of the cellular responses to genotoxic stresses.  In this study, we examd. the physiol. function of Plk3 by generating Plk3-deficient mice.  Plk3-/- mice displayed an increase in wt. and developed tumors in various organs at advanced age.  Many tumors in Plk3-/- mice were large in size, exhibiting enhanced angiogenesis.  Plk3-/- mouse embryonic fibroblasts were hypersensitive to the induction of hypoxia-inducible factor-1α (HIF-1α) under hypoxic conditions or by nickel and cobalt ion treatments.  Ectopic expression of the Plk3-kinase domain (Plk3 kDa), but not its Polo-box domain or a Plk3 kDa mutant, suppressed the nuclear accumulation of HIF-1α induced by nickel or cobalt ions.  Moreover, hypoxia-induced HIF-1α expression was tightly assocd. with a significant down-regulation of Plk3 expression in HeLa cells.  Given the importance of HIF-1α in mediating the activation of the "survival machinery" in cancer cells, these studies strongly suggest that enhanced tumorigenesis in Plk3-null mice is at least partially mediated by a deregulated HIF-1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIbqUM2u8RALVg90H21EOLACvtfcHk0lgBEb4lAalywQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFKmt7c%253D&md5=7ee59d18a7cde4989890a7422d65b7fe</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6182%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DS.%2BA.%2BN.%26aulast%3DKomissarova%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DN.%26aulast%3DAlberts%26aufirst%3DG.%2BF.%26aulast%3DCosta%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWinkles%26aufirst%3DJ.%2BA.%26aulast%3DDai%26aufirst%3DW.%26atitle%3DPolo-like%2520Kinase%25203%2520Functions%2520as%2520a%2520Tumor%2520Suppressor%2520and%2520is%2520a%2520Negative%2520Regulator%2520of%2520Hypoxia-Inducible%2520Factor-1%2520Alpha%2520Under%2520Hypoxic%2520Conditions%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4077%26epage%3D4085%26doi%3D10.1158%2F0008-5472.can-07-6182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanisch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigg, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silljé, H. H. W.</span></span> <span> </span><span class="NLM_article-title">Different Plk1 Functions Show Distinct Dependencies on Polo-Box Domain-Mediated Targeting</span>. <i>Mol. Biol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">448</span>– <span class="NLM_lpage">459</span>, <span class="refDoi"> DOI: 10.1091/mbc.e05-08-0801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1091%2Fmbc.e05-08-0801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=16267267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnpt1CktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=448-459&author=A.+Hanischauthor=A.+Wehnerauthor=E.+A.+Niggauthor=H.+H.+W.+Sillj%C3%A9&title=Different+Plk1+Functions+Show+Distinct+Dependencies+on+Polo-Box+Domain-Mediated+Targeting&doi=10.1091%2Fmbc.e05-08-0801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting</span></div><div class="casAuthors">Hanisch Anja; Wehner Anja; Nigg Erich A; Sillje Herman H W</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology of the cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">448-59</span>
        ISSN:<span class="NLM_cas:issn">1059-1524</span>.
    </div><div class="casAbstract">Polo-like kinase 1 (Plk1) has multiple important functions during M-phase progression.  In addition to a catalytic domain, Plk1 possesses a phosphopeptide-binding motif, the polo-box domain (PBD), which is required for proper localization.  Here, we have explored the importance of correct Plk1 subcellular targeting for its mitotic functions.  We either displaced endogenous Plk1 through overexpression of the PBD or introduced the catalytic domain of Plk1, lacking the PBD, into Plk1-depleted cells.  Both treatments resulted in remarkably similar phenotypes, which were distinct from the Plk1 depletion phenotype.  Cells depleted of Plk1 mostly arrested with monoastral spindles, because of inhibition of centrosome maturation and separation.  In contrast, these functions were not impaired in cells with mislocalized Plk1.  Instead, these latter cells showed a checkpoint-dependent mitotic arrest characterized by impaired chromosome congression.  Thus, whereas chromosome congression requires localized Plk1 activity, other investigated Plk1 functions are less dependent on correct PBD-mediated targeting.  This opens the possibility that PBD-directed drugs might be developed to selectively interfere with a subset of Plk1 functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPXdNL0FVCSq91pGlMMoT5fW6udTcc2eYG81WIzFSmqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnpt1CktQ%253D%253D&md5=d8752dd98fb17f573d9ea4bbf5097f73</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1091%2Fmbc.e05-08-0801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1091%252Fmbc.e05-08-0801%26sid%3Dliteratum%253Aachs%26aulast%3DHanisch%26aufirst%3DA.%26aulast%3DWehner%26aufirst%3DA.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26aulast%3DSillj%25C3%25A9%26aufirst%3DH.%2BH.%2BW.%26atitle%3DDifferent%2520Plk1%2520Functions%2520Show%2520Distinct%2520Dependencies%2520on%2520Polo-Box%2520Domain-Mediated%2520Targeting%26jtitle%3DMol.%2520Biol.%2520Cell%26date%3D2006%26volume%3D17%26spage%3D448%26epage%3D459%26doi%3D10.1091%2Fmbc.e05-08-0801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gräber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Serendipitous Alkylation of a Plk1 Ligand Uncovers a New Binding Channel</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">595</span>– <span class="NLM_lpage">601</span>, <span class="refDoi"> DOI: 10.1038/nchembio.614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnchembio.614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=21765407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFyhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=595-601&author=F.+Liuauthor=J.-E.+Parkauthor=W.-J.+Qianauthor=D.+Limauthor=M.+Gr%C3%A4berauthor=T.+Bergauthor=M.+B.+Yaffeauthor=K.+S.+Leeauthor=T.+R.+Burke&title=Serendipitous+Alkylation+of+a+Plk1+Ligand+Uncovers+a+New+Binding+Channel&doi=10.1038%2Fnchembio.614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel</span></div><div class="casAuthors">Liu, Fa; Park, Jung-Eun; Qian, Wen-Jian; Lim, Dan; Graber, Martin; Berg, Thorsten; Yaffe, Michael B.; Lee, Kyung-S.; Burke, Terrence R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">595-601</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We obtained unanticipated synthetic byproducts from alkylation of the δ1 nitrogen (N3) of the histidineimidazole ring of the polo-like kinase-1 (Plk1) polo-box domain (PBD)-binding peptide PLHSpT.  For the highest-affinity byproduct, bearing a C6H5(CH2)8- group, a Plk1 PBD cocrystal structure revealed a new binding channel that had previously been occluded.  An N-terminal PEGylated version of this peptide contg. a hydrolytically stable phosphothreonyl residue (pT) bound the Plk1 PBD with affinity equal to that of the non-PEGylated parent but showed markedly less interaction with the PBDs of the two closely related proteins Plk2 and Plk3.  Treatment of cultured cells with this PEGylated peptide resulted in delocalization of Plk1 from centrosomes and kinetochores and in chromosome misalignment that effectively induced mitotic block and apoptotic cell death.  This work provides insights that might advance efforts to develop Plk1 PBD-binding inhibitors as potential Plk1-specific anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1mKHC1CmiMrVg90H21EOLACvtfcHk0lgBEb4lAalywQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFyhtL8%253D&md5=42ff203cdf3d912f97dc748a4659a81f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.614%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DGr%25C3%25A4ber%26aufirst%3DM.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26atitle%3DSerendipitous%2520Alkylation%2520of%2520a%2520Plk1%2520Ligand%2520Uncovers%2520a%2520New%2520Binding%2520Channel%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D595%26epage%3D601%26doi%3D10.1038%2Fnchembio.614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Mono-anionic Phosphopeptides Produced by Unexpected Histidine Alkylation Exhibit High Plk1 Polo-Box Domain-Binding Affinities and Enhanced Antiproliferative Effects in HeLa Cells</span>. <i>Biopolymers</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1002/bip.22569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fbip.22569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25283071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVaksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2014&pages=444-455&author=W.-J.+Qianauthor=J.-E.+Parkauthor=D.+Limauthor=C.+C.+Laiauthor=J.+A.+Kelleyauthor=S.-Y.+Parkauthor=K.+W.+Leeauthor=M.+B.+Yaffeauthor=K.+S.+Leeauthor=T.+R.+Burke&title=Mono-anionic+Phosphopeptides+Produced+by+Unexpected+Histidine+Alkylation+Exhibit+High+Plk1+Polo-Box+Domain-Binding+Affinities+and+Enhanced+Antiproliferative+Effects+in+HeLa+Cells&doi=10.1002%2Fbip.22569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells</span></div><div class="casAuthors">Qian, Wen-Jian; Park, Jung-Eun; Lim, Dan; Lai, Christopher C.; Kelley, James A.; Park, Suk-Youl; Lee, Ki Won; Yaffe, Michael B.; Lee, Kyung S.; Burke, Terrence R., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Biopolymers</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">444-455</span>CODEN:
                <span class="NLM_cas:coden">BIPMAA</span>;
        ISSN:<span class="NLM_cas:issn">0006-3525</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Binding of polo-like kinase 1 (Plk1) polo-box domains (PBDs) to phosphothreonine (pThr)/phosphoserine (pSer)-contg. sequences is crit. for the proper function of Plk1.  Although high-affinity synthetic pThr-contg. peptides provide starting points for developing PBD-directed inhibitors, to date the efficacy of such peptides in whole cell assays has been poor.  This potentially reflects limited cell membrane permeability arising, in part, from the di-anionic nature of the phosphoryl group or its mimetics.  In our current article we report the unanticipated on-resin N(τ)-alkylation of histidine residues already bearing a N(π)- alkyl group.  This resulted in cationic imidazolium-contg. pThr peptides, several of which exhibit single-digit nanomolar PBD-binding affinities in extracellular assays and improved antimitotic efficacies in intact cells.  We enhanced the cellular efficacies of these peptides further by applying bio-reversible pivaloyloxymethyl (POM) phosphoryl protection.  New structural insights presented in our current study, including the potential utility of intramol. charge masking, may be useful for the further development of PBD-binding peptides and peptide mimetics. © 2014 Wiley Periodicals, Inc.  Biopolymers (Pept Sci) 102: 444-455, 2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpj60b8IBsXrVg90H21EOLACvtfcHk0lgBEb4lAalywQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVaksb3P&md5=a763d14198e9d304f0eb876cc933350f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fbip.22569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbip.22569%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DW.-J.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DLai%26aufirst%3DC.%2BC.%26aulast%3DKelley%26aufirst%3DJ.%2BA.%26aulast%3DPark%26aufirst%3DS.-Y.%26aulast%3DLee%26aufirst%3DK.%2BW.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26atitle%3DMono-anionic%2520Phosphopeptides%2520Produced%2520by%2520Unexpected%2520Histidine%2520Alkylation%2520Exhibit%2520High%2520Plk1%2520Polo-Box%2520Domain-Binding%2520Affinities%2520and%2520Enhanced%2520Antiproliferative%2520Effects%2520in%2520HeLa%2520Cells%26jtitle%3DBiopolymers%26date%3D2014%26volume%3D102%26spage%3D444%26epage%3D455%26doi%3D10.1002%2Fbip.22569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulaei, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shenoy, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMahon, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicklaus, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaffe, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wlodawer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Analyses of Minimal Phosphopeptides Targeting the Polo-Box Domain of Polo-Like Kinase 1</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">882</span>, <span class="refDoi"> DOI: 10.1038/nsmb.1628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnsmb.1628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19597481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFWhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=876-882&author=S.-M.+Yunauthor=T.+Moulaeiauthor=D.+Limauthor=J.+K.+Bangauthor=J.-E.+Parkauthor=S.+R.+Shenoyauthor=F.+Liuauthor=Y.+H.+Kangauthor=C.+Liaoauthor=N.-K.+Soungauthor=S.+Leeauthor=D.-Y.+Yoonauthor=Y.+Limauthor=D.-H.+Leeauthor=A.+Otakaauthor=E.+Appellaauthor=J.+B.+McMahonauthor=M.+C.+Nicklausauthor=T.+R.+Burkeauthor=M.+B.+Yaffeauthor=A.+Wlodawerauthor=K.+S.+Lee&title=Structural+and+Functional+Analyses+of+Minimal+Phosphopeptides+Targeting+the+Polo-Box+Domain+of+Polo-Like+Kinase+1&doi=10.1038%2Fnsmb.1628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1</span></div><div class="casAuthors">Yun, Sang-Moon; Moulaei, Tinoush; Lim, Dan; Bang, Jeong K.; Park, Jung-Eun; Shenoy, Shilpa R.; Liu, Fa; Kang, Young H.; Liao, Chenzhong; Soung, Nak-Kyun; Lee, Sunhee; Yoon, Do-Young; Lim, Yoongho; Lee, Dong-Hee; Otaka, Akira; Appella, Ettore; McMahon, James B.; Nicklaus, Marc C.; Burke, Terrence R., Jr.; Yaffe, Michael B.; Wlodawer, Alexander; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">876-882</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Polo-like kinase-1 (Plk1) has a pivotal role in cell proliferation and is considered a potential target for anticancer therapy.  The noncatalytic polo-box domain (PBD) of Plk1 forms a phosphoepitope binding module for protein-protein interaction.  Here, we report the identification of minimal phosphopeptides that specifically interact with the PBD of human PLK1, but not those of the closely related PLK2 and PLK3.  Comparative binding studies and analyses of crystal structures of the PLK1 PBD in complex with the minimal phosphopeptides revealed that the C-terminal SpT dipeptide functions as a high-affinity anchor, whereas the N-terminal residues are crucial for providing specificity and affinity to the interaction.  Inhibition of the PLK1 PBD by phosphothreonine mimetic peptides was sufficient to induce mitotic arrest and apoptotic cell death.  The mode of interaction between the minimal peptide and PBD may provide a template for designing therapeutic agents that target PLK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooHCw-v0d9drVg90H21EOLACvtfcHk0lihI7Xn7rYlvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFWhsrk%253D&md5=3f275f41856641fbadbe8c7e54322855</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.1628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.1628%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DS.-M.%26aulast%3DMoulaei%26aufirst%3DT.%26aulast%3DLim%26aufirst%3DD.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DShenoy%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DKang%26aufirst%3DY.%2BH.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DSoung%26aufirst%3DN.-K.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DYoon%26aufirst%3DD.-Y.%26aulast%3DLim%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DD.-H.%26aulast%3DOtaka%26aufirst%3DA.%26aulast%3DAppella%26aufirst%3DE.%26aulast%3DMcMahon%26aufirst%3DJ.%2BB.%26aulast%3DNicklaus%26aufirst%3DM.%2BC.%26aulast%3DBurke%26aufirst%3DT.%2BR.%26aulast%3DYaffe%26aufirst%3DM.%2BB.%26aulast%3DWlodawer%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DStructural%2520and%2520Functional%2520Analyses%2520of%2520Minimal%2520Phosphopeptides%2520Targeting%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-Like%2520Kinase%25201%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D16%26spage%3D876%26epage%3D882%26doi%3D10.1038%2Fnsmb.1628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huggins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laraia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narvaez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts-Thomson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyce, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span> <span> </span><span class="NLM_article-title">Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1</span>. <i>ACS Omega</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1021/acsomega.9b03626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.9b03626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKms7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=822-831&author=D.+J.+Hugginsauthor=B.+S.+Hardwickauthor=P.+Sharmaauthor=A.+Emeryauthor=L.+Laraiaauthor=F.+Zhangauthor=A.+J.+Narvaezauthor=M.+Roberts-Thomsonauthor=A.+T.+Crooksauthor=R.+G.+Boyleauthor=R.+Boyceauthor=D.+W.+Walkerauthor=N.+Mateuauthor=G.+J.+McKenzieauthor=D.+R.+Springauthor=A.+R.+Venkitaraman&title=Development+of+a+Novel+Cell-Permeable+Protein-Protein+Interaction+Inhibitor+for+the+Polo-box+Domain+of+Polo-like+Kinase+1&doi=10.1021%2Facsomega.9b03626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1</span></div><div class="casAuthors">Huggins, David J.; Hardwick, Bryn S.; Sharma, Pooja; Emery, Amy; Laraia, Luca; Zhang, Fengzhi; Narvaez, Ana J.; Roberts-Thomson, Meredith; Crooks, Alex T.; Boyle, Robert G.; Boyce, Richard; Walker, David W.; Mateu, Natalia; McKenzie, Grahame J.; Spring, David R.; Venkitaraman, Ashok R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">822-831</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (PLK1) is a key regulator of mitosis and a recognized drug target for cancer therapy.  Inhibiting the polo-box domain of PLK1 offers potential advantages of increased selectivity and subsequently reduced toxicity compared with targeting the kinase domain.  However, many if not all existing polo-box domain inhibitors have been shown to be unsuitable for further development.  In this paper, we describe a novel compd. series, which inhibits the protein-protein interactions of PLK1 via the polo-box domain.  We combine high throughput screening with mol. modeling and computer-aided design, synthetic chem., and cell biol. to address some of the common problems with protein-protein interaction inhibitors, such as soly. and potency.  We use mol. modeling to improve the soly. of a hit series with initially poor physicochem. properties, enabling biophys. and biochem. characterization.  We isolate and characterize enantiomers to improve potency and demonstrate on-target activity in both cell-free and cell-based assays, entirely consistent with the proposed binding model.  The resulting compd. series represents a promising starting point for further progression along the drug discovery pipeline and a new tool compd. to study kinase-independent PLK functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrWFhsrh2HYrVg90H21EOLACvtfcHk0lihI7Xn7rYlvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKms7%252FF&md5=f1582278a5175d17fa488eb9cc37b799</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facsomega.9b03626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.9b03626%26sid%3Dliteratum%253Aachs%26aulast%3DHuggins%26aufirst%3DD.%2BJ.%26aulast%3DHardwick%26aufirst%3DB.%2BS.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DEmery%26aufirst%3DA.%26aulast%3DLaraia%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DNarvaez%26aufirst%3DA.%2BJ.%26aulast%3DRoberts-Thomson%26aufirst%3DM.%26aulast%3DCrooks%26aufirst%3DA.%2BT.%26aulast%3DBoyle%26aufirst%3DR.%2BG.%26aulast%3DBoyce%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DD.%2BW.%26aulast%3DMateu%26aufirst%3DN.%26aulast%3DMcKenzie%26aufirst%3DG.%2BJ.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DDevelopment%2520of%2520a%2520Novel%2520Cell-Permeable%2520Protein-Protein%2520Interaction%2520Inhibitor%2520for%2520the%2520Polo-box%2520Domain%2520of%2520Polo-like%2520Kinase%25201%26jtitle%3DACS%2520Omega%26date%3D2020%26volume%3D5%26spage%3D822%26epage%3D831%26doi%3D10.1021%2Facsomega.9b03626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huggins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emery, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunciw, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyvonen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkitaraman, A. R.</span></span> <span> </span><span class="NLM_article-title">A Cryptic Hydrophobic Pocket in the Polo-Box Domain of the Polo-like Kinase PLK1 Regulates Substrate Recognition and Mitotic Chromosome Segregation</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">15930</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-50702-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fs41598-019-50702-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=31685831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BB3MjltVKqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=15930&author=P.+Sharmaauthor=R.+Mahenauthor=M.+Rossmannauthor=J.+E.+Stokesauthor=B.+Hardwickauthor=D.+J.+Hugginsauthor=A.+Emeryauthor=D.+L.+Kunciwauthor=M.+Hyvonenauthor=D.+R.+Springauthor=G.+J.+McKenzieauthor=A.+R.+Venkitaraman&title=A+Cryptic+Hydrophobic+Pocket+in+the+Polo-Box+Domain+of+the+Polo-like+Kinase+PLK1+Regulates+Substrate+Recognition+and+Mitotic+Chromosome+Segregation&doi=10.1038%2Fs41598-019-50702-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation</span></div><div class="casAuthors">Sharma Pooja; Mahen Robert; Hardwick Bryn; Emery Amy; McKenzie Grahame J; Venkitaraman Ashok R; Rossmann Maxim; Hyvonen Marko; Stokes Jamie E; Kunciw Dominique L; Spring David R; Huggins David J</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15930</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human polo-like kinase PLK1 coordinates mitotic chromosome segregation by phosphorylating multiple chromatin- and kinetochore-binding proteins.  How PLK1 activity is directed to specific substrates via phosphopeptide recognition by its carboxyl-terminal polo-box domain (PBD) is poorly understood.  Here, we combine molecular, structural and chemical biology to identify a determinant for PLK1 substrate recognition that is essential for proper chromosome segregation.  We show that mutations ablating an evolutionarily conserved, Tyr-lined pocket in human PLK1 PBD trigger cellular anomalies in mitotic progression and timing.  Tyr pocket mutations selectively impair PLK1 binding to the kinetochore phosphoprotein substrate PBIP1, but not to the centrosomal substrate NEDD1.  Through a structure-guided approach, we develop a small-molecule inhibitor, Polotyrin, which occupies the Tyr pocket.  Polotyrin recapitulates the mitotic defects caused by mutations in the Tyr pocket, further evidencing its essential function, and exemplifying a new approach for selective PLK1 inhibition.  Thus, our findings support a model wherein substrate discrimination via the Tyr pocket in the human PLK1 PBD regulates mitotic chromosome segregation to preserve genome integrity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmE_81mdt7jLqxQ2mb9Pu8fW6udTcc2eYmLKp1oKEKQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjltVKqtw%253D%253D&md5=39d6fd4ff6c560ee5256956716d1bd39</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-50702-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-50702-2%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DMahen%26aufirst%3DR.%26aulast%3DRossmann%26aufirst%3DM.%26aulast%3DStokes%26aufirst%3DJ.%2BE.%26aulast%3DHardwick%26aufirst%3DB.%26aulast%3DHuggins%26aufirst%3DD.%2BJ.%26aulast%3DEmery%26aufirst%3DA.%26aulast%3DKunciw%26aufirst%3DD.%2BL.%26aulast%3DHyvonen%26aufirst%3DM.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26aulast%3DMcKenzie%26aufirst%3DG.%2BJ.%26aulast%3DVenkitaraman%26aufirst%3DA.%2BR.%26atitle%3DA%2520Cryptic%2520Hydrophobic%2520Pocket%2520in%2520the%2520Polo-Box%2520Domain%2520of%2520the%2520Polo-like%2520Kinase%2520PLK1%2520Regulates%2520Substrate%2520Recognition%2520and%2520Mitotic%2520Chromosome%2520Segregation%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D15930%26doi%3D10.1038%2Fs41598-019-50702-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">17043</span>– <span class="NLM_lpage">17047</span>, <span class="refDoi"> DOI: 10.1002/anie.201809640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fanie.201809640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlCmu7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=17043-17047&author=S.+Rubnerauthor=A.+Scharowauthor=S.+Schubertauthor=T.+Berg&title=Selective+Degradation+of+Polo-like+Kinase+1+by+a+Hydrophobically+Tagged+Inhibitor+of+the+Polo-Box+Domain&doi=10.1002%2Fanie.201809640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain</span></div><div class="casAuthors">Rubner, Stefan; Scharow, Andrej; Schubert, Sabine; Berg, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">17043-17047</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Hydrophobic tagging (HT) of bioactive compds. can induce target degrdn. via the proteasomal pathway.  The first application of hydrophobic tagging to an existing inhibitor of protein-protein interactions is now presented.  We developed Poloxin-2HT by fusing an adamantyl tag to Poloxin-2, an inhibitor of the polo-box domain (PBD) of the protein kinase Plk1, which is a target for tumor therapy.  Poloxin-2HT selectively reduced the protein levels of Plk1 in HeLa cells and had a significantly stronger effect on cell viability and the induction of apoptosis than the untagged PBD inhibitor Poloxin-2.  The change in cellular phenotype assocd. with the addn. of the hydrophobic tag to Poloxin-2 demonstrated that Poloxin-2HT targets Plk1 in living cells.  Our data validate hydrophobic tagging of selective inhibitors of protein-protein interactions as a novel strategy to target and destroy disease-relevant proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_u-8CJlq93rVg90H21EOLACvtfcHk0lgSQcls07LxZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlCmu7nO&md5=4fc1c52c673ab5636d3bc78c40d90fc2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201809640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201809640%26sid%3Dliteratum%253Aachs%26aulast%3DRubner%26aufirst%3DS.%26aulast%3DScharow%26aufirst%3DA.%26aulast%3DSchubert%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DSelective%2520Degradation%2520of%2520Polo-like%2520Kinase%25201%2520by%2520a%2520Hydrophobically%2520Tagged%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domain%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D17043%26epage%3D17047%26doi%3D10.1002%2Fanie.201809640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelfatah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdoun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greten, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">MCC1019, a Selective Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 as Novel, Potent Anticancer Candidate</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.02.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.apsb.2019.02.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=31649851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BB3MjhsVyiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1021-1034&author=S.+Abdelfatahauthor=A.+Bergauthor=Q.+Huangauthor=L.+J.+Yangauthor=S.+Hamdounauthor=A.+Klingerauthor=H.+J.+Gretenauthor=E.+Fleischerauthor=T.+Bergauthor=V.+K.+W.+Wongauthor=T.+Efferth&title=MCC1019%2C+a+Selective+Inhibitor+of+the+Polo-Box+Domain+of+Polo-like+Kinase+1+as+Novel%2C+Potent+Anticancer+Candidate&doi=10.1016%2Fj.apsb.2019.02.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate</span></div><div class="casAuthors">Abdelfatah Sara; Hamdoun Sami; Efferth Thomas; Berg Angela; Berg Thorsten; Huang Qi; Yang Li Jun; Wong Vincent K W; Klinger Anette; Fleischer Edmond; Greten Henry J</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1021-1034</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">Polo-like kinase (PLK1) has been identified as a potential target for cancer treatment.  Although a number of small molecules have been investigated as PLK1 inhibitors, many of which showed limited selectivity.  PLK1 harbors a regulatory domain, the Polo box domain (PBD), which has a key regulatory function for kinase activity and substrate recognition.  We report on 3-bromomethyl-benzofuran-2-carboxylic acid ethyl ester (designated: MCC1019) as selective PLK1 inhibitor targeting PLK1 PBD.  Cytotoxicity and fluorescence polarization-based screening were applied to a library of 1162 drug-like compounds to identify potential inhibitors of PLK1 PBD.  The activity of compound MC1019 against the PLK1 PBD was confirmed using fluorescence polarization and microscale thermophoresis.  This compound exerted specificity towards PLK1 over PLK2 and PLK3.  MCC1019 showed cytotoxic activity in a panel of different cancer cell lines.  Mechanistic investigations in A549 lung adenocarcinoma cells revealed that MCC1019 induced cell growth inhibition through inactivation of AKT signaling pathway, it also induced prolonged mitotic arrest-a phenomenon known as mitotic catastrophe, which is followed by immediate cell death via apoptosis and necroptosis.  MCC1019 significantly inhibited tumor growth in vivo in a murine lung cancer model without affecting body weight or vital organ size, and reduced the growth of metastatic lesions in the lung.  We propose MCC1019 as promising anti-cancer drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvkjWQNLMrdtts4TFFB11gfW6udTcc2eYmLKp1oKEKQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjhsVyiug%253D%253D&md5=018084162f99502d13b93ae90757af77</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.02.001%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelfatah%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DL.%2BJ.%26aulast%3DHamdoun%26aufirst%3DS.%26aulast%3DKlinger%26aufirst%3DA.%26aulast%3DGreten%26aufirst%3DH.%2BJ.%26aulast%3DFleischer%26aufirst%3DE.%26aulast%3DBerg%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DMCC1019%252C%2520a%2520Selective%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-like%2520Kinase%25201%2520as%2520Novel%252C%2520Potent%2520Anticancer%2520Candidate%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D1021%26epage%3D1034%26doi%3D10.1016%2Fj.apsb.2019.02.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1148</span>, <span class="refDoi"> DOI: 10.1002/cbic.200900059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fcbic.200900059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19350612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVOnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=1145-1148&author=W.+Reindlauthor=J.+Yuanauthor=A.+Kr%C3%A4merauthor=K.+Strebhardtauthor=T.+Berg&title=A+Pan-Specific+Inhibitor+of+the+Polo-Box+Domains+of+Polo-like+Kinases+Arrests+Cancer+Cells+in+Mitosis&doi=10.1002%2Fcbic.200900059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis</span></div><div class="casAuthors">Reindl, Wolfgang; Yuan, Juping; Kraemer, Andrea; Strebhardt, Klaus; Berg, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1145-1148</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Playing polo: Small-mol. inhibitors of polo-like kinase 1 are mostly ATP-competitive, and thus face enormous specificity hurdles.  This communication explores the concept of inhibiting Plk1 with a small-mol. inhibitor of the protein-protein interactions required for Plk1 function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxCZKviUmvb7Vg90H21EOLACvtfcHk0ljbc1WxJ-unpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVOnt74%253D&md5=0eed2290f271030a44edaf04a45a370d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200900059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200900059%26sid%3Dliteratum%253Aachs%26aulast%3DReindl%26aufirst%3DW.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DA%2520Pan-Specific%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domains%2520of%2520Polo-like%2520Kinases%2520Arrests%2520Cancer%2520Cells%2520in%2520Mitosis%26jtitle%3DChemBioChem%26date%3D2009%26volume%3D10%26spage%3D1145%26epage%3D1148%26doi%3D10.1002%2Fcbic.200900059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strebhardt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Polo-Like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2008.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.chembiol.2008.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18482698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVSjsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=459-466&author=W.+Reindlauthor=J.+Yuanauthor=A.+Kr%C3%A4merauthor=K.+Strebhardtauthor=T.+Berg&title=Inhibition+of+Polo-Like+Kinase+1+by+Blocking+Polo-Box+Domain-Dependent+Protein-Protein+Interactions&doi=10.1016%2Fj.chembiol.2008.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions</span></div><div class="casAuthors">Reindl, Wolfgang; Yuan, Juping; Kraemer, Andrea; Strebhardt, Klaus; Berg, Thorsten</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">459-466</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Ser/Thr kinase Polo-like kinase 1 (Plk1) is overexpressed in many types of human cancers, and was implicated as an adverse prognostic marker for cancer patients.  Plk1 localizes to its intracellular anchoring sites via its polo-box domain (PBD).  Here we show that Plk1 can be inhibited by small mols. which interfere with its intracellular localization by inhibiting the function of the PBD.  We report the natural product thymoquinone and, esp., the synthetic thymoquinone deriv. Poloxin as inhibitors of the Plk1 PBD.  Both compds. inhibit the function of the Plk1 PBD in vitro, and cause Plk1 mislocalization, chromosome congression defects, mitotic arrest, and apoptosis in HeLa cells.  These data validate the Plk1 PBD as an anticancer target and provide a rationale for developing thymoquinone derivs. as anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVCWgVzGi04rVg90H21EOLACvtfcHk0ljbc1WxJ-unpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVSjsL8%253D&md5=cb8a592799b8ac1a1d08868d1f0b7033</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DReindl%26aufirst%3DW.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DStrebhardt%26aufirst%3DK.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520Polo-Like%2520Kinase%25201%2520by%2520Blocking%2520Polo-Box%2520Domain-Dependent%2520Protein-Protein%2520Interactions%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D459%26epage%3D466%26doi%3D10.1016%2Fj.chembiol.2008.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, J.-i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, H.</span></span> <span> </span><span class="NLM_article-title">Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-Dependent Recognition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>284</i></span>,  <span class="NLM_fpage">2344</span>– <span class="NLM_lpage">2353</span>, <span class="refDoi"> DOI: 10.1074/jbc.m805308200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1074%2Fjbc.M805308200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=19033445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvFeisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=2344-2353&author=N.+Watanabeauthor=T.+Sekineauthor=M.+Takagiauthor=J.-i.+Iwasakiauthor=N.+Imamotoauthor=H.+Kawasakiauthor=H.+Osada&title=Deficiency+in+Chromosome+Congression+by+the+Inhibition+of+Plk1+Polo+Box+Domain-Dependent+Recognition&doi=10.1074%2Fjbc.m805308200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Deficiency in chromosome congression by the inhibition of Plk1 Polo box domain-dependent recognition</span></div><div class="casAuthors">Watanabe, Nobumoto; Sekine, Tomomi; Takagi, Masatoshi; Iwasaki, Jun-ichi; Imamoto, Naoko; Kawasaki, Hisashi; Osada, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2344-2353</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1) is one of the key regulators of mitotic cell division.  In addn. to an N-terminal protein kinase catalytic domain, Plk1 possesses a phosphopeptide binding domain named polo box domain (PBD) at its C terminus.  PBD is postulated to be essential for Plk1 localization and substrate targeting.  Here, we developed a high-throughput screening system to identify inhibitors of PBD-dependent binding and screened a chem. library.  We isolated a benzotropolone-contg. natural compd. derived from nutgalls (purpurogallin (PPG)) that inhibited PBD-dependent binding in vitro and in vivo.  PPG not only delayed the onset of mitosis but also prolonged the progression of mitosis in HeLa cells.  Although apparently normal bipolar spindles were formed even in the presence of PPG, the perturbation of chromosome alignment at metaphase plates activated the spindle assembly checkpoint pathway.  These results demonstrate the predominant role of PBD-dependent binding on smooth chromosome congression at metaphase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSwEPlVFENJ7Vg90H21EOLACvtfcHk0ljbc1WxJ-unpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvFeisg%253D%253D&md5=21d5ea87349844035483599db5e1f2b9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M805308200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M805308200%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DN.%26aulast%3DSekine%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DJ.-i.%26aulast%3DImamoto%26aufirst%3DN.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DOsada%26aufirst%3DH.%26atitle%3DDeficiency%2520in%2520Chromosome%2520Congression%2520by%2520the%2520Inhibition%2520of%2520Plk1%2520Polo%2520Box%2520Domain-Dependent%2520Recognition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D2344%26epage%3D2353%26doi%3D10.1074%2Fjbc.m805308200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavallee, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beautrait, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guiral, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archambault, V.</span></span> <span> </span><span class="NLM_article-title">Identification of Polo-like Kinase 1 Interaction Inhibitors Using a Novel Cell-Based Assay</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">37581</span>, <span class="refDoi"> DOI: 10.1038/srep37581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fsrep37581" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=37581&author=K.+Normandinauthor=J.+F.+Lavalleeauthor=M.+Futterauthor=A.+Beautraitauthor=J.+Duchaineauthor=S.+Guiralauthor=A.+Marinierauthor=V.+Archambault&title=Identification+of+Polo-like+Kinase+1+Interaction+Inhibitors+Using+a+Novel+Cell-Based+Assay&doi=10.1038%2Fsrep37581"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fsrep37581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep37581%26sid%3Dliteratum%253Aachs%26aulast%3DNormandin%26aufirst%3DK.%26aulast%3DLavallee%26aufirst%3DJ.%2BF.%26aulast%3DFutter%26aufirst%3DM.%26aulast%3DBeautrait%26aufirst%3DA.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DMarinier%26aufirst%3DA.%26aulast%3DArchambault%26aufirst%3DV.%26atitle%3DIdentification%2520of%2520Polo-like%2520Kinase%25201%2520Interaction%2520Inhibitors%2520Using%2520a%2520Novel%2520Cell-Based%2520Assay%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D37581%26doi%3D10.1038%2Fsrep37581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scharow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knappe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, T.</span></span> <span> </span><span class="NLM_article-title">Development of Bifunctional Inhibitors of Polo-like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">767</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fcbic.201500535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26634982" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=759-767&author=A.+Scharowauthor=D.+Knappeauthor=W.+Reindlauthor=R.+Hoffmannauthor=T.+Berg&title=Development+of+Bifunctional+Inhibitors+of+Polo-like+Kinase+1+with+Low-Nanomolar+Activities+Against+the+Polo-Box+Domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201500535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201500535%26sid%3Dliteratum%253Aachs%26aulast%3DScharow%26aufirst%3DA.%26aulast%3DKnappe%26aufirst%3DD.%26aulast%3DReindl%26aufirst%3DW.%26aulast%3DHoffmann%26aufirst%3DR.%26aulast%3DBerg%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520Bifunctional%2520Inhibitors%2520of%2520Polo-like%2520Kinase%25201%2520with%2520Low-Nanomolar%2520Activities%2520Against%2520the%2520Polo-Box%2520Domain%26jtitle%3DChemBioChem%26date%3D2015%26volume%3D17%26spage%3D759%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, S.</span></span> <span> </span><span class="NLM_article-title">Identification of a Novel Polo-like Kinase 1 Inhibitor that Specifically Blocks the Functions of Polo-Box Domain</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1234</span>– <span class="NLM_lpage">1246</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.18632%2Foncotarget.13603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=27902479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC2sjhvFGgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1234-1246&author=Y.+Chenauthor=J.+Zhangauthor=D.+Liauthor=J.+Jiangauthor=Y.+Wangauthor=S.+Si&title=Identification+of+a+Novel+Polo-like+Kinase+1+Inhibitor+that+Specifically+Blocks+the+Functions+of+Polo-Box+Domain&doi=10.18632%2Foncotarget.13603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain</span></div><div class="casAuthors">Chen Yunyu; Zhang Jing; Li Dongsheng; Jiang Jiandong; Wang Yanchang; Si Shuyi; Wang Yanchang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1234-1246</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polo-like kinase 1 (Plk1) is a promising target for cancer therapy due to its essential role in cell division.  In addition to a highly conserved kinase domain, Plk1 also contains a Polo-Box domain (PBD), which is essential for Plk1's subcellular localization and mitotic functions.  We adopted a fluorescence polarization assay and identified a new Plk1 PBD inhibitor T521 from a small-molecule compound library.  T521 specifically inhibits the PBD of Plk1, but not those of Plk2-3.  T521 exhibits covalent binding to some lysine residues of Plk1 PBD, which causes significant changes in the secondary structure of Plk1 PBD.  Using a cell-based assay, we showed that T521 impedes the interaction between Plk1 and Bub1, a mitotic checkpoint protein.  Moreover, HeLa cells treated with T521 exhibited dramatic mitotic defects.  Importantly, T521 suppresses the growth of A549 cells in xenograft nude mice.  Taken together, we have identified a novel Plk1 inhibitor that specifically disrupts the functions of Plk1 PBD and shows anticancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcaWAdrH758FHFYivNCdPRfW6udTcc2ebxL6vGHdZwYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjhvFGgsA%253D%253D&md5=709ae17e7357c8cdc3047014b65daf37</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13603%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520a%2520Novel%2520Polo-like%2520Kinase%25201%2520Inhibitor%2520that%2520Specifically%2520Blocks%2520the%2520Functions%2520of%2520Polo-Box%2520Domain%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D1234%26epage%3D1246%26doi%3D10.18632%2Foncotarget.13603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, K.-S.</span></span> <span> </span><span class="NLM_article-title">Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1462</span>, <span class="refDoi"> DOI: 10.1248/bpb.b17-00283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1248%2Fbpb.b17-00283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28867728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2rsLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2017&pages=1454-1462&author=T.+G.+Kimauthor=J.+H.+Leeauthor=M.+Y.+Leeauthor=K.-U.+Kimauthor=J.+H.+Leeauthor=C.+H.+Parkauthor=B.+H.+Leeauthor=K.-S.+Oh&title=Development+of+a+High-Throughput+Assay+for+Inhibitors+of+the+Polo-Box+Domain+of+Polo-Like+Kinase+1+Based+on+Time-Resolved+Fluorescence+Energy+Transfer&doi=10.1248%2Fbpb.b17-00283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a high-throughput assay for inhibitors of the polo-box domain of polo-like kinase 1 based on time-resolved fluorescence energy transfer</span></div><div class="casAuthors">Kim, Tae Gi; Lee, Ju Hee; Lee, Mi Young; Kim, Ka-Ul; Lee, Jeong Hyun; Park, Chi Hoon; Lee, Byung Ho; Oh, Kwang-Seok</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1454-1462</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Although ELISA (ELISA) technol. has been widely accepted for binding assays against the polo-box domain (PBD) of polo-like kinase-1 (Plk1), these assays have a limitation-related heterogeneous procedure, such as multiple incubations and washing steps to apply high-throughput screenings (HTSs).  In the present study, a Plk1-PBD binding assay based on time-resolved fluorescence energy transfer (TR-FRET) was developed for HTS of PBD-binding inhibitors.  The TR-FRET-based Plk1-PBD binding assay is sensitive and robust and can be miniaturized into the 384-well plate-based format.  Compared with the ELISA-based Plk1-PBD binding assay (Z' factor, 0.53; signal-to-background ratio, 4.19), the TR-FRET-based Plk1-PBD binding assay improved the Z' factor (0.72) and signal-to-background ratio (8.16).  Using TR-FRET based Plk1-PBD binding assay, pilot library screening of 1019 natural compds. was conducted and five hit compds. such as haematoxylin, verbascoside, menadione, lithospermic acid and (1,3-dioxolo[4,5-g]isoquinolinium 5,6,7,8-tetrahydro-4-methoxy-6,6-dimethyl-5-[2-oxo-2-(2-pyridinyl)ethyl]-iodide) (DITMD) were identified as Plk1-PBD inhibitor.  In a functional assay to validate the hit compds., five hit compds. exhibited suppression of HeLa cells proliferation.  These results suggest that TR-FRET-based Plk1-PBD binding assay can be applied for an efficient and less time-consuming HTS of compd. libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT5YDFNeDJ9bVg90H21EOLACvtfcHk0lhvHK3xgX2dRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2rsLnN&md5=f6f8b400d4bd45f1f8139c613f904a72</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1248%2Fbpb.b17-00283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.b17-00283%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DT.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DM.%2BY.%26aulast%3DKim%26aufirst%3DK.-U.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DOh%26aufirst%3DK.-S.%26atitle%3DDevelopment%2520of%2520a%2520High-Throughput%2520Assay%2520for%2520Inhibitors%2520of%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-Like%2520Kinase%25201%2520Based%2520on%2520Time-Resolved%2520Fluorescence%2520Energy%2520Transfer%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2017%26volume%3D40%26spage%3D1454%26epage%3D1462%26doi%3D10.1248%2Fbpb.b17-00283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C.</span></span> <span> </span><span class="NLM_article-title">Identification of Novel and Selective Non-Peptide Inhibitors Targeting the Polo-Box Domain of Polo-Like Kinase 1</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2018.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bioorg.2018.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=30170276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Smsb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2018&pages=278-288&author=Y.+Chenauthor=Z.+Liauthor=Y.+Liuauthor=T.+Linauthor=H.+Sunauthor=D.+Yangauthor=C.+Jiang&title=Identification+of+Novel+and+Selective+Non-Peptide+Inhibitors+Targeting+the+Polo-Box+Domain+of+Polo-Like+Kinase+1&doi=10.1016%2Fj.bioorg.2018.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1</span></div><div class="casAuthors">Chen, Yanhong; Li, Zhiyan; Liu, Yu; Lin, Tongyuan; Sun, Huiyong; Yang, Dasong; Jiang, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">278-288</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of non-peptide inhibitors targeting the polo-box domain (PBD) of polo-like kinase 1 (Plk1) was designed based on the potent and selective minimal tripeptide Plk1 PBD inhibitor.  Seven compds. were designed, synthesized and evaluated for fluorescence polarization (FP) assay.  The most promising compd. 10 bound to Plk1 PBD with IC50 of 3.37 μM and had no binding to Plk2 PBD or Plk3 PBD at 100 μM.  Mol. docking study was performed and possible binding mode was proposed.  MM/GBSA binding free energy calcn. were in agreement with the obsd. exptl. results.  These novel non-peptide selective Plk1 PBD inhibitors provided new lead compds. for further optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKrHsqzfkRRbVg90H21EOLACvtfcHk0lhvHK3xgX2dRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Smsb%252FM&md5=7d4e1b7c50e73280dfdf0159a58fa507</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2018.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2018.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520Novel%2520and%2520Selective%2520Non-Peptide%2520Inhibitors%2520Targeting%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-Like%2520Kinase%25201%26jtitle%3DBioorg.%2520Chem.%26date%3D2018%26volume%3D81%26spage%3D278%26epage%3D288%26doi%3D10.1016%2Fj.bioorg.2018.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelfatah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böckers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efferth, T.</span></span> <span> </span><span class="NLM_article-title">A Selective Inhibitor of the Polo-Box Domain of Polo-like Kinase 1 Identified by Virtual Screening</span>. <i>J. Adv. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.jare.2018.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.jare.2018.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=30899597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKktr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=145-156&author=S.+Abdelfatahauthor=A.+Bergauthor=M.+B%C3%B6ckersauthor=T.+Efferth&title=A+Selective+Inhibitor+of+the+Polo-Box+Domain+of+Polo-like+Kinase+1+Identified+by+Virtual+Screening&doi=10.1016%2Fj.jare.2018.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening</span></div><div class="casAuthors">Abdelfatah, Sara; Berg, Angela; Boeckers, Madeleine; Efferth, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Advanced Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145-156</span>CODEN:
                <span class="NLM_cas:coden">JAROES</span>;
        ISSN:<span class="NLM_cas:issn">2090-1224</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study, in silico virtual drug screening, fluorescence polarization and microscale thermophoresis to identify new scaffolds targeting the polo-box domain of PLK1 was applied.  One compd., 3-{[(1R,9S)-3-(naphthalen-2-yl)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-11-yl]methyl}benzonitrile (designated compd. (1)), out of a total of 30,793 natural product derivs., inhibited the PLK1 PBD with high selectivity (IC50: 17.9 ± 0.5 μM).  This compd. inhibited the growth of cultured leukemia cells (CCRF-CEM and CEM/ADR5000) and arrested the cell cycle in the G2/M phase, which is characteristic for PLK1 inhibitors.  Immunofluorescence analyses showed that treatment with compd. (1) disrupted spindle formation due to the aberrant localization of PLK1 during the mitotic process, leading to G2/M arrest and ultimately cell death.  In conclusion, compd. (1) is a selective PLK1 inhibitor that inhibits cancer cell growth.  It represents a chem. scaffold for the future synthesis of new selective PLK1 inhibitors for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh1DdqorQSvbVg90H21EOLACvtfcHk0lhHqxgQ0sa0tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKktr7L&md5=afd5eead207c623b4407258ad55fe798</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.jare.2018.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jare.2018.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelfatah%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DA.%26aulast%3DB%25C3%25B6ckers%26aufirst%3DM.%26aulast%3DEfferth%26aufirst%3DT.%26atitle%3DA%2520Selective%2520Inhibitor%2520of%2520the%2520Polo-Box%2520Domain%2520of%2520Polo-like%2520Kinase%25201%2520Identified%2520by%2520Virtual%2520Screening%26jtitle%3DJ.%2520Adv.%2520Res.%26date%3D2019%26volume%3D16%26spage%3D145%26epage%3D156%26doi%3D10.1016%2Fj.jare.2018.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, M.-M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate Through Structure-Based Design</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4351</span>– <span class="NLM_lpage">4360</span>, <span class="refDoi"> DOI: 10.3390/molecules24234351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.3390%2Fmolecules24234351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVaisr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=4351-4360&author=Y.+Zhouauthor=F.+Yanauthor=X.+Huoauthor=M.-M.+Niu&title=Discovery+of+a+Potent+PLK1-PBD+Small-Molecule+Inhibitor+as+an+Anticancer+Drug+Candidate+Through+Structure-Based+Design&doi=10.3390%2Fmolecules24234351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent PLK1-PBD small-molecule inhibitor as an anticancer drug candidate through structure-based design</span></div><div class="casAuthors">Zhou, Yunjiang; Yan, Fang; Huo, Xiangyun; Niu, Miao-Miao</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4351</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Polo-box domain of polo-like kinase 1 (PLK1-PBD) has a pivotal role in cell proliferation and could be implicated as a potential anticancer target.  Although some small-mol. inhibitors have been developed, their clin. application has been restricted by the poor selectivity.  Therefore, there is an urgent need to develop effective PLK1-PBD inhibitors.  Herein, we have developed a virtual screening protocol to find PLK1-PBD inhibitors by using combination of structure-based pharmacophore modeling and mol. docking.  This protocol was successfully applied to screen PLK1-PBD inhibitors from specs database.  MTT assay indicated that five screened hits suppressed the growth of HeLa cells.  Particularly, hit-5, as a selective PLK1 inhibitor targeting PLK1-PBD, significantly inhibited the progression of HeLa cells-derived xenograft, with no obvious side effects.  This work demonstrates that hit-5 may be a potential anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV69vyNCDdSLVg90H21EOLACvtfcHk0lhHqxgQ0sa0tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVaisr3N&md5=19a897e8cd7d6c03ab20ced979366e32</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24234351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24234351%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DF.%26aulast%3DHuo%26aufirst%3DX.%26aulast%3DNiu%26aufirst%3DM.-M.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520PLK1-PBD%2520Small-Molecule%2520Inhibitor%2520as%2520an%2520Anticancer%2520Drug%2520Candidate%2520Through%2520Structure-Based%2520Design%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D4351%26epage%3D4360%26doi%3D10.3390%2Fmolecules24234351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idle, J. R.</span></span> <span> </span><span class="NLM_article-title">Pinning Down the Polo-Box Domain</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2008.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.chembiol.2008.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=18482691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVSjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=415-416&author=K.+S.+Leeauthor=J.+R.+Idle&title=Pinning+Down+the+Polo-Box+Domain&doi=10.1016%2Fj.chembiol.2008.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pinning Down the Polo-Box Domain</span></div><div class="casAuthors">Lee, Kyung S.; Idle, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">415-416</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Polo-like kinase 1 (Plk1) appears to be an attractive target for anticancer therapy.  In this issue of Chem. & Biol., the identification of a small mol. called Poloxin is described that appears to interfere with the function of the polo-box domain (PBD) of Plk1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFS4t_tT8iWLVg90H21EOLACvtfcHk0lhHqxgQ0sa0tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVSjs70%253D&md5=b913229af35a2992cc0fd44248d6f01c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2008.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2008.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DIdle%26aufirst%3DJ.%2BR.%26atitle%3DPinning%2520Down%2520the%2520Polo-Box%2520Domain%26jtitle%3DChem.%2520Biol.%26date%3D2008%26volume%3D15%26spage%3D415%26epage%3D416%26doi%3D10.1016%2Fj.chembiol.2008.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Archambault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Normandin, K.</span></span> <span> </span><span class="NLM_article-title">Several Inhibitors of the Plk1 Polo-Box Domain Turn Out to Be Non-Specific Protein Alkylators</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1220</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.1080/15384101.2017.1325043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1080%2F15384101.2017.1325043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28521657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptlSgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1220-1224&author=V.+Archambaultauthor=K.+Normandin&title=Several+Inhibitors+of+the+Plk1+Polo-Box+Domain+Turn+Out+to+Be+Non-Specific+Protein+Alkylators&doi=10.1080%2F15384101.2017.1325043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators</span></div><div class="casAuthors">Archambault, Vincent; Normandin, Karine</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1220-1224</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">For almost a decade, there has been much interest in the development of chem. inhibitors of Polo-like kinase 1 (Plk1) protein interactions.  Plk1 is a master regulator of the cell division cycle that controls numerous substrates.  It is a promising target for cancer drug development.  Inhibitors of the kinase domain of Plk1 had some success in clin. trials.  However, they are not perfectly selective.  In principle, Plk1 can also be inhibited by interfering with its protein interaction domain, the Polo-Box Domain (PBD).  Selective chem. inhibitors of the PBD would constitute tools to probe for PBD-dependent functions of Plk1 and could be advantageous in cancer therapy.  The discovery of Poloxin and thymoquinone as PBD inhibitors indicated that small, cell-permeable chem. inhibitors could be identified.  Other efforts followed, including ours, reporting addnl. mols. capable of blocking the PBD.  It is now clear that, unfortunately, most of these compds. are non-specific protein alkylators (defined here as groups covalently added via a carbon) that have little or no potential for the development of real Plk1 PBD-specific drugs.  This situation should be minded by biologists potentially interested in using these compds. to study Plk1.  Further efforts are needed to develop selective, cell-permeable PBD inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK-O1l-4MHz7Vg90H21EOLACvtfcHk0lhHqxgQ0sa0tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptlSgtbs%253D&md5=5f3a695bd266cc7eb9ebbb089de143b5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F15384101.2017.1325043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2017.1325043%26sid%3Dliteratum%253Aachs%26aulast%3DArchambault%26aufirst%3DV.%26aulast%3DNormandin%26aufirst%3DK.%26atitle%3DSeveral%2520Inhibitors%2520of%2520the%2520Plk1%2520Polo-Box%2520Domain%2520Turn%2520Out%2520to%2520Be%2520Non-Specific%2520Protein%2520Alkylators%26jtitle%3DCell%2520Cycle%26date%3D2017%26volume%3D16%26spage%3D1220%26epage%3D1224%26doi%3D10.1080%2F15384101.2017.1325043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soung, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seong, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garfield, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span> <span> </span><span class="NLM_article-title">Self-regulated Plk1 Recruitment to Kinetochores by the Plk1-PBIP1 Interaction Is Critical for Proper Chromosome Segregation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2006.10.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.molcel.2006.10.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17081991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtF2qs7jE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=409-422&author=Y.+H.+Kangauthor=J.-E.+Parkauthor=L.-R.+Yuauthor=N.-K.+Soungauthor=S.-M.+Yunauthor=J.+K.+Bangauthor=Y.-S.+Seongauthor=H.+Yuauthor=S.+Garfieldauthor=T.+D.+Veenstraauthor=K.+S.+Lee&title=Self-regulated+Plk1+Recruitment+to+Kinetochores+by+the+Plk1-PBIP1+Interaction+Is+Critical+for+Proper+Chromosome+Segregation&doi=10.1016%2Fj.molcel.2006.10.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation</span></div><div class="casAuthors">Kang, Young H.; Park, Jung-Eun; Yu, Li-Rong; Soung, Nak-Kyun; Yun, Sang-Moon; Bang, Jeong K.; Seong, Yeon-Sun; Yu, Hongtao; Garfield, Susan; Veenstra, Timothy D.; Lee, Kyung S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">409-422</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The polo-box domain (PBD) of mammalian polo-like kinase 1 (Plk1) is essential in targeting its catalytic activity to specific subcellular structures crit. for mitosis.  The mechanism underlying Plk1 recruitment to the kinetochores and the role of Plk1 at this site remain elusive.  Here, we demonstrate that a PBD-binding protein, PBIP1, is crucial for recruiting Plk1 to the interphase and mitotic kinetochores.  Unprecedentedly, Plk1 phosphorylated PBIP1 at T78, creating a self-tethering site that specifically interacted with the PBD of Plk1, but not Plk2 or Plk3.  Later in mitosis, Plk1 also induced PBIP1 degrdn. in a T78-dependent manner, thereby enabling itself to interact with other components crit. for proper kinetochore functions.  Absence of the p-T78-dependent Plk1 localization induced a chromosome congression defect and compromised the spindle checkpoint, ultimately leading to aneuploidy.  Thus, Plk1 self-regulates the Plk1-PBIP1 interaction to localize to the kinetochores in a timely fashion and to promote proper chromosome segregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAlddiJGIfzrVg90H21EOLACvtfcHk0liFFj8YsmPmQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtF2qs7jE&md5=db1bb5711b4dd5c83288cf5e88a524e7</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2006.10.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2006.10.016%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BH.%26aulast%3DPark%26aufirst%3DJ.-E.%26aulast%3DYu%26aufirst%3DL.-R.%26aulast%3DSoung%26aufirst%3DN.-K.%26aulast%3DYun%26aufirst%3DS.-M.%26aulast%3DBang%26aufirst%3DJ.%2BK.%26aulast%3DSeong%26aufirst%3DY.-S.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DGarfield%26aufirst%3DS.%26aulast%3DVeenstra%26aufirst%3DT.%2BD.%26aulast%3DLee%26aufirst%3DK.%2BS.%26atitle%3DSelf-regulated%2520Plk1%2520Recruitment%2520to%2520Kinetochores%2520by%2520the%2520Plk1-PBIP1%2520Interaction%2520Is%2520Critical%2520for%2520Proper%2520Chromosome%2520Segregation%26jtitle%3DMol.%2520Cell%26date%3D2006%26volume%3D24%26spage%3D409%26epage%3D422%26doi%3D10.1016%2Fj.molcel.2006.10.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irwin, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Discovery of A<sub>2A</sub> Adenosine Receptor Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">3748</span>– <span class="NLM_lpage">3755</span>, <span class="refDoi"> DOI: 10.1021/jm100240h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100240h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3748-3755&author=J.+Carlssonauthor=L.+Yooauthor=Z.-G.+Gaoauthor=J.+J.+Irwinauthor=B.+K.+Shoichetauthor=K.+A.+Jacobson&title=Structure-Based+Discovery+of+A2A+Adenosine+Receptor+Ligands&doi=10.1021%2Fjm100240h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Discovery of A2A Adenosine Receptor Ligands</span></div><div class="casAuthors">Carlsson, Jens; Yoo, Lena; Gao, Zhan-Guo; Irwin, John J.; Shoichet, Brian K.; Jacobson, Kenneth A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3748-3755</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent detn. of X-ray structures of pharmacol. relevant GPCRs has made these targets accessible to structure-based ligand discovery.  Here we explore whether novel chemotypes may be discovered for the A2A adenosine receptor, based on complementarity to its recently detd. structure.  The A2A adenosine receptor signals in the periphery and the CNS, with agonists explored as anti-inflammatory drugs and antagonists explored for neurodegenerative diseases.  We used mol. docking to screen a 1.4 million compd. database against the X-ray structure computationally and tested 20 high-ranking, previously unknown mols. exptl.  Of these 35% showed substantial activity with affinities between 200 nM and 9 μM.  For the most potent of these new inhibitors, over 50-fold specificity was obsd. for the A2A vs. the related A1 and A3 subtypes.  These high hit rates and affinities at least partly reflect the bias of com. libraries toward GPCR-like chemotypes, an issue that we attempt to investigate quant.  Despite this bias, many of the most potent new ligands were novel, dissimilar from known ligands, providing new lead structures for modulation of this medically important target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzvS6-9T9bd7Vg90H21EOLACvtfcHk0liFFj8YsmPmQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqsL8%253D&md5=c36c941d52d2cec06387d79c4c423d46</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm100240h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100240h%26sid%3Dliteratum%253Aachs%26aulast%3DCarlsson%26aufirst%3DJ.%26aulast%3DYoo%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DZ.-G.%26aulast%3DIrwin%26aufirst%3DJ.%2BJ.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26atitle%3DStructure-Based%2520Discovery%2520of%2520A2A%2520Adenosine%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3748%26epage%3D3755%26doi%3D10.1021%2Fjm100240h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urban, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimacombe, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheff, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titus, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karavadhi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boxer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span> <span> </span><span class="NLM_article-title">Assessing Inhibitors of Mutant Isocitrate Dehydrogenase Using a Suite of Pre-Clinical Discovery Assays</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12758</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-12630-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fs41598-017-12630-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28986582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FmtFKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=12758&author=D.+J.+Urbanauthor=N.+J.+Martinezauthor=M.+I.+Davisauthor=K.+R.+Brimacombeauthor=D.+M.+Cheffauthor=T.+D.+Leeauthor=M.+J.+Hendersonauthor=S.+A.+Titusauthor=R.+Praganiauthor=J.+M.+Rohdeauthor=L.+Liuauthor=Y.+Fangauthor=S.+Karavadhiauthor=P.+Shahauthor=O.+W.+Leeauthor=A.+Wangauthor=A.+McIverauthor=H.+Zhengauthor=X.+Wangauthor=X.+Xuauthor=A.+Jadhavauthor=A.+Simeonovauthor=M.+Shenauthor=M.+B.+Boxerauthor=M.+D.+Hall&title=Assessing+Inhibitors+of+Mutant+Isocitrate+Dehydrogenase+Using+a+Suite+of+Pre-Clinical+Discovery+Assays&doi=10.1038%2Fs41598-017-12630-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays</span></div><div class="casAuthors">Urban Daniel J; Martinez Natalia J; Davis Mindy I; Brimacombe Kyle R; Cheff Dorian M; Lee Tobie D; Henderson Mark J; Titus Steven A; Pragani Rajan; Rohde Jason M; Liu Li; Fang Yuhong; Karavadhi Surendra; Shah Pranav; Lee Olivia W; Wang Amy; Xu Xin; Jadhav Ajit; Simeonov Anton; Shen Min; Boxer Matthew B; Hall Matthew D; McIver Andrew; Zheng Hongchao; Wang Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12758</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that are mutated in a variety of cancers to confer a gain-of-function activity resulting in the accumulation of an oncometabolite, D-2-hydroxyglutarate (2-HG).  Accumulation of 2-HG can result in epigenetic dysregulation and a block in cellular differentiation, suggesting these mutations play a role in neoplasia.  Based on its potential as a cancer target, a number of small molecule inhibitors have been developed to specifically inhibit mutant forms of IDH (mIDH1 and mIDH2).  We present a comprehensive suite of in vitro preclinical drug development assays that can be used as a tool-box to identify lead compounds for mIDH drug discovery programs, as well as what we believe is the most comprehensive publically available dataset on the top mIDH inhibitors.  This involved biochemical, cell-based, and tier-one ADME techniques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVx3wC5R7hFEodMGTatQ7LfW6udTcc2ebNDOzfua6bG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FmtFKitA%253D%253D&md5=0e9c5c76a90bd7575413735e7ca1a5e9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-12630-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-12630-x%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DD.%2BJ.%26aulast%3DMartinez%26aufirst%3DN.%2BJ.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DBrimacombe%26aufirst%3DK.%2BR.%26aulast%3DCheff%26aufirst%3DD.%2BM.%26aulast%3DLee%26aufirst%3DT.%2BD.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DTitus%26aufirst%3DS.%2BA.%26aulast%3DPragani%26aufirst%3DR.%26aulast%3DRohde%26aufirst%3DJ.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DKaravadhi%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DO.%2BW.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DMcIver%26aufirst%3DA.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DBoxer%26aufirst%3DM.%2BB.%26aulast%3DHall%26aufirst%3DM.%2BD.%26atitle%3DAssessing%2520Inhibitors%2520of%2520Mutant%2520Isocitrate%2520Dehydrogenase%2520Using%2520a%2520Suite%2520of%2520Pre-Clinical%2520Discovery%2520Assays%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D12758%26doi%3D10.1038%2Fs41598-017-12630-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Highly Predictive and Interpretable Models for PAMPA Permeability</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmc.2016.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=28082071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntlOhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1266-1276&author=H.+Sunauthor=K.+Nguyenauthor=E.+Kernsauthor=Z.+Yanauthor=K.+R.+Yuauthor=P.+Shahauthor=A.+Jadhavauthor=X.+Xu&title=Highly+Predictive+and+Interpretable+Models+for+PAMPA+Permeability&doi=10.1016%2Fj.bmc.2016.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Highly predictive and interpretable models for PAMPA permeability</span></div><div class="casAuthors">Sun, Hongmao; Nguyen, Kimloan; Kerns, Edward; Yan, Zhengyin; Yu, Kyeong Ri; Shah, Pranav; Jadhav, Ajit; Xu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug mol.  An in silico model predicting drug permeability is described, which is built based on a large permeability dataset of 7488 compd. entries or 5435 structurally unique mols. measured by the same lab using parallel artificial membrane permeability assay (PAMPA).  On the basis of customized mol. descriptors, the support vector regression (SVR) model trained with 4071 compds. with quant. data is able to predict the remaining 1364 compds. with the qual. data with an area under the curve of receiver operating characteristic (AUC-ROC) of 0.90.  The support vector classification (SVC) model trained with half of the whole dataset comprised of both the quant. and the qual. data produced accurate predictions to the remaining data with the AUC-ROC of 0.88.  The results suggest that the developed SVR model is highly predictive and provides medicinal chemists a useful in silico tool to facilitate design and synthesis of novel compds. with optimal drug-like properties, and thus accelerate the lead optimization in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y8FhTLLqbrVg90H21EOLACvtfcHk0lj6kedl4UoO4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntlOhsA%253D%253D&md5=2f6b60dfcd168b5bf837405ca52457b2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DKerns%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DK.%2BR.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DJadhav%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DHighly%2520Predictive%2520and%2520Interpretable%2520Models%2520for%2520PAMPA%2520Permeability%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D1266%26epage%3D1276%26doi%3D10.1016%2Fj.bmc.2016.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span> <span> </span><span class="NLM_article-title">Predictive Models of Aqueous Solubility of Organic Compounds Built on a Large Dataset of High Integrity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3110</span>– <span class="NLM_lpage">3114</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.05.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.bmc.2019.05.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=31176566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFClsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3110-3114&author=H.+Sunauthor=P.+Shahauthor=K.+Nguyenauthor=K.+R.+Yuauthor=E.+Kernsauthor=M.+Kabirauthor=Y.+Wangauthor=X.+Xu&title=Predictive+Models+of+Aqueous+Solubility+of+Organic+Compounds+Built+on+a+Large+Dataset+of+High+Integrity&doi=10.1016%2Fj.bmc.2019.05.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity</span></div><div class="casAuthors">Sun, Hongmao; Shah, Pranav; Nguyen, Kimloan; Yu, Katherine; Kerns, Ed; Kabir, Md; Wang, Yuhong; Xu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3110-3114</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aq. soly. is one of the most important properties in drug discovery, as it has profound impact on various drug properties, including biol. activity, pharmacokinetics (PK), toxicity, and in vivo efficacy.  Both kinetic and thermodn. solubilities are detd. during different stages of drug discovery and development.  Since kinetic soly. is more relevant in preclin. drug discovery research, esp. during the structure optimization process, the authors have developed predictive models for kinetic soly. with inhouse data generated from 11,780 compds. collected from over 200 NCATS intramural research projects.  This represents one of the largest kinetic soly. datasets of high quality and integrity.  Based on the customized atom type descriptors, the support vector classification (SVC) models were trained on 80% of the whole dataset, and exhibited high predictive performance for estg. the soly. of the remaining 20% compds. within the test set.  The values of the area under the receiver operating characteristic curve (AUC-ROC) for the compds. in the test sets reached 0.93 and 0.91, when the threshold for insol. compds. was set to 10 and 50 μg/mL, resp.  The predictive models of aq. soly. can be used to identify insol. compds. in drug discovery pipeline, provide design ideas for improving soly. by analyzing the atom types assocd. with poor soly. and prioritize compd. libraries to be purchased or synthesized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfBZqnazp8KLVg90H21EOLACvtfcHk0lj6kedl4UoO4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFClsrnN&md5=8981617a93473ab5bc1112fc96e2c9fa</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.05.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.05.037%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DK.%2BR.%26aulast%3DKerns%26aufirst%3DE.%26aulast%3DKabir%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DX.%26atitle%3DPredictive%2520Models%2520of%2520Aqueous%2520Solubility%2520of%2520Organic%2520Compounds%2520Built%2520on%2520a%2520Large%2520Dataset%2520of%2520High%2520Integrity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D3110%26epage%3D3114%26doi%3D10.1016%2Fj.bmc.2019.05.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lénárt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steegmaier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Fiore, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipp, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.-M.</span></span> <span> </span><span class="NLM_article-title">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights Into Mitotic Roles of Polo-Like Kinase 1</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/j.cub.2006.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.cub.2006.12.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17291761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=304-315&author=P.+L%C3%A9n%C3%A1rtauthor=M.+Petronczkiauthor=M.+Steegmaierauthor=B.+Di+Fioreauthor=J.+J.+Lippauthor=M.+Hoffmannauthor=W.+J.+Rettigauthor=N.+Krautauthor=J.-M.+Peters&title=The+Small-Molecule+Inhibitor+BI+2536+Reveals+Novel+Insights+Into+Mitotic+Roles+of+Polo-Like+Kinase+1&doi=10.1016%2Fj.cub.2006.12.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1</span></div><div class="casAuthors">Lenart, Peter; Petronczki, Mark; Steegmaier, Martin; Di Fiore, Barbara; Lipp, Jesse J.; Hoffmann, Matthias; Rettig, Wolfgang J.; Kraut, Norbert; Peters, Jan-Michael</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">304-315</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensively to further understanding of mitotic mechanisms and as potential targets for cancer therapy.  Cdk1 and Aurora kinase studies have been facilitated by small-mol. inhibitors, but few if any potent Plk1 inhibitors have been identified.  We describe the cellular effects of a novel compd., BI 2536, a potent and selective inhibitor of Plk1.  The fact that BI 2536 blocks Plk1 activity fully and instantaneously enabled us to study controversial and unknown functions of Plk1.  Cells treated with BI 2536 are delayed in prophase but eventually import Cdk1-cyclin B into the nucleus, enter prometaphase, and degrade cyclin A, although BI 2536 prevents degrdn. of the APC/C inhibitor Emi1.  BI 2536-treated cells lack prophase microtubule asters and thus polymerize mitotic microtubules only after nuclear-envelope breakdown and form monopolar spindles that do not stably attach to kinetochores.  Mad2 accumulates at kinetochores, and cells arrest with an activated spindle-assembly checkpoint.  BI 2536 prevents Plk1's enrichment at kinetochores and centrosomes, and when added to metaphase cells, it induces detachment of microtubules from kinetochores and leads to spindle collapse.  Our results suggest that Plk1's accumulation at centrosomes and kinetochores depends on its own activity and that this activity is required for maintaining centrosome and kinetochore function.  Our data also show that Plk1 is not required for prophase entry, but delays transition to prometaphase, and that Emi1 destruction in prometaphase is not essential for APC/C-mediated cyclin A degrdn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCmCcyKwjrX7Vg90H21EOLACvtfcHk0lj6kedl4UoO4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvVyjtbs%253D&md5=4f0bc426138f64db93e17bf10a5f4db9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.cub.2006.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cub.2006.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A9n%25C3%25A1rt%26aufirst%3DP.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DSteegmaier%26aufirst%3DM.%26aulast%3DDi%2BFiore%26aufirst%3DB.%26aulast%3DLipp%26aufirst%3DJ.%2BJ.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DPeters%26aufirst%3DJ.-M.%26atitle%3DThe%2520Small-Molecule%2520Inhibitor%2520BI%25202536%2520Reveals%2520Novel%2520Insights%2520Into%2520Mitotic%2520Roles%2520of%2520Polo-Like%2520Kinase%25201%26jtitle%3DCurr.%2520Biol.%26date%3D2007%26volume%3D17%26spage%3D304%26epage%3D315%26doi%3D10.1016%2Fj.cub.2006.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P. S.</span></span> <span> </span><span class="NLM_article-title">Targeted Anti-Mitotic Therapies: Can We Improve on Tubulin Agents?</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1038/nrc2049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnrc2049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=17251917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFOjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=107-117&author=J.+R.+Jacksonauthor=D.+R.+Patrickauthor=M.+M.+Darauthor=P.+S.+Huang&title=Targeted+Anti-Mitotic+Therapies%3A+Can+We+Improve+on+Tubulin+Agents%3F&doi=10.1038%2Fnrc2049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted anti-mitotic therapies: can we improve on tubulin agents?</span></div><div class="casAuthors">Jackson, Jeffrey R.; Patrick, Denis R.; Dar, Mohammed M.; Huang, Pearl S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-117</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The advent of molecularly targeted drug discovery has facilitated the identification of a new generation of anti-mitotic therapies that target proteins with specific functions in mitosis.  The exquisite selectivity for mitosis and the distinct ways in which these new agents interfere with mitosis provides the potential to not only overcome certain limitations of current tubulin-targeted anti-mitotic drugs, but to expand the scope of clin. efficacy that those drugs have established.  The development of these new anti-mitotic drugs as targeted therapies faces significant challenges; nevertheless, these potential therapies also serve as unique tools to dissect the mol. mechanisms of the mitotic-checkpoint response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTEI9t3GggVrVg90H21EOLACvtfcHk0lhehOij0dsAOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFOjtA%253D%253D&md5=67a94114629154b9be66428e697835bc</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc2049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2049%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DTargeted%2520Anti-Mitotic%2520Therapies%253A%2520Can%2520We%2520Improve%2520on%2520Tubulin%2520Agents%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D107%26epage%3D117%26doi%3D10.1038%2Fnrc2049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Münch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, A.-V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wäsch, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogatyreva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschke, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">May, A. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Polo-Like Kinase 1 Inhibition Results in Mitotic Arrest and Subsequent Cell Death of Blasts in the Bone Marrow of AML Patients and Has Similar Effects in Non-Neoplastic Cell Lines</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2015.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.leukres.2015.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25697066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFygt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=462-470&author=C.+M%C3%BCnchauthor=D.+Dragoiauthor=A.-V.+Freyauthor=K.+Thurigauthor=M.+L%C3%BCbbertauthor=R.+W%C3%A4schauthor=L.+Bogatyrevaauthor=D.+Hauschkeauthor=S.+Lassmannauthor=M.+Wernerauthor=A.+M.+May&title=Therapeutic+Polo-Like+Kinase+1+Inhibition+Results+in+Mitotic+Arrest+and+Subsequent+Cell+Death+of+Blasts+in+the+Bone+Marrow+of+AML+Patients+and+Has+Similar+Effects+in+Non-Neoplastic+Cell+Lines&doi=10.1016%2Fj.leukres.2015.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines</span></div><div class="casAuthors">Muench, Claudia; Dragoi, Diana; Frey, Anna-Verena; Thurig, Katja; Luebbert, Michael; Waesch, Ralph; Bogatyreva, Lioudmila; Hauschke, Dieter; Lassmann, Silke; Werner, Martin; May, Annette M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">462-470</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (PLK1) is an important regulator of the cell cycle and is overexpressed in various solid and hematol. malignancies.  Small mol. inhibitors targeting PLK1, such as BI2536 or BI6727 (Volasertib) are a promising therapeutic approach in such malignancies.  Here, we show a loss of specifically localized PLK1 in AML blasts in vivo, accompanied by mitotic arrest with transition into apoptosis, in bone marrow biopsies of AML patients after treatment with BI2536.  We verify these results in live cell imaging expts. with the AML cell line HL-60, and demonstrate that non-neoplastic, immortalized lymphoblastoid cells are also sensitive to PLK1 inhibition.  It is demonstrated that normal granulopoietic precursors have similar PLK1 expression levels as leukemic blasts.  These results are in line with the adverse effects of PLK1 inhibition and underline the great potential of PLK1 inhibitors in the treatment of AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouncr8B53VwLVg90H21EOLACvtfcHk0lhehOij0dsAOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFygt7s%253D&md5=41b58df73efc6e8f3a63d6810b8fc1cd</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2015.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2015.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCnch%26aufirst%3DC.%26aulast%3DDragoi%26aufirst%3DD.%26aulast%3DFrey%26aufirst%3DA.-V.%26aulast%3DThurig%26aufirst%3DK.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DW%25C3%25A4sch%26aufirst%3DR.%26aulast%3DBogatyreva%26aufirst%3DL.%26aulast%3DHauschke%26aufirst%3DD.%26aulast%3DLassmann%26aufirst%3DS.%26aulast%3DWerner%26aufirst%3DM.%26aulast%3DMay%26aufirst%3DA.%2BM.%26atitle%3DTherapeutic%2520Polo-Like%2520Kinase%25201%2520Inhibition%2520Results%2520in%2520Mitotic%2520Arrest%2520and%2520Subsequent%2520Cell%2520Death%2520of%2520Blasts%2520in%2520the%2520Bone%2520Marrow%2520of%2520AML%2520Patients%2520and%2520Has%2520Similar%2520Effects%2520in%2520Non-Neoplastic%2520Cell%2520Lines%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D462%26epage%3D470%26doi%3D10.1016%2Fj.leukres.2015.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lübbert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haaland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandwein, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepretre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottmann, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Tidow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffoux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döhner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlenk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maertens, J.</span></span> <span> </span><span class="NLM_article-title">Randomized, Phase 2 Trial of Low-Dose Cytarabine With or Without Volasertib in AML Patients Not Suitable for Induction Therapy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">1426</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-03-560557</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1182%2Fblood-2014-03-560557" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25006120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC2cbgsFKksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=1426-1433&author=H.+D%C3%B6hnerauthor=M.+L%C3%BCbbertauthor=W.+Fiedlerauthor=L.+Fouillardauthor=A.+Haalandauthor=J.+M.+Brandweinauthor=S.+Lepretreauthor=O.+Remanauthor=P.+Turlureauthor=O.+G.+Ottmannauthor=C.+M%C3%BCller-Tidowauthor=A.+Kr%C3%A4merauthor=E.+Raffouxauthor=K.+D%C3%B6hnerauthor=R.+F.+Schlenkauthor=F.+Vossauthor=T.+Taubeauthor=H.+Fritschauthor=J.+Maertens&title=Randomized%2C+Phase+2+Trial+of+Low-Dose+Cytarabine+With+or+Without+Volasertib+in+AML+Patients+Not+Suitable+for+Induction+Therapy&doi=10.1182%2Fblood-2014-03-560557"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy</span></div><div class="casAuthors">Dohner Hartmut; Dohner Konstanze; Schlenk Richard F; Lubbert Michael; Fiedler Walter; Fouillard Loic; Haaland Alf; Brandwein Joseph M; Lepretre Stephane; Reman Oumedaly; Turlure Pascal; Ottmann Oliver G; Muller-Tidow Carsten; Kramer Alwin; Raffoux Emmanuel; Voss Florian; Taube Tillmann; Fritsch Holger; Maertens Johan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1426-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal.  This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without volasertib, a highly potent and selective inhibitor of polo-like kinases.  Eighty-seven patients (median age 75 years) received LDAC 20 mg twice daily subcutaneously days 1-10 or LDAC + volasertib 350 mg IV days 1 + 15 every 4 weeks.  Response rate (complete remission and complete remission with incomplete blood count recovery) was higher for LDAC + volasertib vs LDAC (31.0% vs 13.3%; odds ratio, 2.91; P = .052).  Responses in the LDAC + volasertib arm were observed across all genetic groups, including 5 of 14 patients with adverse cytogenetics.  Median event-free survival was significantly prolonged by LDAC + volasertib compared with LDAC (5.6 vs 2.3 months; hazard ratio, 0.57; 95% confidence interval, 0.35-0.92; P = .021); median overall survival was 8.0 vs 5.2 months, respectively (hazard ratio, 0.63; 95% confidence interval, 0.40-1.00; P = .047).  LDAC + volasertib led to an increased frequency of adverse events that was most pronounced for neutropenic fever/infections and gastrointestinal events; there was no increase in the death rate at days 60 + 90.  This study was registered at www.clinicaltrials.gov as #NCT00804856.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS913fFJ9KQsu2mnZh2OgS0fW6udTcc2eaUH5_Hs9b4RLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbgsFKksg%253D%253D&md5=b749d6547cea7f559c51559fb5f0add2</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-03-560557&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-03-560557%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26aulast%3DL%25C3%25BCbbert%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DFouillard%26aufirst%3DL.%26aulast%3DHaaland%26aufirst%3DA.%26aulast%3DBrandwein%26aufirst%3DJ.%2BM.%26aulast%3DLepretre%26aufirst%3DS.%26aulast%3DReman%26aufirst%3DO.%26aulast%3DTurlure%26aufirst%3DP.%26aulast%3DOttmann%26aufirst%3DO.%2BG.%26aulast%3DM%25C3%25BCller-Tidow%26aufirst%3DC.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DA.%26aulast%3DRaffoux%26aufirst%3DE.%26aulast%3DD%25C3%25B6hner%26aufirst%3DK.%26aulast%3DSchlenk%26aufirst%3DR.%2BF.%26aulast%3DVoss%26aufirst%3DF.%26aulast%3DTaube%26aufirst%3DT.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DMaertens%26aufirst%3DJ.%26atitle%3DRandomized%252C%2520Phase%25202%2520Trial%2520of%2520Low-Dose%2520Cytarabine%2520With%2520or%2520Without%2520Volasertib%2520in%2520AML%2520Patients%2520Not%2520Suitable%2520for%2520Induction%2520Therapy%26jtitle%3DBlood%26date%3D2014%26volume%3D124%26spage%3D1426%26epage%3D1433%26doi%3D10.1182%2Fblood-2014-03-560557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiedler, W.</span></span> <span> </span><span class="NLM_article-title">Volasertib for the Treatment of Acute Myeloid Leukemia: A Review of Preclinical and Clinical Development</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1165</span>, <span class="refDoi"> DOI: 10.2217/fon.14.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.2217%2Ffon.14.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24947257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=1157-1165&author=M.+Janningauthor=W.+Fiedler&title=Volasertib+for+the+Treatment+of+Acute+Myeloid+Leukemia%3A+A+Review+of+Preclinical+and+Clinical+Development&doi=10.2217%2Ffon.14.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development</span></div><div class="casAuthors">Janning, Melanie; Fiedler, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1157-1165</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and PLK3.  PLKs are key regulators of the cell cycle and volasertib blocks cells in G2-M phase of the cell cycle.  The compd. has been evaluated in Phase I and II studies in acute myeloid leukemia and solid tumors.  Side effects are mainly hematol.  In acute myeloid leukemia (AML), a randomized Phase II study has been conducted in elderly patients unfit for intensive chemotherapy.  Patients have been randomized to a combination of volarsetib and low-dose cytarabine vs. low-dose cytarabine alone.  Preliminary results show significantly higher rates of complete remission and of complete remission with incomplete hematol. recovery in the combination vs. the monotherapy arm, with 31% and 13%, resp.  Longer event-free survival was obsd. with the combination with 5.6 vs. 2.3 mo, resp. (p = 0.0237).  These encouraging data supported the initiation of an international Phase III trial, which currently underway, to confirm these results.  Volasertib has not yet been approved for regular clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhCAxXOP3iebVg90H21EOLACvtfcHk0ljwFbc5lSd-Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWmsLjJ&md5=3a820e3d98b5bc9695aa67c5801e383e</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.53%26sid%3Dliteratum%253Aachs%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DFiedler%26aufirst%3DW.%26atitle%3DVolasertib%2520for%2520the%2520Treatment%2520of%2520Acute%2520Myeloid%2520Leukemia%253A%2520A%2520Review%2520of%2520Preclinical%2520and%2520Clinical%2520Development%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D1157%26epage%3D1165%26doi%3D10.2217%2Ffon.14.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftimos, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costermans, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forceville, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berghmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meeus, M.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span> <span> </span><span class="NLM_article-title">Phase I Trial of Volasertib, a Polo-like Kinase Inhibitor, Plus Platinum Agents in Solid Tumors: Safety, Pharmacokinetics and Activity</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0223-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1007%2Fs10637-015-0223-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25794535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvFentrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=611-620&author=A.+Awadaauthor=H.+Dumezauthor=P.+G.+Aftimosauthor=J.+Costermansauthor=S.+Bartholomeusauthor=K.+Forcevilleauthor=T.+Berghmansauthor=M.-A.+Meeusauthor=J.+Cescuttiauthor=G.+Munzertauthor=K.+Pilzauthor=D.+Liuauthor=P.+Sch%C3%B6ffski&title=Phase+I+Trial+of+Volasertib%2C+a+Polo-like+Kinase+Inhibitor%2C+Plus+Platinum+Agents+in+Solid+Tumors%3A+Safety%2C+Pharmacokinetics+and+Activity&doi=10.1007%2Fs10637-015-0223-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity</span></div><div class="casAuthors">Awada, Ahmad; Dumez, Herlinde; Aftimos, Philippe G.; Costermans, Jo; Bartholomeus, Sylvie; Forceville, Kathleen; Berghmans, Thierry; Meeus, Marie-Anne; Cescutti, Jessica; Munzert, Gerd; Pilz, Korinna; Liu, Dan; Schoffski, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">611-620</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background This trial evaluated the max. tolerated dose (MTD), safety, pharmacokinetics, and activity of volasertib, a selective Polo-like kinase 1 inhibitor that induces mitotic arrest and apoptosis, combined with cisplatin or carboplatin in patients with advanced/metastatic solid tumors (NCT00969761; 1230.6).  Methods Sequential patient cohorts (3 + 3 dose-escalation design) received a single infusion of volasertib (100-350 mg) with cisplatin (60-100 mg/m2) or carboplatin (area under the concn. vs. time curve [AUC]4-AUC6) on day 1 every 3 wk for up to six cycles.  Sixty-one patients received volasertib/cisplatin (n = 30) or volasertib/carboplatin (n = 31) for a median of 3.5 (range, 1-6) and 2.0 (range, 1-6) treatment cycles, resp.  Results The most common cycle 1 dose-limiting toxicities (DLTs) were thrombocytopenia, neutropenia and fatigue.  MTDs (based on cycle 1 DLTs) were detd. to be volasertib 300 mg plus cisplatin 100 mg/m2 and volasertib 300 mg plus carboplatin AUC6.  Co-administration did not affect the pharmacokinetics of each drug.  Partial responses were obsd. in two patients in each arm.  Stable disease was achieved in 11 and six patients treated with volasertib/cisplatin and volasertib/carboplatin, resp.  Conclusions Volasertib plus cisplatin or carboplatin at full single-agent doses was generally manageable and demonstrated activity in heavily pretreated patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_OcICZV1kyLVg90H21EOLACvtfcHk0ljwFbc5lSd-Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvFentrg%253D&md5=42ad57a310c9369b071600dc76391719</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0223-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0223-9%26sid%3Dliteratum%253Aachs%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DAftimos%26aufirst%3DP.%2BG.%26aulast%3DCostermans%26aufirst%3DJ.%26aulast%3DBartholomeus%26aufirst%3DS.%26aulast%3DForceville%26aufirst%3DK.%26aulast%3DBerghmans%26aufirst%3DT.%26aulast%3DMeeus%26aufirst%3DM.-A.%26aulast%3DCescutti%26aufirst%3DJ.%26aulast%3DMunzert%26aufirst%3DG.%26aulast%3DPilz%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26atitle%3DPhase%2520I%2520Trial%2520of%2520Volasertib%252C%2520a%2520Polo-like%2520Kinase%2520Inhibitor%252C%2520Plus%2520Platinum%2520Agents%2520in%2520Solid%2520Tumors%253A%2520Safety%252C%2520Pharmacokinetics%2520and%2520Activity%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D611%26epage%3D620%26doi%3D10.1007%2Fs10637-015-0223-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willemze, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suciu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meloni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marie, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halkes, C. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistrik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specchia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbiano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nobile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sborgia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selleslag, D. L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefrère, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beksac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berneman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melillo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leoni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luppi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marijt, E. W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venditti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagemeijer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilloni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisolini, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Witte, T.</span></span> <span> </span><span class="NLM_article-title">High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.51.8571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1200%2FJCO.2013.51.8571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24297940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFWnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=219-228&author=R.+Willemzeauthor=S.+Suciuauthor=G.+Meloniauthor=B.+Labarauthor=J.-P.+Marieauthor=C.+J.+M.+Halkesauthor=P.+Muusauthor=M.+Mistrikauthor=S.+Amadoriauthor=G.+Specchiaauthor=F.+Fabbianoauthor=F.+Nobileauthor=M.+Sborgiaauthor=A.+Cameraauthor=D.+L.+D.+Selleslagauthor=F.+Lefr%C3%A8reauthor=D.+Magroauthor=S.+Sicaauthor=N.+Cantoreauthor=M.+Beksacauthor=Z.+Bernemanauthor=X.+Thomasauthor=L.+Melilloauthor=J.+E.+Guimaraesauthor=P.+Leoniauthor=M.+Luppiauthor=M.+E.+Mitraauthor=D.+Mitraauthor=G.+Bronauthor=E.+W.+A.+Marijtauthor=A.+Vendittiauthor=A.+Hagemeijerauthor=M.+Manciniauthor=J.+Jansenauthor=D.+Cilloniauthor=L.+Meertauthor=P.+Faziauthor=M.+Vignettiauthor=S.+M.+Trisoliniauthor=F.+Mandelliauthor=T.+de+Witteauthor=T.+de+Witte&title=High-Dose+Cytarabine+in+Induction+Treatment+Improves+the+Outcome+of+Adult+Patients+Younger+Than+Age+46+Years+With+Acute+Myeloid+Leukemia%3A+Results+of+the+EORTC-GIMEMA+AML-12+Trial&doi=10.1200%2Fjco.2013.51.8571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial</span></div><div class="casAuthors">Willemze, Roelof; Suciu, Stefan; Meloni, Giovanna; Labar, Boris; Marie, Jean-Pierre; Halkes, Constantijn J. M.; Muus, Petra; Mistrik, Martin; Amadori, Sergio; Specchia, Giorgina; Fabbiano, Francesco; Nobile, Francesco; Sborgia, Marco; Camera, Andrea; Selleslag, Dominik L. D.; Lefrere, Francois, Sr.; Magro, Domenico; Sica, Simona; Cantore, Nicola; Beksac, Meral; Berneman, Zwi; Thomas, Xavier; Melillo, Lorella; Guimaraes, Jose E.; Leoni, Pietro; Luppi, Mario; Mitra, Maria E.; Bron, Dominique; Fillet, Georges; Marijt, Erik W. A.; Venditti, Adriano; Hagemeijer, Anne; Mancini, Marco; Jansen, Joop; Cilloni, Daniela; Meert, Liv; Fazi, Paola; Vignetti, Marco; Trisolini, Silvia M.; Mandelli, Franco; de Witte, Theo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML).  Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m2 for remission induction.  Consensus has not been reached on the benefit of higher dosages of cytarabine.  Patients and Methods: The European Organization for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Leukemia Groups conducted a randomized trial (AML-12; Combination Chemotherapy, Stem Cell Transplant and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia) in 1,942 newly diagnosed patients with AML, age 15 to 60 years, comparing remission induction treatment contg. daunorubicin, etoposide, and either std.-dose (SD) cytarabine (100 mg/m2 per day by continuous infusion for 10 days) or high-dose (HD) cytarabine (3,000 mg/m2 every 12 h by 3-h infusion on days 1, 3, 5, and 7).  Patients in complete remission (CR) received a single consolidation cycle contg. daunorubicin and intermediate-dose cytarabine (500 mg/m2 every 12 h for 6 days).  Subsequently, a stem-cell transplantation was planned.  The primary end point was survival.  Results: At a median follow-up of 6 years, overall survival was 38.7% for patients randomly assigned to SD cytarabine and 42.5% for those randomly assigned to HD cytarabine (log-rank test P = .06; multivariable anal. P = .009).  For patients younger than age 46 years, survival was 43.3% and 51.9%, resp. (P = .009; multivariable anal. P = .003), and for patients age 46 to 60 years, survival was 33.9% and 32.9%, resp. (P = .91).  CR rates were 72.0% and 78.7%, resp. (P < .001) and were 75.6% and 82.4% for patients younger than age 46 years (P = .01) and 68.3% and 74.8% for patients age 46 years and older (P = .03).  Patients of all ages with very-bad-risk cytogenetic abnormalities and/or FLT3-ITD (internal tandem duplication) mutation, or with secondary AML benefitted from HD cytarabine.  Conclusion: HD cytarabine produces higher remission and survival rates than SD cytarabine, esp. in patients younger than age 46 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Iny8nPust7Vg90H21EOLACvtfcHk0lgMKr7OG9u27g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFWnsro%253D&md5=7fcedb1679c242f077a192966e5b1dfd</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.51.8571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.51.8571%26sid%3Dliteratum%253Aachs%26aulast%3DWillemze%26aufirst%3DR.%26aulast%3DSuciu%26aufirst%3DS.%26aulast%3DMeloni%26aufirst%3DG.%26aulast%3DLabar%26aufirst%3DB.%26aulast%3DMarie%26aufirst%3DJ.-P.%26aulast%3DHalkes%26aufirst%3DC.%2BJ.%2BM.%26aulast%3DMuus%26aufirst%3DP.%26aulast%3DMistrik%26aufirst%3DM.%26aulast%3DAmadori%26aufirst%3DS.%26aulast%3DSpecchia%26aufirst%3DG.%26aulast%3DFabbiano%26aufirst%3DF.%26aulast%3DNobile%26aufirst%3DF.%26aulast%3DSborgia%26aufirst%3DM.%26aulast%3DCamera%26aufirst%3DA.%26aulast%3DSelleslag%26aufirst%3DD.%2BL.%2BD.%26aulast%3DLefr%25C3%25A8re%26aufirst%3DF.%26aulast%3DMagro%26aufirst%3DD.%26aulast%3DSica%26aufirst%3DS.%26aulast%3DCantore%26aufirst%3DN.%26aulast%3DBeksac%26aufirst%3DM.%26aulast%3DBerneman%26aufirst%3DZ.%26aulast%3DThomas%26aufirst%3DX.%26aulast%3DMelillo%26aufirst%3DL.%26aulast%3DGuimaraes%26aufirst%3DJ.%2BE.%26aulast%3DLeoni%26aufirst%3DP.%26aulast%3DLuppi%26aufirst%3DM.%26aulast%3DMitra%26aufirst%3DM.%2BE.%26aulast%3DMitra%26aufirst%3DD.%26aulast%3DBron%26aufirst%3DG.%26aulast%3DMarijt%26aufirst%3DE.%2BW.%2BA.%26aulast%3DVenditti%26aufirst%3DA.%26aulast%3DHagemeijer%26aufirst%3DA.%26aulast%3DMancini%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%26aulast%3DCilloni%26aufirst%3DD.%26aulast%3DMeert%26aufirst%3DL.%26aulast%3DFazi%26aufirst%3DP.%26aulast%3DVignetti%26aufirst%3DM.%26aulast%3DTrisolini%26aufirst%3DS.%2BM.%26aulast%3DMandelli%26aufirst%3DF.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26aulast%3Dde%2BWitte%26aufirst%3DT.%26atitle%3DHigh-Dose%2520Cytarabine%2520in%2520Induction%2520Treatment%2520Improves%2520the%2520Outcome%2520of%2520Adult%2520Patients%2520Younger%2520Than%2520Age%252046%2520Years%2520With%2520Acute%2520Myeloid%2520Leukemia%253A%2520Results%2520of%2520the%2520EORTC-GIMEMA%2520AML-12%2520Trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D219%26epage%3D228%26doi%3D10.1200%2Fjco.2013.51.8571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Two Dosing Schedules of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Patients With Advanced Solid Malignancies</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">2434</span>– <span class="NLM_lpage">2440</span>, <span class="refDoi"> DOI: 10.1038/bjc.2014.195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fbjc.2014.195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=24755882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntVShs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2014&pages=2434-2440&author=C.-C.+Linauthor=W.-C.+Suauthor=C.-J.+Yenauthor=C.-H.+Hsuauthor=W.-P.+Suauthor=K.-H.+Yehauthor=Y.-S.+Luauthor=A.-L.+Chengauthor=D.+C.-L.+Huangauthor=H.+Fritschauthor=F.+Vossauthor=T.+Taubeauthor=J.+C.-H.+Yang&title=A+Phase+I+Study+of+Two+Dosing+Schedules+of+Volasertib+%28BI+6727%29%2C+an+Intravenous+Polo-Like+Kinase+Inhibitor%2C+in+Patients+With+Advanced+Solid+Malignancies&doi=10.1038%2Fbjc.2014.195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies</span></div><div class="casAuthors">Lin, C.-C.; Su, W.-C.; Yen, C.-J.; Hsu, C.-H.; Su, W.-P.; Yeh, K.-H.; Lu, Y.-S.; Cheng, A.-L.; Huang, D. C.-L.; Fritsch, H.; Voss, F.; Taube, T.; Yang, J. C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2434-2440</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Polo-like kinase 1 (Plk1) has an important role in mitosis.  Volasertib (BI 6727), a potent and selective cell cycle kinase inhibitor, induces mitotic arrest and apoptosis by targeting Plk; this phase I study sought to det. its max. tolerated dose (MTD) in Asian patients with advanced solid tumors.  Methods: Patients were enrolled simultaneously into two 3-wk schedules of volasertib: a 2-h infusion on day 1 (schedule A) or days 1 and 8 (schedule B).  Dose escalation followed a 3+3 design.  The MTD was detd. based on dose-limiting toxicities (DLT) in the first treatment course.  Results: Among 59 treated patients, the most common first course DLTs were reversible thrombocytopenia, neutropenia and febrile neutropenia; MTDs were 300 mg for schedule A and 150 mg for schedule B.  Volasertib exhibited multi-exponential pharmacokinetics (PK), a long terminal half-life of ∼135 h, a large vol. of distribution (>3000 l), and a moderate clearance.  Partial responses were obsd. in two pre-treated patients (ureteral cancer; melanoma).  Volasertib was generally well tolerated, with an adverse event profile consistent with its antimitotic mode of action and a favorable PK profile.  Conclusions: These data support further development of volasertib and a harmonized dosing for Asian and Caucasian patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oPJHGDc887Vg90H21EOLACvtfcHk0lgW3twpd1au3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntVShs7Y%253D&md5=c9007f0690e8034f62a9af551a64e5d7</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2014.195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2014.195%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DYen%26aufirst%3DC.-J.%26aulast%3DHsu%26aufirst%3DC.-H.%26aulast%3DSu%26aufirst%3DW.-P.%26aulast%3DYeh%26aufirst%3DK.-H.%26aulast%3DLu%26aufirst%3DY.-S.%26aulast%3DCheng%26aufirst%3DA.-L.%26aulast%3DHuang%26aufirst%3DD.%2BC.-L.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DVoss%26aufirst%3DF.%26aulast%3DTaube%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Two%2520Dosing%2520Schedules%2520of%2520Volasertib%2520%2528BI%25206727%2529%252C%2520an%2520Intravenous%2520Polo-Like%2520Kinase%2520Inhibitor%252C%2520in%2520Patients%2520With%2520Advanced%2520Solid%2520Malignancies%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2014%26volume%3D110%26spage%3D2434%26epage%3D2440%26doi%3D10.1038%2Fbjc.2014.195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Machiels, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herremans, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surmont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Specenier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Smet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelkowa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rottey, S.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of Volasertib Combined With Afatinib, in Advanced Solid Tumors</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1007/s00280-015-2860-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1007%2Fs00280-015-2860-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26349473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=843-851&author=J.-P.+Machielsauthor=M.+Peetersauthor=C.+Herremansauthor=V.+Surmontauthor=P.+Specenierauthor=M.+De+Smetauthor=K.+Pilzauthor=N.+Strelkowaauthor=D.+Liuauthor=S.+Rottey&title=A+Phase+I+Study+of+Volasertib+Combined+With+Afatinib%2C+in+Advanced+Solid+Tumors&doi=10.1007%2Fs00280-015-2860-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of volasertib combined with afatinib, in advanced solid tumors</span></div><div class="casAuthors">Machiels, Jean-Pascal; Peeters, Marc; Herremans, Catherine; Surmont, Veerle; Specenier, Pol; De Smet, Marina; Pilz, Korinna; Strelkowa, Natalja; Liu, Dan; Rottey, Sylvie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843-851</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To det. the max. tolerated dose (MTD) of volasertib, a Polo-like kinase inhibitor, combined with afatinib, an oral irreversible ErbB family blocker, in patients with advanced solid tumors (NCT01206816; Study 1230.20).  Methods: Patients with advanced non-resectable and/or metastatic disease following failure of conventional treatment received i.v. volasertib 150-300 mg on day 1 every 21 days, combined with oral afatinib 30-40 mg on days 2-21 of a 3-wk cycle (Schedule A), or 50-90 mg on days 2-6 of a 3-wk cycle (Schedule B).  The primary objective was to det. the MTD of volasertib in combination with afatinib.  Results: Fifty-seven patients (Schedule A, N = 29; Schedule B, N = 28) were treated.  The MTDs were volasertib 300 mg plus afatinib 30 mg days 2-21 and 70 mg days 2-6 of a 3-wk cycle for Schedules A and B, resp.  The most common Grade 3/4 adverse events were neutropenia (31.0 %), diarrhea (13.8 %), and thrombocytopenia (10.3 %) in Schedule A; neutropenia (39.3 %), thrombocytopenia (35.7 %), hypokalemia (14.3 %), febrile neutropenia, and nausea (each 10.7 %) in Schedule B.  The best overall response was two partial responses (6.9 %; both in Schedule A); eight patients in each schedule achieved stable disease.  Volasertib showed multi-exponential pharmacokinetic (PK) behavior; co-administration of volasertib and afatinib had no significant effects on the PK profile of either drug.  Conclusions: Volasertib combined with afatinib had manageable adverse effects and limited antitumor activity in this heavily pretreated population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqWgk2_lwPvbVg90H21EOLACvtfcHk0lgW3twpd1au3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagtbzP&md5=efbb81662f63d69d7508b5dd35486eb0</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs00280-015-2860-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-015-2860-2%26sid%3Dliteratum%253Aachs%26aulast%3DMachiels%26aufirst%3DJ.-P.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DHerremans%26aufirst%3DC.%26aulast%3DSurmont%26aufirst%3DV.%26aulast%3DSpecenier%26aufirst%3DP.%26aulast%3DDe%2BSmet%26aufirst%3DM.%26aulast%3DPilz%26aufirst%3DK.%26aulast%3DStrelkowa%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DRottey%26aufirst%3DS.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520Volasertib%2520Combined%2520With%2520Afatinib%252C%2520in%2520Advanced%2520Solid%2520Tumors%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2015%26volume%3D76%26spage%3D843%26epage%3D851%26doi%3D10.1007%2Fs00280-015-2860-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascinu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitaleri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clementi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pas, T.</span></span> <span> </span><span class="NLM_article-title">A Phase I, Dose-Escalation Study of Volasertib Combined With Nintedanib in Advanced Solid Tumors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2341</span>– <span class="NLM_lpage">2346</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1093%2Fannonc%2Fmdv354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26395347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC283kslSisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2341-2346&author=F.+de%0ABraudauthor=S.+Cascinuauthor=G.+Spitaleriauthor=K.+Pilzauthor=L.+Clementiauthor=D.+Liuauthor=P.+Sikkenauthor=T.+De+Pas&title=A+Phase+I%2C+Dose-Escalation+Study+of+Volasertib+Combined+With+Nintedanib+in+Advanced+Solid+Tumors&doi=10.1093%2Fannonc%2Fmdv354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors</span></div><div class="casAuthors">de Braud F; Cascinu S; Spitaleri G; De Pas T; Pilz K; Liu D; Sikken P; Clementi L</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2341-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases.  This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors.  PATIENTS AND METHODS:  This open-label, dose-escalation trial recruited patients with advanced metastatic solid tumors following failure of conventional treatment (NCT01022853; Study 1230.7).  Volasertib was administered by intravenous infusion over 2 h, starting at 100 mg in the first dose cohort.  Nintedanib was administered orally at a dose of 200 mg twice daily.  The first treatment cycle comprised 28 days (days 1-7 and days 9-28: nintedanib; day 8: volasertib).  From cycle 2 onwards, volasertib was administered on day 1 of a 21-day cycle and nintedanib was administered days 2-21.  The primary objective was the MTD of volasertib in combination with nintedanib.  RESULTS:  Thirty patients were treated.  The MTD of volasertib plus fixed-dose nintedanib was 300 mg once every 3 weeks, the same as the recommended single-agent dose of volasertib in solid tumors.  Two of 12 assessable patients treated with the MTD experienced dose-limiting toxicities [grade 3 increased alanine aminotransferase (ALT); grade 3 ALT increase and grade 3 increased aspartate aminotransferase].  Disease control [stable disease (SD)/partial response (PR)/complete response (CR)] was achieved in 18 patients (60%): 1 CR (breast cancer), 1 PR (nonsmall-cell lung cancer), and 16 patients with SD.  Volasertib showed that multiexponential pharmacokinetic behavior and co-administration of nintedanib had no significant effects on its exposure.  CONCLUSIONS:  Volasertib could be combined with fixed-dose nintedanib at the recommended single-agent dose.  At this dose, the combination had a manageable safety profile without unexpected or overlapping adverse events, and showed antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRChqUf96U1lrGbPKh4T9eAfW6udTcc2eYkvAvH1UyJ8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283kslSisA%253D%253D&md5=afbd9117a3d69caf440aa0909fe8c2b3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv354%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DCascinu%26aufirst%3DS.%26aulast%3DSpitaleri%26aufirst%3DG.%26aulast%3DPilz%26aufirst%3DK.%26aulast%3DClementi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DSikken%26aufirst%3DP.%26aulast%3DDe%2BPas%26aufirst%3DT.%26atitle%3DA%2520Phase%2520I%252C%2520Dose-Escalation%2520Study%2520of%2520Volasertib%2520Combined%2520With%2520Nintedanib%2520in%2520Advanced%2520Solid%2520Tumors%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D2341%26epage%3D2346%26doi%3D10.1093%2Fannonc%2Fmdv354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olmos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetto, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taegtmeyer, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriuso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhardt, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lampkin, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dar, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span> <span> </span><span class="NLM_article-title">Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients With Advanced Solid Malignancies</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3420</span>– <span class="NLM_lpage">3430</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-10-2946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1158%2F1078-0432.CCR-10-2946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=21459796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3420-3430&author=D.+Olmosauthor=D.+Barkerauthor=R.+Sharmaauthor=A.+T.+Brunettoauthor=T.+A.+Yapauthor=A.+B.+Taegtmeyerauthor=J.+Barriusoauthor=H.+Medaniauthor=Y.+Y.+Degenhardtauthor=A.+J.+Allredauthor=D.+A.+Smithauthor=S.+C.+Murrayauthor=T.+A.+Lampkinauthor=M.+M.+Darauthor=R.+Wilsonauthor=J.+S.+de+Bonoauthor=S.+P.+Blagden&title=Phase+I+Study+of+GSK461364%2C+a+Specific+and+Competitive+Polo-like+Kinase+1+Inhibitor%2C+in+Patients+With+Advanced+Solid+Malignancies&doi=10.1158%2F1078-0432.ccr-10-2946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Olmos, David; Barker, Douglas; Sharma, Rohini; Brunetto, Andre T.; Yap, Timothy A.; Taegtmeyer, Anne B.; Barriuso, Jorge; Medani, Hanine; Degenhardt, Yan Y.; Allred, Alicia J.; Smith, Deborah A.; Murray, Sharon C.; Lampkin, Thomas A.; Dar, Mohammed M.; Wilson, Richard; de Bono, Johann S.; Blagden, Sarah P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3420-3430</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1).  A phase I study of two schedules of i.v. GSK461364 was conducted.  Exptl. Design: GSK461364 was administered in escalating doses to patients with solid malignancies by two schedules, either on days 1, 8, and 15 of 28-day cycles (schedule A) or on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (schedule B).  Assessments included pharmacokinetic and pharmacodynamic profiles, as well as marker expression studies in pretreatment tumor biopsies.  RESULTS: Forty patients received GSK461364: 23 patients in schedule A and 17 in schedule B. Dose-limiting toxicities (DLT) in schedule A at 300 mg (2 of 7 patients) and 225 mg (1 of 8 patients) cohorts included grade 4 neutropenia and/or grade 3-4 thrombocytopenia.  In schedule B, DLTs of grade 4 pulmonary emboli and grade 4 neutropenia occurred at 7 or more days at 100 mg dose level.  Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3-4, drug-related events.  Pharmacokinetic data indicated that AUC (area under the curve) and Cmax (max. concn.) were proportional across doses, with a half-life of 9 to 13 h.  Pharmacodynamic studies in circulating tumor cells revealed an increase in phosphorylated histone H3 (pHH3) following drug administration.  A best response of prolonged stable disease of more than 16 wk occurred in 6 (15%) patients, including 4 esophageal cancer patients.  Those with prolonged stable disease had greater expression of Ki-67, pHH3, and Plk1 in archived tumor biopsies.  CONCLUSIONS: The final recommended phase II dose for GSK461364 was 225 mg administered i.v. in schedule A. Because of the high incidence (20%) of VTE, for further clin. evaluation, GSK461364 should involve coadministration of prophylactic anticoagulation.  Clin Cancer Res; 17(10); 3420-30.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOJ4inVI09-rVg90H21EOLACvtfcHk0liLvnROQbeh-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D&md5=3cf3213934f3a34aaeee469dc9cb6529</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2946%26sid%3Dliteratum%253Aachs%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DBarker%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DBrunetto%26aufirst%3DA.%2BT.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTaegtmeyer%26aufirst%3DA.%2BB.%26aulast%3DBarriuso%26aufirst%3DJ.%26aulast%3DMedani%26aufirst%3DH.%26aulast%3DDegenhardt%26aufirst%3DY.%2BY.%26aulast%3DAllred%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DMurray%26aufirst%3DS.%2BC.%26aulast%3DLampkin%26aufirst%3DT.%2BA.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26atitle%3DPhase%2520I%2520Study%2520of%2520GSK461364%252C%2520a%2520Specific%2520and%2520Competitive%2520Polo-like%2520Kinase%25201%2520Inhibitor%252C%2520in%2520Patients%2520With%2520Advanced%2520Solid%2520Malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D3420%26epage%3D3430%26doi%3D10.1158%2F1078-0432.ccr-10-2946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomeus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glomb, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzert, G.</span></span> <span> </span><span class="NLM_article-title">A Phase I, Dose-Escalation Study of the Novel Polo-like Kinase Inhibitor Volasertib (BI 6727) In Patients With Advanced Solid Tumours</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2011.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.ejca.2011.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=22119200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC387gs1Oitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=179-186&author=P.+Sch%C3%B6ffskiauthor=A.+Awadaauthor=H.+Dumezauthor=T.+Gilauthor=S.+Bartholomeusauthor=P.+Wolterauthor=M.+Tatonauthor=H.+Fritschauthor=P.+Glombauthor=G.+Munzert&title=A+Phase+I%2C+Dose-Escalation+Study+of+the+Novel+Polo-like+Kinase+Inhibitor+Volasertib+%28BI+6727%29+In+Patients+With+Advanced+Solid+Tumours&doi=10.1016%2Fj.ejca.2011.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours</span></div><div class="casAuthors">Schoffski Patrick; Awada Ahmad; Dumez Herlinde; Gil Thierry; Bartholomeus Sylvie; Wolter Pascal; Taton Martine; Fritsch Holger; Glomb Patricia; Munzert Gerd</div><div class="citationInfo"><span class="NLM_cas:title">European journal of cancer (Oxford, England : 1990)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk).  This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of volasertib, safety and efficacy, and pharmacokinetic (PK) parameters.  METHODS:  This trial followed an open-label, toxicity-guided dose-titration design.  Patients with progressive advanced or metastatic solid tumours received a single 1-h infusion of volasertib every 3 weeks.  A total of 65 patients were treated at doses of 12-450 mg.  RESULTS:  Reversible haematological toxicity was the main side-effect; thrombocytopenia, neutropenia, and febrile neutropenia constituting the main dose-limiting events.  Anaemia (all grades 22%; grade 3: 8%), neutropenia (15%; grade 3/4: 14%), fatigue (15%; grade 3: 2%), and thrombocytopenia (14%; grade 3/4: 14%) were the most frequent drug-related adverse events.  The MTD was 400mg; however, 300 mg was the recommended dose for further development based on overall tolerability.  Three patients achieved confirmed partial response.  Stable disease as best response was reported in 40% of patients.  Two patients remained progression free for >1 year.  PK analysis showed no indication of deviation from 'dose-linear PK' behaviour, a large volume of distribution (>4000 l), moderate clearance and a long half-life (~111 h).  CONCLUSION:  This first-in-man trial demonstrated a favourable PK profile of volasertib, with manageable toxicities.  As expected, the most common events were haematological.  Encouraging preliminary antitumour activity has been observed, supporting Plk inhibition as a therapeutic approach.  Clinical development of volasertib in phase II monotherapy and combination trials is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2sE1eVKpQRHRxY89Cm6SyfW6udTcc2eZJLg5_Y6VDTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387gs1Oitg%253D%253D&md5=ca4316cf6705a2cb92ab243c1c151c35</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2011.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2011.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DDumez%26aufirst%3DH.%26aulast%3DGil%26aufirst%3DT.%26aulast%3DBartholomeus%26aufirst%3DS.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DTaton%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DH.%26aulast%3DGlomb%26aufirst%3DP.%26aulast%3DMunzert%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%252C%2520Dose-Escalation%2520Study%2520of%2520the%2520Novel%2520Polo-like%2520Kinase%2520Inhibitor%2520Volasertib%2520%2528BI%25206727%2529%2520In%2520Patients%2520With%2520Advanced%2520Solid%2520Tumours%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2012%26volume%3D48%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.ejca.2011.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bojadzic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180531092503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.2174%2F1568026618666180531092503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=29848279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=674-699&author=D.+Bojadzicauthor=P.+Buchwald&title=Toward+Small-Molecule+Inhibition+of+Protein-Protein+Interactions%3A+General+Aspects+and+Recent+Progress+in+Targeting+Costimulatory+and+Coinhibitory+%28Immune+Checkpoint%29+Interactions&doi=10.2174%2F1568026618666180531092503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions</span></div><div class="casAuthors">Bojadzic, Damir; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">674-699</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein-Protein Interactions (PPIs) that are part of the costimulatory and coinhibitory (immune checkpoint) signaling are crit. for adequate T cell response and are important therapeutic targets for immunomodulation.  Biologics targeting them have already achieved considerable clin. success in the treatment of autoimmune diseases or transplant recipients (e.g., abatacept, belatacept, and belimumab) as well as cancer (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab).  In view of such progress, there have been only relatively limited efforts toward developing small-mol. PPI inhibitors (SMPPIIs) targeting these cosignaling interactions, possibly because they, as all other PPIs, are difficult to target by small mols. and were not considered druggable.  Nevertheless, substantial progress has been achieved during the last decade.  SMPPIIs proving the feasibility of such approaches have been identified through various strategies for a no. of cosignaling interactions including CD40-CD40L, OX40-OX40L, BAFFR-BAFF, CD80-CD28, and PD-1-PD-L1s.  Here, after an overview of the general aspects and challenges of SMPPII-focused drug discovery, we review them briefly together with relevant structural, immune-signaling, physicochem., and medicinal chem. aspects.  While so far only a few of these SMPPIIs have shown activity in animal models (DRI-C21045 for CD40-D40L, KR33426 for BAFFR-BAFF) or reached clin. development (RhuDex for CD80-CD28, CA-170 for PD-1-PD-L1), there is proof-of-principle evidence for the feasibility of such approaches in immunomodulation.  They can result in products that are easier to develop/ manuf. and are less likely to be immunogenic or encounter postmarket safety events than corresponding biologics, and, contrary to them, can even become orally bioavailable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxFgcfDDFwirVg90H21EOLACvtfcHk0liLvnROQbeh-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM&md5=0c3c3adbf37198bf3db786209abb5892</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180531092503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180531092503%26sid%3Dliteratum%253Aachs%26aulast%3DBojadzic%26aufirst%3DD.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DToward%2520Small-Molecule%2520Inhibition%2520of%2520Protein-Protein%2520Interactions%253A%2520General%2520Aspects%2520and%2520Recent%2520Progress%2520in%2520Targeting%2520Costimulatory%2520and%2520Coinhibitory%2520%2528Immune%2520Checkpoint%2529%2520Interactions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D674%26epage%3D699%26doi%3D10.2174%2F1568026618666180531092503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rognan, D.</span></span> <span> </span><span class="NLM_article-title">Rational design of protein–protein interaction inhibitors</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1039/c4md00328d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1039%2FC4MD00328D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsLzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=51-60&author=D.+Rognan&title=Rational+design+of+protein%E2%80%93protein+interaction+inhibitors&doi=10.1039%2Fc4md00328d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of protein-protein interaction inhibitors</span></div><div class="casAuthors">Rognan, Didier</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions are at the heart of most physiopathol. processes.  As such, they have attracted considerable attention for designing drugs of the future.  Although initially considered as high-value but difficult to identify, low mol. wt. compds. able to selectively and potently modulate protein-protein interactions have recently reached clin. trials.  Along with high-throughput screening of compd. libraries, combining structural and computational approaches has boosted this formerly minor area of research into a currently tremendously active field.  This review highlights the very recent developments in the rational design of protein-protein interaction inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrLT1KBf_9U7Vg90H21EOLACvtfcHk0lgBMxVnuRyv7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyqsLzF&md5=dc97477ed0e63d4338af4a7af59ac374</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1039%2FC4MD00328D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4MD00328D%26sid%3Dliteratum%253Aachs%26aulast%3DRognan%26aufirst%3DD.%26atitle%3DRational%2520design%2520of%2520protein%25E2%2580%2593protein%2520interaction%2520inhibitors%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D51%26epage%3D60%26doi%3D10.1039%2Fc4md00328d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ceesay, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couchman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wade, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliuca, A.</span></span> <span> </span><span class="NLM_article-title">Triazole Antifungals Used for Prophylaxis and Treatment of Invasive Fungal Disease in Adult Haematology Patients: Trough Serum Concentrations in Relation to Outcome</span>. <i>Med. Mycol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1093/mmy/myw031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1093%2Fmmy%2Fmyw031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=27161786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjt1Wmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2016&pages=691-698&author=M.+M.+Ceesayauthor=L.+Couchmanauthor=M.+Smithauthor=J.+Wadeauthor=R.+J.+Flanaganauthor=A.+Pagliuca&title=Triazole+Antifungals+Used+for+Prophylaxis+and+Treatment+of+Invasive+Fungal+Disease+in+Adult+Haematology+Patients%3A+Trough+Serum+Concentrations+in+Relation+to+Outcome&doi=10.1093%2Fmmy%2Fmyw031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole antifungals used for prophylaxis and treatment of invasive fungal disease in adult haematology patients: trough serum concentrations in relation to outcome</span></div><div class="casAuthors">Ceesay, M. Mansour; Couchman, Lewis; Smith, Melvyn; Wade, Jim; Flanagan, Robert J.; Pagliuca, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Medical Mycology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">691-698</span>CODEN:
                <span class="NLM_cas:coden">MEMYFR</span>;
        ISSN:<span class="NLM_cas:issn">1369-3786</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Triazole antifungal drugs are widely used for the prophylaxis and treatment of invasive fungal disease (IFD).  Efficacy may depend on attaining min. effective plasma concns.  The aim of this study was to ascertain the proportion of samples in which the recommended concns. were achieved in patients given these drugs in relation to outcome.  In-patients prescribed std. doses of fluconazole, itraconazole soln., posaconazole suspension, or oral voriconazole for at least one week were studied.  Pre-dose serum triazole concns. were measured using validated methods.  There were 359 samples from 90 patients.  The median (range) no. of samples per patient was 3 (1-13), and the median (range) fluconazole, itraconazole, posaconazole (prophylaxis), posaconazole (treatment), and voriconazole serum concns. were 5.64 (0.11-18), 0.57 (0-5.3), 0.31 (0.02-2.5), 0.65 (0.02-2.5), and 0.95 (0.10-5.4) mg/l, resp.  The no. of samples in which the recommended pre-dose concns. were achieved was 98 (54%), 9 (20%), 2 (18%), and 29 (49%) for itraconazole, posaconazole (>0.7 mg/l prophylaxis), posaconazole (treatment), and voriconazole, resp.  No significant differences were detected in the median triazole trough concns. between patients with proven/probable IFD compared to those with no evidence of IFD.  However, itraconazole was not detected in 10 samples (7 patients).  The small no. of patients who achieved the recommended trough posaconazole concns. may explain the high rate of break-through IFD obsd. in patients prescribed this drug.  Except for fluconazole, the no. of patients prescribed std. doses of triazoles who achieved recommended trough triazole concns. was low.  The prospective use of serum triazole measurements assay may have improved outcomes with itraconazole, posaconazole, and with voriconazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOpa98pzPvG7Vg90H21EOLACvtfcHk0lgBMxVnuRyv7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjt1Wmuro%253D&md5=a019097c496b15d3291dc90c6e69e883</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1093%2Fmmy%2Fmyw031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmmy%252Fmyw031%26sid%3Dliteratum%253Aachs%26aulast%3DCeesay%26aufirst%3DM.%2BM.%26aulast%3DCouchman%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DWade%26aufirst%3DJ.%26aulast%3DFlanagan%26aufirst%3DR.%2BJ.%26aulast%3DPagliuca%26aufirst%3DA.%26atitle%3DTriazole%2520Antifungals%2520Used%2520for%2520Prophylaxis%2520and%2520Treatment%2520of%2520Invasive%2520Fungal%2520Disease%2520in%2520Adult%2520Haematology%2520Patients%253A%2520Trough%2520Serum%2520Concentrations%2520in%2520Relation%2520to%2520Outcome%26jtitle%3DMed.%2520Mycol.%26date%3D2016%26volume%3D54%26spage%3D691%26epage%3D698%26doi%3D10.1093%2Fmmy%2Fmyw031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lass-Flörl, C.</span></span> <span> </span><span class="NLM_article-title">Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2405</span>– <span class="NLM_lpage">2419</span>, <span class="refDoi"> DOI: 10.2165/11596540-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.2165%2F11596540-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=22141384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FltFajsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2405-2419&author=C.+Lass-Fl%C3%B6rl&title=Triazole+Antifungal+Agents+in+Invasive+Fungal+Infections%3A+A+Comparative+Review&doi=10.2165%2F11596540-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole antifungal agents in invasive fungal infections: a comparative review</span></div><div class="casAuthors">Lass-Florl Cornelia</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2405-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Invasive fungal disease continues to be a problem associated with significant morbidity and high mortality in immunocompromised and, to a lesser extent, immunocompetent individuals.  Triazole antifungals have emerged as front-line drugs for the treatment and prophylaxis of many systemic mycoses.  Fluconazole plays an excellent role in prophylaxis, empirical therapy, and the treatment of both superficial and invasive yeast fungal infections.  Voriconazole is strongly recommended for pulmonary invasive aspergillosis.  Posaconazole shows a very wide spectrum of activity and its primary clinical indications are as salvage therapy for patients with invasive aspergillosis and prophylaxis for patients with neutropenia and haematopoietic stem-cell transplant recipients.  Itraconazole also has a role in the treatment of fungal skin and nail infections as well as dematiaceous fungi and endemic mycoses.  Fluconazole and voriconazole are well absorbed and exhibit high oral bioavailability, whereas the oral bioavailability of itraconazole and posaconazole is lower and more variable.  Posaconazole absorption depends on administration with a high-fat meal or nutritional supplements.  Itraconazole and voriconazole undergo extensive hepatic metabolism involving the cytochrome P450 system.  The therapeutic window for triazoles is narrow, and inattention to their pharmacokinetic properties can lead to drug levels too low for efficacy or too high for good tolerability or safety.  This makes these agents prime candidates for therapeutic drug monitoring (TDM).  Target drug concentrations for voriconazole and itraconazole should be >1 μg/mL and for posaconazole >1.5 μg/mL for treatment.  Blood should be drawn once the patient reaches steady state, which occurs after 5 and 7 days of triazole therapy.  Routine TDM of fluconazole is not required given its highly favourable pharmacokinetic profile and wide therapeutic index.  The aim of this review is to provide a brief update on the pharmacology, activity, clinical efficacy, safety and cost of triazole agents (itraconazole, fluconazole, voriconazole and posaconazole) and highlight the clinical implications of similarities and differences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdDzNfOIknD4IRAdBLKY41fW6udTcc2eYjCTNpj3VZD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FltFajsw%253D%253D&md5=7f032dbd61751d93e10358852c7b89bb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2165%2F11596540-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596540-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DLass-Fl%25C3%25B6rl%26aufirst%3DC.%26atitle%3DTriazole%2520Antifungal%2520Agents%2520in%2520Invasive%2520Fungal%2520Infections%253A%2520A%2520Comparative%2520Review%26jtitle%3DDrugs%26date%3D2011%26volume%3D71%26spage%3D2405%26epage%3D2419%26doi%3D10.2165%2F11596540-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shagufta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span> <span> </span><span class="NLM_article-title">An Insight Into the Therapeutic Potential of Quinazoline Derivatives as Anticancer Agents</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">871</span>– <span class="NLM_lpage">885</span>, <span class="refDoi"> DOI: 10.1039/c7md00097a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1039%2FC7MD00097A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=30108803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslCrtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=871-885&author=S.+Shaguftaauthor=I.+Ahmad&title=An+Insight+Into+the+Therapeutic+Potential+of+Quinazoline+Derivatives+as+Anticancer+Agents&doi=10.1039%2Fc7md00097a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">An insight into the therapeutic potential of quinazoline derivatives as anticancer agents</span></div><div class="casAuthors">Shagufta; Ahmad, Irshad</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">871-885</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Cancer is one of the major causes of worldwide human mortality.  A wide range of cytotoxic drugs are available on the market, and several compds. are in different phases of clin. trials.  Many studies suggest that these cytotoxic mols. are also assocd. with different types of adverse side effects; therefore researchers around the globe are involved in the development of more efficient and safer anticancer drugs.  In recent years, quinazoline and its derivs. have been considered as a novel class of cancer chemotherapeutic agents that show promising activity against different tumors.  The aim of this article is to comprehensively review and highlight the recent developments concerning the anticancer activity of quinazoline derivs. as well as offer perspectives on the development of novel quinazoline derivs. as anticancer agents in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ0qD4nxDYQLVg90H21EOLACvtfcHk0ljrVl9eBzEv4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslCrtbw%253D&md5=2b5e331baaa9beb7e6dc14e7e439add3</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1039%2FC7MD00097A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00097A%26sid%3Dliteratum%253Aachs%26aulast%3DShagufta%26aufirst%3DS.%26aulast%3DAhmad%26aufirst%3DI.%26atitle%3DAn%2520Insight%2520Into%2520the%2520Therapeutic%2520Potential%2520of%2520Quinazoline%2520Derivatives%2520as%2520Anticancer%2520Agents%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D871%26epage%3D885%26doi%3D10.1039%2Fc7md00097a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritschel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, S. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreurs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Heuvel, J. J. M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenderink, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greupink, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russel, F. G. M.</span></span> <span> </span><span class="NLM_article-title">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds Through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">873</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1021/tx5000393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx5000393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=873-881&author=T.+Ritschelauthor=S.+M.+A.+Hermansauthor=M.+Schreursauthor=J.+J.+M.+W.+van+den+Heuvelauthor=J.+B.+Koenderinkauthor=R.+Greupinkauthor=F.+G.+M.+Russel&title=In+Silico+Identification+and+in+Vitro+Validation+of+Potential+Cholestatic+Compounds+Through+3D+Ligand-Based+Pharmacophore+Modeling+of+BSEP+Inhibitors&doi=10.1021%2Ftx5000393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors</span></div><div class="casAuthors">Ritschel, Tina; Hermans, Susanne M. A.; Schreurs, Marieke; van den Heuvel, Jeroen J. M. W.; Koenderink, Jan B.; Greupink, Rick; Russel, Frans G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">873-881</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced cholestasis is a frequently obsd. side effect of drugs and is often caused by an unexpected interaction with the bile salt export pump (BSEP/ABCB11).  BSEP is the key membrane transporter responsible for the transport of bile acids from hepatocytes into bile.  Here, we developed a pharmacophore model that describes the mol. features of compds. assocd. with BSEP inhibitory activity.  To generate input and validation data sets, in vitro expts. with membrane vesicles overexpressing human BSEP were used to assess the effect of compds. (50 μM) on BSEP-mediated 3H-taurocholic acid transport.  The model contains two hydrogen bond acceptor/anionic features, two hydrogen bond acceptor vector features, four hydrophobic/arom. features, and exclusion vols.  The pharmacophore was validated against a set of 59 compds., including registered drugs.  The model recognized 9 out of 12 inhibitors (75%), which could not be identified based on general parameters, such as mol. wt. or SlogP, alone.  Finally, the model was used to screen a virtual compd. database.  A no. of compds. found via virtual screening were tested and displayed statistically significant BSEP inhibition, ranging from 13±1% to 67±7% of control (P < 0.05).  In conclusion, we developed and validated a pharmacophore model that describes mol. features found in BSEP inhibitors.  The model may be used as an in silico screening tool to identify potentially harmful drug candidates at an early stage in drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDhv5ltUmvILVg90H21EOLACvtfcHk0ljrVl9eBzEv4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlslSmur0%253D&md5=95ecfad2ba7f4cd40dc2ed2f064ed7fb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Ftx5000393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx5000393%26sid%3Dliteratum%253Aachs%26aulast%3DRitschel%26aufirst%3DT.%26aulast%3DHermans%26aufirst%3DS.%2BM.%2BA.%26aulast%3DSchreurs%26aufirst%3DM.%26aulast%3Dvan%2Bden%2BHeuvel%26aufirst%3DJ.%2BJ.%2BM.%2BW.%26aulast%3DKoenderink%26aufirst%3DJ.%2BB.%26aulast%3DGreupink%26aufirst%3DR.%26aulast%3DRussel%26aufirst%3DF.%2BG.%2BM.%26atitle%3DIn%2520Silico%2520Identification%2520and%2520in%2520Vitro%2520Validation%2520of%2520Potential%2520Cholestatic%2520Compounds%2520Through%25203D%2520Ligand-Based%2520Pharmacophore%2520Modeling%2520of%2520BSEP%2520Inhibitors%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D873%26epage%3D881%26doi%3D10.1021%2Ftx5000393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, L.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one and Its Derivatives</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">564</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1002/ardp.201500115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fardp.201500115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26053879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Wgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=564-574&author=H.-J.+Zhangauthor=P.+Jinauthor=S.-B.+Wangauthor=F.-N.+Liauthor=L.-P.+Guanauthor=Z.-S.+Quan&title=Synthesis+and+Anticonvulsant+Activity+Evaluation+of+4-Phenyl-%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-a%5Dquinazolin-5%284H%29-one+and+Its+Derivatives&doi=10.1002%2Fardp.201500115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Anticonvulsant Activity Evaluation of 4-Phenyl-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one and Its Derivatives</span></div><div class="casAuthors">Zhang, Hong-Jian; Jin, Peng; Wang, Shi-Ben; Li, Fu-Nan; Guan, Li-Ping; Quan, Zhe-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">564-574</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A series of 4-(substituted-phenyl)-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones I [R = H, 4-Cl, 2-F, 3,4-Me2, etc.] and other heterocyclic compds., e.g., II, were synthesized and evaluated for their anticonvulsant activity and neurotoxicity by maximal electroshock (MES) and rotarod neurotoxicity tests.  Among the compds. studied, I [R = 4-Cl, 4-Br] (III) showed wide margins of safety with protective indexes (PIs) that were much higher than those of currently used drugs (PI6o >25.5, PI6q >26.0).  III showed significant oral activity against MES-induced seizures in mice, with ED50 values of 88.02 and 94.6 mg/kg, resp.  Moreover, these two compds. were also found to have potent activity against seizures that were induced by pentylenetetrazole and bicuculline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpECw9881KEoLVg90H21EOLACvtfcHk0ljrVl9eBzEv4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Wgtbk%253D&md5=0fe407922af8fcefd5fc924bafaa3252</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fardp.201500115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201500115%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DLi%26aufirst%3DF.-N.%26aulast%3DGuan%26aufirst%3DL.-P.%26aulast%3DQuan%26aufirst%3DZ.-S.%26atitle%3DSynthesis%2520and%2520Anticonvulsant%2520Activity%2520Evaluation%2520of%25204-Phenyl-%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-a%255Dquinazolin-5%25284H%2529-one%2520and%2520Its%2520Derivatives%26jtitle%3DArch.%2520Pharm.%26date%3D2015%26volume%3D348%26spage%3D564%26epage%3D574%26doi%3D10.1002%2Fardp.201500115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antidepressant Activities of 4-(substituted-phenyl)tetrazolo[1,5-a]quinazolin-5(4H)-ones and Their Derivatives</span>. <i>Mol. Divers.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1007/s11030-015-9623-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1007%2Fs11030-015-9623-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=26251313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12lsr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=817-828&author=H.-J.+Zhangauthor=S.-B.+Wangauthor=Z.-S.+Quan&title=Synthesis+and+Antidepressant+Activities+of+4-%28substituted-phenyl%29tetrazolo%5B1%2C5-a%5Dquinazolin-5%284H%29-ones+and+Their+Derivatives&doi=10.1007%2Fs11030-015-9623-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antidepressant activities of 4-(substituted-phenyl)tetrazolo[1,5-a]quinazolin-5(4H)-ones and their derivatives</span></div><div class="casAuthors">Zhang, Hong-Jian; Wang, Shi-Ben; Quan, Zhe-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Diversity</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">817-828</span>CODEN:
                <span class="NLM_cas:coden">MODIF4</span>;
        ISSN:<span class="NLM_cas:issn">1381-1991</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A series of novel 4-(substituted-phenyl) tetrazolo[1,5-a]quinazolin-5(4H)-ones (6a-x) and their derivs. with tetrazole and other heterocyclic substituents (7-14) were designed, synthesized, and evaluated for antidepressant activities in mice.  Pharmacol. tests showed that three compds. (6l, 6u, and 6v) at a dose of 50 mg/kg significantly reduced the immobility time in the forced swimming test.  The most active compd. was 4-(p-tolyl)tetrazolo[1,5-a]quinazolin-5(4H)-one (6v), which decreased the immobility time by 82.69 % at 50 mg/kg.  Moreover, 6v did not affect spontaneous activity in the open-field test, and this effect was comparable to the antidepressant effect of fluoxetine.  Noradrenaline (NE) and 5-hydroxytryptamine (5-HT) levels in the brains of mice in the test sample groups significantly increased at a dose of 50 mg/kg compared with that in the control group.  The monoamine oxidase (MAO) level of all test groups was reduced, but this result was not significantly different between the groups.  Therefore, we can infer that their underlying mechanisms may involve the regulation of brain monoamine neurotransmitter homeostasis, based on the detected content of NE, 5-HT, and MAO in mouse brain tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsF4abAq8MGbVg90H21EOLACvtfcHk0lhjxsAXTVn22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12lsr7L&md5=4bf045c4170c367d78076f5522c15a2a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs11030-015-9623-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-015-9623-1%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DWang%26aufirst%3DS.-B.%26aulast%3DQuan%26aufirst%3DZ.-S.%26atitle%3DSynthesis%2520and%2520Antidepressant%2520Activities%2520of%25204-%2528substituted-phenyl%2529tetrazolo%255B1%252C5-a%255Dquinazolin-5%25284H%2529-ones%2520and%2520Their%2520Derivatives%26jtitle%3DMol.%2520Divers.%26date%3D2015%26volume%3D19%26spage%3D817%26epage%3D828%26doi%3D10.1007%2Fs11030-015-9623-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span>; <span class="NLM_string-name">Nagpal, N.</span>; <span class="NLM_string-name">Fong, Y.</span></span> <span> </span><span class="NLM_article-title">PAPD5 Inhibitors and Methods of Use Thereof</span>. U.S. Patent <span class="NLM_patent">WO 2019084271 A1</span>, May 2, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Agarwal&author=N.+Nagpal&author=Y.+Fong&title=PAPD5+Inhibitors+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26atitle%3DPAPD5%2520Inhibitors%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ram, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srimal, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushwaha, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, L.</span></span> <span> </span><span class="NLM_article-title">Chemoterapeutic Agents. XIX. Synthesis of [1,2,4]-Triazoloquinazolinones and Related Compounds as Antihypertensive Agents</span>. <i>J. Prakt. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">639</span>, <span class="refDoi"> DOI: 10.1002/prac.19903320507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1002%2Fprac.19903320507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADyaK3MXhs1Citrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=1990&pages=629-639&author=V.+J.+Ramauthor=R.+C.+Srimalauthor=D.+S.+Kushwahaauthor=L.+Mishra&title=Chemoterapeutic+Agents.+XIX.+Synthesis+of+%5B1%2C2%2C4%5D-Triazoloquinazolinones+and+Related+Compounds+as+Antihypertensive+Agents&doi=10.1002%2Fprac.19903320507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapeutic agents.  XIX.  Synthesis of [1,2,4]triazoloquinazolinones and related compounds as antihypertensive agents</span></div><div class="casAuthors">Ram, V. J.; Srimal, R. C.; Kushwaha, D. S.; Mishra, L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal fuer Praktische Chemie (Leipzig)</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">629-39</span>CODEN:
                <span class="NLM_cas:coden">JPCEAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-8383</span>.
    </div><div class="casAbstract">A series of [1,2,4]triazolo[4,3-a]quinazolin-5-ones, e.g. I (R = Me, Et, R4 = H, Me, R5 = Me, aryl, R6 = H, Me), were prepd. starting from appropriate quinazolinones.  Only II (R = Me) and I (R = Me, R4 = R6 = H, R5 = Me) exhibited antihypertensive activity in mice; all others were inactive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLD5rs3Ek2-rVg90H21EOLACvtfcHk0lhjxsAXTVn22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhs1Citrs%253D&md5=0d9f5fdb3ae1e0a09aa613d9f6495f37</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1002%2Fprac.19903320507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprac.19903320507%26sid%3Dliteratum%253Aachs%26aulast%3DRam%26aufirst%3DV.%2BJ.%26aulast%3DSrimal%26aufirst%3DR.%2BC.%26aulast%3DKushwaha%26aufirst%3DD.%2BS.%26aulast%3DMishra%26aufirst%3DL.%26atitle%3DChemoterapeutic%2520Agents.%2520XIX.%2520Synthesis%2520of%2520%255B1%252C2%252C4%255D-Triazoloquinazolinones%2520and%2520Related%2520Compounds%2520as%2520Antihypertensive%2520Agents%26jtitle%3DJ.%2520Prakt.%2520Chem.%26date%3D1990%26volume%3D332%26spage%3D629%26epage%3D639%26doi%3D10.1002%2Fprac.19903320507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ram, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaul, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapil, A.</span></span> <span> </span><span class="NLM_article-title">Latent Leishmanicidal Activity of Quinazolinones and 1,2,4-Triazoloquinazolinones</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">2087</span>– <span class="NLM_lpage">2090</span>, <span class="refDoi"> DOI: 10.1016/s0960-894x(01)80107-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2FS0960-894X%2801%2980107-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADyaK2MXovVyisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1994&pages=2087-2090&author=V.+J.+Ramauthor=A.+Goelauthor=M.+Vermaauthor=I.+B.+Kaulauthor=A.+Kapil&title=Latent+Leishmanicidal+Activity+of+Quinazolinones+and+1%2C2%2C4-Triazoloquinazolinones&doi=10.1016%2Fs0960-894x%2801%2980107-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Latent leishmanicidal activity of quinazolinones and 1,2,4-triazoloquinazolinones</span></div><div class="casAuthors">Ram, Vishnu Ji; Goel, Atul; Verma, Monika; Kaul, Indu Bala; Kapil, Aruna</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2087-90</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    </div><div class="casAbstract">Derivs. of quinazolinones (I, e.g., R = 6-OMe, or 7-Cl, R1 = Me or Et, R2 = H or Me) and various 1,2,4-triazoloquinazolinones were prepd. and evaluated for in vitro leishmanicidal activity against Leishmania donovani promastigotes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxzDlAZfgjKLVg90H21EOLACvtfcHk0lhjxsAXTVn22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXovVyisg%253D%253D&md5=a4ccc2798af97690c83a5bd510b0a962</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2980107-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252980107-4%26sid%3Dliteratum%253Aachs%26aulast%3DRam%26aufirst%3DV.%2BJ.%26aulast%3DGoel%26aufirst%3DA.%26aulast%3DVerma%26aufirst%3DM.%26aulast%3DKaul%26aufirst%3DI.%2BB.%26aulast%3DKapil%26aufirst%3DA.%26atitle%3DLatent%2520Leishmanicidal%2520Activity%2520of%2520Quinazolinones%2520and%25201%252C2%252C4-Triazoloquinazolinones%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1994%26volume%3D4%26spage%3D2087%26epage%3D2090%26doi%3D10.1016%2Fs0960-894x%2801%2980107-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Besnard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruda, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setola, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abecassis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguiz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sassano, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidah, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Constam, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bickerton, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetsel, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span> <span> </span><span class="NLM_article-title">Automated Design of Ligands to Polypharmacological Profiles</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1038/nature11691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fnature11691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23235874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2012&pages=215-220&author=J.+Besnardauthor=G.+F.+Rudaauthor=V.+Setolaauthor=K.+Abecassisauthor=R.+M.+Rodriguizauthor=X.-P.+Huangauthor=S.+Norvalauthor=M.+F.+Sassanoauthor=A.+I.+Shinauthor=L.+A.+Websterauthor=F.+R.+C.+Simeonsauthor=L.+Stojanovskiauthor=A.+Pratauthor=N.+G.+Seidahauthor=D.+B.+Constamauthor=G.+R.+Bickertonauthor=K.+D.+Readauthor=W.+C.+Wetselauthor=I.+H.+Gilbertauthor=B.+L.+Rothauthor=A.+L.+Hopkins&title=Automated+Design+of+Ligands+to+Polypharmacological+Profiles&doi=10.1038%2Fnature11691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design of ligands to polypharmacological profiles</span></div><div class="casAuthors">Besnard, Jeremy; Ruda, Gian Filippo; Setola, Vincent; Abecassis, Keren; Rodriguiz, Ramona M.; Huang, Xi-Ping; Norval, Suzanne; Sassano, Maria F.; Shin, Antony I.; Webster, Lauren A.; Simeons, Frederick R. C.; Stojanovski, Laste; Prat, Annik; Seidah, Nabil G.; Constam, Daniel B.; Bickerton, G. Richard; Read, Kevin D.; Wetsel, William C.; Gilbert, Ian H.; Roth, Bryan L.; Hopkins, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue">7428</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy and safety of a drug is detd. by its activity profile across many proteins in the proteome.  However, designing drugs with a specific multi-target profile is both complex and difficult.  Therefore methods to design drugs rationally a priori against profiles of several proteins would have immense value in drug discovery.  Here is described a new approach for the automated design of ligands against profiles of multiple drug targets.  The method is demonstrated by the evolution of an approved acetylcholinesterase inhibitor drug donepezil (I) into brain-penetrable ligands with either specific polypharmacol. or exquisite selectivity profiles for G-protein-coupled receptors.  Overall, 800 ligand-target predictions of prospectively designed ligands were tested exptl., of which 75% were confirmed to be correct.  Target engagement in vivo is also demonstrated.  The approach can be a useful source of drug leads when multi-target profiles are required to achieve either selectivity over other drug targets or a desired polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNu5bwrBD3tbVg90H21EOLACvtfcHk0lhjxsAXTVn22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVamurfN&md5=ace6cced250cf968d327b482a5bf1798</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1038%2Fnature11691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11691%26sid%3Dliteratum%253Aachs%26aulast%3DBesnard%26aufirst%3DJ.%26aulast%3DRuda%26aufirst%3DG.%2BF.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DAbecassis%26aufirst%3DK.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DShin%26aufirst%3DA.%2BI.%26aulast%3DWebster%26aufirst%3DL.%2BA.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSeidah%26aufirst%3DN.%2BG.%26aulast%3DConstam%26aufirst%3DD.%2BB.%26aulast%3DBickerton%26aufirst%3DG.%2BR.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26atitle%3DAutomated%2520Design%2520of%2520Ligands%2520to%2520Polypharmacological%2520Profiles%26jtitle%3DNature%26date%3D2012%26volume%3D492%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fnature11691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brassesco, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezuk, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho de Oliveira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberto, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicioli da Silva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco de Oliveira, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scrideli, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, L. G.</span></span> <span> </span><span class="NLM_article-title">In Vitro Targeting of Polo-like Kinase 1 in Bladder Carcinoma: Comparative Effects of Four Potent Inhibitors</span>. <i>Canc. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.4161/cbt.25087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.4161%2Fcbt.25087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=23792639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjs1yit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=648-657&author=M.+S.+Brassescoauthor=J.+A.+Pezukauthor=A.+G.+Moralesauthor=J.+Carvalho+de+Oliveiraauthor=G.+M.+Robertoauthor=G.+Nicioli+da+Silvaauthor=H.+Francisco+de+Oliveiraauthor=C.+A.+Scrideliauthor=L.+G.+Tone&title=In+Vitro+Targeting+of+Polo-like+Kinase+1+in+Bladder+Carcinoma%3A+Comparative+Effects+of+Four+Potent+Inhibitors&doi=10.4161%2Fcbt.25087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors</span></div><div class="casAuthors">Brassesco, Maria Sol; Pezuk, Julia Alejandra; Morales, Andressa Gois; Carvalho de Oliveira, Jaqueline; Roberto, Gabriela Molinari; Nicioli da Silva, Glenda; Francisco de Oliveira, Harley; Scrideli, Carlos Alberto; Tone, Luiz Gonzaga</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">648-657</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Despite the improvements in neoadjuvant chemotherapy, the outcome of patients with advanced bladder cancer has changed very little over the past 30 years.  In the present study we tested and compared the in vitro antitumor activities of four different inhibitors of Polo-like kinase 1 (PLK1) (BI 2536, BI 6727, GW843682X, and GSK461364), against 3 bladder carcinoma cell lines RT4, 5637 and T24.  The impact on radiosensitivity and drug interactions in simultaneous treatments with cisplatin, methotrexate, and doxorubicin were also investigated.  Our results showed that PLK1 inhibition prevented cell proliferation and clonogenicity, causing significant inhibition of invasion of tumor cells, though modest differences were obsd. between drugs.  Moreover, all PLK1 inhibitors induced G2/M arrest, with the subsequent induction of death in all 3 cell lines.  Drug interactions studies showed auspicious results for all PLK1 inhibitors when combined with the commonly used cisplatin and methotrexate, though combinations with doxorubicin showed mostly antagonistic effects.  Comparably, the four PLK1 inhibitors efficiently sensitized cells to ionizing radiation.  Our findings demonstrate that irresp. of the inhibitor used, the pharmacol. inhibition of PLK1 constrains bladder cancer growth and dissemination, providing new opportunities for future therapeutic intervention.  However, further laboratorial and preclin. tests are still needed to corroborate the usefulness of using them in combination with other commonly used chemotherapeutic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSY13bvs2NQbVg90H21EOLACvtfcHk0ljHiI5D4va0Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjs1yit74%253D&md5=cc07290ff65e479d69518edd7cc7b606</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4161%2Fcbt.25087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.25087%26sid%3Dliteratum%253Aachs%26aulast%3DBrassesco%26aufirst%3DM.%2BS.%26aulast%3DPezuk%26aufirst%3DJ.%2BA.%26aulast%3DMorales%26aufirst%3DA.%2BG.%26aulast%3DCarvalho%2Bde%2BOliveira%26aufirst%3DJ.%26aulast%3DRoberto%26aufirst%3DG.%2BM.%26aulast%3DNicioli%2Bda%2BSilva%26aufirst%3DG.%26aulast%3DFrancisco%2Bde%2BOliveira%26aufirst%3DH.%26aulast%3DScrideli%26aufirst%3DC.%2BA.%26aulast%3DTone%26aufirst%3DL.%2BG.%26atitle%3DIn%2520Vitro%2520Targeting%2520of%2520Polo-like%2520Kinase%25201%2520in%2520Bladder%2520Carcinoma%253A%2520Comparative%2520Effects%2520of%2520Four%2520Potent%2520Inhibitors%26jtitle%3DCanc.%2520Biol.%2520Ther.%26date%3D2013%26volume%3D14%26spage%3D648%26epage%3D657%26doi%3D10.4161%2Fcbt.25087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogado, R. F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezuk, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tone, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassesco, M. S.</span></span> <span> </span><span class="NLM_article-title">6727 and GSK461364 Suppress Growth and Radiosensitize Osteosarcoma Cells, but Show Limited Cytotoxic Effects When Combined With Conventional Treatments</span>. <i>Anticancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1097/cad.0000000000000157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1097%2FCAD.0000000000000157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A280%3ADC%252BC2cbosVKntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=56-63&author=R.+F.+E.+Bogadoauthor=J.+A.+Pezukauthor=H.+F.+de+Oliveiraauthor=L.+G.+Toneauthor=M.+S.+Brassesco&title=6727+and+GSK461364+Suppress+Growth+and+Radiosensitize+Osteosarcoma+Cells%2C+but+Show+Limited+Cytotoxic+Effects+When+Combined+With+Conventional+Treatments&doi=10.1097%2Fcad.0000000000000157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments</span></div><div class="casAuthors">Bogado Rodrigo F E; Pezuk Julia A; de Oliveira Harley F; Tone Luiz G; Brassesco Maria S</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Polo-like kinase 1 (PLK1), a key regulator of mitosis, is often overexpressed in childhood cancers and is associated with poor prognosis.  Previous reports have shown that inhibition of PLK1 might serve as a promising anticancer treatment for osteosarcoma.  In this study, we tested the second-generation PLK1 inhibitors BI 6727 and GSK461364 in HOS and MG-63 cell lines, both as a single agent and in combination with methotrexate, cisplatin, vinblastine, doxorubicin, or ionizing radiation.  Both PLK1 inhibitors worked equally in terms of cell growth arrest, apoptosis induction, and radiosensitization.  Combining BI 6727 or GSK461364 with conventional treatments, however, showed trivial synergistic antitumor effects in vitro.  Our results reinforce the potential use of PLK1 inhibitors for a pharmacologic intervention in osteosarcoma, although their applicability in polychemotherapeutic regimens deserves further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZTZEKqodBsijiVMCqkKxVfW6udTcc2eaFbdey7tThO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbosVKntA%253D%253D&md5=00ebcecda322493e8b92b1e83bb8f855</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000157%26sid%3Dliteratum%253Aachs%26aulast%3DBogado%26aufirst%3DR.%2BF.%2BE.%26aulast%3DPezuk%26aufirst%3DJ.%2BA.%26aulast%3Dde%2BOliveira%26aufirst%3DH.%2BF.%26aulast%3DTone%26aufirst%3DL.%2BG.%26aulast%3DBrassesco%26aufirst%3DM.%2BS.%26atitle%3D6727%2520and%2520GSK461364%2520Suppress%2520Growth%2520and%2520Radiosensitize%2520Osteosarcoma%2520Cells%252C%2520but%2520Show%2520Limited%2520Cytotoxic%2520Effects%2520When%2520Combined%2520With%2520Conventional%2520Treatments%26jtitle%3DAnticancer%2520Drugs%26date%3D2015%26volume%3D26%26spage%3D56%26epage%3D63%26doi%3D10.1097%2Fcad.0000000000000157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impagnatiello, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaukopf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlich, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tontsch-Grunt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wernitznig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savarese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geiselmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reschke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moll, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-like Kinases, in Preclinical Models of Acute Myeloid Leukemia</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">579</span>– <span class="NLM_lpage">589</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.221150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1124%2Fjpet.114.221150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25576074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=579-589&author=D.+Rudolphauthor=M.+A.+Impagnatielloauthor=C.+Blaukopfauthor=C.+Sommerauthor=D.+W.+Gerlichauthor=M.+Rothauthor=U.+Tontsch-Gruntauthor=A.+Wernitznigauthor=F.+Savareseauthor=M.+H.+Hofmannauthor=C.+Albrechtauthor=L.+Geiselmannauthor=M.+Reschkeauthor=P.+Garin-Chesaauthor=J.+Zuberauthor=J.+Mollauthor=G.+R.+Adolfauthor=N.+Kraut&title=Efficacy+and+Mechanism+of+Action+of+Volasertib%2C+a+Potent+and+Selective+Inhibitor+of+Polo-like+Kinases%2C+in+Preclinical+Models+of+Acute+Myeloid+Leukemia&doi=10.1124%2Fjpet.114.221150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of polo-like kinases, in preclinical models of acute myeloid leukemia</span></div><div class="casAuthors">Rudolph, Dorothea; Impagnatiello, Maria Antonietta; Blaukopf, Claudia; Sommer, Christoph; Gerlich, Daniel W.; Roth, Mareike; Tontsch-Grunt, Ulrike; Wernitznig, Andreas; Savarese, Fabio; Hofmann, Marco H.; Albrecht, Christoph; Geiselmann, Lena; Reschke, Markus; Pilar, Garin-Chesa; Zuber, Johannes; Moll, Juergen; Adolf, Guenther R.; Krauf, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">579-589, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family of serine/threonine kinases, is a key regulator of multiple steps in mitosis.  Here we report on the pharmacol. profile of volasertib, a potent and selective Plk inhibitor, in multiple preclin. models of acute myeloid leukemia (AML) including established cell lines, bone marrow samples from AML patients in short-term culture, and s.c. as well as disseminated in vivo models in immune-deficient mice.  Our results indicate that volasertib is highly efficacious as a single agent and in combination with established and emerging AML drugs, including the antimetabolite cytarabine, hypomethylating agents (decitabine, azacitidine), and quizartinib, a signal transduction inhibitor targeting FLT3.  Collectively, these preclin. data support the use of volasertib as a new therapeutic approach for the treatment of AML patients, and provide a foundation for combination approaches that may further improve and prolong clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD6Oj8vQUjU7Vg90H21EOLACvtfcHk0ljHiI5D4va0Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omur8%253D&md5=da04fc2f3bea64606b938c4f9518b78f</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221150%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DD.%26aulast%3DImpagnatiello%26aufirst%3DM.%2BA.%26aulast%3DBlaukopf%26aufirst%3DC.%26aulast%3DSommer%26aufirst%3DC.%26aulast%3DGerlich%26aufirst%3DD.%2BW.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWernitznig%26aufirst%3DA.%26aulast%3DSavarese%26aufirst%3DF.%26aulast%3DHofmann%26aufirst%3DM.%2BH.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DGeiselmann%26aufirst%3DL.%26aulast%3DReschke%26aufirst%3DM.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DZuber%26aufirst%3DJ.%26aulast%3DMoll%26aufirst%3DJ.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26aulast%3DKraut%26aufirst%3DN.%26atitle%3DEfficacy%2520and%2520Mechanism%2520of%2520Action%2520of%2520Volasertib%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Polo-like%2520Kinases%252C%2520in%2520Preclinical%2520Models%2520of%2520Acute%2520Myeloid%2520Leukemia%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D579%26epage%3D589%26doi%3D10.1124%2Fjpet.114.221150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gjertsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schöffski, P.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of the Polo-like Kinase Inhibitor Volasertib in Cancer Therapy</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1038/leu.2014.222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1038%2Fleu.2014.222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25027517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=11-19&author=B.+T.+Gjertsenauthor=P.+Sch%C3%B6ffski&title=Discovery+and+Development+of+the+Polo-like+Kinase+Inhibitor+Volasertib+in+Cancer+Therapy&doi=10.1038%2Fleu.2014.222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy</span></div><div class="casAuthors">Gjertsen, B. T.; Schoffski, P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-19</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Owing to their integral involvement in cell cycle regulation, the Polo-like kinase (Plk) family, particularly Plk1, has emerged as an attractive therapeutic target in oncol.  In recent years, several Plk1 inhibitors have been developed, with some agents showing encouraging results in early-phase clin. trials.  This review focuses on volasertib (BI 6727; an investigational agent), a potent and selective Plk inhibitor.  Volasertib has shown promising activity in various cancer cell lines and xenograft models of human cancer.  Trials performed to date suggest that volasertib has clin. efficacy in a range of malignancies, with the most promising results seen in patients with acute myeloid leukemia (AML).  Encouragingly, recent phase II data have demonstrated that volasertib combined with low-dose cytarabine (LDAC) was assocd. with higher response rates and improved event-free survival than LDAC alone in patients with previously untreated AML.  Based on these observations, and its presumably manageable safety profile, volasertib is currently in phase III development as a potential treatment for patients with AML who are ineligible for intensive remission induction therapy.  Given that many patients with AML are of an older age and frail, this constitutes an area of major unmet need.  In this review, we discuss the biol. rationale for Plk1 inhibitors in cancer, the clin. development of volasertib to date in solid tumors and AML, and the future identification of biomarkers that might predict response to volasertib and help det. the role of this agent in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9D-SO9pn3cbVg90H21EOLACvtfcHk0ljcdQV2_9OomA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKgs7%252FE&md5=cabf0c81a92b210b09c4bdc23150c5bb</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fleu.2014.222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2014.222%26sid%3Dliteratum%253Aachs%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520the%2520Polo-like%2520Kinase%2520Inhibitor%2520Volasertib%2520in%2520Cancer%2520Therapy%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D11%26epage%3D19%26doi%3D10.1038%2Fleu.2014.222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erba, H. P.</span></span> <span> </span><span class="NLM_article-title">Finding the Optimal Combination Therapy for the Treatment of Newly Diagnosed AML in Older Patients Unfit for Intensive Therapy</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2014.11.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=10.1016%2Fj.leukres.2014.11.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=25577399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFShsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=183-191&author=H.+P.+Erba&title=Finding+the+Optimal+Combination+Therapy+for+the+Treatment+of+Newly+Diagnosed+AML+in+Older+Patients+Unfit+for+Intensive+Therapy&doi=10.1016%2Fj.leukres.2014.11.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy</span></div><div class="casAuthors">Erba, Harry P.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-191</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  There is no std. of care for older patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity therapies (decitabine, azacitidine, and low-dose cytarabine [LDAC]) remains poor.  One promising strategy is to combine low-intensity treatments with novel agents.  Gemtuzumab ozogamicin, tipifarnib, and barasertib have been investigated in phase 2/3 or 3 trials combined with LDAC, and phase 3 trials are currently investigating sapacitabine plus decitabine, and volasertib plus LDAC in AML.  This review discusses current treatment recommendations and the development of combination therapies for older patients unfit for intensive therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU81UBDc5q_7Vg90H21EOLACvtfcHk0ljcdQV2_9OomA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFShsrfN&md5=a295426b269466ec140c7fe5074effdc</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2014.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2014.11.027%26sid%3Dliteratum%253Aachs%26aulast%3DErba%26aufirst%3DH.%2BP.%26atitle%3DFinding%2520the%2520Optimal%2520Combination%2520Therapy%2520for%2520the%2520Treatment%2520of%2520Newly%2520Diagnosed%2520AML%2520in%2520Older%2520Patients%2520Unfit%2520for%2520Intensive%2520Therapy%26jtitle%3DLeuk.%2520Res.%26date%3D2015%26volume%3D39%26spage%3D183%26epage%3D191%26doi%3D10.1016%2Fj.leukres.2014.11.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i179"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01669">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_73600"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01669?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01669</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Extracted ion chromatograms of selected compounds and their glucuronides in MLM incubations with UDPGA after 60 min; MS/MS spectrum of selected compounds and their glucuronides; comparative FP-based assays showing the ability of additional triazoloquinazolinone-derived compounds (<b>20</b>, <b>27</b>, <b>89</b>, and <b>90</b>) to specifically inhibit Plk1 PBD; acyl-transfer from <b>142</b>; extracted ion chromatograms of <b>143</b> and its metabolites in MLM incubations with NADPH and UDPGA after 60 min, MS/MS spectrum of <b>143</b>, its hydroxylated metabolite, and its demethylated metabolite, and proposed metabolic pathways of <b>143</b> in mice; extracted ion chromatograms of <b>143</b> and its metabolites from MS after 20 mg/kg IP injection of C57BL/6 mice analyzed 4 h post injection and extracted ion chromatograms of <b>145</b> and its metabolites from MS after 20 mg/kg IP injection of C57BL/6 mice analyzed 4 h post injection; inactive S-alkylated compounds; multispecies microsome and cytosol stability of selected compounds; and in vitro and in vivo stability of selected prodrugs (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_001.pdf">jm0c01669_si_001.pdf (8.68 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01669/suppl_file/jm0c01669_si_002.csv">jm0c01669_si_002.csv (9.53 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01669&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01669%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01669" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799855c6bc7d1df","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
